Compounds > carfilzomib
Page last updated: 2024-11-12

carfilzomib

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID11556711
CHEMBL ID451887
CHEBI ID65347
SCHEMBL ID85165
MeSH IDM0516378

Synonyms (77)

Synonym
ono-7057
pr-171
carfilzomib ,
kyprolis
CHEMBL451887 ,
nsc-758252
chebi:65347 ,
carfilzomib (jan/usan/inn)
868540-17-4
D08880
kyprolis (tn)
bdbm50277889
NCGC00249613-01
dtxsid4048690 ,
cas-868540-17-4
dtxcid0028616
tox21_113079
nsc 758252
carfilzomib [usan:inn]
unii-72x6e3j5ar
l-phenylalaninamide, (alphas)-alpha-((4-morpholinylacetyl)amino)benzenebutanoyl-l-leucyl-n-((1s)-3-methyl-1-(((2r)-2-methyloxiranyl)carbonyl)butyl)-
72x6e3j5ar ,
(2s)-n-((1s)-1-benzyl-2-(((1s)-3-methyl-1-(((2r)-2-methyloxiran-2-yl)carbonyl)butyl)amino)-2-oxoethyl)-4-methyl-2-(((2s)-2-((morpholin-4-ylacetyl)amino)-4-phenylbutanoyl)amino)pentanamide
HY-10455
CS-0984
NCGC00249613-03
carfilzomib (pr-171)
carfilzomib [vandf]
carfilzomib [usan]
(2s)-n-[(1s)-1-benzyl-2-[[(1s)-3-methyl-1-[[(2r)-2-methyloxiran-2-yl]carbonyl]butyl]amino]-2-oxoethyl]-4-methyl-2-[[(2s)-2-[(morpholin-4-ylacetyl)amino]-4-phenylbutanoyl]amino]pentanamide
carfilzomib [inn]
l-phenylalaninamide, (.alpha.s)-.alpha.-((4-morpholinylacetyl)amino)benzenebutanoyl-l-leucyl-n-((1s)-3-methyl-1-(((2r)-2-methyloxiranyl)carbonyl)butyl)-
carfilzomib [who-dd]
carfilzomib [orange book]
carfilzomib [mi]
carfilzomib [jan]
n-{(2s)-2-[(morpholin-4-ylacetyl)amino]-4-phenylbutanoyl}-l-leucyl-n-{(2s)-4-methyl-1-[(2r)-2-methyloxiran-2-yl]-1-oxopentan-2-yl}-l-phenylalaninamide
S2853
(2s)-4-methyl-n-[(2s)-1-[[(2s)-4-methyl-1-[(2r)-2-methyloxiran-2-yl]-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]-2-[[(2s)-2-[(2-morpholin-4-ylacetyl)amino]-4-phenylbutanoyl]amino]pentanamide
gtpl7420
DB08889
(s)-4-methyl-n-((s)-1-(((s)-4-methyl-1-((r)-2-methyloxiran-2-yl)-1-oxopentan-2-yl)amino)-1-oxo-3-phenylpropan-2-yl)-2-((s)-2-(2-morpholinoacetamido)-4-phenylbutanamido)pentanamide
BLMPQMFVWMYDKT-NZTKNTHTSA-N
SCHEMBL85165
MLS006011102
smr004660024
NCGC00249613-02
tox21_113079_1
(alphas)-alpha-((4-morpholinylacetyl)amino)benzenebutanoyl-l-leucyl-n-((1s)-3-methyl-1-(((2r)-2-methyloxiranyl)carbonyl)butyl)-l-phe nylalaninamide
J-501773
AC-27051
AB01565867_02
AKOS025401910
SR-01000941582-1
sr-01000941582
CS-W004540
(s)-4-methyl-n-((s)-1-((s)-4-methyl-1-((r)-2- methyloxiran-2-yl)-1 -oxopentan-2-ylamino)-1-oxo-3-phenylpropan-2-yl)-2-((s)-2-(2-morpholinoacetamido)-4-phenylbutanamido)pentanamide
SW218090-2
(s)-4-methyl-n-((s)-1-((s)-4-methyl-1-((r)-2-methyloxiran-2-yl)-1-oxopentan-2-ylamino)-1-oxo-3-phenylpropan-2-yl)-2-((s)-2-(2-morpholinoacetamido)-4-phenylbutanamido)pentanamide
carfilzomib (pr171)
(alphas)-alpha-[[2-(4-morpholinyl)acetyl]amino]benzenebutanoyl-l-leucyl-n-[(1s)-3-methyl-1-[[(2r)-2-methyl-2-oxiranyl]carbonyl]butyl]-l-phenylalaninamide
AS-17059
Q15366934
AMY4357
CCG-270405
NCGC00249613-11
carfilzomib; pr171
EX-A2037
NCGC00249613-08
NCGC00249613-13
nsc756640
nsc-756640
nsc758252
n-((2s)-2-((morpholin-4-ylacetyl)amino)-4-phenylbutanoyl)-l-leucyl-l-phenylalanin-n-((2s)-4-methyl-1-((2r)-2-methyloxiran-2-yl)-1-oxopentan-2-yl)amide
n-((2s)-2-((morpholin-4-ylacetyl)amino)-4-phenylbutanoyl)-l-leucyl-n-((2s)-4-methyl-1-((2r)-2-methyloxiran-2-yl)-1-oxopentan-2-yl)-l-phenylalaninamide
l01xx45
carfilzomibum

Research Excerpts

Overview

Carrilzomib (CFZ) is an FDA-approved proteasome inhibitor with antineoplastic properties against various cancers. Its short blood retention time after intravenous injection makes clinical applications limited to multiple myeloma.

ExcerptReferenceRelevance
"Carfilzomib (CFZ) is an FDA-approved proteasome inhibitor with antineoplastic properties against various cancers, yet its short blood retention time after intravenous injection (< 30 min) makes clinical applications limited to multiple myeloma. "( Effects of Organic Acids on Drug Release From Ternary Polypeptide Nanoparticles Entrapping Carfilzomib.
Agbana, P; Bae, Y; Jackson, S; Kim, KB, 2022)		2.38
"Carfilzomib is a proteasome inhibitor widely used for the treatment of multiple myeloma. "( Evaluation of Cardiac Adverse Events Associated with Carfilzomib Using a Japanese Real-World Database.
Nakao, S; Okamoto, K; Satoki, A; Shimizu, T; Uchida, M; Uesawa, Y, 2022)		2.41
"Carfilzomib is a first-line proteasome inhibitor indicated for relapsed/refractory multiple myeloma (MM), with its clinical use being hampered by cardiotoxic phenomena. "( Elucidating Carfilzomib's Induced Cardiotoxicity in an In Vivo Model of Aging: Prophylactic Potential of Metformin.
Andreadou, I; Chatzistefanou, M; Davos, CH; Dimopoulos, MA; Efentakis, P; Gavriatopoulou, M; Nikolaou, PE; Papanagnou, ED; Psarakou, G; Terpos, E; Trougakos, IP; Varela, A, 2021)		2.44
"Carfilzomib (CFZ) is a new-generation proteasome inhibitor and has been found to affect bone metabolism."( Carfilzomib alleviated osteoporosis by targeting PSME1/2 to activate Wnt/β-catenin signaling.
Attarilar, S; Han, C; Huang, K; Lan, C; Li, K; Liu, J; Mozafari, M; Tang, Y; Wang, C; Wang, L; Xie, K; Yang, C; Zhang, F, 2022)		2.89
"Carfilzomib is a selective proteasome inhibitor approved to treat selected patients with Multiple Myeloma (MM)."( Carfilzomib-induced thrombotic microangiopathy. A case report.
Alterini, B; Cesaroni, E; Merilli, I; Scheggi, V, 2022)		2.89
"Carfilzomib is a last generation proteasome inhibitor (PI) with proven clinical efficacy in the treatment of relapsed/refractory multiple myeloma. "( Insulin-Degrading Enzyme Is a Non Proteasomal Target of Carfilzomib and Affects the 20S Proteasome Inhibition by the Drug.
Atzori, MG; Bellia, F; Cascio, P; Coletta, M; Grasso, G; Graziani, G; Macari, G; Marini, S; Milardi, D; Oddone, F; Parravano, M; Polticelli, F; Santoro, AM; Sbardella, D; Tundo, GR, 2022)		2.41
"Carfilzomib is a second-generation inhibitor and was developed to decrease the side effects of bortezomib."( Combination of Second-Generation Proteasome Inhibitor Carfilzomib with Bortezomib in Four Different Breast Cancer Cell Lines.
Altundag, EM; Sahin, A; Yilmaz, AM; Yilmaz, BK, 2022)		1.69
"Carfilzomib is a selective proteosome inhibitor that is commonly used in the treatment of relapsed or refractory multiple myeloma. "( Severe pulmonary toxicity related to carfilzomib use: a rare but serious side effect.
Bhama, S; Kachira, JJ; Sridhar, A; Yohannan, B, 2022)		2.44
"Carfilzomib is a medicine that was recently approved for the treatment of cancer of bone marrow (multiple myeloma) that comes back or does not respond to previous treatment (relapsed or refractory). "( Post-marketing surveillance of carfilzomib in Japanese patients with relapsed or refractory multiple myeloma.
Chou, T; Kawasaki, A; Kizaki, M; Matsushita, M; Murakami, H, 2022)		2.45
"Carfilzomib (CFZ) is a second-generation proteasome inhibitor effective in blood cancer therapy. "( Size optimization of carfilzomib nanocrystals for systemic delivery to solid tumors.
Armstrong, AT; Fathalla, D; Gadalla, HH; Habib, F; Jeong, H; Kim, H; Lee, S; Lee, W; Yeo, Y, 2022)		2.48
"Carfilzomib (Cfz) is an anti-cancer drug related to cardiorenal adverse events, with cardiovascular and renal complications limiting its clinical use. "( An Untargeted Metabolomics Approach on Carfilzomib-Induced Nephrotoxicity.
Andreadou, I; Barla, I; Dimopoulos, MA; Efentakis, P; Gavriatopoulou, M; Gikas, E; Lamprou, S; Terpos, E; Thomaidis, N, 2022)		2.43
"Carfilzomib (CFZ) is an anticancer medication acting as a selective proteasome inhibitor. "( Zingerone Attenuates Carfilzomib-Induced Cardiotoxicity in Rats through Oxidative Stress and Inflammatory Cytokine Network.
Adawi, MM; Ahmed, RA; Alam, MF; Algassmi, SM; Alqahtani, SS; Alshahrani, S; Anwer, T; Hijri, SI; Jali, AM; Moni, SS; Shaheen, ES, 2022)		2.48
"Carfilzomib (CFZ) is a proteasome inhibitor approved for relapsed/refractory multiple myeloma (MM) but its clinical use is limited by cardiovascular toxicity. "( Canagliflozin mitigates carfilzomib-induced endothelial apoptosis via an AMPK-dependent pathway.
Abdelgawad, IY; Dabour, MS; El-Sawaf, ES; Grant, MKO; Zordoky, BN, 2023)		2.66
"Carfilzomib is a second-generation selective proteasome inhibitor that is commonly used in the treatment of relapsed or refractory multiple myeloma. "( Carfilzomib-induced life-threatening lung injury in refractory multiple myeloma.
Alshurafa, A; Benkhadra, M; Elsabah, H; Ghasoub, R; Kassem, N, 2023)		3.8
"Carfilzomib is a selective proteasome inhibitor approved for treating relapsed or refractory multiple myeloma (RRMM). "( Risk factors associated with overall survival in patients with multiple myeloma following carfilzomib treatment: A retrospective study from a large claims database in Japan.
Fukuta, H; Hagiwara, H; Hashimoto, H; Iida, S; Ikuta, K; Kamiya, T; Kusumoto, S; Nakayama, T, 2023)		2.57
"(1) Carfilzomib (Cfz) is an antineoplastic agent indicated for the treatment of multiple myeloma. "( Metabolomics Point out the Effects of Carfilzomib on Aromatic Amino Acid Biosynthesis and Degradation.
Andreadou, I; Barla, I; Dimopoulos, MA; Efentakis, P; Gavriatopoulou, M; Gikas, E; Lamprou, S; Terpos, E; Thomaidis, N, 2023)		1.74
"Carfilzomib (CFZ) is a second-generation proteasome inhibitor approved for treating relapsed/refractory multiple myeloma (MM). "( A6 Peptide-Tagged Core-Disulfide-Cross-Linked Micelles for Targeted Delivery of Proteasome Inhibitor Carfilzomib to Multiple Myeloma In Vivo.
Cheng, R; Wang, X; Zhang, C; Zhong, Z, 2020)		2.22
"Carfilzomib is an irreversible proteasome inhibitor currently approved for the treatment of relapsed multiple myeloma. "( Carfilzomib-induced Thrombotic Microangiopathy: A Case Based Review.
Ahluwalia, J; Jain, A; Jandial, A; Jindal, N; Khadwal, A; Lad, D; Malhotra, P; Nada, R; Prakash, G; Sethi, J, 2023)		3.8
"Carfilzomib (CFZ) is a non-reversible proteasome inhibitor approved for the treatment of patients with relapsed and refractory myeloma (RRMM). "( Carfilzomib-associated renal toxicity is common and unpredictable: a comprehensive analysis of 114 multiple myeloma patients.
Delavinia, C; Dialoupi, I; Dimopoulos, MA; Efstathiou, K; Eleutherakis-Papaiakovou, E; Fotiou, D; Gakiopoulou, C; Gavriatopoulou, M; Giannouli, S; Kanellias, N; Kastritis, E; Kontogiannis, S; Migkou, M; Psimenou, E; Roussou, M; Terpos, E, 2020)		3.44
"Carfilzomib is a second-generation irreversible proteasome inhibitor that is efficacious in the treatment of myeloma and carries less risk of peripheral neuropathy than first-generation proteasome inhibitors, making it more amenable to combination therapy."( Carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide (KRdc) as induction therapy for transplant-eligible, newly diagnosed multiple myeloma patients (Myeloma XI+): Interim analysis of an open-label randomised controlled trial.
Cairns, DA; Collett, C; Cook, G; Davies, FE; de Tute, RM; Drayson, MT; Garg, M; Gregory, WM; Hockaday, A; Jackson, GH; Jenner, MW; Jones, JR; Kaiser, MF; Karunanithi, K; Kishore, B; Lindsay, J; Morgan, GJ; Owen, RG; Pawlyn, C; Rocci, A; Russell, NH; Snowden, JA; Williams, CD, 2021)		3.51
"Carfilzomib (CFZ) is a new proteasome inhibitor used for the treatment of multiple myeloma. "( Spasmogenic Effects of the Proteasome Inhibitor Carfilzomib on Coronary Resistance, Vascular Tone and Reactivity.
Chen-Scarabelli, C; Corsetti, G; Dioguardi, FS; Gavazzoni, M; Knight, R; Narula, J; Pasini, E; Patel, H; Raddino, R; Sahni, G; Saravolatz, L; Scarabelli, TM, 2017)		2.15
"Carfilzomib is a second-generation proteasome inhibitor that binds selectively and irreversibly with the chymotrypsin-like site of the proteolytic core. "( An overview of the role of carfilzomib in the treatment of multiple myeloma.
Dimopoulos, MA; Kastritis, E; Terpos, E; Ziogas, DC, 2017)		2.19
"Carfilzomib is a second-generation proteasome inhibitor (PI) that is approved for patients with relapsed or refractory multiple myeloma (RRMM) who failed ≥1 prior lines of therapy. "( Cardiotoxicity associated with carfilzomib: systematic review and meta-analysis.
Bejjanki, H; Bishnoi, R; Jain, A; Moreb, JS; Shah, C; Wang, Y; Xiong, S; Zou, F, 2018)		2.21
"Carfilzomib is a next-generation proteasome inhibitor shown to improve both progression-free and overall survival in relapsed and refractory multiple myeloma in combination with lenalidomide and dexamethasone (KRd)."( Proteasome inhibitor-based therapy for treatment of newly diagnosed multiple myeloma.
Vandross, A, 2017)		1.18
"Carfilzomib is a newer drug approved for the treatment of relapsing and refractory multiple myeloma. "( A case of acute liver failure due to carfilzomib in multiple myeloma.
Kathi, PR; Kundumadam, S; Mutchnick, M; Naylor, P; Tama, M, 2018)		2.2
"Carfilzomib is a selective proteasome inhibitor approved for the treatment of relapsed and/or refractory multiple myeloma (RRMM). "( Analysis of carfilzomib cardiovascular safety profile across relapsed and/or refractory multiple myeloma clinical trials.
Banchs, J; Batty, GN; Chari, A; Groarke, J; Hajek, R; Herrmann, J; Huang, M; Iskander, KS; Lenihan, D; Lyon, AR; Moreau, P; Ro, S; Russell, SD; Stewart, AK, 2018)		2.3
"Carfilzomib (CFZ) is a potent, second-generation proteasome inhibitor (PI), with significant activity as a single agent and in combination with other antimyeloma agents in patients with relapsed or refractory multiple myeloma (RRMM). "( Carfilzomib.
Ajayi, S; Dold, SM; Engelhardt, M; Müller, SJ; Scheubeck, S; Szymaniak-Vits, M; Wäsch, R, )		3.02
"Carfilzomib (CFZ) is a second-generation, selective PI approved in 2012 for the treatment of relapsed/refractory multiple myeloma (RRMM) in patients who received 2 prior therapies or have evidence of disease progression within 60 days of completion of last therapy."( Carfilzomib Induced Tumor Lysis Syndrome and Other Adverse Events.
Sandy, EB; Terjanian, T; Weerasinghe, C, 2020)		2.72
"Carfilzomib is a next-generation proteasome inhibitor that has shown promising results against refractory adult hematological malignancies."( Targeting the Proteasome in Refractory Pediatric Leukemia Cells: Characterization of Effective Cytotoxicity of Carfilzomib.
Anderson, R; Boklan, J; Jayanthan, A; Narendran, A; Ruan, Y; Swift, L; Trippett, T, 2018)		1.41
"Carfilzomib (Kyprolis™) is a new proteasome inhibitor that shows promise for the treatment of relapsing multiple myeloma."( Apremilast ameliorates carfilzomib-induced pulmonary inflammation and vascular injuries.
Al-Harbi, MM; Al-Harbi, NO; Alanazi, AZ; Alhazzani, K; Aljerian, K; Alsanea, S; Belali, OM; Imam, F; Qamar, W, 2019)		1.55
"Carfilzomib is a next-generation proteasome inhibitor with proven efficacy in relapsed/refractory MM. "( Carfilzomib-induced tumor lysis syndrome in relapsed multiple myeloma: a report of two cases.
Birtas Atesoglu, E; Eren, N; Gedük, A; Hacıhanefioğlu, A; Mehtap, O; Tarkun, P; Terzi Demirsoy, E, 2019)		3.4
"Carfilzomib (CFZ) is a proteasome inhibitor used for oncology indications including treating multiple myeloma. "( Carfilzomib Is Not an Appropriate Payload of Antibody-Drug Conjugates Due to Rapid Inactivation by Lysosomal Enzymes.
Dela Cruz-Chuh, J; Dragovich, PS; Khojasteh, SC; Ma, Y; Pillow, TH; Zhang, D, 2019)		3.4
"Carfilzomib is an effective upfront treatment option in AL patients with peripheral and/or autonomic neuropathy (without severe cardiac or renal involvement)."( Carfilzomib is an effective upfront treatment in AL amyloidosis patients with peripheral and autonomic neuropathy.
Cheesman, S; Gillmore, JD; Hawkins, PN; Kyriakou, C; Lachmann, HJ; Mahmood, S; Manwani, R; Popat, R; Rabin, N; Sachchithanantham, S; Shah, R; Sharpley, F; Smith, M; Wechalekar, AD; Worthington, S; Yong, K, 2019)		2.68
"Carfilzomib is a second-generation selective proteasome inhibitor that has been recently approved in the use for refractory multiple myeloma. "( Carfilzomib for the treatment of multiple myeloma.
Goel, S; Lue, J; Mazumder, A, 2013)		3.28
"Carfilzomib is a potent, selective, irreversible inhibitor of the ubiquitin-proteasome pathway."( Carfilzomib: a next-generation proteasome inhibitor for multiple myeloma treatment.
Bilotti, E, 2013)		2.55
"Carfilzomib (CFZ) is a more selective proteasome inhibitor that is structurally distinct from BTZ."( The novel proteasome inhibitor carfilzomib induces cell cycle arrest, apoptosis and potentiates the anti-tumour activity of chemotherapy in rituximab-resistant lymphoma.
Czuczman, MS; Czuczman, NM; Gu, JJ; Hernandez-Ilizaliturri, FJ; Kaufman, GP; Mavis, C; Skitzki, JJ, 2013)		1.4
"Carfilzomib is a second-generation proteasome inhibitor, demonstrating promising results in relapsed/refractory (RR) and newly diagnosed (ND) MM patients."( The mechanism of action, pharmacokinetics, and clinical efficacy of carfilzomib for the treatment of multiple myeloma.
Bringhen, S; Cerrato, C; Magarotto, V; Palumbo, A; Pautasso, C, 2013)		1.35
"Carfilzomib is a new agent for the treatment of relapsed and refractory multiple myeloma (MM). "( Carfilzomib: a novel agent for multiple myeloma.
Redic, K, 2013)		3.28
"Carfilzomib is a selective proteasome inhibitor that differs structurally and mechanistically from bortezomib. "( Carfilzomib: a novel agent for multiple myeloma.
Redic, K, 2013)		3.28
"Carfilzomib is a proteasome inhibitor that selectively and irreversibly binds to its target, resulting in sustained inhibition absent of off-target effects relative to bortezomib. "( The emerging role of carfilzomib combination therapy in the management of multiple myeloma.
Moreau, P, 2014)		2.16
"Carfilzomib is a proteasome inhibitor that binds selectively and irreversibly to its target. "( Evolution of carfilzomib dose and schedule in patients with multiple myeloma: a historical overview.
Jakubowiak, AJ, 2014)		2.21
"Carfilzomib is a second-generation epoxyketone proteasome inhibitor that is approved for treatment of relapsed and refractory multiple myeloma. "( Carfilzomib-related acute kidney injury may be prevented by N-acetyl-L-cysteine.
Jhaveri, KD; Khan, S; Kolitz, JE; Wanchoo, R, 2015)		3.3
"Carfilzomib is a neuropathy-sparing proteasome inhibitor."( Carfilzomib, rituximab, and dexamethasone (CaRD) treatment offers a neuropathy-sparing approach for treating Waldenström's macroglobulinemia.
Cao, Y; Castillo, JJ; Chuma, S; Ghobrial, IM; Hunter, ZR; Kanan, S; Liu, X; Meid, K; Patterson, CJ; Sheehy, P; Treon, SP; Tripsas, CK; Turnbull, B; Warren, D; Xu, L; Yang, G, 2014)		2.57
"Carfilzomib (CFZ) is a novel proteasome inhibitor that has been recently approved by the FDA and is in clinical use for the treatment of multiple myeloma, but little is known about its activity against CRC."( Enhanced anti-colorectal cancer effects of carfilzomib combined with CPT-11 via downregulation of nuclear factor-κB in vitro and in vivo.
Chen, Q; Chen, S; Huang, C; Li, J; Liao, J; Liu, F; Su, G; Tang, W; Ye, Y, 2014)		1.39
"Carfilzomib is a selective proteasome inhibitor approved in the United States as a single agent for the treatment of relapsed and refractory MM."( Incidence and management of renal adverse events in patients with relapsed and/or refractory multiple myeloma treated with single-agent carfilzomib.
Shah, JJ, 2013)		1.31
"Carfilzomib is a selective proteasome inhibitor that was recently approved in the United States for the treatment of patients with relapsed and/or refractory MM who had received two or more prior therapies, including bortezomib and an immunomodulatory agent, and who demonstrated disease progression within 60 days of completion of the last therapy."( Overview and management of cardiac and pulmonary adverse events in patients with relapsed and/or refractory multiple myeloma treated with single-agent carfilzomib.
Cheng, J; Wang, M, 2013)		1.31
"Carfilzomib is an irreversible inhibitor of the constitutive proteasome and immunoproteasome. "( Phase I study of 30-minute infusion of carfilzomib as single agent or in combination with low-dose dexamethasone in patients with relapsed and/or refractory multiple myeloma.
Badros, A; Holahan, JR; Lee, P; Lee, S; Papadopoulos, KP; Rosen, ST; Siegel, DS; Vesole, DH; Wang, Z; Zojwalla, N, 2015)		2.13
"Carfilzomib is a novel irreversible proteasome inhibitor (PI) used with increasing frequency to treat patients with relapsed and/or refractory multiple myeloma (RRMM). "( Patterns of cardiac toxicity associated with irreversible proteasome inhibition in the treatment of multiple myeloma.
Carver, J; Cornell, RF; Grandin, EW; Ky, B; Lenihan, DJ, 2015)		1.86
"Carfilzomib is a selective proteasome inhibitor approved in the United States in 2012 for the treatment of relapsed and refractory multiple myeloma. "( Case series discussion of cardiac and vascular events following carfilzomib treatment: possible mechanism, screening, and monitoring.
Chari, A; Hajje, D, 2014)		2.08
"Carfilzomib (CFZ) is a proteasome inhibitor that selectively and irreversibly binds to its target and has been approved in the US for treatment of relapsed and refractory multiple myeloma. "( Carfilzomib demonstrates broad anti-tumor activity in pre-clinical non-small cell and small cell lung cancer models.
Anderl, JL; Baker, AF; Carbajal, L; Garland, LL; Hanke, NT; Sands, BJ, 2014)		3.29
"Carfilzomib is a potent proteasome inhibitor which induces rapid chronic lymphocytic leukemia (CLL) cell apoptosis in vitro."( Phase I dose escalation trial of the novel proteasome inhibitor carfilzomib in patients with relapsed chronic lymphocytic leukemia and small lymphocytic lymphoma.
Andritsos, LA; Awan, FT; Byrd, JC; Chase, W; Flynn, JM; Jiang, Y; Jones, JA; Ling, Y; Lucas, DM; Lucas, MS; Maddocks, KJ; Phelps, MA; Sass, EJ; Waymer, S; Woyach, JA, 2015)		1.38
"Carfilzomib is an irreversible inhibitor and binds to a different site than bortezomib on the proteasome."( Carfilzomib: a second-generation proteasome inhibitor for the treatment of multiple myeloma.
Klaus, JO; McBride, A; Stockerl-Goldstein, K, 2015)		2.58
"Carfilzomib (CFZ) is a second generation proteasome inhibitor approved for the treatment of patients with multiple myeloma. "( The novel proteasome inhibitor carfilzomib activates and enhances extrinsic apoptosis involving stabilization of death receptor 5.
Deng, J; Han, B; Khuri, FR; Li, S; Oh, YT; Sun, SY; Tong, JS; Yao, W; Yue, P, 2015)		2.15
"Carfilzomib (Kyprolis™) is a second-generation proteasome inhibitor for the treatment of relapsing multiple myeloma (MM). "( Fatal pulmonary toxicity due to carfilzomib (Kyprolis™).
Lataifeh, AR; Nusair, A, 2016)		2.16
"Carfilzomib is a proteasome inhibitor that irreversibly binds to its target, resulting in sustained proteasomal inhibition with minimal off-target effects. "( Carfilzomib for the treatment of patients with relapsed and/or refractory multiple myeloma.
Stewart, AK, 2015)		3.3
"Carfilzomib (CFZ) is a second-generation proteasome inhibitor drug approved for the treatment of multiple myeloma. "( Polymer micelle formulations of proteasome inhibitor carfilzomib for improved metabolic stability and anticancer efficacy in human multiple myeloma and lung cancer cell lines.
Ao, L; Bae, Y; Hu, D; Jeong, H; Kim, KB; Lee, W; Reichel, D, 2015)		2.11
"Carfilzomib (CFZ), is a second-generation proteasome inhibitor, used to treat relapsed and refractory MM."( Carfilzomib enhances natural killer cell-mediated lysis of myeloma linked with decreasing expression of HLA class I.
Gao, L; Gao, M; Han, Y; Kong, Y; Meng, X; Shi, J; Tao, Y; Wu, H; Wu, X; Xu, H; Yang, G; Zhan, F; Zhang, Y, 2015)		2.58
"Carfilzomib is a proteasome inhibitor, commonly used in multiple myeloma, but its clinical use may be limited due to cardiotoxicity. "( Rutin Attenuates Carfilzomib-Induced Cardiotoxicity Through Inhibition of NF-κB, Hypertrophic Gene Expression and Oxidative Stress.
Afzal, M; Al-Harbi, NO; Al-Harbia, MM; Ansari, MA; Bahashwan, S; Imam, F; Iqbal, M; Kazmi, I; Khalid Anwer, M; Korashy, HM; Nagi, MN; Sayed-Ahmed, MM, 2017)		2.24
"Carfilzomib is a proteasome inhibitor and immunomodulator used to treat patients with multiple myeloma who have disease progression refractory to bortezomib. "( Heart failure secondary to carfilzomib-induced heart block in multiple myeloma patients.
Gupta, AK; Tjionas, H, 2017)		2.19
"Carfilzomib (CFZ) is an inhibitor of proteasome that is generally used in the treatment of multiple myeloma but due to its cardiotoxicity clinical use may be limited. "( Carfilzomib-induced cardiotoxicity mitigated by dexrazoxane through inhibition of hypertrophic gene expression and oxidative stress in rats.
Al-Harbi, NO, 2016)		3.32
"Carfilzomib is a proteasome inhibitor that is approved for use as a single agent in patients with relapsed and refractory multiple myeloma and when used in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma (1-3 prior lines of therapy). "( Management of Carfilzomib-Associated Cardiac Adverse Events.
Mikhael, J, 2016)		2.24
"Carfilzomib (Kyprolis®) is a proteasome inhibitor that binds selectively and irreversibly to the 20S proteasome (the proteolytic core particle within the 26S proteasome), inducing growth arrest and apoptosis. "( Carfilzomib Triple Combination Therapy: A Review in Relapsed Multiple Myeloma.
Hoy, SM, 2016)		3.32
"Carfilzomib is a selective proteosome inhibitor approved for treatment of relapsed and refractory multiple myeloma. "( Carfilzomib: A cause of drug associated thrombotic microangiopathy.
Adamski, J; Chakkera, HA; Fonseca, R; Qaqish, I; Schlam, IM, 2016)		3.32
"Carfilzomib (CFZ) is a second-generation proteasome inhibitor that is Food and Drug Administration and European Commission approved for the treatment of relapsed or refractory multiple myeloma. "( Specificity of Protein Covalent Modification by the Electrophilic Proteasome Inhibitor Carfilzomib in Human Cells.
Albertolle, ME; Codreanu, SG; Federspiel, JD; Goyal, S; Guengerich, FP; Liebler, DC; Lowe, E; Teague, J; Wong, H, 2016)		2.1
"Carfilzomib is an irreversible proteasome inhibitor that showed great efficacy in clinical studies."( Second Generation Proteasome Inhibitors in Multiple Myeloma.
Bocchia, M; Brambilla, CZ; Candi, V; Gozzetti, A; Papini, G; Sirianni, S, 2017)		1.18
"Carfilzomib (CFZ), is a potent, selective second generation proteasome inhibitor, used for the treatment of multiple myeloma. "( Apremilast reversed carfilzomib-induced cardiotoxicity through inhibition of oxidative stress, NF-κB and MAPK signaling in rats.
Ahmad, SF; Al-Harbi, MM; Al-Harbi, NO; Aljerian, K; Almukhlafi, TS; Almutairi, MM; Alshammari, M; Ansari, MA; Ansari, MN; Imam, F, 2016)		2.2
"Carfilzomib is a second-generation tetrapeptide epoxyketone proteasome inhibitor used in current clinical therapy of hematologic malignancies. "( Carfilzomib induces G2/M cell cycle arrest in human endometrial cancer cells via upregulation of p21
Luo, W; Wang, K; Wang, R; Zhen, S; Zhou, Y, 2016)		3.32
"Carfilzomib (CFZ) is a peptide epoxyketone proteasome inhibitor approved for the treatment of multiple myeloma (MM). "( Polymer micelle formulation for the proteasome inhibitor drug carfilzomib: Anticancer efficacy and pharmacokinetic studies in mice.
Bae, SK; Bae, Y; Chun, SE; Han, S; Kim, KB; Lee, HY; Lee, SC; Lee, W; Min, JS; Oh, Y; Park, JE; Park, SH; Reichel, D; Ryoo, G; Ryu, HM, 2017)		2.14
"Carfilzomib is a proteasome inhibitor in clinical development that primarily targets the chymotrypsin-like (CT-L) subunits in both the constitutive proteasome (c20S) and the immunoproteasome (i20S). "( Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome.
Aujay, M; Bennett, MK; Lee, SJ; Levitsky, K; Lorens, JB; Lu, Y; Micklem, DR; Parlati, F; Ruurs, P; Shenk, KD; Suzuki, E; Sylvain, C, 2009)		3.24
"Carfilzomib is an irreversible proteasome inhibitor with favorable toxicity profile (minimal neuropathy) and response rates of 17-54% depending on the disease stage treated."( Novel therapeutics in multiple myeloma.
Stewart, AK, 2012)		1.1
"Carfilzomib is a selective proteasome inhibitor that binds irreversibly to its target. "( An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma.
Alsina, M; Bahlis, NJ; Belch, A; Gabrail, NY; Jagannath, S; Jakubowiak, AJ; Kaufman, JL; Kukreti, V; Kunkel, LA; Lee, P; Lonial, S; Matous, JV; McDonagh, KT; Orlowski, RZ; Reu, FJ; Rosen, P; Sebag, M; Siegel, DS; Stewart, AK; Vesole, DH; Vij, R; Wang, M; Wear, SM; Wong, AF, 2012)		2.06
"Carfilzomib is a novel class of peptidyl epoxyketone proteasome inhibitor and has demonstrated promising activity in multiple clinical trials to treat patients with multiple myeloma and other types of cancers. "( Development of peptide-based reversing agents for p-glycoprotein-mediated resistance to carfilzomib.
Ao, L; Jang, ER; Kim, D; Kim, K; Kim, KB; Lee, DM; Lee, W; Wu, Y, 2012)		2.04
"Carfilzomib is a next-generation, selective, proteasome inhibitor with clinical activity in relapsed and/or refractory multiple myeloma. "( A phase I single-agent study of twice-weekly consecutive-day dosing of the proteasome inhibitor carfilzomib in patients with relapsed or refractory multiple myeloma or lymphoma.
Alsina, M; Comenzo, RL; Furman, RR; Goy, A; Kunkel, LA; Molineaux, CJ; O'Connor, OA; Rosen, PJ; Trudel, S; Wong, A, 2012)		2.04
"Carfilzomib is a next-generation, selective proteasome inhibitor being evaluated for the treatment of relapsed and refractory multiple myeloma. "( A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma.
Alsina, M; Bahlis, N; Buadi, F; Chanan-Khan, A; Jagannath, S; Jakubowiak, AJ; Kukreti, V; Kunkel, L; Lonial, S; Martin, T; Orlowski, RZ; Reu, FJ; Siegel, DS; Somlo, G; Song, K; Stadtmauer, E; Stewart, AK; Trudel, S; Vij, R; Wang, M; Wear, S; Wong, AF; Zonder, J, 2012)		2.11
"Carfilzomib is a next-generation proteasome inhibitor that selectively and irreversibly binds to its target. "( An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib.
Bahlis, N; Belch, A; Jagannath, S; Jakubowiak, AJ; Kunkel, LA; McDonagh, K; Siegel, DS; Stewart, AK; Vij, R; Wang, M; Wear, S; Wong, AF, 2012)		2.07
"Carfilzomib is a selective, irreversible inhibitor of the chymotrypsin-like activity of the proteasome and is undergoing clinical evaluation in myeloma. "( Carfilzomib and ONX 0912 inhibit cell survival and tumor growth of head and neck cancer and their activities are enhanced by suppression of Mcl-1 or autophagy.
Chan, ET; DeLancey, HM; Freilino, ML; Grandis, JR; Johnson, DE; Kirk, CJ; Li, C; Thomas, SM; Zang, Y, 2012)		3.26
"Carfilzomib is a next-generation proteasome inhibitor with single-agent activity in patients with relapsed and refractory multiple myeloma (R/R MM). "( Design and rationale of FOCUS (PX-171-011): a randomized, open-label, phase 3 study of carfilzomib versus best supportive care regimen in patients with relapsed and refractory multiple myeloma (R/R MM).
Bryce, R; Hájek, R; Klencke, B; Ludwig, H; Ro, S, 2012)		2.04
"Carfilzomib is a next-generation selective proteasome inhibitor that irreversibly binds its target and has demonstrated single-agent activity in patients with bortezomib-resistant multiple myeloma (MM). "( An open-label single-arm pilot phase II study (PX-171-003-A0) of low-dose, single-agent carfilzomib in patients with relapsed and refractory multiple myeloma.
Bahlis, N; Jagannath, S; Jakubowiak, AJ; Kunkel, LA; Lonial, S; Orlowski, RZ; Reiman, T; Siegel, DS; Somlo, G; Stewart, AK; Trudel, S; Vij, R; Wong, A, 2012)		2.04
"Carfilzomib is a new proteasome inhibitor that primarily targets the chymotrypsin-like activity of the 20S proteasome."( Carfilzomib: A new proteasome inhibitor for relapsed or refractory multiple myeloma.
Steele, JM, 2013)		2.55
"Carfilzomib is a new PI that differs in pharmacology and pharmacokinetics from bortezomib, the first-in-class PI. "( Carfilzomib: a second-generation proteasome inhibitor for the treatment of relapsed and refractory multiple myeloma.
Thompson, JL, 2013)		3.28
"Carfilzomib is a safe and effective new treatment option for patients with relapsed MM refractory to bortezomib and thalidomide or lenalidomide. "( Carfilzomib: a second-generation proteasome inhibitor for the treatment of relapsed and refractory multiple myeloma.
Thompson, JL, 2013)		3.28

Effects

Carrilzomib has a similar adverse-effect profile to bortezomib, including anemia, thrombocytopenia, fatigue, dyspnea, and nausea. It does not result in the development or worsening of peripheral neuropathy.

Carfilzomib (Cfz) has been associated with an ~5% incidence of unexplained and unpredictable cardiovascular toxicity in clinical trials. The drug has been approved for use in relapsed and refractory multiple myeloma (RRMM)

ExcerptReferenceRelevance
"Carfilzomib has a favorable benefit-risk profile in MM; adopting proactive practices can assist in the prevention, early detection, and management of carfilzomib-associated cardiovascular events, which may allow for continuation of therapy with this effective agent."( Cardiovascular events during carfilzomib therapy for relapsed myeloma: practical management aspects from two case studies.
DeCara, JM; Jakubowiak, AJ; Mezzi, K, 2017)		2.19
"Carfilzomib has a similar adverse-effect profile to bortezomib, including anemia, thrombocytopenia, fatigue, dyspnea, and nausea; however, it does not result in the development or worsening of peripheral neuropathy."( Carfilzomib: a second-generation proteasome inhibitor for the treatment of multiple myeloma.
Klaus, JO; McBride, A; Stockerl-Goldstein, K, 2015)		2.58
"Carfilzomib has shown excellent outcomes for relapsed Multiple Myeloma. "( Fatal pulmonary toxicity following Carfilzomib administration.
Gravalos, TL; Marschall, A; Merino, JCF, 2021)		2.34
"Carfilzomib has been commonly associated with respiratory side effects."( Severe pulmonary toxicity related to carfilzomib use: a rare but serious side effect.
Bhama, S; Kachira, JJ; Sridhar, A; Yohannan, B, 2022)		1.72
"Carfilzomib has been associated with the development of thrombotic microangiopathy (TMA) in relapsed/refractory multiple myeloma patients, a severe disease with no currently available aetiological treatment. "( Complement as the enabler of carfilzomib-induced thrombotic microangiopathy.
Bladé, J; Blasco, M; Campistol, JM; Carreras, E; Castro, P; Cibeira, MT; Diaz-Ricart, M; Fernández de Larrea, C; Fernández, S; Garcia-Herrera, A; Guillen, E; Jimenez, R; Martínez-Roca, A; Palomo, M; Poch, E; Quintana, LF; Rodríguez-Lobato, LG; Rosiñol, L; Tovar, N, 2021)		2.36
"Carfilzomib has been approved for use in relapsed and refractory multiple myeloma (RRMM). "( Incidence and risk of cardiac toxicities in patients with relapsed and refractory multiple myeloma treated with carfilzomib.
He, C; Liu, J; Wang, J; Xu, W; Yang, B; Yin, F; Zhang, R; Zhao, F, 2018)		2.13
"Carfilzomib has been extensively studied in adult hematological malignancies, providing the rationale for evaluating proof-of-concept activity of carfilzomib in pediatric leukemia."( Targeting the Proteasome in Refractory Pediatric Leukemia Cells: Characterization of Effective Cytotoxicity of Carfilzomib.
Anderson, R; Boklan, J; Jayanthan, A; Narendran, A; Ruan, Y; Swift, L; Trippett, T, 2018)		2.14
"Carfilzomib has been established in previous years as a treatment for patients with relapsed and/or refractory multiple myeloma (RR-MM). "( Efficacy and safety of salvage therapy using Carfilzomib for relapsed or refractory multiple myeloma patients: a multicentre retrospective observational study.
Avivi, I; Chubar, E; Cohen, YC; Ganzel, C; Gatt, ME; Lavi, N; Magen, H; Muchtar, E; Raanani, P; Rouvio, O; Shevetz, O; Shochat, T; Suriu, C; Tadmor, T, 2016)		2.14
"Carfilzomib (Cfz) has been associated with an ~5% incidence of unexplained and unpredictable cardiovascular toxicity in clinical trials. "( Carfilzomib and the cardiorenal system in myeloma: an endothelial effect?
Belohlavek, M; Bergsagel, PL; Fonseca, R; Kortüm, KM; Luthi, J; Mayo, A; Mikhael, JR; Mookadam, F; Reeder, CB; Rosenthal, A; Stewart, AK, 2016)		3.32

Actions

Carrilzomib inhibits the chymotrypsin-like catalytic activity of the 20S proteasome core particle, which results in cell growth arrest and apoptosis.

ExcerptReferenceRelevance
"Carfilzomib can inhibit the growth of MCL cells, its inhibitory rate on the MCL cells is higher than that of Bortezomib."( [Effect of Carfilzomib on Proliferation and Apoptosis of Mantle Cell Lymphoma Cells].
Chen, JX; Chen, M; Jiang, GX; Li, DY; Liu, YC; Shi, XF, 2019)		2.35
"Carfilzomib displays high selectivity for and irreversibly inhibits the chymotrypsin-like catalytic activity of the 20S proteasome core particle, which results in cell growth arrest and apoptosis."( Carfilzomib: in relapsed, or relapsed and refractory, multiple myeloma.
McCormack, PL, 2012)		2.54

Treatment

Carrilzomib treatment reduced mitochondrial membrane potential, ATP production, and mitochondrial oxidative respiration and increased mitochondrial oxidative stress. CarfilZomib-based treatment is efficient in advanced multiple myeloma.

ExcerptReferenceRelevance
"Carfilzomib treatment reduced mitochondrial membrane potential, ATP production, and mitochondrial oxidative respiration and increased mitochondrial oxidative stress."( Carfilzomib Treatment Causes Molecular and Functional Alterations of Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes.
Forghani, P; Hwang, H; Lee, MR; Li, D; Liu, R; Mandawat, A; Maxwell, JT; Rashid, A; Salaita, K; Sun, F; Wu, R; Xu, C, 2021)		2.79
"Carfilzomib treatment was applied after a median of 3 (range: 1-7) therapy lines."( Carfilzomib-induced hemolysis is noticeably common but rarely shows features of thrombotic microangiopathy: A retrospective study.
Åström, M; Kameran Behnam, K; Kozlowski, P; Uggla, B, 2020)		2.72
"Carfilzomib treatment may lead to rapid and deep responses, irrespective of most patient characteristics."( Efficacy and safety profile of deep responders to carfilzomib-based therapy: a subgroup analysis from ASPIRE and ENDEAVOR.
Cook, G; DeCosta, L; Delforge, M; Desgraz, R; Gay, F; Mateos, MV; Moreau, P; Szabo, Z; Weisel, K, 2021)		1.6
"Carfilzomib treatment of mice with established, widely metastatic disease significantly increased their survival, without significant toxicity."( Carfilzomib is an effective anticancer agent in anaplastic thyroid cancer.
Boufraqech, M; Kebebew, E; Mehta, A; Patel, D; Shen, M; Zhang, L; Zhang, Y, 2015)		2.58
"Carfilzomib-based treatment is efficient in advanced multiple myeloma. "( 'Real-life' experience of preapproval carfilzomib-based therapy in myeloma - analysis of cardiac toxicity and predisposing factors.
Danhof, S; Einsele, H; Knop, S; Rasche, L; Schreder, M; Strifler, S, 2016)		2.15
"Carfilzomib treatment significantly induced p21"( Carfilzomib induces G2/M cell cycle arrest in human endometrial cancer cells via upregulation of p21
Luo, W; Wang, K; Wang, R; Zhen, S; Zhou, Y, 2016)		2.6
"Treatment with carfilzomib was stopped permanently."( Carfilzomib-induced life-threatening lung injury in refractory multiple myeloma.
Alshurafa, A; Benkhadra, M; Elsabah, H; Ghasoub, R; Kassem, N, 2023)		2.69
"Pretreatment with carfilzomib reduced in vivo metastases (lung, bone, liver, and kidney) and disease progression, and decreased N-cadherin expression."( Carfilzomib is an effective anticancer agent in anaplastic thyroid cancer.
Boufraqech, M; Kebebew, E; Mehta, A; Patel, D; Shen, M; Zhang, L; Zhang, Y, 2015)		2.18

Toxicity

Carfilzomib (Cfz) is an anti-cancer drug related to cardiorenal adverse events, with cardiovascular and renal complications limiting its clinical use. Adverse events of grade 3 or worse that occurred with a higher incidence were dyspnea, hypertension, acute kidney injury, and heart failure. The temporal relationship between the first exposure to carfilZomib and development of symptoms, and the exclusion of other possible etiologies, leads us to believe that our patient's lung toxicity is a possible adverse reaction.

ExcerptReferenceRelevance
" Grade 3/4 adverse events (AEs) included anemia (28."( Carfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safety.
Badros, AZ; Kunkel, L; Lee, S; Martin, T; Niesvizky, R; Vij, R; Wang, Z; Wong, AF; Zonder, JA, 2013)		1.83
" Overall analyses of adverse events and treatment modifications are presented, as well as specific analyses of adverse events by organ system."( Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies.
Badros, AZ; Harvey, RD; Jagannath, S; Lonial, S; Martin, T; McCulloch, L; Niesvizky, R; Nooka, A; Rajangam, K; Siegel, D; Vij, R, 2013)		0.65
"Hematologic adverse events (AEs) are commonly encountered in patients with multiple myeloma (MM) owing to the nature of the disease and the adverse effects related to myeloma treatment."( Management of hematologic adverse events in patients with relapsed and/or refractory multiple myeloma treated with single-agent carfilzomib.
Nooka, AK, 2013)		0.6
"Patients with multiple myeloma (MM) frequently experience renal dysfunction owing to patient-specific risk factors, the pathophysiology of MM, and treatment-related adverse events."( Incidence and management of renal adverse events in patients with relapsed and/or refractory multiple myeloma treated with single-agent carfilzomib.
Shah, JJ, 2013)		0.59
" An understanding of the cardiopulmonary adverse events associated with anti-MM treatment is, therefore, an important component of therapy selection."( Overview and management of cardiac and pulmonary adverse events in patients with relapsed and/or refractory multiple myeloma treated with single-agent carfilzomib.
Cheng, J; Wang, M, 2013)		0.59
" Salvage therapy must be tailored according to an individual patient's clinical profile, with the risks and potential effects of treatment-related adverse events being major determinants of the choice of therapy."( Treatment-related adverse events in patients with relapsed/refractory multiple myeloma.
Vij, R, 2011)		0.37
" Safe readministration of carfilzomib with dose modification was possible in some cases."( Patterns of cardiac toxicity associated with irreversible proteasome inhibition in the treatment of multiple myeloma.
Carver, J; Cornell, RF; Grandin, EW; Ky, B; Lenihan, DJ, 2015)		0.72
"The temporal relationship between the first exposure to carfilzomib and development of symptoms, and the exclusion of other possible etiologies, leads us to believe that our patient's lung toxicity is a possible adverse reaction to carfilzomib."( Fatal pulmonary toxicity due to carfilzomib (Kyprolis™).
Lataifeh, AR; Nusair, A, 2016)		0.96
" Grade 3/4 adverse events (AEs) occurred in 50% of patients with 23% experiencing left ventricular failure."( 'Real-life' experience of preapproval carfilzomib-based therapy in myeloma - analysis of cardiac toxicity and predisposing factors.
Danhof, S; Einsele, H; Knop, S; Rasche, L; Schreder, M; Strifler, S, 2016)		0.71
" Furthermore, DZR also attenuated the effects of CFZ-induced toxic effect on redox markers such as malondialdehyde and reduced glutathione."( Carfilzomib-induced cardiotoxicity mitigated by dexrazoxane through inhibition of hypertrophic gene expression and oxidative stress in rats.
Al-Harbi, NO, 2016)		1.88
" Cardiac and cardiopulmonary adverse events have been reported to be associated with carfilzomib-based treatment regimens."( Management of Carfilzomib-Associated Cardiac Adverse Events.
Mikhael, J, 2016)		1.02
" In contrast, we demonstrate that the β5 equivalent LMP7 of the immunoproteasome represents a safe target for subunit-specific inhibitors in DOX-exposed cardiomyocytes."( Inhibition of chymotryptic-like standard proteasome activity exacerbates doxorubicin-induced cytotoxicity in primary cardiomyocytes.
Althof, N; Heuser, A; Klingel, K; Overkleeft, HS; Respondek, D; Spur, EM; Voigt, A, 2016)		0.43
" Group 2, served as the toxic group, received CFZ (4 mg/kg, intraperitoneally [i."( Apremilast reversed carfilzomib-induced cardiotoxicity through inhibition of oxidative stress, NF-κB and MAPK signaling in rats.
Ahmad, SF; Al-Harbi, MM; Al-Harbi, NO; Aljerian, K; Almukhlafi, TS; Almutairi, MM; Alshammari, M; Ansari, MA; Ansari, MN; Imam, F, 2016)		0.76
" Areas covered: This review focuses on the safety data from clinical trials for the three approved PIs and how to manage adverse effects."( Safety of proteasome inhibitors for treatment of multiple myeloma.
Lonial, S; Panjic, EH; Schlafer, D; Shah, KS, 2017)		0.46
" We focused on adverse events associated with such agents and described how they should be managed."( Management of adverse events induced by next-generation immunomodulatory drug and proteasome inhibitors in multiple myeloma.
Boccadoro, M; Bonello, F; Larocca, A; Salvini, M, 2017)		0.46
"In the last decade, the availability of new drugs for the treatment of Multiple Myeloma (MM) significantly improved patients' outcomes, but also raised attention towards a new spectrum of adverse events."( Safety issues and management of toxicities associated with new treatments for multiple myeloma.
Brioli, A; Hochhaus, A; Mügge, LO; Von Lilienfeld-Toal, M, 2017)		0.46
" Interestingly, several adverse effects are less common, compared to BTZ, in patients treated with CFZ."( Milder degenerative effects of Carfilzomib vs. Bortezomib in the Drosophila model: a link to clinical adverse events.
Bagratuni, T; Brieudes, V; Dimopoulos, MA; Florea, BI; Halabalaki, M; Kastritis, E; Overkleeft, HS; Papanagnou, ED; Scorrano, L; Skaltsounis, AL; Terpos, E; Trougakos, IP; Tsakiri, EN, 2017)		0.74
"Cardiovascular adverse events (CVAE) with carfilzomib in patients with multiple myeloma can be potentially life-threatening and remain incompletely characterized."( Carfilzomib-Associated Cardiovascular Adverse Events: A Systematic Review and Meta-analysis.
Carver, J; Clasen, S; Cohen, AD; Garfall, A; Hwang, WT; Ky, B; O'Quinn, R; Stadtmauer, EA; Vogl, DT; Waxman, AJ; Weiss, BM, 2018)		2.19
"Phase 1 to 3 prospective clinical trials of carfilzomib in patients with multiple myeloma with evaluable toxic effects data were eligible for meta-analysis."( Carfilzomib-Associated Cardiovascular Adverse Events: A Systematic Review and Meta-analysis.
Carver, J; Clasen, S; Cohen, AD; Garfall, A; Hwang, WT; Ky, B; O'Quinn, R; Stadtmauer, EA; Vogl, DT; Waxman, AJ; Weiss, BM, 2018)		2.18
"Cardiovascular adverse events were defined as heart failure, hypertension, ischemia, and arrhythmia."( Carfilzomib-Associated Cardiovascular Adverse Events: A Systematic Review and Meta-analysis.
Carver, J; Clasen, S; Cohen, AD; Garfall, A; Hwang, WT; Ky, B; O'Quinn, R; Stadtmauer, EA; Vogl, DT; Waxman, AJ; Weiss, BM, 2018)		1.92
" Carfilzomib (CFZ) has high selectivity and minimal off-target adverse effects including lower rates of PNP."( Efficacy and toxicity profile of carfilzomib based regimens for treatment of multiple myeloma: A systematic review.
Abraham, I; Anwer, F; Iftikhar, A; Kapoor, V; Latif, A; McBride, A; Mushtaq, A; Riaz, IB; Zahid, U, 2018)		1.67
" This analysis evaluated phase 1-3 trials with >2000 RRMM patients exposed to carfilzomib to describe the incidence of CV adverse events (AEs)."( Analysis of carfilzomib cardiovascular safety profile across relapsed and/or refractory multiple myeloma clinical trials.
Banchs, J; Batty, GN; Chari, A; Groarke, J; Hajek, R; Herrmann, J; Huang, M; Iskander, KS; Lenihan, D; Lyon, AR; Moreau, P; Ro, S; Russell, SD; Stewart, AK, 2018)		1.09
" Its safety profile reported adverse events (AEs) ranging from drug-related AEs (nausea and vomiting), hematologic AEs (neutropenia and thrombocytopenia), and nonhematologic AEs (electrolyte imbalances)."( Carfilzomib Induced Tumor Lysis Syndrome and Other Adverse Events.
Sandy, EB; Terjanian, T; Weerasinghe, C, 2020)		2
" However, carfilzomib-related cardiovascular adverse events (CVAEs) - including hypertension (all grades: 12."( Prevention, monitoring and treatment of cardiovascular adverse events in myeloma patients receiving carfilzomib A consensus paper by the European Myeloma Network and the Italian Society of Arterial Hypertension.
Auner, HW; Boccadoro, M; Bringhen, S; Caers, J; Cavo, M; D'Agostino, M; Dimopoulos, MA; Driessen, C; Einsele, H; Engelhardt, M; Ferri, C; Gay, F; Goldschmidt, H; Gramatzki, M; Larocca, A; Ludwig, H; Milan, A; Offidani, M; Sonneveld, P; Terpos, E; Wäsch, R; Zweegman, S, 2019)		1.13
" Exposure-adjusted incidences per 100 patient-years of adverse events (AEs) were 1352."( Carfilzomib-Dexamethasone Versus Bortezomib-Dexamethasone in Relapsed or Refractory Multiple Myeloma: Updated Overall Survival, Safety, and Subgroups.
Chng, WJ; Dimopoulos, M; Goldschmidt, H; Kimball, AS; Ludwig, H; Moreau, P; Niesvizky, R; Oriol, A; Orlowski, RZ; Yang, Z, 2019)		1.96
"Cardiovascular adverse events (CVAEs) are of considerable importance in patients with multiple myeloma (MM), given the significant prevalence of coexisting cardiovascular risk factors and the potential treatment-induced toxicity."( Safe Use of Carfilzomib in a Patient with Multiple Myeloma and Intermittent Type 1 Brugada ECG Pattern: A Case Report.
Aglietta, M; Becco, P; Bonzano, A; Fizzotti, M; Gay, F; Ghisoni, E; Lombardi, P; Marandino, L; Rota Scalabrini, D, 2020)		0.94
" In this systematic review, associations of the efficacy of each approved regimen with adverse events (AEs) and the total cost per cycle were compared with a Bayesian network meta-analysis (NMA) of phase 3 randomized controlled trials (RCTs)."( Association of adverse events and associated cost with efficacy for approved relapsed and/or refractory multiple myeloma regimens: A Bayesian network meta-analysis of phase 3 randomized controlled trials.
Aryal, M; Chhabra, S; D'Souza, A; Dhakal, B; Ghose, S; Giri, S; Hamadani, M; Hari, PN; Janz, S; Narra, RK; Pathak, LK; Smunt, TL; Szabo, A, 2020)		0.56
" Kidney toxicity is an important adverse effect of carfilzomib-based regimens."( Risk of kidney toxicity with carfilzomib in multiple myeloma: a meta-analysis of randomized controlled trials.
Anwer, F; Ball, S; Behera, TR; Chakraborty, R, 2020)		1.1
"Carfilzomib's (Cfz) adverse events in myeloma patients include cardiovascular toxicity."( Investigating the Vascular Toxicity Outcomes of the Irreversible Proteasome Inhibitor Carfilzomib.
Andreadou, I; Dimopoulos, MA; Doerschmann, H; Efentakis, P; Kastritis, E; Nikolaou, PE; Siemer, S; Stauber, R; Terpos, E; Wenzel, P; Witzler, C, 2020)		2.22
" Despite the longer treatment duration, fewer patients with ≥CR versus VGPR/PR experienced treatment-emergent adverse events that led to discontinuation of carfilzomib-based treatment in ASPIRE or ENDEAVOR."( Efficacy and safety profile of deep responders to carfilzomib-based therapy: a subgroup analysis from ASPIRE and ENDEAVOR.
Cook, G; DeCosta, L; Delforge, M; Desgraz, R; Gay, F; Mateos, MV; Moreau, P; Szabo, Z; Weisel, K, 2021)		1.07
" Main grade 3-4 adverse events were neutropenia (21%), infections (11%), and hypertension (6%)."( A real-world efficacy and safety analysis of combined carfilzomib, lenalidomide, and dexamethasone (KRd) in relapsed/refractory multiple myeloma.
Antonioli, E; Barilà, G; Bonalumi, A; Buda, G; Cavo, M; Cea, M; di Giovanni Bezzi, C; Dozza, L; Furlan, A; Mancuso, K; Martello, M; Marzocchi, G; Pantani, L; Petrini, M; Quaresima, M; Rizzello, I; Rocchi, S; Scalese, M; Staderini, M; Tacchetti, P; Zamagni, E, 2021)		0.87
" In all 3 studies, rates of grade ≥3 treatment-emergent adverse events were consistent with those observed in the primary studies."( Efficacy and safety of carfilzomib-based regimens in frail patients with relapsed and/or refractory multiple myeloma.
Bringhen, S; Dimopoulos, MA; Facon, T; Goldrick, A; Ho, PJ; Klippel, Z; Kumar, S; Ludwig, H; Mateos, MV; Mezzi, K; Niesvizky, R; Obreja, M; Rosenbaum, C; Siegel, D; Tekle, C; Wang, K; Weisel, K; Yang, Z, 2020)		0.87
" With this study, we aim to further study the hazards and underlying risk factors for cardiovascular adverse events associated with carfilzomib."( Real-world experience of carfilzomib-associated cardiovascular adverse events: SEER-Medicare data set analysis.
Bian, J; Bishnoi, R; Farhadfar, N; Murthy, HS; Shah, C; Wingard, JR; Xie, Z, 2021)		1.13
"The ASPIRE and ENDEAVOUR trials have shown cardiovascular adverse effects in patients treated with carfilzomib-based regimens."( Incidence and Management of Carfilzomib-induced Cardiovascular Toxicity; A Systematic Review and Meta-analysis.
Ahmad, N; Ahsan, MJ; Anwer, F; Kapoor, V; Khouri, J; Lateef, N; Latif, A; Malik, SU; Rosko, N; Rudoni, J; Usman, RM; William, P, 2021)		1.13
" Most common (≥2 patients) grade 3 or 4 adverse events were neutropenia (12 patients [27%]), rash (4 patients [9%]), lung infection (3 patients [7%]), and increased alanine aminotransferase level (2 patients [4%])."( Safety and Effectiveness of Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma: The MANHATTAN Nonrandomized Clinical Trial.
Arcila, ME; Caple, J; Chansakul, A; Chung, DJ; Ciardello, A; Concepcion, I; Derkach, A; Diamond, B; Dogan, A; Giralt, SA; Harrison, A; Hassoun, H; Ho, C; Hultcrantz, M; Jones, K; Korde, N; Lahoud, OB; Landau, HJ; Landgren, O; Lesokhin, AM; Lu, SX; Maclaughlan, K; Mailankody, S; Maura, F; Murata, K; Piacentini, C; Ramanathan, L; Rispoli, J; Roshal, M; Rustad, EH; Salcedo, M; Sams, A; Schlossman, J; Scordo, M; Shah, G; Shah, UA; Shekarkhand, T; Tan, C; Tavitian, E; Thoren, K; Verducci, D; Werner, K; Yellapantula, V, 2021)		0.9
" However, cardiac adverse events (CAEs) are a serious side effect of carfilzomib administration."( Evaluation of Cardiac Adverse Events Associated with Carfilzomib Using a Japanese Real-World Database.
Nakao, S; Okamoto, K; Satoki, A; Shimizu, T; Uchida, M; Uesawa, Y, 2022)		1.21
"The purpose of this study was to identify the trends in carfilzomib-associated adverse events, the time to onset of CAEs, and the clinical outcomes after the occurrence of CAEs using the Japanese Adverse Drug Event Report (JADER) database."( Evaluation of Cardiac Adverse Events Associated with Carfilzomib Using a Japanese Real-World Database.
Nakao, S; Okamoto, K; Satoki, A; Shimizu, T; Uchida, M; Uesawa, Y, 2022)		1.22
"We analyzed data from the JADER database, which contains reports of spontaneous adverse events submitted to the Pharmaceutical and Medical Device Agency, between April 2004 and December 2020."( Evaluation of Cardiac Adverse Events Associated with Carfilzomib Using a Japanese Real-World Database.
Nakao, S; Okamoto, K; Satoki, A; Shimizu, T; Uchida, M; Uesawa, Y, 2022)		0.97
" The adverse events with the largest proportion of fatal clinical outcomes were acute heart failure (26%) and heart failure (9."( Evaluation of Cardiac Adverse Events Associated with Carfilzomib Using a Japanese Real-World Database.
Nakao, S; Okamoto, K; Satoki, A; Shimizu, T; Uchida, M; Uesawa, Y, 2022)		0.97
" The novel quadruplet combination was overall well-tolerated, with clinically manageable adverse events."( A phase 2 trial of the efficacy and safety of elotuzumab in combination with pomalidomide, carfilzomib and dexamethasone for high-risk relapsed/refractory multiple myeloma.
Berenson, JR; Eades, B; Eshaghian, S; Ghermezi, M; Lim, S; Martinez, D; Schwartz, G; Spektor, TM; Swift, RA; Vescio, R; Yashar, D, 2022)		0.94
" There have been increasing reports on cardiovascular adverse events."( Fatal pulmonary toxicity following Carfilzomib administration.
Gravalos, TL; Marschall, A; Merino, JCF, 2021)		0.9
" Adverse events of grade 3 or worse that occurred with a higher incidence in the carfilzomib-based regimens group compared with the bortezomib-based regimens group were dyspnea, hypertension, acute kidney injury, and heart failure."( Efficacy and toxicity of carfilzomib- or bortezomib-based regimens for treatment of transplant-ineligible patients with newly diagnosed multiple myeloma: A meta-analysis.
Huang, J; Liu, Q; Wei, M; Wu, F; Xie, C; Yang, F, 2022)		1.25
"Carfilzomib (Cfz) is an anti-cancer drug related to cardiorenal adverse events, with cardiovascular and renal complications limiting its clinical use."( An Untargeted Metabolomics Approach on Carfilzomib-Induced Nephrotoxicity.
Andreadou, I; Barla, I; Dimopoulos, MA; Efentakis, P; Gavriatopoulou, M; Gikas, E; Lamprou, S; Terpos, E; Thomaidis, N, 2022)		2.43

Pharmacokinetics

ExcerptReferenceRelevance
" Carfilzomib displayed high plasma clearance [195-319 ml/(min · kg)], a short-terminal half-life (5-20 min), and rapid and wide tissue distribution in rats."( Pharmacokinetics, pharmacodynamics, metabolism, distribution, and excretion of carfilzomib in rats.
Bennett, MK; Fang, Y; Jiang, J; Kirk, CJ; Molineaux, CJ; Wang, Z; Wong, H; Yang, J; Zhao, F, 2011)		1.51
" The systemic half-life was short and the systemic clearance rate was higher than hepatic blood flow."( Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib.
Alsina, M; Badros, A; Bomba, D; Fang, Y; Infante, JR; Kirk, C; Li, J; Papadopoulos, K; Wang, Z; Wong, A; Woo, T; Yang, J, 2013)		0.63
" Here, we prepared the CFZ-loaded PM, PEG-PCL-deoxycholic acid (CFZ-PM) and assessed its in vivo anticancer efficacy and pharmacokinetic profiles."( Polymer micelle formulation for the proteasome inhibitor drug carfilzomib: Anticancer efficacy and pharmacokinetic studies in mice.
Bae, SK; Bae, Y; Chun, SE; Han, S; Kim, KB; Lee, HY; Lee, SC; Lee, W; Min, JS; Oh, Y; Park, JE; Park, SH; Reichel, D; Ryoo, G; Ryu, HM, 2017)		0.7
" Additionally, a population pharmacokinetic (PK) analysis and simulations were used to compare the PK profiles of the split first dose regimen with the recommended single first dose regimens of daratumumab in previously approved indications."( Split First Dose Administration of Intravenous Daratumumab for the Treatment of Multiple Myeloma (MM): Clinical and Population Pharmacokinetic Analyses.
Bladé, J; Clemens, PL; Deraedt, W; Jakubowiak, A; Krishnan, A; Lonial, S; Luo, M; Moreau, P; Nnane, I; Oriol, A; Qi, M; Sun, YN; Ukropec, J; Usmani, SZ; Xu, XS; Zhou, H, 2020)		0.56

Compound-Compound Interactions

Carfilzomib in combination with bendamustine and rituximab is a safe and well-tolerated treatment for patients with relapsed/refractory non-Hodgkin lymphoma.

ExcerptReferenceRelevance
" Other research groups showed that histone deacetylase inhibitors (valproic acid or benzamide derivative MS-275) in combination with NPI-0052 or PR-171 induced greater levels of acute leukemia cell death than in combination with bortezomib."( Antiproliferative and proapoptotic effects of proteasome inhibitors and their combination with histone deacetylase inhibitors on leukemia cells.
Fuchs, O; Kuzelova, K; Marinov, I; Provaznikova, D; Spicka, I, 2009)		0.35
" Here we summarize the clinical pharmacokinetics (PK), metabolism, and drug-drug interaction (DDI) profile of carfilzomib."( Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib.
Alsina, M; Badros, A; Bomba, D; Fang, Y; Infante, JR; Kirk, C; Li, J; Papadopoulos, K; Wang, Z; Wong, A; Woo, T; Yang, J, 2013)		0.84
" As CC-292 did not show potent in vitro anti-MM activity, we next evaluated it in combination with the proteasome inhibitor, carfilzomib."( A novel Bruton's tyrosine kinase inhibitor CC-292 in combination with the proteasome inhibitor carfilzomib impacts the bone microenvironment in a multiple myeloma model with resultant antimyeloma activity.
Arastu-Kapur, S; Cirstea, DD; Eda, H; Evans, E; Kirk, CJ; Mishima, Y; Nemani, N; Raje, NS; Santo, L; Scullen, TA; Singh, J; Waterman, PR; Westlin, WF; Yee, AJ, 2014)		0.83
" The aim of the present study was to explore whether CFZ alone or in combination with CPT-11 is effective in CRC treatment."( Enhanced anti-colorectal cancer effects of carfilzomib combined with CPT-11 via downregulation of nuclear factor-κB in vitro and in vivo.
Chen, Q; Chen, S; Huang, C; Li, J; Liao, J; Liu, F; Su, G; Tang, W; Ye, Y, 2014)		0.67
" Safety and efficacy of carfilzomib as a single agent or in combination with low-dose dexamethasone were assessed."( Phase I study of 30-minute infusion of carfilzomib as single agent or in combination with low-dose dexamethasone in patients with relapsed and/or refractory multiple myeloma.
Badros, A; Holahan, JR; Lee, P; Lee, S; Papadopoulos, KP; Rosen, ST; Siegel, DS; Vesole, DH; Wang, Z; Zojwalla, N, 2015)		0.99
" Additionally, carfilzomib was combined with low-dose dexamethasone (40 mg/wk)."( Phase I study of 30-minute infusion of carfilzomib as single agent or in combination with low-dose dexamethasone in patients with relapsed and/or refractory multiple myeloma.
Badros, A; Holahan, JR; Lee, P; Lee, S; Papadopoulos, KP; Rosen, ST; Siegel, DS; Vesole, DH; Wang, Z; Zojwalla, N, 2015)		1.04
" We here compare bortezomib with carfilzomib and LU-102 in MM and MCL in vitro with regard to their effects on pIκB/NF-κB signaling and their cytotoxic activity in combination with ibrutinib."( The novel β2-selective proteasome inhibitor LU-102 decreases phosphorylation of I kappa B and induces highly synergistic cytotoxicity in combination with ibrutinib in multiple myeloma cells.
Bader, J; Besse, L; de Bruin, G; Driessen, C; Geurink, PP; Kisselev, AF; Kraus, J; Kraus, M; Liu, N; Overkleeft, H, 2015)		0.7
"The use of carfilzomib/pomalidomide single-agent or in combination with other agents in patients with refractory/relapsed multiple myeloma (RRMM) was not clearly clarified in clinical practice."( Carfilzomib/pomalidomide single-agent or in combination with other agents for the management of relapsed/refractory multiple myeloma: a meta-analysis of 37 trials.
Fan, L; Hu, C; Ma, X; Ran, X; Yu, H; Zou, Y, 2017)		2.29
" Here, we found for the first time that carfizomib dramatically augmented ex vivo exp-NK cell cytotoxicity against patient autologous MM cells, suggesting the use of exp-NK alone or in combination with the drug to treat MM patient."( Carfilzomib combined with ex vivo-expanded patient autologous natural killer cells for myeloma immunotherapy.
Chang, SK; Chen, GG; Gao, L; Hou, J; Hu, LN; Kong, YY; Shi, JM; Tao, Y; Wu, HQ; Xiao, WQ; Xie, YS; Yu, DD, 2018)		1.92
"To predict the real-world (RW) cost-effectiveness of carfilzomib in combination with lenalidomide and dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd) in relapsed multiple myeloma (MM) patients after one to three prior therapies."( Methodology and results of real-world cost-effectiveness of carfilzomib in combination with lenalidomide and dexamethasone in relapsed multiple myeloma using registry data.
Agirrezabal, I; Campioni, M; Gonzalez-McQuire, S; Hajek, R; Jandova, P; Maisnar, V; Minarik, J; Pour, L; Spicka, I, 2020)		1.05
" Recently, Phase Ib and Phase III trials evaluated the triplet drug combination daratumumab-carfilzomib-dexamethasone in the relapse setting and demonstrated strong clinical efficacy, especially in lenalidomide refractory patients."( Carfilzomib in combination with daratumumab in the management of relapsed multiple myeloma.
Antier, C; Moreau, P; Touzeau, C, 2021)		2.28
"The protocol followed a 3+3 design of carfilzomib dose escalation combined with standard doses of bendamustine and rituximab."( Carfilzomib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma: A Phase I Trial.
Ai, WZ; Andreadis, CB; Aoun, C; Castillo, M; Cavallone, E; Crawford, E; Fakhri, B; Kambhampati, S; Kaplan, LD; Le, D; Martinelli, M; Padilla, M; Reiner, J; Sudhindra, A; Ta, T; Tuscano, JM; Wieduwilt, MJ, 2021)		2.34
"Carfilzomib in combination with bendamustine and rituximab is a safe and well-tolerated treatment for patients with relapsed/refractory non-Hodgkin lymphoma."( Carfilzomib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma: A Phase I Trial.
Ai, WZ; Andreadis, CB; Aoun, C; Castillo, M; Cavallone, E; Crawford, E; Fakhri, B; Kambhampati, S; Kaplan, LD; Le, D; Martinelli, M; Padilla, M; Reiner, J; Sudhindra, A; Ta, T; Tuscano, JM; Wieduwilt, MJ, 2021)		3.51
" We compared the activity of these proteasome inhibitors in combination with cyclophosphamide and dexamethasone (KCd vs."( Carfilzomib or bortezomib in combination with cyclophosphamide and dexamethasone followed by carfilzomib maintenance for patients with multiple myeloma after one prior therapy: results from a multicenter, phase II, randomized, controlled trial (MUK
Auner, HW; Brown, SR; Bygrave, C; Cavenagh, J; Croft, J; Davies, F; De Tute, RM; Flanagan, L; Garg, M; Hawkins, S; Hinsley, S; Kaiser, MF; Morgan, G; Owen, RG; Rabin, NK; Ramasamy, K; Sherratt, D; Williams, C; Yong, KL, 2021)		2.06
" This phase 2 study evaluated the efficacy and safety of elotuzumab in combination with pomalidomide, carfilzomib, and low-dose dexamethasone for patients with high-risk relapsed/refractory (RR)MM (NCT03104270)."( A phase 2 trial of the efficacy and safety of elotuzumab in combination with pomalidomide, carfilzomib and dexamethasone for high-risk relapsed/refractory multiple myeloma.
Berenson, JR; Eades, B; Eshaghian, S; Ghermezi, M; Lim, S; Martinez, D; Schwartz, G; Spektor, TM; Swift, RA; Vescio, R; Yashar, D, 2022)		1.16
" We conducted an investigator initiated, single-center, open-label, prospective phase 1 study evaluating the safety and efficacy of CFZ in combination with rituximab, ifosfamide, carboplatin, and etoposide (C-R-ICE) in high-dose chemotherapy with autologous stem cell transplant (HDC-ASCT) eligible patients with R/R DLBCL (NCT01959698)."( Carfilzomib combined with rituximab, ifosfamide, carboplatin, and etoposide for relapsed or refractory DLBCL.
Anampa-Guzmán, A; Block, A; Darrall, A; DeMarco, J; Ghione, P; Groman, A; Hernandez-Ilizaliturri, FJ; Hutson, A; Johnson, M; Kader, A; Kostrewa, J; Lund, I; Mavis, C; McWhite, K; Mohr, A; Nichols, J; Przespolewski, E; Sait, SJ; Sundaram, S; Thomas, R; Torka, P; Wong, J, 2023)		2.35
" In this study, we used a cardiomyocyte model to investigate the molecular cardiotoxic mechanisms of carfilzomib (CFZ) and ixazomib (IXZ) alone or in combination with the immunomodulatory drug dexamethasone (DEX) which is frequently used in combination therapies in the clinic."( Molecular Cardiotoxic Effects of Proteasome Inhibitors Carfilzomib and Ixazomib and Their Combination with Dexamethasone Involve Mitochondrial Dysregulation.
Alpertunga, B; Arslan Eseryel, S; Gunaydin Akyildiz, A; Jannuzzi, AT; Karademir Yilmaz, B; Korkmaz, NS, 2023)		1.37
" Carfilzomib, an irreversible proteasome inhibitor, can overcome acquired rituximab-chemotherapy resistance and, when combined with R-ICE, improves outcomes in patients with R/R DLBCL."( Population Pharmacokinetics and Pharmacodynamics of Carfilzomib in Combination with Rituximab, Ifosfamide, Carboplatin, and Etoposide in Adult Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma.
Burke, SM; Ghasemi, M; Goey, AKL; Hernandez-Ilizaliturri, FJ; Lin, LH; Mager, DE; Mavis, CK; Nichols, JR; Torka, P, 2023)		2.07
" Further research is needed to identify sources of variability in response to treatment with carfilzomib in combination with R-ICE."( Population Pharmacokinetics and Pharmacodynamics of Carfilzomib in Combination with Rituximab, Ifosfamide, Carboplatin, and Etoposide in Adult Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma.
Burke, SM; Ghasemi, M; Goey, AKL; Hernandez-Ilizaliturri, FJ; Lin, LH; Mager, DE; Mavis, CK; Nichols, JR; Torka, P, 2023)		1.38

Bioavailability

Carrilzomib is a second-generation, highly-selective, proteasome inhibitors. orally bioavailable analogues would have potential for improved dosing flexibility and patient convenience over intravenously administered agents.

ExcerptReferenceRelevance
" A chemistry effort was initiated to discover orally bioavailable analogues of carfilzomib, which would have potential for improved dosing flexibility and patient convenience over intravenously administered agents."( Design and synthesis of an orally bioavailable and selective peptide epoxyketone proteasome inhibitor (PR-047).
Aujay, MA; Bennett, MK; Dajee, M; Demo, SD; Fang, Y; Ho, MN; Jiang, J; Kirk, CJ; Laidig, GJ; Lewis, ER; Lu, Y; Muchamuel, T; Parlati, F; Ring, E; Shenk, KD; Shields, J; Shwonek, PJ; Stanton, T; Sun, CM; Sylvain, C; Woo, TM; Yang, J; Zhou, HJ, 2009)		0.58
" Carfilzomib and its orally bioavailable analog oprozomib, effectively decreased MM cell viability following continual or transient treatment mimicking in vivo pharmacokinetics."( The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects.
Blanco, JF; Collins, L; Garayoa, M; Garcia-Gomez, A; Hornick, MC; Hurchla, MA; Kirk, CJ; Li, A; Ocio, EM; Pandiella, A; Piwnica-Worms, D; San Miguel, JF; Tomasson, MH; Vij, R; Weilbaecher, KN, 2013)		1.56
" ONX 0912 (oprozomib) is an orally bioavailable derivative."( Carfilzomib and ONX 0912 inhibit cell survival and tumor growth of head and neck cancer and their activities are enhanced by suppression of Mcl-1 or autophagy.
Chan, ET; DeLancey, HM; Freilino, ML; Grandis, JR; Johnson, DE; Kirk, CJ; Li, C; Thomas, SM; Zang, Y, 2012)		1.82
" Carfilzomib and its orally bioavailable structural analog oprozomib are second-generation, highly-selective, proteasome inhibitors."( Carfilzomib and oprozomib synergize with histone deacetylase inhibitors in head and neck squamous cell carcinoma models of acquired resistance to proteasome inhibitors.
Johnson, DE; Kirk, CJ; Zang, Y, 2014)		2.76
"Cell membrane permeability is an important determinant for oral absorption and bioavailability of a drug molecule."( Highly predictive and interpretable models for PAMPA permeability.
Jadhav, A; Kerns, E; Nguyen, K; Shah, P; Sun, H; Xu, X; Yan, Z; Yu, KR, 2017)		0.46
" Many recent studies have investigated the safety of orally bioavailable proteasome inhibitors, such as ixazomib and oprozomib."( Proteasome inhibitor-induced gastrointestinal toxicity.
Gibson, RJ; Stansborough, RL, 2017)		0.46
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019)		0.51
" CFZ suffers, nevertheless, metabolic instability and poor bioavailability and may induce severe cardiovascular and renal adverse events."( Antibody-Mediated Nanodrug of Proteasome Inhibitor Carfilzomib Boosts the Treatment of Multiple Myeloma.
Chen, R; Cheng, R; Deng, C; Mao, Y; Yang, J; Zhao, X; Zhong, Z, 2023)		1.16

Dosage Studied

Carrilzomib 15 to 27 mg/m(2) on days 1, 2, 8, 9, 15, and 16; lenalidomide 10 to 25 mg on days1 to 21; and dexamethasone 40 mg weekly. Escalated dosing of carfilzomIB on a schedule of 2 consecutive days for 3 weeks of a 4-week cycle was tolerable and showed promising activity.

ExcerptRelevanceReference
" The antitumor efficacy of PR-171 delivered on 2 consecutive days is stronger than that of bortezomib administered on its clinical dosing schedule."( Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome.
Aujay, MA; Bennett, MK; Buchholz, TJ; Dajee, M; Demo, SD; Ho, MN; Jiang, J; Kirk, CJ; Laidig, GJ; Lewis, ER; Molineaux, CJ; Parlati, F; Shenk, KD; Smyth, MS; Sun, CM; Vallone, MK; Woo, TM, 2007)		0.34
" A chemistry effort was initiated to discover orally bioavailable analogues of carfilzomib, which would have potential for improved dosing flexibility and patient convenience over intravenously administered agents."( Design and synthesis of an orally bioavailable and selective peptide epoxyketone proteasome inhibitor (PR-047).
Aujay, MA; Bennett, MK; Dajee, M; Demo, SD; Fang, Y; Ho, MN; Jiang, J; Kirk, CJ; Laidig, GJ; Lewis, ER; Lu, Y; Muchamuel, T; Parlati, F; Ring, E; Shenk, KD; Shields, J; Shwonek, PJ; Stanton, T; Sun, CM; Sylvain, C; Woo, TM; Yang, J; Zhou, HJ, 2009)		0.58
" Dosing in the expansion cohort was well tolerated."( A phase I single-agent study of twice-weekly consecutive-day dosing of the proteasome inhibitor carfilzomib in patients with relapsed or refractory multiple myeloma or lymphoma.
Alsina, M; Comenzo, RL; Furman, RR; Goy, A; Kunkel, LA; Molineaux, CJ; O'Connor, OA; Rosen, PJ; Trudel, S; Wong, A, 2012)		0.6
"Escalated dosing of carfilzomib on a schedule of 2 consecutive days for 3 weeks of a 4-week cycle was tolerable and showed promising activity."( A phase I single-agent study of twice-weekly consecutive-day dosing of the proteasome inhibitor carfilzomib in patients with relapsed or refractory multiple myeloma or lymphoma.
Alsina, M; Comenzo, RL; Furman, RR; Goy, A; Kunkel, LA; Molineaux, CJ; O'Connor, OA; Rosen, PJ; Trudel, S; Wong, A, 2012)		0.92
" In this phase 2, open-label, multicentre clinical trial, 35 patients with relapsed and/or refractory MM following 1-3 prior therapies, including at least one bortezomib-based regimen, received carfilzomib 20 mg/m(2) in a twice-weekly, consecutive-day dosing schedule for ≤12 monthly cycles."( An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib.
Bahlis, N; Belch, A; Jagannath, S; Jakubowiak, AJ; Kunkel, LA; McDonagh, K; Siegel, DS; Stewart, AK; Vij, R; Wang, M; Wear, S; Wong, AF, 2012)		0.81
"The pharmacology, pharmacokinetics, clinical trials, adverse effects, dosage recommendations, and economic considerations of carfilzomib are reviewed."( Carfilzomib: A new proteasome inhibitor for relapsed or refractory multiple myeloma.
Steele, JM, 2013)		2.04
" CRd was administered on 28-day dosing cycles: carfilzomib 15 to 27 mg/m(2) on days 1, 2, 8, 9, 15, and 16; lenalidomide 10 to 25 mg on days 1 to 21; and dexamethasone 40 mg weekly."( Phase Ib dose-escalation study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma.
Alsina, M; Bensinger, WI; Kunkel, LA; Lee, S; Martin, TG; Niesvizky, R; Orlowski, RZ; Siegel, DS; Wang, M; Wong, AF, 2013)		0.9
" The safety of carfilzomib was evaluated in 526 patients with multiple myeloma treated with various dosing regimens."( U.s. Food and Drug Administration approval: carfilzomib for the treatment of multiple myeloma.
Adams, W; Bray, JD; Brown, J; Bullock, J; Deisseroth, A; Dorantes, A; Farrell, AT; Habtemariam, B; Hawes, J; Herndon, TM; Jee, J; Kaminskas, E; Kane, RC; Koti, KM; Mahayni, H; Palmby, TR; Pazdur, R; Rothmann, MD; Sridhara, R, 2013)		1
" This article presents a comprehensive overview of the pharmacokinetics, pharmacodynamics, dosing schedule, safety, efficacy, preparation and administration of carfilzomib, and its role in treating MM patients."( Carfilzomib: a novel agent for multiple myeloma.
Redic, K, 2013)		2.03
" Approved carfilzomib dosing is based on body surface area, and is given on days 1, 2, 8, 9, 15 and 16 of a 28-day cycle (20 mg/m(2) in cycle 1; 27 mg/m(2) in cycle 2+)."( Carfilzomib: a novel agent for multiple myeloma.
Redic, K, 2013)		2.23
" Available experimental evidences and published patents are indicative of broadening the circle of the applications in point of both technological advantages and dosage forms."( [Pharmaceutical applications of sulfobuthylether-beta-cyclodextrin].
Sebestyén, Z; Szabó, B; Szepesi, K, 2013)		0.39
" Based on in vitro and in vivo findings and encouraging phase I tolerability data, a consecutive-day, twice-weekly dosing schedule was implemented early in the development program."( Evolution of carfilzomib dose and schedule in patients with multiple myeloma: a historical overview.
Jakubowiak, AJ, 2014)		0.77
" Frequently these patients receive reduced or modified dosing regimens, which can result in under-dosing and may adversely affect treatment efficacy."( Incidence and management of renal adverse events in patients with relapsed and/or refractory multiple myeloma treated with single-agent carfilzomib.
Shah, JJ, 2013)		0.59
" Treatment-specific tools and clinical assessments can be useful for optimizing dosing and schedule adjustments to increase therapy duration, and implementing supportive care strategies (e."( Treatment-related symptom management in patients with multiple myeloma: a review.
Colson, K, 2015)		0.42
" In addition to appropriate drug dosing and administration, effective supportive care and health maintenance are crucial for maximizing quality of life and disease control."( Treatment-related symptom management in patients with multiple myeloma: a review.
Colson, K, 2015)		0.42
"The pharmacology, clinical efficacy, safety, cost, dosage and administration, and place in therapy of carfilzomib for the treatment of multiple myeloma (MM) are reviewed."( Carfilzomib: a second-generation proteasome inhibitor for the treatment of multiple myeloma.
Klaus, JO; McBride, A; Stockerl-Goldstein, K, 2015)		2.08
" Dosing is based on the patient's actual body surface area."( Carfilzomib: a second-generation proteasome inhibitor for the treatment of multiple myeloma.
Klaus, JO; McBride, A; Stockerl-Goldstein, K, 2015)		1.86
" In the phase 1 portion of the study, 24 patients received CMP at carfilzomib dosing levels of 20 mg/m(2), 27 mg/m(2), 36 mg/m(2), and 45 mg/m(2)."( Phase 1/2 study of carfilzomib plus melphalan and prednisone in patients aged over 65 years with newly diagnosed multiple myeloma.
Attal, M; Avet-Loiseau, H; Benboubker, L; Caillot, D; Chaleteix, C; Chiffoleau, A; Facon, T; Fortin, J; Hulin, C; Kolb, B; Leleu, X; Mary, JY; Moreau, P; Planche, L; Roussel, M; Tiab, M; Touzeau, C, 2015)		0.98
"This post hoc analysis provides evidence for a dose-response relationship between the administered dose of carfilzomib and efficacy."( Relationship Between Carfilzomib Dose and Efficacy Outcomes in Patients With Relapsed and/or Refractory Multiple Myeloma.
Buyse, M; Jagannath, S; Michiels, S; Rajangam, K; Ro, SK; Saad, ED; Siegel, D; Squifflet, P; Vij, R, 2015)		0.95
" Carfilzomib was administered in a twice-weekly, consecutive-day dosing schedule."( A phase 1/2 study of carfilzomib in Japanese patients with relapsed and/or refractory multiple myeloma.
Ando, K; Chou, T; Hatake, K; Iida, S; Ishida, T; Ishikawa, T; Izutsu, K; Kashihara, T; Matsumoto, M; Ozaki, S; Shibayama, H; Shumiya, Y; Sunami, K; Suzuki, K; Taniwaki, M; Tobinai, K; Uike, N; Watanabe, T, 2016)		1.66
" These findings merit additional evaluation of the once-weekly dosing regimen."( CHAMPION-1: a phase 1/2 study of once-weekly carfilzomib and dexamethasone for relapsed or refractory multiple myeloma.
Agajanian, R; Aggarwal, S; Anderl, J; Berdeja, JG; Berenson, JR; Bessudo, A; Boccia, R; Cartmell, A; Coleman, M; Dixon, S; Harb, W; Lyons, RM; Moss, RA; Ou, Y; Patel, P; Rifkin, RM; Tzachanis, D, 2016)		0.69
" Mice dosed with INCB (30 mg/kg) showed significant reductions in tumor volume on days 28, 35, 42, 49, 56, and 63."( The anti-myeloma effects of the selective JAK1 inhibitor (INCB052793) alone and in combination in vitro and in vivo.
Berenson, JR; Chen, H; Hekmati, T; Li, M; Nosrati, JD; Patil, S; Sanchez, E; Schlossberg, RE; Soof, CM; Tanenbaum, EJ; Tang, G; Vidisheva, A; Wang, C; Zahab, B, 2019)		0.51
" Splitting the first intravenous infusion of daratumumab over 2 days is an approved alternative dosing regimen to reduce the duration of the first infusion and provide flexibility for patients and healthcare providers."( Split First Dose Administration of Intravenous Daratumumab for the Treatment of Multiple Myeloma (MM): Clinical and Population Pharmacokinetic Analyses.
Bladé, J; Clemens, PL; Deraedt, W; Jakubowiak, A; Krishnan, A; Lonial, S; Luo, M; Moreau, P; Nnane, I; Oriol, A; Qi, M; Sun, YN; Ukropec, J; Usmani, SZ; Xu, XS; Zhou, H, 2020)		0.56
" The population PK simulations demonstrated virtually identical PK profiles after the first day of treatment for all approved indications and recommended dosing schedules of daratumumab."( Split First Dose Administration of Intravenous Daratumumab for the Treatment of Multiple Myeloma (MM): Clinical and Population Pharmacokinetic Analyses.
Bladé, J; Clemens, PL; Deraedt, W; Jakubowiak, A; Krishnan, A; Lonial, S; Luo, M; Moreau, P; Nnane, I; Oriol, A; Qi, M; Sun, YN; Ukropec, J; Usmani, SZ; Xu, XS; Zhou, H, 2020)		0.56
" A total of 15 patients discontinued CFZ and dosing was reinitiated at a lower level in one patient with AKI."( Carfilzomib-associated renal toxicity is common and unpredictable: a comprehensive analysis of 114 multiple myeloma patients.
Delavinia, C; Dialoupi, I; Dimopoulos, MA; Efstathiou, K; Eleutherakis-Papaiakovou, E; Fotiou, D; Gakiopoulou, C; Gavriatopoulou, M; Giannouli, S; Kanellias, N; Kastritis, E; Kontogiannis, S; Migkou, M; Psimenou, E; Roussou, M; Terpos, E, 2020)		2
" The KdD triplet has two recommended dosage regimens, carfilzomib once-weekly (KdD70 QW) and carfilzomib twice-weekly (KdD56 BIW), with comparable efficacy and safety profiles."( A combination of carfilzomib, dexamethasone, and daratumumab for treatment of adult patients with relapsed/refractory multiple myeloma in two dosing regimens: once-weekly and twice-weekly.
Chari, A; Khurana, M; Leleu, X; Richard, S; Usmani, SZ; Yusuf, A, 2021)		1.21
"Optimal carfilzomib dosing is a matter of debate."( High-dose carfilzomib achieves superior anti-tumor activity over low-dose and recaptures response in relapsed/refractory multiple myeloma resistant to lowdose carfilzomib by co-inhibiting the β2 and β1 subunits of the proteasome complex.
Besse, A; Besse, L; Driessen, C; Einsele, H; Florea, B; Haertle, L; Han, S; Hornburger, H; Kortüm, KM; Lopez, MM; Maurits, E; Munawar, U; Nerreter, S; Overkleeft, HS; Peter, J; Rasche, L; Riedel, A; Stanojkovska, E; Steinhardt, MJ; Teufel, E; Vogt, C; Xiao, X; Zhou, X, 2023)		1.75
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
antineoplastic agentA substance that inhibits or prevents the proliferation of neoplasms.
proteasome inhibitorA drug that blocks the action of proteasomes, cellular complexes that break down proteins.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
tetrapeptideAny molecule that contains four amino-acid residues connected by peptide linkages.
morpholinesAny compound containing morpholine as part of its structure.
epoxideAny cyclic ether in which the oxygen atom forms part of a 3-membered ring.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (83)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
acetylcholinesteraseHomo sapiens (human)Potency30.90080.002541.796015,848.9004AID1347398
RAR-related orphan receptor gammaMus musculus (house mouse)Potency0.84960.006038.004119,952.5996AID1159521; AID1159523
Fumarate hydrataseHomo sapiens (human)Potency0.37430.00308.794948.0869AID1347053
PPM1D proteinHomo sapiens (human)Potency0.02620.00529.466132.9993AID1347411
TDP1 proteinHomo sapiens (human)Potency0.00540.000811.382244.6684AID686978; AID686979
GLI family zinc finger 3Homo sapiens (human)Potency0.01650.000714.592883.7951AID1259369; AID1259392
AR proteinHomo sapiens (human)Potency0.25640.000221.22318,912.5098AID1259243; AID1259247; AID743035; AID743036; AID743042; AID743054; AID743063
caspase 7, apoptosis-related cysteine proteaseHomo sapiens (human)Potency0.26600.013326.981070.7614AID1346978
estrogen receptor 2 (ER beta)Homo sapiens (human)Potency0.94390.000657.913322,387.1992AID1259377; AID1259378
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency0.38650.001022.650876.6163AID1224838; AID1224839; AID1224893
progesterone receptorHomo sapiens (human)Potency1.45090.000417.946075.1148AID1346784; AID1346795
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency1.54870.01237.983543.2770AID1645841
EWS/FLI fusion proteinHomo sapiens (human)Potency0.02100.001310.157742.8575AID1259252; AID1259253; AID1259255; AID1259256
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency0.16200.000214.376460.0339AID720691; AID720692; AID720719
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency0.03940.003041.611522,387.1992AID1159552; AID1159553; AID1159555
retinoid X nuclear receptor alphaHomo sapiens (human)Potency0.17510.000817.505159.3239AID1159527; AID1159531
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency0.06590.001530.607315,848.9004AID1224841; AID1224842; AID1224848; AID1224849; AID1259401; AID1259403
farnesoid X nuclear receptorHomo sapiens (human)Potency0.92820.375827.485161.6524AID743217; AID743220
pregnane X nuclear receptorHomo sapiens (human)Potency0.03760.005428.02631,258.9301AID1346982
estrogen nuclear receptor alphaHomo sapiens (human)Potency0.27190.000229.305416,493.5996AID1259244; AID1259248; AID743069; AID743075; AID743077; AID743078; AID743079; AID743080; AID743091
polyproteinZika virusPotency0.37430.00308.794948.0869AID1347053
peroxisome proliferator-activated receptor deltaHomo sapiens (human)Potency0.54230.001024.504861.6448AID743212; AID743215
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency0.10450.001019.414170.9645AID743094; AID743191
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency1.38190.023723.228263.5986AID743222; AID743223; AID743241
caspase-3Homo sapiens (human)Potency0.26600.013326.981070.7614AID1346978
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency0.03350.001723.839378.1014AID743083
Caspase-7Cricetulus griseus (Chinese hamster)Potency0.04730.006723.496068.5896AID1346980
caspase-3Cricetulus griseus (Chinese hamster)Potency0.04730.006723.496068.5896AID1346980
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency0.10780.000323.4451159.6830AID743065; AID743066; AID743067
heat shock protein beta-1Homo sapiens (human)Potency0.12760.042027.378961.6448AID743210; AID743228
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency0.05570.000627.21521,122.0200AID743202; AID743219
Voltage-dependent calcium channel gamma-2 subunitMus musculus (house mouse)Potency0.16790.001557.789015,848.9004AID1259244
Interferon betaHomo sapiens (human)Potency0.04310.00339.158239.8107AID1347407; AID1347411
Cellular tumor antigen p53Homo sapiens (human)Potency0.07430.002319.595674.0614AID651631; AID720552
Glutamate receptor 2Rattus norvegicus (Norway rat)Potency0.16790.001551.739315,848.9004AID1259244
Spike glycoproteinSevere acute respiratory syndrome-related coronavirusPotency0.84030.009610.525035.4813AID1479145; AID1479148
ATPase family AAA domain-containing protein 5Homo sapiens (human)Potency0.11010.011917.942071.5630AID651632; AID720516
Ataxin-2Homo sapiens (human)Potency0.10590.011912.222168.7989AID651632
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Proteasome subunit beta type-11Homo sapiens (human)IC50 (µMol)0.06080.00130.70995.0000AID1141825; AID1384571; AID1624025; AID1770085; AID1770086
26S proteasome non-ATPase regulatory subunit 11Homo sapiens (human)IC50 (µMol)0.00860.00700.71182.0000AID1141825
26S proteasome non-ATPase regulatory subunit 12Homo sapiens (human)IC50 (µMol)0.00860.00700.71182.0000AID1141825
26S proteasome non-ATPase regulatory subunit 14Homo sapiens (human)IC50 (µMol)0.00860.00701.09812.5000AID1141825
Proteasome subunit alpha type-7Homo sapiens (human)IC50 (µMol)0.06080.00130.70995.0000AID1141825; AID1384571; AID1624025; AID1770085; AID1770086
26S proteasome non-ATPase regulatory subunit 3Homo sapiens (human)IC50 (µMol)0.00860.00700.71182.0000AID1141825
Cathepsin BHomo sapiens (human)IC50 (µMol)11.00000.00021.845310.0000AID1128237
Cathepsin GHomo sapiens (human)IC50 (µMol)30.00000.01372.42247.4130AID1128238
Lysosomal protective proteinHomo sapiens (human)IC50 (µMol)30.00000.60006.600010.0000AID1128236
26S proteasome regulatory subunit 6AHomo sapiens (human)IC50 (µMol)0.00860.00700.71182.0000AID1141825
Proteasome subunit beta type-1Homo sapiens (human)IC50 (µMol)0.59370.00060.73766.3700AID1141825; AID1384571; AID1532131; AID1604182; AID1624025; AID1770085; AID1770086
Proteasome subunit alpha type-1Homo sapiens (human)IC50 (µMol)0.06080.00130.70995.0000AID1141825; AID1384571; AID1624025; AID1770085; AID1770086
Proteasome subunit alpha type-2Homo sapiens (human)IC50 (µMol)0.06080.00130.70995.0000AID1141825; AID1384571; AID1624025; AID1770085; AID1770086
Proteasome subunit alpha type-3Homo sapiens (human)IC50 (µMol)0.06080.00130.70995.0000AID1141825; AID1384571; AID1624025; AID1770085; AID1770086
Proteasome subunit alpha type-4Homo sapiens (human)IC50 (µMol)0.06080.00130.70995.0000AID1141825; AID1384571; AID1624025; AID1770085; AID1770086
Proteasome subunit beta type-8Homo sapiens (human)IC50 (µMol)0.04070.00130.36985.0000AID1141825; AID1384571; AID1408290; AID1532133; AID1604187; AID1624025; AID1624027; AID1770085; AID1770086; AID1895437; AID354000
Proteasome subunit beta type-9Homo sapiens (human)IC50 (µMol)0.71660.00100.76115.0000AID1141825; AID1384571; AID1595603; AID1604183; AID1624025; AID1770085; AID1770086; AID1895435
Proteasome subunit alpha type-5Homo sapiens (human)IC50 (µMol)0.06080.00130.70995.0000AID1141825; AID1384571; AID1624025; AID1770085; AID1770086
Proteasome subunit beta type-4Homo sapiens (human)IC50 (µMol)0.06080.00130.70995.0000AID1141825; AID1384571; AID1624025; AID1770085; AID1770086
Proteasome subunit beta type-6Homo sapiens (human)IC50 (µMol)0.19900.00130.69125.0000AID1141825; AID1384571; AID1624025; AID1770085; AID1770086; AID1895438
Proteasome subunit beta type-5Homo sapiens (human)IC50 (µMol)0.02370.00050.939410.0000AID1141825; AID1325161; AID1384571; AID1408278; AID1436349; AID1532129; AID1595614; AID1597890; AID1604186; AID1613994; AID1624025; AID1624026; AID1683221; AID1770085; AID1770086; AID1800498; AID1895440
26S proteasome regulatory subunit 7Homo sapiens (human)IC50 (µMol)0.00860.00700.71182.0000AID1141825
Proteasome subunit beta type-10Homo sapiens (human)IC50 (µMol)0.13390.00130.81515.0000AID1141825; AID1384571; AID1604185; AID1624025; AID1770085; AID1770086; AID1895436
26S proteasome regulatory subunit 6BHomo sapiens (human)IC50 (µMol)0.00860.00700.71182.0000AID1141825
26S proteasome non-ATPase regulatory subunit 8Homo sapiens (human)IC50 (µMol)0.00860.00700.71182.0000AID1141825
Proteasome subunit beta type-3Homo sapiens (human)IC50 (µMol)0.06080.00130.70995.0000AID1141825; AID1384571; AID1624025; AID1770085; AID1770086
Proteasome subunit beta type-2Homo sapiens (human)IC50 (µMol)0.74930.00131.39067.9540AID1141825; AID1384571; AID1408289; AID1532132; AID1604184; AID1624025; AID1624028; AID1770085; AID1770086
26S proteasome non-ATPase regulatory subunit 7Homo sapiens (human)IC50 (µMol)0.00860.00700.71182.0000AID1141825
26S proteasome non-ATPase regulatory subunit 4Homo sapiens (human)IC50 (µMol)0.00860.00700.71182.0000AID1141825
26S proteasome complex subunit SEM1Homo sapiens (human)IC50 (µMol)0.00860.00700.71182.0000AID1141825
Proteasome subunit alpha type-6Homo sapiens (human)IC50 (µMol)0.06080.00130.70995.0000AID1141825; AID1384571; AID1624025; AID1770085; AID1770086
26S proteasome regulatory subunit 4Homo sapiens (human)IC50 (µMol)0.00860.00700.71182.0000AID1141825
26S proteasome regulatory subunit 8Homo sapiens (human)IC50 (µMol)0.00860.00700.71182.0000AID1141825
26S proteasome regulatory subunit 10BHomo sapiens (human)IC50 (µMol)0.00860.00700.71182.0000AID1141825
Glutathione S-transferase omega-1Homo sapiens (human)IC50 (µMol)0.15000.02801.60404.6000AID1384570
Potassium voltage-gated channel subfamily H member 2Homo sapiens (human)IC50 (µMol)92.10000.00091.901410.0000AID1597905
26S proteasome non-ATPase regulatory subunit 2Homo sapiens (human)IC50 (µMol)0.00860.00700.71182.0000AID1141825
26S proteasome non-ATPase regulatory subunit 6Homo sapiens (human)IC50 (µMol)0.00860.00700.71182.0000AID1141825
Proteasomal ubiquitin receptor ADRM1Homo sapiens (human)IC50 (µMol)0.00860.00700.71182.0000AID1141825
Proteasome subunit alpha-type 8Homo sapiens (human)IC50 (µMol)0.06080.00130.70995.0000AID1141825; AID1384571; AID1624025; AID1770085; AID1770086
Proteasome subunit beta type-7Homo sapiens (human)IC50 (µMol)0.05780.00130.68435.0000AID1141825; AID1384571; AID1624025; AID1770085; AID1770086; AID1895439
26S proteasome non-ATPase regulatory subunit 1Homo sapiens (human)IC50 (µMol)0.00860.00700.71182.0000AID1141825
26S proteasome non-ATPase regulatory subunit 13Homo sapiens (human)IC50 (µMol)0.00860.00700.71182.0000AID1141825
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (271)

Processvia Protein(s)Taxonomy
proteolysisProteasome subunit beta type-11Homo sapiens (human)
T cell differentiation in thymusProteasome subunit beta type-11Homo sapiens (human)
CD8-positive, alpha-beta T cell differentiationProteasome subunit beta type-11Homo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic processProteasome subunit beta type-11Homo sapiens (human)
ubiquitin-dependent protein catabolic process26S proteasome non-ATPase regulatory subunit 11Homo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic process26S proteasome non-ATPase regulatory subunit 11Homo sapiens (human)
proteasome assembly26S proteasome non-ATPase regulatory subunit 11Homo sapiens (human)
stem cell differentiation26S proteasome non-ATPase regulatory subunit 11Homo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic process26S proteasome non-ATPase regulatory subunit 12Homo sapiens (human)
double-strand break repair via homologous recombination26S proteasome non-ATPase regulatory subunit 14Homo sapiens (human)
double-strand break repair via nonhomologous end joining26S proteasome non-ATPase regulatory subunit 14Homo sapiens (human)
ubiquitin-dependent protein catabolic process26S proteasome non-ATPase regulatory subunit 14Homo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic process26S proteasome non-ATPase regulatory subunit 14Homo sapiens (human)
response to ethanol26S proteasome non-ATPase regulatory subunit 14Homo sapiens (human)
regulation of proteasomal protein catabolic process26S proteasome non-ATPase regulatory subunit 14Homo sapiens (human)
protein K63-linked deubiquitination26S proteasome non-ATPase regulatory subunit 14Homo sapiens (human)
protein deubiquitination26S proteasome non-ATPase regulatory subunit 14Homo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic processProteasome subunit alpha type-7Homo sapiens (human)
regulation of protein catabolic process26S proteasome non-ATPase regulatory subunit 3Homo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic process26S proteasome non-ATPase regulatory subunit 3Homo sapiens (human)
ubiquitin-dependent protein catabolic process26S proteasome non-ATPase regulatory subunit 3Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
proteolysisCathepsin BHomo sapiens (human)
thyroid hormone generationCathepsin BHomo sapiens (human)
collagen catabolic processCathepsin BHomo sapiens (human)
epithelial cell differentiationCathepsin BHomo sapiens (human)
regulation of apoptotic processCathepsin BHomo sapiens (human)
decidualizationCathepsin BHomo sapiens (human)
symbiont entry into host cellCathepsin BHomo sapiens (human)
proteolysis involved in protein catabolic processCathepsin BHomo sapiens (human)
cellular response to thyroid hormone stimulusCathepsin BHomo sapiens (human)
proteolysisCathepsin GHomo sapiens (human)
angiotensin maturationCathepsin GHomo sapiens (human)
monocyte chemotaxisCathepsin GHomo sapiens (human)
protein phosphorylationCathepsin GHomo sapiens (human)
proteolysisCathepsin GHomo sapiens (human)
immune responseCathepsin GHomo sapiens (human)
protein processingCathepsin GHomo sapiens (human)
cytokine-mediated signaling pathwayCathepsin GHomo sapiens (human)
protein metabolic processCathepsin GHomo sapiens (human)
antibacterial humoral responseCathepsin GHomo sapiens (human)
extracellular matrix disassemblyCathepsin GHomo sapiens (human)
platelet activationCathepsin GHomo sapiens (human)
purinergic nucleotide receptor signaling pathwayCathepsin GHomo sapiens (human)
neutrophil activationCathepsin GHomo sapiens (human)
positive regulation of immune responseCathepsin GHomo sapiens (human)
defense response to Gram-negative bacteriumCathepsin GHomo sapiens (human)
defense response to Gram-positive bacteriumCathepsin GHomo sapiens (human)
defense response to fungusCathepsin GHomo sapiens (human)
negative regulation of T cell activationCathepsin GHomo sapiens (human)
neutrophil-mediated killing of gram-positive bacteriumCathepsin GHomo sapiens (human)
cellular response to lipopolysaccharideCathepsin GHomo sapiens (human)
biofilm matrix disassemblyCathepsin GHomo sapiens (human)
positive regulation of platelet aggregationCathepsin GHomo sapiens (human)
proteolysisLysosomal protective proteinHomo sapiens (human)
intracellular protein transportLysosomal protective proteinHomo sapiens (human)
regulation of protein stabilityLysosomal protective proteinHomo sapiens (human)
regulation of chaperone-mediated autophagyLysosomal protective proteinHomo sapiens (human)
negative regulation of chaperone-mediated autophagyLysosomal protective proteinHomo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic process26S proteasome regulatory subunit 6AHomo sapiens (human)
modulation by host of viral transcription26S proteasome regulatory subunit 6AHomo sapiens (human)
positive regulation of transcription by RNA polymerase II26S proteasome regulatory subunit 6AHomo sapiens (human)
positive regulation of proteasomal protein catabolic process26S proteasome regulatory subunit 6AHomo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic processProteasome subunit beta type-1Homo sapiens (human)
proteolysis involved in protein catabolic processProteasome subunit beta type-1Homo sapiens (human)
immune system processProteasome subunit alpha type-1Homo sapiens (human)
negative regulation of inflammatory response to antigenic stimulusProteasome subunit alpha type-1Homo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic processProteasome subunit alpha type-1Homo sapiens (human)
response to virusProteasome subunit alpha type-2Homo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic processProteasome subunit alpha type-2Homo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic processProteasome subunit alpha type-3Homo sapiens (human)
regulation of endopeptidase activityProteasome subunit alpha type-3Homo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic processProteasome subunit alpha type-4Homo sapiens (human)
antigen processing and presentationProteasome subunit beta type-8Homo sapiens (human)
fat cell differentiationProteasome subunit beta type-8Homo sapiens (human)
regulation of endopeptidase activityProteasome subunit beta type-8Homo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic processProteasome subunit beta type-8Homo sapiens (human)
immune system processProteasome subunit beta type-9Homo sapiens (human)
regulation of cysteine-type endopeptidase activityProteasome subunit beta type-9Homo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic processProteasome subunit beta type-9Homo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic processProteasome subunit alpha type-5Homo sapiens (human)
negative regulation of inflammatory response to antigenic stimulusProteasome subunit beta type-4Homo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic processProteasome subunit beta type-4Homo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic processProteasome subunit beta type-6Homo sapiens (human)
proteolysisProteasome subunit beta type-5Homo sapiens (human)
response to oxidative stressProteasome subunit beta type-5Homo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic processProteasome subunit beta type-5Homo sapiens (human)
osteoblast differentiation26S proteasome regulatory subunit 7Homo sapiens (human)
ubiquitin-dependent protein catabolic process26S proteasome regulatory subunit 7Homo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic process26S proteasome regulatory subunit 7Homo sapiens (human)
positive regulation of proteasomal protein catabolic process26S proteasome regulatory subunit 7Homo sapiens (human)
cell morphogenesisProteasome subunit beta type-10Homo sapiens (human)
humoral immune responseProteasome subunit beta type-10Homo sapiens (human)
T cell proliferationProteasome subunit beta type-10Homo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic processProteasome subunit beta type-10Homo sapiens (human)
blastocyst development26S proteasome regulatory subunit 6BHomo sapiens (human)
proteolysis26S proteasome regulatory subunit 6BHomo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic process26S proteasome regulatory subunit 6BHomo sapiens (human)
positive regulation of proteasomal protein catabolic process26S proteasome regulatory subunit 6BHomo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic process26S proteasome non-ATPase regulatory subunit 8Homo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic processProteasome subunit beta type-3Homo sapiens (human)
response to organonitrogen compoundProteasome subunit beta type-2Homo sapiens (human)
response to organic cyclic compoundProteasome subunit beta type-2Homo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic processProteasome subunit beta type-2Homo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic process26S proteasome non-ATPase regulatory subunit 7Homo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic process26S proteasome non-ATPase regulatory subunit 4Homo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic processProteasome subunit alpha type-6Homo sapiens (human)
regulation of inflammatory responseProteasome subunit alpha type-6Homo sapiens (human)
positive regulation of NF-kappaB transcription factor activityProteasome subunit alpha type-6Homo sapiens (human)
proteolysis involved in protein catabolic processProteasome subunit alpha type-6Homo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic process26S proteasome regulatory subunit 4Homo sapiens (human)
positive regulation of proteasomal protein catabolic process26S proteasome regulatory subunit 4Homo sapiens (human)
regulation of transcription by RNA polymerase II26S proteasome regulatory subunit 8Homo sapiens (human)
negative regulation of programmed cell death26S proteasome regulatory subunit 8Homo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic process26S proteasome regulatory subunit 8Homo sapiens (human)
negative regulation of DNA-templated transcription26S proteasome regulatory subunit 8Homo sapiens (human)
positive regulation of DNA-templated transcription26S proteasome regulatory subunit 8Homo sapiens (human)
positive regulation of proteasomal protein catabolic process26S proteasome regulatory subunit 8Homo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic process26S proteasome regulatory subunit 10BHomo sapiens (human)
positive regulation of inclusion body assembly26S proteasome regulatory subunit 10BHomo sapiens (human)
positive regulation of proteasomal protein catabolic process26S proteasome regulatory subunit 10BHomo sapiens (human)
ERAD pathway26S proteasome regulatory subunit 10BHomo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assembly26S proteasome regulatory subunit 10BHomo sapiens (human)
regulation of release of sequestered calcium ion into cytosol by sarcoplasmic reticulumGlutathione S-transferase omega-1Homo sapiens (human)
regulation of cardiac muscle contraction by regulation of the release of sequestered calcium ionGlutathione S-transferase omega-1Homo sapiens (human)
positive regulation of skeletal muscle contraction by regulation of release of sequestered calcium ionGlutathione S-transferase omega-1Homo sapiens (human)
L-ascorbic acid metabolic processGlutathione S-transferase omega-1Homo sapiens (human)
xenobiotic catabolic processGlutathione S-transferase omega-1Homo sapiens (human)
negative regulation of ryanodine-sensitive calcium-release channel activityGlutathione S-transferase omega-1Homo sapiens (human)
positive regulation of ryanodine-sensitive calcium-release channel activityGlutathione S-transferase omega-1Homo sapiens (human)
cellular response to arsenic-containing substanceGlutathione S-transferase omega-1Homo sapiens (human)
cellular oxidant detoxificationGlutathione S-transferase omega-1Homo sapiens (human)
glutathione metabolic processGlutathione S-transferase omega-1Homo sapiens (human)
regulation of heart rate by cardiac conductionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of heart rate by hormonePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of membrane potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
positive regulation of DNA-templated transcriptionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion homeostasisPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cardiac muscle contractionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of ventricular cardiac muscle cell membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cellular response to xenobiotic stimulusPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
ventricular cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane depolarization during action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of heart rate by cardiac conductionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion export across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during ventricular cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
negative regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
positive regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
negative regulation of potassium ion export across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion import across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of protein catabolic process26S proteasome non-ATPase regulatory subunit 2Homo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic process26S proteasome non-ATPase regulatory subunit 2Homo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic process26S proteasome non-ATPase regulatory subunit 6Homo sapiens (human)
transcription elongation by RNA polymerase IIProteasomal ubiquitin receptor ADRM1Homo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic processProteasomal ubiquitin receptor ADRM1Homo sapiens (human)
proteasome assemblyProteasomal ubiquitin receptor ADRM1Homo sapiens (human)
spermatogenesisProteasome subunit alpha-type 8Homo sapiens (human)
proteasomal protein catabolic processProteasome subunit alpha-type 8Homo sapiens (human)
cell differentiationProteasome subunit alpha-type 8Homo sapiens (human)
meiotic cell cycleProteasome subunit alpha-type 8Homo sapiens (human)
regulation of meiosis IProteasome subunit alpha-type 8Homo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic processProteasome subunit alpha-type 8Homo sapiens (human)
cell population proliferationATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of B cell proliferationATPase family AAA domain-containing protein 5Homo sapiens (human)
nuclear DNA replicationATPase family AAA domain-containing protein 5Homo sapiens (human)
signal transduction in response to DNA damageATPase family AAA domain-containing protein 5Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorATPase family AAA domain-containing protein 5Homo sapiens (human)
isotype switchingATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of DNA replicationATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of isotype switching to IgG isotypesATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA clamp unloadingATPase family AAA domain-containing protein 5Homo sapiens (human)
regulation of mitotic cell cycle phase transitionATPase family AAA domain-containing protein 5Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of cell cycle G2/M phase transitionATPase family AAA domain-containing protein 5Homo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic processProteasome subunit beta type-7Homo sapiens (human)
regulation of protein catabolic process26S proteasome non-ATPase regulatory subunit 1Homo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic process26S proteasome non-ATPase regulatory subunit 1Homo sapiens (human)
negative regulation of receptor internalizationAtaxin-2Homo sapiens (human)
regulation of translationAtaxin-2Homo sapiens (human)
RNA metabolic processAtaxin-2Homo sapiens (human)
P-body assemblyAtaxin-2Homo sapiens (human)
stress granule assemblyAtaxin-2Homo sapiens (human)
RNA transportAtaxin-2Homo sapiens (human)
meiosis I26S proteasome non-ATPase regulatory subunit 13Homo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic process26S proteasome non-ATPase regulatory subunit 13Homo sapiens (human)
ubiquitin-dependent protein catabolic process26S proteasome non-ATPase regulatory subunit 13Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (91)

Processvia Protein(s)Taxonomy
threonine-type endopeptidase activityProteasome subunit beta type-11Homo sapiens (human)
protein bindingProteasome subunit beta type-11Homo sapiens (human)
peptidase activityProteasome subunit beta type-11Homo sapiens (human)
endopeptidase activityProteasome subunit beta type-11Homo sapiens (human)
protein binding26S proteasome non-ATPase regulatory subunit 11Homo sapiens (human)
structural molecule activity26S proteasome non-ATPase regulatory subunit 11Homo sapiens (human)
protein binding26S proteasome non-ATPase regulatory subunit 12Homo sapiens (human)
protein binding26S proteasome non-ATPase regulatory subunit 14Homo sapiens (human)
metallopeptidase activity26S proteasome non-ATPase regulatory subunit 14Homo sapiens (human)
metal ion binding26S proteasome non-ATPase regulatory subunit 14Homo sapiens (human)
endopeptidase activator activity26S proteasome non-ATPase regulatory subunit 14Homo sapiens (human)
K63-linked deubiquitinase activity26S proteasome non-ATPase regulatory subunit 14Homo sapiens (human)
proteasome binding26S proteasome non-ATPase regulatory subunit 14Homo sapiens (human)
metal-dependent deubiquitinase activity26S proteasome non-ATPase regulatory subunit 14Homo sapiens (human)
protein bindingProteasome subunit alpha type-7Homo sapiens (human)
identical protein bindingProteasome subunit alpha type-7Homo sapiens (human)
protein binding26S proteasome non-ATPase regulatory subunit 3Homo sapiens (human)
enzyme regulator activity26S proteasome non-ATPase regulatory subunit 3Homo sapiens (human)
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
cysteine-type endopeptidase activityCathepsin BHomo sapiens (human)
protein bindingCathepsin BHomo sapiens (human)
collagen bindingCathepsin BHomo sapiens (human)
peptidase activityCathepsin BHomo sapiens (human)
cysteine-type peptidase activityCathepsin BHomo sapiens (human)
proteoglycan bindingCathepsin BHomo sapiens (human)
serine-type endopeptidase activityCathepsin GHomo sapiens (human)
protein bindingCathepsin GHomo sapiens (human)
heparin bindingCathepsin GHomo sapiens (human)
peptidase activityCathepsin GHomo sapiens (human)
serine-type peptidase activityCathepsin GHomo sapiens (human)
receptor ligand activityCathepsin GHomo sapiens (human)
caspase bindingCathepsin GHomo sapiens (human)
carboxypeptidase activityLysosomal protective proteinHomo sapiens (human)
serine-type carboxypeptidase activityLysosomal protective proteinHomo sapiens (human)
enzyme activator activityLysosomal protective proteinHomo sapiens (human)
protein binding26S proteasome regulatory subunit 6AHomo sapiens (human)
ATP binding26S proteasome regulatory subunit 6AHomo sapiens (human)
ATP hydrolysis activity26S proteasome regulatory subunit 6AHomo sapiens (human)
proteasome-activating activity26S proteasome regulatory subunit 6AHomo sapiens (human)
identical protein binding26S proteasome regulatory subunit 6AHomo sapiens (human)
protein bindingProteasome subunit beta type-1Homo sapiens (human)
lipopolysaccharide bindingProteasome subunit alpha type-1Homo sapiens (human)
protein bindingProteasome subunit alpha type-1Homo sapiens (human)
protein bindingProteasome subunit alpha type-2Homo sapiens (human)
protein bindingProteasome subunit alpha type-3Homo sapiens (human)
ubiquitin protein ligase bindingProteasome subunit alpha type-3Homo sapiens (human)
protein bindingProteasome subunit alpha type-4Homo sapiens (human)
threonine-type endopeptidase activityProteasome subunit beta type-8Homo sapiens (human)
protein bindingProteasome subunit beta type-8Homo sapiens (human)
endopeptidase activityProteasome subunit beta type-8Homo sapiens (human)
threonine-type endopeptidase activityProteasome subunit beta type-9Homo sapiens (human)
protein bindingProteasome subunit beta type-9Homo sapiens (human)
endopeptidase activityProteasome subunit beta type-9Homo sapiens (human)
protein bindingProteasome subunit alpha type-5Homo sapiens (human)
lipopolysaccharide bindingProteasome subunit beta type-4Homo sapiens (human)
protein bindingProteasome subunit beta type-4Homo sapiens (human)
endopeptidase activityProteasome subunit beta type-6Homo sapiens (human)
threonine-type endopeptidase activityProteasome subunit beta type-6Homo sapiens (human)
protein bindingProteasome subunit beta type-6Homo sapiens (human)
cadherin bindingProteasome subunit beta type-6Homo sapiens (human)
threonine-type endopeptidase activityProteasome subunit beta type-5Homo sapiens (human)
protein bindingProteasome subunit beta type-5Homo sapiens (human)
peptidase activityProteasome subunit beta type-5Homo sapiens (human)
endopeptidase activityProteasome subunit beta type-5Homo sapiens (human)
protein binding26S proteasome regulatory subunit 7Homo sapiens (human)
ATP binding26S proteasome regulatory subunit 7Homo sapiens (human)
ATP hydrolysis activity26S proteasome regulatory subunit 7Homo sapiens (human)
proteasome-activating activity26S proteasome regulatory subunit 7Homo sapiens (human)
threonine-type endopeptidase activityProteasome subunit beta type-10Homo sapiens (human)
protein bindingProteasome subunit beta type-10Homo sapiens (human)
endopeptidase activityProteasome subunit beta type-10Homo sapiens (human)
protein binding26S proteasome regulatory subunit 6BHomo sapiens (human)
ATP binding26S proteasome regulatory subunit 6BHomo sapiens (human)
ATP hydrolysis activity26S proteasome regulatory subunit 6BHomo sapiens (human)
proteasome-activating activity26S proteasome regulatory subunit 6BHomo sapiens (human)
protein binding26S proteasome non-ATPase regulatory subunit 8Homo sapiens (human)
protein bindingProteasome subunit beta type-3Homo sapiens (human)
protein bindingProteasome subunit beta type-2Homo sapiens (human)
peptidase activity26S proteasome non-ATPase regulatory subunit 7Homo sapiens (human)
metal-dependent deubiquitinase activity26S proteasome non-ATPase regulatory subunit 7Homo sapiens (human)
protein binding26S proteasome non-ATPase regulatory subunit 7Homo sapiens (human)
protein homodimerization activity26S proteasome non-ATPase regulatory subunit 7Homo sapiens (human)
RNA binding26S proteasome non-ATPase regulatory subunit 4Homo sapiens (human)
protein binding26S proteasome non-ATPase regulatory subunit 4Homo sapiens (human)
identical protein binding26S proteasome non-ATPase regulatory subunit 4Homo sapiens (human)
molecular adaptor activity26S proteasome non-ATPase regulatory subunit 4Homo sapiens (human)
polyubiquitin modification-dependent protein binding26S proteasome non-ATPase regulatory subunit 4Homo sapiens (human)
RNA bindingProteasome subunit alpha type-6Homo sapiens (human)
endopeptidase activityProteasome subunit alpha type-6Homo sapiens (human)
protein bindingProteasome subunit alpha type-6Homo sapiens (human)
purine ribonucleoside triphosphate bindingProteasome subunit alpha type-6Homo sapiens (human)
NF-kappaB bindingProteasome subunit alpha type-6Homo sapiens (human)
RNA binding26S proteasome regulatory subunit 4Homo sapiens (human)
protein binding26S proteasome regulatory subunit 4Homo sapiens (human)
ATP binding26S proteasome regulatory subunit 4Homo sapiens (human)
ATP hydrolysis activity26S proteasome regulatory subunit 4Homo sapiens (human)
proteasome-activating activity26S proteasome regulatory subunit 4Homo sapiens (human)
protein binding26S proteasome regulatory subunit 8Homo sapiens (human)
ATP binding26S proteasome regulatory subunit 8Homo sapiens (human)
transcription factor binding26S proteasome regulatory subunit 8Homo sapiens (human)
ATP hydrolysis activity26S proteasome regulatory subunit 8Homo sapiens (human)
thyrotropin-releasing hormone receptor binding26S proteasome regulatory subunit 8Homo sapiens (human)
proteasome-activating activity26S proteasome regulatory subunit 8Homo sapiens (human)
general transcription initiation factor binding26S proteasome regulatory subunit 8Homo sapiens (human)
DNA-binding transcription factor binding26S proteasome regulatory subunit 8Homo sapiens (human)
protein binding26S proteasome regulatory subunit 10BHomo sapiens (human)
ATP binding26S proteasome regulatory subunit 10BHomo sapiens (human)
ATP hydrolysis activity26S proteasome regulatory subunit 10BHomo sapiens (human)
protein-macromolecule adaptor activity26S proteasome regulatory subunit 10BHomo sapiens (human)
proteasome-activating activity26S proteasome regulatory subunit 10BHomo sapiens (human)
identical protein binding26S proteasome regulatory subunit 10BHomo sapiens (human)
glutathione transferase activityGlutathione S-transferase omega-1Homo sapiens (human)
protein bindingGlutathione S-transferase omega-1Homo sapiens (human)
oxidoreductase activityGlutathione S-transferase omega-1Homo sapiens (human)
glutathione dehydrogenase (ascorbate) activityGlutathione S-transferase omega-1Homo sapiens (human)
methylarsonate reductase activityGlutathione S-transferase omega-1Homo sapiens (human)
transcription cis-regulatory region bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
inward rectifier potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
delayed rectifier potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
ubiquitin protein ligase bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
identical protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
protein homodimerization activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
C3HC4-type RING finger domain bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activity involved in cardiac muscle cell action potential repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
scaffold protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
protein binding26S proteasome non-ATPase regulatory subunit 2Homo sapiens (human)
enzyme regulator activity26S proteasome non-ATPase regulatory subunit 2Homo sapiens (human)
protein binding26S proteasome non-ATPase regulatory subunit 6Homo sapiens (human)
protease bindingProteasomal ubiquitin receptor ADRM1Homo sapiens (human)
protein bindingProteasomal ubiquitin receptor ADRM1Homo sapiens (human)
endopeptidase activator activityProteasomal ubiquitin receptor ADRM1Homo sapiens (human)
proteasome bindingProteasomal ubiquitin receptor ADRM1Homo sapiens (human)
molecular function inhibitor activityProteasomal ubiquitin receptor ADRM1Homo sapiens (human)
protein bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
ATP bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
ATP hydrolysis activityATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA clamp unloader activityATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
threonine-type endopeptidase activityProteasome subunit beta type-7Homo sapiens (human)
protein bindingProteasome subunit beta type-7Homo sapiens (human)
endopeptidase activityProteasome subunit beta type-7Homo sapiens (human)
protein binding26S proteasome non-ATPase regulatory subunit 1Homo sapiens (human)
enzyme regulator activity26S proteasome non-ATPase regulatory subunit 1Homo sapiens (human)
ubiquitin protein ligase binding26S proteasome non-ATPase regulatory subunit 1Homo sapiens (human)
RNA bindingAtaxin-2Homo sapiens (human)
epidermal growth factor receptor bindingAtaxin-2Homo sapiens (human)
protein bindingAtaxin-2Homo sapiens (human)
mRNA bindingAtaxin-2Homo sapiens (human)
structural molecule activity26S proteasome non-ATPase regulatory subunit 13Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (70)

Processvia Protein(s)Taxonomy
cytosolProteasome subunit beta type-11Homo sapiens (human)
proteasome core complex, beta-subunit complexProteasome subunit beta type-11Homo sapiens (human)
nucleusProteasome subunit beta type-11Homo sapiens (human)
cytosolProteasome subunit beta type-11Homo sapiens (human)
proteasome complex26S proteasome non-ATPase regulatory subunit 11Homo sapiens (human)
extracellular region26S proteasome non-ATPase regulatory subunit 11Homo sapiens (human)
nucleus26S proteasome non-ATPase regulatory subunit 11Homo sapiens (human)
nucleoplasm26S proteasome non-ATPase regulatory subunit 11Homo sapiens (human)
cytosol26S proteasome non-ATPase regulatory subunit 11Homo sapiens (human)
membrane26S proteasome non-ATPase regulatory subunit 11Homo sapiens (human)
secretory granule lumen26S proteasome non-ATPase regulatory subunit 11Homo sapiens (human)
ficolin-1-rich granule lumen26S proteasome non-ATPase regulatory subunit 11Homo sapiens (human)
proteasome accessory complex26S proteasome non-ATPase regulatory subunit 11Homo sapiens (human)
proteasome regulatory particle, lid subcomplex26S proteasome non-ATPase regulatory subunit 11Homo sapiens (human)
proteasome complex26S proteasome non-ATPase regulatory subunit 12Homo sapiens (human)
extracellular region26S proteasome non-ATPase regulatory subunit 12Homo sapiens (human)
nucleoplasm26S proteasome non-ATPase regulatory subunit 12Homo sapiens (human)
cytosol26S proteasome non-ATPase regulatory subunit 12Homo sapiens (human)
membrane26S proteasome non-ATPase regulatory subunit 12Homo sapiens (human)
secretory granule lumen26S proteasome non-ATPase regulatory subunit 12Homo sapiens (human)
extracellular exosome26S proteasome non-ATPase regulatory subunit 12Homo sapiens (human)
ficolin-1-rich granule lumen26S proteasome non-ATPase regulatory subunit 12Homo sapiens (human)
proteasome regulatory particle26S proteasome non-ATPase regulatory subunit 12Homo sapiens (human)
proteasome accessory complex26S proteasome non-ATPase regulatory subunit 12Homo sapiens (human)
proteasome regulatory particle, lid subcomplex26S proteasome non-ATPase regulatory subunit 12Homo sapiens (human)
cytoplasm26S proteasome non-ATPase regulatory subunit 12Homo sapiens (human)
proteasome complex26S proteasome non-ATPase regulatory subunit 14Homo sapiens (human)
extracellular region26S proteasome non-ATPase regulatory subunit 14Homo sapiens (human)
nucleus26S proteasome non-ATPase regulatory subunit 14Homo sapiens (human)
nucleoplasm26S proteasome non-ATPase regulatory subunit 14Homo sapiens (human)
cytosol26S proteasome non-ATPase regulatory subunit 14Homo sapiens (human)
secretory granule lumen26S proteasome non-ATPase regulatory subunit 14Homo sapiens (human)
ficolin-1-rich granule lumen26S proteasome non-ATPase regulatory subunit 14Homo sapiens (human)
proteasome regulatory particle, lid subcomplex26S proteasome non-ATPase regulatory subunit 14Homo sapiens (human)
proteasome accessory complex26S proteasome non-ATPase regulatory subunit 14Homo sapiens (human)
cytosolic proteasome complex26S proteasome non-ATPase regulatory subunit 14Homo sapiens (human)
nucleus26S proteasome non-ATPase regulatory subunit 14Homo sapiens (human)
nucleusProteasome subunit alpha type-7Homo sapiens (human)
cytoplasmProteasome subunit alpha type-7Homo sapiens (human)
proteasome complexProteasome subunit alpha type-7Homo sapiens (human)
nucleusProteasome subunit alpha type-7Homo sapiens (human)
nucleoplasmProteasome subunit alpha type-7Homo sapiens (human)
cytosolProteasome subunit alpha type-7Homo sapiens (human)
extracellular exosomeProteasome subunit alpha type-7Homo sapiens (human)
postsynapseProteasome subunit alpha type-7Homo sapiens (human)
proteasome core complexProteasome subunit alpha type-7Homo sapiens (human)
proteasome core complex, alpha-subunit complexProteasome subunit alpha type-7Homo sapiens (human)
proteasome complex26S proteasome non-ATPase regulatory subunit 3Homo sapiens (human)
extracellular region26S proteasome non-ATPase regulatory subunit 3Homo sapiens (human)
nucleus26S proteasome non-ATPase regulatory subunit 3Homo sapiens (human)
nucleoplasm26S proteasome non-ATPase regulatory subunit 3Homo sapiens (human)
cytosol26S proteasome non-ATPase regulatory subunit 3Homo sapiens (human)
membrane26S proteasome non-ATPase regulatory subunit 3Homo sapiens (human)
secretory granule lumen26S proteasome non-ATPase regulatory subunit 3Homo sapiens (human)
extracellular exosome26S proteasome non-ATPase regulatory subunit 3Homo sapiens (human)
ficolin-1-rich granule lumen26S proteasome non-ATPase regulatory subunit 3Homo sapiens (human)
proteasome accessory complex26S proteasome non-ATPase regulatory subunit 3Homo sapiens (human)
proteasome regulatory particle, lid subcomplex26S proteasome non-ATPase regulatory subunit 3Homo sapiens (human)
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
collagen-containing extracellular matrixCathepsin BHomo sapiens (human)
extracellular regionCathepsin BHomo sapiens (human)
extracellular spaceCathepsin BHomo sapiens (human)
lysosomeCathepsin BHomo sapiens (human)
external side of plasma membraneCathepsin BHomo sapiens (human)
apical plasma membraneCathepsin BHomo sapiens (human)
endolysosome lumenCathepsin BHomo sapiens (human)
melanosomeCathepsin BHomo sapiens (human)
perinuclear region of cytoplasmCathepsin BHomo sapiens (human)
collagen-containing extracellular matrixCathepsin BHomo sapiens (human)
extracellular exosomeCathepsin BHomo sapiens (human)
peptidase inhibitor complexCathepsin BHomo sapiens (human)
ficolin-1-rich granule lumenCathepsin BHomo sapiens (human)
extracellular spaceCathepsin BHomo sapiens (human)
lysosomeCathepsin BHomo sapiens (human)
collagen-containing extracellular matrixCathepsin GHomo sapiens (human)
extracellular regionCathepsin GHomo sapiens (human)
extracellular spaceCathepsin GHomo sapiens (human)
nucleusCathepsin GHomo sapiens (human)
lysosomeCathepsin GHomo sapiens (human)
cytosolCathepsin GHomo sapiens (human)
plasma membraneCathepsin GHomo sapiens (human)
cytoplasmic stress granuleCathepsin GHomo sapiens (human)
membraneCathepsin GHomo sapiens (human)
secretory granuleCathepsin GHomo sapiens (human)
azurophil granule lumenCathepsin GHomo sapiens (human)
collagen-containing extracellular matrixCathepsin GHomo sapiens (human)
extracellular exosomeCathepsin GHomo sapiens (human)
cytoplasmCathepsin GHomo sapiens (human)
intracellular membrane-bounded organelleCathepsin GHomo sapiens (human)
lumenal side of lysosomal membraneLysosomal protective proteinHomo sapiens (human)
extracellular regionLysosomal protective proteinHomo sapiens (human)
lysosomeLysosomal protective proteinHomo sapiens (human)
endoplasmic reticulumLysosomal protective proteinHomo sapiens (human)
membraneLysosomal protective proteinHomo sapiens (human)
azurophil granule lumenLysosomal protective proteinHomo sapiens (human)
lysosomal lumenLysosomal protective proteinHomo sapiens (human)
intracellular membrane-bounded organelleLysosomal protective proteinHomo sapiens (human)
extracellular exosomeLysosomal protective proteinHomo sapiens (human)
proteasome complex26S proteasome regulatory subunit 6AHomo sapiens (human)
P-body26S proteasome regulatory subunit 6AHomo sapiens (human)
extracellular region26S proteasome regulatory subunit 6AHomo sapiens (human)
nucleus26S proteasome regulatory subunit 6AHomo sapiens (human)
nucleoplasm26S proteasome regulatory subunit 6AHomo sapiens (human)
cytosol26S proteasome regulatory subunit 6AHomo sapiens (human)
membrane26S proteasome regulatory subunit 6AHomo sapiens (human)
secretory granule lumen26S proteasome regulatory subunit 6AHomo sapiens (human)
ficolin-1-rich granule lumen26S proteasome regulatory subunit 6AHomo sapiens (human)
proteasome accessory complex26S proteasome regulatory subunit 6AHomo sapiens (human)
proteasome regulatory particle, base subcomplex26S proteasome regulatory subunit 6AHomo sapiens (human)
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
nucleusProteasome subunit beta type-1Homo sapiens (human)
cytoplasmProteasome subunit beta type-1Homo sapiens (human)
proteasome complexProteasome subunit beta type-1Homo sapiens (human)
extracellular regionProteasome subunit beta type-1Homo sapiens (human)
nucleusProteasome subunit beta type-1Homo sapiens (human)
nucleoplasmProteasome subunit beta type-1Homo sapiens (human)
cytosolProteasome subunit beta type-1Homo sapiens (human)
secretory granule lumenProteasome subunit beta type-1Homo sapiens (human)
extracellular exosomeProteasome subunit beta type-1Homo sapiens (human)
ficolin-1-rich granule lumenProteasome subunit beta type-1Homo sapiens (human)
proteasome core complexProteasome subunit beta type-1Homo sapiens (human)
proteasome core complex, beta-subunit complexProteasome subunit beta type-1Homo sapiens (human)
nucleusProteasome subunit alpha type-1Homo sapiens (human)
cytoplasmProteasome subunit alpha type-1Homo sapiens (human)
proteasome complexProteasome subunit alpha type-1Homo sapiens (human)
nucleusProteasome subunit alpha type-1Homo sapiens (human)
nucleoplasmProteasome subunit alpha type-1Homo sapiens (human)
centrosomeProteasome subunit alpha type-1Homo sapiens (human)
cytosolProteasome subunit alpha type-1Homo sapiens (human)
extracellular exosomeProteasome subunit alpha type-1Homo sapiens (human)
proteasome core complexProteasome subunit alpha type-1Homo sapiens (human)
proteasome core complex, alpha-subunit complexProteasome subunit alpha type-1Homo sapiens (human)
nucleusProteasome subunit alpha type-2Homo sapiens (human)
cytoplasmProteasome subunit alpha type-2Homo sapiens (human)
proteasome complexProteasome subunit alpha type-2Homo sapiens (human)
P-bodyProteasome subunit alpha type-2Homo sapiens (human)
extracellular regionProteasome subunit alpha type-2Homo sapiens (human)
nucleusProteasome subunit alpha type-2Homo sapiens (human)
nucleoplasmProteasome subunit alpha type-2Homo sapiens (human)
cytosolProteasome subunit alpha type-2Homo sapiens (human)
secretory granule lumenProteasome subunit alpha type-2Homo sapiens (human)
extracellular exosomeProteasome subunit alpha type-2Homo sapiens (human)
ficolin-1-rich granule lumenProteasome subunit alpha type-2Homo sapiens (human)
proteasome core complexProteasome subunit alpha type-2Homo sapiens (human)
proteasome core complex, alpha-subunit complexProteasome subunit alpha type-2Homo sapiens (human)
nucleusProteasome subunit alpha type-3Homo sapiens (human)
cytoplasmProteasome subunit alpha type-3Homo sapiens (human)
proteasome complexProteasome subunit alpha type-3Homo sapiens (human)
nucleusProteasome subunit alpha type-3Homo sapiens (human)
nucleoplasmProteasome subunit alpha type-3Homo sapiens (human)
cytoplasmProteasome subunit alpha type-3Homo sapiens (human)
cytosolProteasome subunit alpha type-3Homo sapiens (human)
extracellular exosomeProteasome subunit alpha type-3Homo sapiens (human)
proteasome core complexProteasome subunit alpha type-3Homo sapiens (human)
proteasome core complex, alpha-subunit complexProteasome subunit alpha type-3Homo sapiens (human)
synapseProteasome subunit alpha type-3Homo sapiens (human)
nucleusProteasome subunit alpha type-4Homo sapiens (human)
cytoplasmProteasome subunit alpha type-4Homo sapiens (human)
proteasome complexProteasome subunit alpha type-4Homo sapiens (human)
P-bodyProteasome subunit alpha type-4Homo sapiens (human)
nucleusProteasome subunit alpha type-4Homo sapiens (human)
nucleoplasmProteasome subunit alpha type-4Homo sapiens (human)
cytosolProteasome subunit alpha type-4Homo sapiens (human)
intracellular membrane-bounded organelleProteasome subunit alpha type-4Homo sapiens (human)
extracellular exosomeProteasome subunit alpha type-4Homo sapiens (human)
proteasome core complexProteasome subunit alpha type-4Homo sapiens (human)
proteasome core complex, alpha-subunit complexProteasome subunit alpha type-4Homo sapiens (human)
cytosolProteasome subunit alpha type-4Homo sapiens (human)
nucleoplasmProteasome subunit beta type-8Homo sapiens (human)
cytosolProteasome subunit beta type-8Homo sapiens (human)
extracellular exosomeProteasome subunit beta type-8Homo sapiens (human)
proteasome complexProteasome subunit beta type-8Homo sapiens (human)
proteasome core complexProteasome subunit beta type-8Homo sapiens (human)
proteasome core complex, beta-subunit complexProteasome subunit beta type-8Homo sapiens (human)
spermatoproteasome complexProteasome subunit beta type-8Homo sapiens (human)
nucleusProteasome subunit beta type-8Homo sapiens (human)
cytosolProteasome subunit beta type-8Homo sapiens (human)
nucleoplasmProteasome subunit beta type-9Homo sapiens (human)
cytosolProteasome subunit beta type-9Homo sapiens (human)
extracellular exosomeProteasome subunit beta type-9Homo sapiens (human)
proteasome complexProteasome subunit beta type-9Homo sapiens (human)
proteasome core complexProteasome subunit beta type-9Homo sapiens (human)
proteasome core complex, beta-subunit complexProteasome subunit beta type-9Homo sapiens (human)
spermatoproteasome complexProteasome subunit beta type-9Homo sapiens (human)
cytosolProteasome subunit beta type-9Homo sapiens (human)
nucleusProteasome subunit beta type-9Homo sapiens (human)
nucleusProteasome subunit alpha type-5Homo sapiens (human)
cytoplasmProteasome subunit alpha type-5Homo sapiens (human)
proteasome complexProteasome subunit alpha type-5Homo sapiens (human)
extracellular regionProteasome subunit alpha type-5Homo sapiens (human)
nucleusProteasome subunit alpha type-5Homo sapiens (human)
nucleoplasmProteasome subunit alpha type-5Homo sapiens (human)
cytosolProteasome subunit alpha type-5Homo sapiens (human)
secretory granule lumenProteasome subunit alpha type-5Homo sapiens (human)
extracellular exosomeProteasome subunit alpha type-5Homo sapiens (human)
ficolin-1-rich granule lumenProteasome subunit alpha type-5Homo sapiens (human)
proteasome core complexProteasome subunit alpha type-5Homo sapiens (human)
proteasome core complex, alpha-subunit complexProteasome subunit alpha type-5Homo sapiens (human)
nucleusProteasome subunit beta type-4Homo sapiens (human)
cytoplasmProteasome subunit beta type-4Homo sapiens (human)
proteasome complexProteasome subunit beta type-4Homo sapiens (human)
nucleusProteasome subunit beta type-4Homo sapiens (human)
nucleoplasmProteasome subunit beta type-4Homo sapiens (human)
mitochondrionProteasome subunit beta type-4Homo sapiens (human)
cytosolProteasome subunit beta type-4Homo sapiens (human)
ciliary basal bodyProteasome subunit beta type-4Homo sapiens (human)
extracellular exosomeProteasome subunit beta type-4Homo sapiens (human)
proteasome core complexProteasome subunit beta type-4Homo sapiens (human)
proteasome core complex, beta-subunit complexProteasome subunit beta type-4Homo sapiens (human)
cytosolProteasome subunit beta type-4Homo sapiens (human)
nucleusProteasome subunit beta type-6Homo sapiens (human)
cytoplasmProteasome subunit beta type-6Homo sapiens (human)
proteasome complexProteasome subunit beta type-6Homo sapiens (human)
nucleusProteasome subunit beta type-6Homo sapiens (human)
nucleoplasmProteasome subunit beta type-6Homo sapiens (human)
mitochondrionProteasome subunit beta type-6Homo sapiens (human)
cytosolProteasome subunit beta type-6Homo sapiens (human)
extracellular exosomeProteasome subunit beta type-6Homo sapiens (human)
proteasome core complexProteasome subunit beta type-6Homo sapiens (human)
proteasome core complex, beta-subunit complexProteasome subunit beta type-6Homo sapiens (human)
cytosolProteasome subunit beta type-6Homo sapiens (human)
nucleusProteasome subunit beta type-5Homo sapiens (human)
cytoplasmProteasome subunit beta type-5Homo sapiens (human)
proteasome complexProteasome subunit beta type-5Homo sapiens (human)
nucleusProteasome subunit beta type-5Homo sapiens (human)
nucleoplasmProteasome subunit beta type-5Homo sapiens (human)
centrosomeProteasome subunit beta type-5Homo sapiens (human)
cytosolProteasome subunit beta type-5Homo sapiens (human)
extracellular exosomeProteasome subunit beta type-5Homo sapiens (human)
proteasome core complexProteasome subunit beta type-5Homo sapiens (human)
proteasome core complex, beta-subunit complexProteasome subunit beta type-5Homo sapiens (human)
cytosolProteasome subunit beta type-5Homo sapiens (human)
proteasome complex26S proteasome regulatory subunit 7Homo sapiens (human)
P-body26S proteasome regulatory subunit 7Homo sapiens (human)
extracellular region26S proteasome regulatory subunit 7Homo sapiens (human)
nucleus26S proteasome regulatory subunit 7Homo sapiens (human)
nucleoplasm26S proteasome regulatory subunit 7Homo sapiens (human)
cytoplasm26S proteasome regulatory subunit 7Homo sapiens (human)
cytosol26S proteasome regulatory subunit 7Homo sapiens (human)
membrane26S proteasome regulatory subunit 7Homo sapiens (human)
secretory granule lumen26S proteasome regulatory subunit 7Homo sapiens (human)
cytoplasmic ribonucleoprotein granule26S proteasome regulatory subunit 7Homo sapiens (human)
ficolin-1-rich granule lumen26S proteasome regulatory subunit 7Homo sapiens (human)
proteasome accessory complex26S proteasome regulatory subunit 7Homo sapiens (human)
proteasome regulatory particle, base subcomplex26S proteasome regulatory subunit 7Homo sapiens (human)
nucleoplasmProteasome subunit beta type-10Homo sapiens (human)
cytosolProteasome subunit beta type-10Homo sapiens (human)
proteasome complexProteasome subunit beta type-10Homo sapiens (human)
proteasome core complexProteasome subunit beta type-10Homo sapiens (human)
proteasome core complex, beta-subunit complexProteasome subunit beta type-10Homo sapiens (human)
spermatoproteasome complexProteasome subunit beta type-10Homo sapiens (human)
cytosolProteasome subunit beta type-10Homo sapiens (human)
nucleusProteasome subunit beta type-10Homo sapiens (human)
proteasome complex26S proteasome regulatory subunit 6BHomo sapiens (human)
nucleus26S proteasome regulatory subunit 6BHomo sapiens (human)
nucleoplasm26S proteasome regulatory subunit 6BHomo sapiens (human)
cytosol26S proteasome regulatory subunit 6BHomo sapiens (human)
membrane26S proteasome regulatory subunit 6BHomo sapiens (human)
inclusion body26S proteasome regulatory subunit 6BHomo sapiens (human)
synapse26S proteasome regulatory subunit 6BHomo sapiens (human)
proteasome accessory complex26S proteasome regulatory subunit 6BHomo sapiens (human)
cytosolic proteasome complex26S proteasome regulatory subunit 6BHomo sapiens (human)
proteasome regulatory particle, base subcomplex26S proteasome regulatory subunit 6BHomo sapiens (human)
proteasome complex26S proteasome non-ATPase regulatory subunit 8Homo sapiens (human)
nucleus26S proteasome non-ATPase regulatory subunit 8Homo sapiens (human)
nucleoplasm26S proteasome non-ATPase regulatory subunit 8Homo sapiens (human)
cytosol26S proteasome non-ATPase regulatory subunit 8Homo sapiens (human)
proteasome regulatory particle26S proteasome non-ATPase regulatory subunit 8Homo sapiens (human)
proteasome regulatory particle, lid subcomplex26S proteasome non-ATPase regulatory subunit 8Homo sapiens (human)
proteasome accessory complex26S proteasome non-ATPase regulatory subunit 8Homo sapiens (human)
nucleus26S proteasome non-ATPase regulatory subunit 8Homo sapiens (human)
nucleusProteasome subunit beta type-3Homo sapiens (human)
cytoplasmProteasome subunit beta type-3Homo sapiens (human)
proteasome complexProteasome subunit beta type-3Homo sapiens (human)
nucleusProteasome subunit beta type-3Homo sapiens (human)
nucleoplasmProteasome subunit beta type-3Homo sapiens (human)
cytosolProteasome subunit beta type-3Homo sapiens (human)
extracellular exosomeProteasome subunit beta type-3Homo sapiens (human)
proteasome core complexProteasome subunit beta type-3Homo sapiens (human)
proteasome core complex, beta-subunit complexProteasome subunit beta type-3Homo sapiens (human)
cytosolProteasome subunit beta type-3Homo sapiens (human)
nucleusProteasome subunit beta type-2Homo sapiens (human)
cytoplasmProteasome subunit beta type-2Homo sapiens (human)
proteasome complexProteasome subunit beta type-2Homo sapiens (human)
nucleusProteasome subunit beta type-2Homo sapiens (human)
nucleoplasmProteasome subunit beta type-2Homo sapiens (human)
cytosolProteasome subunit beta type-2Homo sapiens (human)
membraneProteasome subunit beta type-2Homo sapiens (human)
extracellular exosomeProteasome subunit beta type-2Homo sapiens (human)
proteasome core complexProteasome subunit beta type-2Homo sapiens (human)
proteasome core complex, beta-subunit complexProteasome subunit beta type-2Homo sapiens (human)
cytosolProteasome subunit beta type-2Homo sapiens (human)
proteasome complex26S proteasome non-ATPase regulatory subunit 7Homo sapiens (human)
extracellular region26S proteasome non-ATPase regulatory subunit 7Homo sapiens (human)
nucleus26S proteasome non-ATPase regulatory subunit 7Homo sapiens (human)
nucleoplasm26S proteasome non-ATPase regulatory subunit 7Homo sapiens (human)
cytosol26S proteasome non-ATPase regulatory subunit 7Homo sapiens (human)
membrane26S proteasome non-ATPase regulatory subunit 7Homo sapiens (human)
secretory granule lumen26S proteasome non-ATPase regulatory subunit 7Homo sapiens (human)
extracellular exosome26S proteasome non-ATPase regulatory subunit 7Homo sapiens (human)
ficolin-1-rich granule lumen26S proteasome non-ATPase regulatory subunit 7Homo sapiens (human)
proteasome regulatory particle26S proteasome non-ATPase regulatory subunit 7Homo sapiens (human)
proteasome complex26S proteasome non-ATPase regulatory subunit 4Homo sapiens (human)
nucleoplasm26S proteasome non-ATPase regulatory subunit 4Homo sapiens (human)
cytosol26S proteasome non-ATPase regulatory subunit 4Homo sapiens (human)
proteasome accessory complex26S proteasome non-ATPase regulatory subunit 4Homo sapiens (human)
proteasome regulatory particle, base subcomplex26S proteasome non-ATPase regulatory subunit 4Homo sapiens (human)
nucleus26S proteasome non-ATPase regulatory subunit 4Homo sapiens (human)
cytosol26S proteasome non-ATPase regulatory subunit 4Homo sapiens (human)
virion membraneSpike glycoproteinSevere acute respiratory syndrome-related coronavirus
nucleoplasm26S proteasome complex subunit SEM1Homo sapiens (human)
cytosol26S proteasome complex subunit SEM1Homo sapiens (human)
nucleusProteasome subunit alpha type-6Homo sapiens (human)
cytoplasmProteasome subunit alpha type-6Homo sapiens (human)
proteasome complexProteasome subunit alpha type-6Homo sapiens (human)
P-bodyProteasome subunit alpha type-6Homo sapiens (human)
nucleusProteasome subunit alpha type-6Homo sapiens (human)
nucleoplasmProteasome subunit alpha type-6Homo sapiens (human)
cytosolProteasome subunit alpha type-6Homo sapiens (human)
ribosomeProteasome subunit alpha type-6Homo sapiens (human)
nuclear matrixProteasome subunit alpha type-6Homo sapiens (human)
myofibrilProteasome subunit alpha type-6Homo sapiens (human)
sarcomereProteasome subunit alpha type-6Homo sapiens (human)
extracellular exosomeProteasome subunit alpha type-6Homo sapiens (human)
proteasome core complexProteasome subunit alpha type-6Homo sapiens (human)
proteasome core complex, alpha-subunit complexProteasome subunit alpha type-6Homo sapiens (human)
proteasome complex26S proteasome regulatory subunit 4Homo sapiens (human)
nucleus26S proteasome regulatory subunit 4Homo sapiens (human)
nucleoplasm26S proteasome regulatory subunit 4Homo sapiens (human)
cytosol26S proteasome regulatory subunit 4Homo sapiens (human)
membrane26S proteasome regulatory subunit 4Homo sapiens (human)
proteasome accessory complex26S proteasome regulatory subunit 4Homo sapiens (human)
proteasome regulatory particle, base subcomplex26S proteasome regulatory subunit 4Homo sapiens (human)
proteasome complex26S proteasome regulatory subunit 8Homo sapiens (human)
nucleus26S proteasome regulatory subunit 8Homo sapiens (human)
nucleoplasm26S proteasome regulatory subunit 8Homo sapiens (human)
cytoplasm26S proteasome regulatory subunit 8Homo sapiens (human)
cytosol26S proteasome regulatory subunit 8Homo sapiens (human)
membrane26S proteasome regulatory subunit 8Homo sapiens (human)
cytoplasmic vesicle26S proteasome regulatory subunit 8Homo sapiens (human)
extracellular exosome26S proteasome regulatory subunit 8Homo sapiens (human)
blood microparticle26S proteasome regulatory subunit 8Homo sapiens (human)
proteasome accessory complex26S proteasome regulatory subunit 8Homo sapiens (human)
proteasome regulatory particle, base subcomplex26S proteasome regulatory subunit 8Homo sapiens (human)
proteasome complex26S proteasome regulatory subunit 10BHomo sapiens (human)
nucleus26S proteasome regulatory subunit 10BHomo sapiens (human)
nucleoplasm26S proteasome regulatory subunit 10BHomo sapiens (human)
cytosol26S proteasome regulatory subunit 10BHomo sapiens (human)
membrane26S proteasome regulatory subunit 10BHomo sapiens (human)
inclusion body26S proteasome regulatory subunit 10BHomo sapiens (human)
extracellular exosome26S proteasome regulatory subunit 10BHomo sapiens (human)
proteasome accessory complex26S proteasome regulatory subunit 10BHomo sapiens (human)
cytosolic proteasome complex26S proteasome regulatory subunit 10BHomo sapiens (human)
proteasome regulatory particle, base subcomplex26S proteasome regulatory subunit 10BHomo sapiens (human)
cytoplasmGlutathione S-transferase omega-1Homo sapiens (human)
cytosolGlutathione S-transferase omega-1Homo sapiens (human)
extracellular exosomeGlutathione S-transferase omega-1Homo sapiens (human)
cytoplasmGlutathione S-transferase omega-1Homo sapiens (human)
plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cell surfacePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
perinuclear region of cytoplasmPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel complexPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
inward rectifier potassium channel complexPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
proteasome complex26S proteasome non-ATPase regulatory subunit 2Homo sapiens (human)
extracellular region26S proteasome non-ATPase regulatory subunit 2Homo sapiens (human)
nucleoplasm26S proteasome non-ATPase regulatory subunit 2Homo sapiens (human)
cytosol26S proteasome non-ATPase regulatory subunit 2Homo sapiens (human)
membrane26S proteasome non-ATPase regulatory subunit 2Homo sapiens (human)
secretory granule lumen26S proteasome non-ATPase regulatory subunit 2Homo sapiens (human)
extracellular exosome26S proteasome non-ATPase regulatory subunit 2Homo sapiens (human)
ficolin-1-rich granule lumen26S proteasome non-ATPase regulatory subunit 2Homo sapiens (human)
proteasome regulatory particle26S proteasome non-ATPase regulatory subunit 2Homo sapiens (human)
proteasome accessory complex26S proteasome non-ATPase regulatory subunit 2Homo sapiens (human)
proteasome storage granule26S proteasome non-ATPase regulatory subunit 2Homo sapiens (human)
proteasome regulatory particle, base subcomplex26S proteasome non-ATPase regulatory subunit 2Homo sapiens (human)
nucleus26S proteasome non-ATPase regulatory subunit 2Homo sapiens (human)
proteasome complex26S proteasome non-ATPase regulatory subunit 6Homo sapiens (human)
extracellular region26S proteasome non-ATPase regulatory subunit 6Homo sapiens (human)
nucleoplasm26S proteasome non-ATPase regulatory subunit 6Homo sapiens (human)
cytosol26S proteasome non-ATPase regulatory subunit 6Homo sapiens (human)
secretory granule lumen26S proteasome non-ATPase regulatory subunit 6Homo sapiens (human)
ficolin-1-rich granule lumen26S proteasome non-ATPase regulatory subunit 6Homo sapiens (human)
proteasome accessory complex26S proteasome non-ATPase regulatory subunit 6Homo sapiens (human)
proteasome regulatory particle26S proteasome non-ATPase regulatory subunit 6Homo sapiens (human)
proteasome complexProteasomal ubiquitin receptor ADRM1Homo sapiens (human)
nucleoplasmProteasomal ubiquitin receptor ADRM1Homo sapiens (human)
cytosolProteasomal ubiquitin receptor ADRM1Homo sapiens (human)
plasma membraneProteasomal ubiquitin receptor ADRM1Homo sapiens (human)
proteasome regulatory particle, lid subcomplexProteasomal ubiquitin receptor ADRM1Homo sapiens (human)
nucleusProteasome subunit alpha-type 8Homo sapiens (human)
cytosolProteasome subunit alpha-type 8Homo sapiens (human)
extracellular exosomeProteasome subunit alpha-type 8Homo sapiens (human)
proteasome core complex, alpha-subunit complexProteasome subunit alpha-type 8Homo sapiens (human)
spermatoproteasome complexProteasome subunit alpha-type 8Homo sapiens (human)
nucleusProteasome subunit alpha-type 8Homo sapiens (human)
Elg1 RFC-like complexATPase family AAA domain-containing protein 5Homo sapiens (human)
nucleusATPase family AAA domain-containing protein 5Homo sapiens (human)
nucleusProteasome subunit beta type-7Homo sapiens (human)
cytoplasmProteasome subunit beta type-7Homo sapiens (human)
proteasome complexProteasome subunit beta type-7Homo sapiens (human)
extracellular regionProteasome subunit beta type-7Homo sapiens (human)
nucleusProteasome subunit beta type-7Homo sapiens (human)
nucleoplasmProteasome subunit beta type-7Homo sapiens (human)
cytosolProteasome subunit beta type-7Homo sapiens (human)
nuclear bodyProteasome subunit beta type-7Homo sapiens (human)
secretory granule lumenProteasome subunit beta type-7Homo sapiens (human)
ficolin-1-rich granule lumenProteasome subunit beta type-7Homo sapiens (human)
proteasome core complexProteasome subunit beta type-7Homo sapiens (human)
proteasome core complex, beta-subunit complexProteasome subunit beta type-7Homo sapiens (human)
cytosolProteasome subunit beta type-7Homo sapiens (human)
proteasome complex26S proteasome non-ATPase regulatory subunit 1Homo sapiens (human)
extracellular region26S proteasome non-ATPase regulatory subunit 1Homo sapiens (human)
nucleoplasm26S proteasome non-ATPase regulatory subunit 1Homo sapiens (human)
cytosol26S proteasome non-ATPase regulatory subunit 1Homo sapiens (human)
membrane26S proteasome non-ATPase regulatory subunit 1Homo sapiens (human)
azurophil granule lumen26S proteasome non-ATPase regulatory subunit 1Homo sapiens (human)
proteasome regulatory particle26S proteasome non-ATPase regulatory subunit 1Homo sapiens (human)
proteasome accessory complex26S proteasome non-ATPase regulatory subunit 1Homo sapiens (human)
nucleus26S proteasome non-ATPase regulatory subunit 1Homo sapiens (human)
proteasome regulatory particle, base subcomplex26S proteasome non-ATPase regulatory subunit 1Homo sapiens (human)
proteasome storage granule26S proteasome non-ATPase regulatory subunit 1Homo sapiens (human)
cytoplasmAtaxin-2Homo sapiens (human)
Golgi apparatusAtaxin-2Homo sapiens (human)
trans-Golgi networkAtaxin-2Homo sapiens (human)
cytosolAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
membraneAtaxin-2Homo sapiens (human)
perinuclear region of cytoplasmAtaxin-2Homo sapiens (human)
ribonucleoprotein complexAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
proteasome complex26S proteasome non-ATPase regulatory subunit 13Homo sapiens (human)
extracellular region26S proteasome non-ATPase regulatory subunit 13Homo sapiens (human)
nucleus26S proteasome non-ATPase regulatory subunit 13Homo sapiens (human)
nucleoplasm26S proteasome non-ATPase regulatory subunit 13Homo sapiens (human)
cytosol26S proteasome non-ATPase regulatory subunit 13Homo sapiens (human)
membrane26S proteasome non-ATPase regulatory subunit 13Homo sapiens (human)
secretory granule lumen26S proteasome non-ATPase regulatory subunit 13Homo sapiens (human)
ficolin-1-rich granule lumen26S proteasome non-ATPase regulatory subunit 13Homo sapiens (human)
proteasome regulatory particle26S proteasome non-ATPase regulatory subunit 13Homo sapiens (human)
proteasome accessory complex26S proteasome non-ATPase regulatory subunit 13Homo sapiens (human)
cytosol26S proteasome non-ATPase regulatory subunit 13Homo sapiens (human)
proteasome regulatory particle, lid subcomplex26S proteasome non-ATPase regulatory subunit 13Homo sapiens (human)
nucleus26S proteasome non-ATPase regulatory subunit 13Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (319)

Assay IDTitleYearJournalArticle
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508591NCATS Rat Liver Microsome Stability Profiling2020Scientific reports, 11-26, Volume: 10, Issue:1
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID686947qHTS for small molecule inhibitors of Yes1 kinase: Primary Screen2013Bioorganic & medicinal chemistry letters, Aug-01, Volume: 23, Issue:15
Identification of potent Yes1 kinase inhibitors using a library screening approach.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347128qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347137qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for Daoy cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347119qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347114qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347138qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D caspase screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347121qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347135qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347129qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347136qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347123qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508612NCATS Parallel Artificial Membrane Permeability Assay (PAMPA) Profiling2017Bioorganic & medicinal chemistry, 02-01, Volume: 25, Issue:3
Highly predictive and interpretable models for PAMPA permeability.
AID1347117qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347115qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347127qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347111qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347125qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347126qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347118qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347122qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347139qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347140qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347113qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347109qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347110qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for A673 cells)2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347141qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347116qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347124qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347112qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1895439Inhibition of human 20S proteasome beta2 subunit using Ac-RLR-AMC as substrate preincubated for 2 hrs followed by substrate addition and measured after 1 hr by fluorescence intensity assay2021Journal of medicinal chemistry, 07-22, Volume: 64, Issue:14
Structure-Based Optimization and Discovery of M3258, a Specific Inhibitor of the Immunoproteasome Subunit LMP7 (β5i).
AID1604185Inhibition of 20S proteasome beta 2i (unknown origin) after 1 hr by fluorescence based assay2019European journal of medicinal chemistry, Nov-15, Volume: 182Immunoproteasome-selective inhibitors: An overview of recent developments as potential drugs for hematologic malignancies and autoimmune diseases.
AID1219198Drug metabolism in pooled human hepatocytes assessed as disapperance rate at 1 uM by LC-MS/MS analysis in presence of 30 uM CYP1A2 inhibitor furafylline2013Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1
Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib.
AID1624026Inhibition of human 20s constitutive proteasome beta5 chymotrypsin-like activity using Suc-LLVY-AMC as substrate preincubated for 15 mins followed by substrate addition2019European journal of medicinal chemistry, Feb-15, Volume: 164Covalent docking modelling-based discovery of tripeptidyl epoxyketone proteasome inhibitors composed of aliphatic-heterocycles.
AID1825581Cytotoxicity in human bone marrow mononuclear cell assessed as total number of mononuclear cells at 50 nM measured after 72 hrs by Annexin V staining based flow cytometric analysis (Rvb =78.2%)2022Journal of medicinal chemistry, 02-10, Volume: 65, Issue:3
Synthesis and Evaluation of Structurally Diverse C-2-Substituted Thienopyrimidine-Based Inhibitors of the Human Geranylgeranyl Pyrophosphate Synthase.
AID1683219Antiproliferative activity against human NCI-H929 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay2021Bioorganic & medicinal chemistry, 01-01, Volume: 29Optimization of piperidine constructed peptidyl derivatives as proteasome inhibitors.
AID1219248Cytotoxicity against human hepatocytes assessed as cell viability by MTT assay2013Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1
Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib.
AID353775Metabolic stability in mouse liver microsomes assessed as extraction ratio at 1 uM2009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
Design and synthesis of an orally bioavailable and selective peptide epoxyketone proteasome inhibitor (PR-047).
AID1624055Antiproliferative activity against human MM1S cells after 72 hrs by MTS assay2019European journal of medicinal chemistry, Feb-15, Volume: 164Covalent docking modelling-based discovery of tripeptidyl epoxyketone proteasome inhibitors composed of aliphatic-heterocycles.
AID1128238Inhibition of recombinant cathepsin G (unknown origin) using Suc-Ala-Ala-Pro-Phe-AMC as substrate by spectrofluorometer analysis2014Journal of medicinal chemistry, Mar-27, Volume: 57, Issue:6
Structurally novel highly potent proteasome inhibitors created by the structure-based hybridization of nonpeptidic belactosin derivatives and peptide boronates.
AID1624040Antiproliferative activity against human MGC803 cells after 72 hrs by MTS assay2019European journal of medicinal chemistry, Feb-15, Volume: 164Covalent docking modelling-based discovery of tripeptidyl epoxyketone proteasome inhibitors composed of aliphatic-heterocycles.
AID1595607Cytotoxicity against human RPMI8226 cells after 72 hrs by CellTiter 96 AQueous one solution cell proliferation assay2019Journal of medicinal chemistry, 05-09, Volume: 62, Issue:9
Development of Novel Epoxyketone-Based Proteasome Inhibitors as a Strategy To Overcome Cancer Resistance to Carfilzomib and Bortezomib.
AID734741Irreversible inhibition of chymotrypsin-like activity of human 20S proteasome beta 5 subunit using Suc-LLVY-AMC as substrate incubated for 12 hrs prior to substrate addition followed by compound wash out measured after 1 hr by dialysis method2013Journal of medicinal chemistry, May-09, Volume: 56, Issue:9
Potent proteasome inhibitors derived from the unnatural cis-cyclopropane isomer of Belactosin A: synthesis, biological activity, and mode of action.
AID1895435Inhibition of human 20S immunoproteasome beta-1i subunit using (Ac-PAL)2R110 as substrate preincubated for 2 hrs followed by substrate addition and measured after 1 hr by fluorescence intensity assay2021Journal of medicinal chemistry, 07-22, Volume: 64, Issue:14
Structure-Based Optimization and Discovery of M3258, a Specific Inhibitor of the Immunoproteasome Subunit LMP7 (β5i).
AID1219181AUC last in human patient with relapsed solid tumor at 20 mg/m'2, iv administered on days 1, 2, 8, 9, 15 and 16 of 28-day cycle over 2 to 10 mins measured on day 16 of cycle 1 by LC-MS/MS analysis2013Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1
Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib.
AID1325163Antiproliferative activity against human MM1S cells measured after 72 hrs by MTS assay2016Bioorganic & medicinal chemistry, 12-01, Volume: 24, Issue:23
Design, synthesis and biological evaluation of novel non-covalent piperidine-containing peptidyl proteasome inhibitors.
AID1604184Inhibition of 20S proteasome beta 2c (unknown origin) after 1 hr by fluorescence based assay2019European journal of medicinal chemistry, Nov-15, Volume: 182Immunoproteasome-selective inhibitors: An overview of recent developments as potential drugs for hematologic malignancies and autoimmune diseases.
AID1325785Cytotoxicity against human IMR90 cells harboring wild type p53 assessed as reduction in cell viability after 48 hrs by 7AAD-staining based FACS analysis
AID1690820Volume of distribution at steady state in Sprague-Dawley rat at 4 mg/kg, iv measured up to 48 hrs by LC-MS/MS analysis
AID1690823Toxicity in BALB/c athymic nude mouse xenografted with human HCT-116 cells assessed as reduction in body weight at 5 mg/kg, iv administered twice a week for 28 days
AID1825582Cytotoxicity in human bone marrow mononuclear cell assessed as viable cells at 50 nM measured after 72 hrs by Annexin V staining based flow cytometric analysis (Rvb = 77.9%)2022Journal of medicinal chemistry, 02-10, Volume: 65, Issue:3
Synthesis and Evaluation of Structurally Diverse C-2-Substituted Thienopyrimidine-Based Inhibitors of the Human Geranylgeranyl Pyrophosphate Synthase.
AID1325777Cytotoxicity against human RD-ES cells harboring p53 mutant assessed as reduction in cell viability after 48 hrs by 7AAD-staining based FACS analysis
AID1219195Drug metabolism in pooled human hepatocytes assessed as disapperance rate at 1 uM by LC-MS/MS analysis in presence of 10 uM CYP2C19 inhibitor (+)-N-3-benzylnirvanol2013Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1
Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib.
AID1325771Inhibition of trypsin like activity of rabbit 20S proteasome using Bz-Val-Gly-Arg-AMC as substrate preincubated for 15 mins followed by substrate addition measured after 2 hrs by fluorescence-based assay
AID1532132Inhibition of human trypsin-like activity of 20S constitutive proteasome using Z-VLR-AMC as substrate preincubated for 15 mins followed by substrate addition by fluorescence assay2019European journal of medicinal chemistry, Jan-01, Volume: 161Design, synthesis, and biological evaluation of novel phenol ether derivatives as non-covalent proteasome inhibitors.
AID1624054Toxicity in human RPMI8226 cells xenografted CB17 NOD/SCID mouse assessed as induction of mouse mortality at 4 mg/kg, iv administered for 18 days through regimen of twice weekly for three weeks on days 1 and 22019European journal of medicinal chemistry, Feb-15, Volume: 164Covalent docking modelling-based discovery of tripeptidyl epoxyketone proteasome inhibitors composed of aliphatic-heterocycles.
AID1219229Inhibition of CYP3A in human liver microsomes assessed as substrate metabolite formation using midazolam as substrate preincubated with microsomes for 30 mins prior to substrate addition measured after 5 mins by LC-MS/MS analysis2013Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1
Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib.
AID1219239Time-dependent inhibition of CYP3A in human liver microsomes assessed as testosterone 6-hydroxylation using testosterone as substrate by LC-MS/MS analysis2013Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1
Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib.
AID706731Ratio of Kinact to Ki for human 20S proteasome subunit beta22012Journal of medicinal chemistry, Dec-13, Volume: 55, Issue:23
Molecular mechanisms of acquired proteasome inhibitor resistance.
AID1219249Inhibition of CYP3A in human liver microsomes assessed as substrate metabolite formation using midazolam as substrate measured after 5 mins by LC-MS/MS analysis2013Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1
Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib.
AID1252355Antiproliferative activity against human RKO cells after 72 hrs by oxyluciferin luminescence assay2015Bioorganic & medicinal chemistry letters, Nov-01, Volume: 25, Issue:21
Structure-activity relationship study of syringolin A as a potential anticancer agent.
AID1141826Cytotoxic activity against human RPMI8226 cells after 72 hrs by MTS assay2014Bioorganic & medicinal chemistry, Jun-01, Volume: 22, Issue:11
Design, synthesis and biological evaluation of novel tripeptidyl epoxyketone derivatives constructed from β-amino acid as proteasome inhibitors.
AID1384571Inhibition of 20S proteasome activity in human ANBL-6 cells2018Journal of medicinal chemistry, 09-13, Volume: 61, Issue:17
Reviewing Hit Discovery Literature for Difficult Targets: Glutathione Transferase Omega-1 as an Example.
AID1408289Inhibition of 20S proteasome beta2 subunit in human Jurkat cell lysate using Suc-RLR-AMC as substrate pretreated for 30 mins followed by substrate addition and measured after 60 mins by fluorescence assay2018European journal of medicinal chemistry, Sep-05, Volume: 157Design, synthesis, and evaluation of cystargolide-based β-lactones as potent proteasome inhibitors.
AID1141827Cytotoxic activity against human NCI-H929 cells after 72 hrs by MTS assay2014Bioorganic & medicinal chemistry, Jun-01, Volume: 22, Issue:11
Design, synthesis and biological evaluation of novel tripeptidyl epoxyketone derivatives constructed from β-amino acid as proteasome inhibitors.
AID1624052Toxicity in human RPMI8226 cells xenografted CB17 NOD/SCID mouse assessed as effect on body weight at 4 to 5 mg/kg, iv administered for 18 days through regimen of twice weekly for three weeks on days 1 and 22019European journal of medicinal chemistry, Feb-15, Volume: 164Covalent docking modelling-based discovery of tripeptidyl epoxyketone proteasome inhibitors composed of aliphatic-heterocycles.
AID1325780Cytotoxicity against human MCF7 cells harboring wild type p53 assessed as reduction in cell viability after 48 hrs by 7AAD-staining based FACS analysis
AID1128236Inhibition of recombinant cathepsin A (unknown origin) using Mca-Arg-Pro-Pro-Gly-Phe-Ser-Ala-Phe-Lys(Dnp)-OH as substrate incubated with enzyme for 5 mins prior to substrate challenge for 2 hrs by spectrofluorometer analysis2014Journal of medicinal chemistry, Mar-27, Volume: 57, Issue:6
Structurally novel highly potent proteasome inhibitors created by the structure-based hybridization of nonpeptidic belactosin derivatives and peptide boronates.
AID1690794Irreversible inhibition of human 20S proteasome beta5 subunit assessed as residual enzyme activity using Suc-LLVY-Glo as substrate preincubated for 2 hrs followed by compound washout and further incubated for 4 hrs followed by substrate addition and measu
AID1219199Drug metabolism in pooled human hepatocytes assessed as disapperance rate at 1 uM by LC-MS/MS analysis2013Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1
Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib.
AID353767Inhibition of chymotrypsin-like activity of 20S proteasome in human MOLT4 cells after 1 hr by CellTiter-Glo luminescent assay2009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
Design and synthesis of an orally bioavailable and selective peptide epoxyketone proteasome inhibitor (PR-047).
AID1604187Inhibition of 20S proteasome beta 5i (unknown origin) after 1 hr by fluorescence based assay2019European journal of medicinal chemistry, Nov-15, Volume: 182Immunoproteasome-selective inhibitors: An overview of recent developments as potential drugs for hematologic malignancies and autoimmune diseases.
AID1595601Stability in Sprague-Dawley rat liver microsomes at 1 uM measured up to 120 mins by LC-MS/MS analysis2019Journal of medicinal chemistry, 05-09, Volume: 62, Issue:9
Development of Novel Epoxyketone-Based Proteasome Inhibitors as a Strategy To Overcome Cancer Resistance to Carfilzomib and Bortezomib.
AID1219203Drug excretion in urine of iv dosed human patient with relapsed and refractory hematological malignancies assessed as morpholino-hPhe-Leu metabolite formation administered on days 1, 2, 8, 9, 15 and 16 of 28-day cycle over 2 to 10 mins by LC-MS/MS analysi2013Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1
Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib.
AID1532133Inhibition of 20S immunoproteasome LMP7 (unknown origin) using Ac-ANW-AMC as substrate preincubated for 15 mins followed by substrate addition by fluorescence assay2019European journal of medicinal chemistry, Jan-01, Volume: 161Design, synthesis, and biological evaluation of novel phenol ether derivatives as non-covalent proteasome inhibitors.
AID1219173Drug metabolism in plasma of iv dosed human patient with relapsed and refractory hematological malignancies assessed as morpholino-hPhe metabolite formation administered on days 1, 2, 8, 9, 15 and 16 of 28-day cycle over 2 to 10 mins by LC-MS/MS analysis2013Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1
Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib.
AID1219206Drug metabolism in plasma of iv dosed human patient with relapsed and refractory hematological malignancies assessed as morpholino-hPhe-Leu metabolite formation administered on days 1, 2, 8, 9, 15 and 16 of 28-day cycle over 2 to 10 mins by LC-MS/MS analy2013Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1
Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib.
AID1325778Cytotoxicity against human KGN cells harboring wild type p53 assessed as reduction in cell viability after 48 hrs by 7AAD-staining based FACS analysis
AID1408281Inhibition of yeast 20S proteasome beta5 subunit using Suc-LLVY-AMC as substrate pretreated for 30 mins followed by substrate addition and measured after 60 mins by fluorescence assay2018European journal of medicinal chemistry, Sep-05, Volume: 157Design, synthesis, and evaluation of cystargolide-based β-lactones as potent proteasome inhibitors.
AID706507P-gp-mediated drug resistance in human CEM/VLB cells relative to control2012Journal of medicinal chemistry, Dec-13, Volume: 55, Issue:23
Molecular mechanisms of acquired proteasome inhibitor resistance.
AID1624044MRT in ICR mouse at 5 mg/kg, iv by LC-MS/MS analysis2019European journal of medicinal chemistry, Feb-15, Volume: 164Covalent docking modelling-based discovery of tripeptidyl epoxyketone proteasome inhibitors composed of aliphatic-heterocycles.
AID1325791Inhibition of 26S proteasome in human MCF7 cells assessed as accumulation of high molecular weight polyubiquitin-conjugated proteins at 35 nM after 4 hrs by Western blot analysis
AID353773Chemical stability in simulated gastric fluid assessed as compound remaining at 4 uM after 15 mins2009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
Design and synthesis of an orally bioavailable and selective peptide epoxyketone proteasome inhibitor (PR-047).
AID1604186Inhibition of 20S proteasome beta 5c (unknown origin) after 1 hr by fluorescence based assay2019European journal of medicinal chemistry, Nov-15, Volume: 182Immunoproteasome-selective inhibitors: An overview of recent developments as potential drugs for hematologic malignancies and autoimmune diseases.
AID1219194Drug metabolism in pooled human hepatocytes assessed as disapperance rate at 1 uM by LC-MS/MS analysis in presence of 10 uM CYP2D6 inhibitor quinidine2013Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1
Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib.
AID1895437Inhibition of human 20S immunoproteasome beta-5i subunit using Suc-LLVY-AMC as substrate preincubated for 2 hrs followed by substrate addition and measured after 1 hr by fluorescence intensity assay2021Journal of medicinal chemistry, 07-22, Volume: 64, Issue:14
Structure-Based Optimization and Discovery of M3258, a Specific Inhibitor of the Immunoproteasome Subunit LMP7 (β5i).
AID1219238Time-dependent inhibition of CYP3A in human liver microsomes assessed as midazolam 1'-hydroxylation using midazolam as substrate measured after 25-fold diution by LC-MS/MS analysis in presence of NADPH2013Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1
Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib.
AID1690813AUC(0 to t) in Sprague-Dawley rat at 4 mg/kg, iv measured up to 48 hrs by LC-MS/MS analysis
AID1624027Inhibition of human 20s immunoproteasome beta5i activity using Suc-LLVY-AMC as substrate preincubated for 15 mins followed by substrate addition2019European journal of medicinal chemistry, Feb-15, Volume: 164Covalent docking modelling-based discovery of tripeptidyl epoxyketone proteasome inhibitors composed of aliphatic-heterocycles.
AID1225670Inhibition of proteasome (unknown origin)2015Journal of natural products, Apr-24, Volume: 78, Issue:4
Cystargolides, 20S Proteasome Inhibitors Isolated from Kitasatospora cystarginea.
AID1219205Drug metabolism in plasma of iv dosed human patient with relapsed and refractory hematological malignancies assessed as morpholino-hPhe-Leu-Phe-Leu-diol metabolite formation administered on days 1, 2, 8, 9, 15 and 16 of 28-day cycle over 2 to 10 mins by L2013Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1
Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib.
AID1219213Drug excretion in urine of human multiple myeloma patient with normal renal function at 15 mg/m'2, iv on days 1, 2, 8, 9, 15 and 16 of 28-day cycle over 2 to 10 mins by LC-MS/MS analysis relative to total drug dose2013Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1
Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib.
AID1597895Half life in human liver microsomes at 1 uM pre-incubated for 5 mins followed by NADP+ addition and measured up to 20 mins by LC-MS analysis
AID1219208Decrease in CYP3A gene expression in human hepatocytes at 2.5 uM after 3 days by qPCR analysis2013Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1
Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib.
AID1597894Half life in dog liver microsomes at 1 uM pre-incubated for 5 mins followed by NADP+ addition and measured up to 20 mins by LC-MS analysis
AID1141825Inhibition of chymotrypsin-like enzyme activity of purified human 20S proteasome using Suc-Leu-Leu-Val-Tyr-AMC as substrate by fluorescence method2014Bioorganic & medicinal chemistry, Jun-01, Volume: 22, Issue:11
Design, synthesis and biological evaluation of novel tripeptidyl epoxyketone derivatives constructed from β-amino acid as proteasome inhibitors.
AID1597891Half life in rat liver microsomes at 1 uM pre-incubated for 5 mins followed by NADP+ addition and measured up to 20 mins by LC-MS analysis
AID1624030Inhibition of MMP12 (unknown origin) at 10 ug/mL using Ac-Pro-Leu-Gly-[(S)-2-mercapto-4-methyl-pentanoyl]-Leu-Gly-Oet as substrate relative to control2019European journal of medicinal chemistry, Feb-15, Volume: 164Covalent docking modelling-based discovery of tripeptidyl epoxyketone proteasome inhibitors composed of aliphatic-heterocycles.
AID1770086Inhibition of human 20S proteasome chymotrypsin-like activity in human RPMI-8226 cells overexpressing ABCB1 using Suc-LLVY-AMC as fluorogenic substrate incubated for 3 hrs by fluorescence assay2021Journal of medicinal chemistry, 08-12, Volume: 64, Issue:15
Macrocyclic Immunoproteasome Inhibitors as a Potential Therapy for Alzheimer's Disease.
AID1128245Irreversible inhibition of chymotrypsin-like activity of human 20S proteasome using Suc-LLVY-AMC as substrate measured after drug wash-out2014Journal of medicinal chemistry, Mar-27, Volume: 57, Issue:6
Structurally novel highly potent proteasome inhibitors created by the structure-based hybridization of nonpeptidic belactosin derivatives and peptide boronates.
AID1325161Inhibition of chymotrypsin-like activity of human 20S proteasome preincubated for 15 mins followed by addition of Suc-Leu-Leu-Val-Tyr-AMC as substrate by fluorescence analysis2016Bioorganic & medicinal chemistry, 12-01, Volume: 24, Issue:23
Design, synthesis and biological evaluation of novel non-covalent piperidine-containing peptidyl proteasome inhibitors.
AID353772Cytotoxicity against multidrug resistance transporter expressing doxorubicin resistant human MESSA cells assessed as cell viability after 72 hrs by CellTiter-Glo luminescent assay2009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
Design and synthesis of an orally bioavailable and selective peptide epoxyketone proteasome inhibitor (PR-047).
AID1219189Inhibition of CYP2C19 in human liver microsomes using S-mephenytoin as substrate after 5 mins by LC-MS/MS analysis2013Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1
Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib.
AID1436351Cytotoxicity against human MM1S cells measured after 72 hrs by MTS assay2017European journal of medicinal chemistry, Jan-27, Volume: 126Exploration of novel piperazine or piperidine constructed non-covalent peptidyl derivatives as proteasome inhibitors.
AID1198170Metabolic stability in Balb/c mouse liver microsomes2015Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4
Proteasome inhibitors with pyrazole scaffolds from structure-based virtual screening.
AID1128237Inhibition of recombinant cathepsin B (unknown origin) using Z-Leu-Arg-AMC as substrate by spectrofluorometer analysis2014Journal of medicinal chemistry, Mar-27, Volume: 57, Issue:6
Structurally novel highly potent proteasome inhibitors created by the structure-based hybridization of nonpeptidic belactosin derivatives and peptide boronates.
AID1597903Cytotoxicity against human RPMI8226 cells assessed as cell viability measured after 72 hrs by celltiter96 aqueous cell proliferation assay
AID1624042AUC (0 to t) in ICR mouse at 5 mg/kg, iv by LC-MS/MS analysis2019European journal of medicinal chemistry, Feb-15, Volume: 164Covalent docking modelling-based discovery of tripeptidyl epoxyketone proteasome inhibitors composed of aliphatic-heterocycles.
AID1624028Inhibition of human 20s proteasome subunit beta2 caspase-like activity using Z-LLE-AMC as substrate preincubated for 15 mins followed by substrate addition2019European journal of medicinal chemistry, Feb-15, Volume: 164Covalent docking modelling-based discovery of tripeptidyl epoxyketone proteasome inhibitors composed of aliphatic-heterocycles.
AID1690818Clearance in Sprague-Dawley rat at 4 mg/kg, iv measured up to 48 hrs by LC-MS/MS analysis
AID706517Resistance factor, ratio of IC50 for 100 nM bortezonib-resistant human RPMI8226 cells harboring proteosome subunit beta5 A49T mutant to IC50 for wild type human RPMI8226 cells2012Journal of medicinal chemistry, Dec-13, Volume: 55, Issue:23
Molecular mechanisms of acquired proteasome inhibitor resistance.
AID1219250Inhibition of CYP3A in human liver microsomes assessed as substrate metabolite formation using testosterone as substrate measured after 5 mins by LC-MS/MS analysis2013Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1
Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib.
AID1683227Induction of apoptosis in human RPMI-8226 cells assessed as increase in caspase 3 cleavage at 10 nM measured after 48 hrs by Western blot analysis2021Bioorganic & medicinal chemistry, 01-01, Volume: 29Optimization of piperidine constructed peptidyl derivatives as proteasome inhibitors.
AID1624035Antiproliferative activity against human LP-1 cells after 72 hrs by MTS assay2019European journal of medicinal chemistry, Feb-15, Volume: 164Covalent docking modelling-based discovery of tripeptidyl epoxyketone proteasome inhibitors composed of aliphatic-heterocycles.
AID354000Inhibition of chymotrypsin-like activity of LMP7 immunoproteasome by proteasome active site ELISA2009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
Design and synthesis of an orally bioavailable and selective peptide epoxyketone proteasome inhibitor (PR-047).
AID1408283Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay2018European journal of medicinal chemistry, Sep-05, Volume: 157Design, synthesis, and evaluation of cystargolide-based β-lactones as potent proteasome inhibitors.
AID1595602Half life in patient with relapsed and refractory multiple myeloma2019Journal of medicinal chemistry, 05-09, Volume: 62, Issue:9
Development of Novel Epoxyketone-Based Proteasome Inhibitors as a Strategy To Overcome Cancer Resistance to Carfilzomib and Bortezomib.
AID1325786Cytotoxicity against HNDF cells harboring wild type p53 assessed as reduction in cell viability after 48 hrs by 7AAD-staining based FACS analysis
AID1683221Inhibition of chymotrypsin-like activity of human 20S proteasome using Suc-Leu-Leu-Val-Tyr-AMC as substrate preincubated for 15 mins followed by substrate addition by fluorescence assay2021Bioorganic & medicinal chemistry, 01-01, Volume: 29Optimization of piperidine constructed peptidyl derivatives as proteasome inhibitors.
AID1219179AUC infinity in human patient with relapsed solid tumor at 20 mg/m'2, iv administered on days 1, 2, 8, 9, 15 and 16 of 28-day cycle over 2 to 10 mins measured on day 16 of cycle 1 by LC-MS/MS analysis2013Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1
Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib.
AID1624045Half life in ICR mouse at 5 mg/kg, iv by LC-MS/MS analysis2019European journal of medicinal chemistry, Feb-15, Volume: 164Covalent docking modelling-based discovery of tripeptidyl epoxyketone proteasome inhibitors composed of aliphatic-heterocycles.
AID1825585Cytotoxicity in human bone marrow mononuclear cell assessed as apoptotic cells at 50 nM measured after 72 hrs by Annexin V staining based flow cytometric analysis (Rvb = 21.7%)2022Journal of medicinal chemistry, 02-10, Volume: 65, Issue:3
Synthesis and Evaluation of Structurally Diverse C-2-Substituted Thienopyrimidine-Based Inhibitors of the Human Geranylgeranyl Pyrophosphate Synthase.
AID1624043AUC (0 to infinity) in ICR mouse at 5 mg/kg, iv by LC-MS/MS analysis2019European journal of medicinal chemistry, Feb-15, Volume: 164Covalent docking modelling-based discovery of tripeptidyl epoxyketone proteasome inhibitors composed of aliphatic-heterocycles.
AID1572953Protac activity against VHL/cullin2/ERalpha in human MCF7 cells assessed as ERalpha degradation by measuring reduction in ER protein level pre-treated with raloxifene for 2 hrs followed by compound exposure at 30 nM for 4 hrs by Western blot analysis2019Journal of medicinal chemistry, 02-14, Volume: 62, Issue:3
Discovery of ERD-308 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Estrogen Receptor (ER).
AID1219188Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate after 5 mins by LC-MS/MS analysis2013Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1
Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib.
AID1595609Selectivity ratio of IC50 for human RPMI8226/Cfzr cells to IC50 for human RPMI8226 cells2019Journal of medicinal chemistry, 05-09, Volume: 62, Issue:9
Development of Novel Epoxyketone-Based Proteasome Inhibitors as a Strategy To Overcome Cancer Resistance to Carfilzomib and Bortezomib.
AID1595614Inhibition of 20S proteasome beta5 subunit in human RPMI8226 cell lysate using Suc-LLVY-AMC as substrate pretreated for 1 hr followed by substrate addition and measured at 1 min interval by fluorescence assay2019Journal of medicinal chemistry, 05-09, Volume: 62, Issue:9
Development of Novel Epoxyketone-Based Proteasome Inhibitors as a Strategy To Overcome Cancer Resistance to Carfilzomib and Bortezomib.
AID353768Inhibition of chymotrypsin-like activity of 20S proteasome in BALB/c mouse liver at 40 mg/kg, po after 1 hr2009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
Design and synthesis of an orally bioavailable and selective peptide epoxyketone proteasome inhibitor (PR-047).
AID1597898Intrinsic clearance in dog liver microsomes at 1 uM pre-incubated for 5 mins followed by NADP+ addition and measured up to 20 mins by LC-MS analysis
AID1604182Inhibition of 20S proteasome beta 1c (unknown origin) after 1 hr by fluorescence based assay2019European journal of medicinal chemistry, Nov-15, Volume: 182Immunoproteasome-selective inhibitors: An overview of recent developments as potential drugs for hematologic malignancies and autoimmune diseases.
AID1683228Inhibition of proteasome in human RPMI-8226 cells assessed as accumulation of ubiquitinated proteins at 10 nM measured after 48 hrs by Western blot analysis2021Bioorganic & medicinal chemistry, 01-01, Volume: 29Optimization of piperidine constructed peptidyl derivatives as proteasome inhibitors.
AID1299910Inhibition of trypsin-like activity of rabbit 20S proteasome using Cbz-ARR-AMC substrate incubated at 37 degC by fluorometric assay2016ACS medicinal chemistry letters, Mar-10, Volume: 7, Issue:3
Synthesis and Evaluation of Macrocyclic Peptide Aldehydes as Potent and Selective Inhibitors of the 20S Proteasome.
AID1595603Inhibition of purified human 20S immunoproteasome beta1 subunit using Ac-Pro-Ala-Leu-AMC as substrate pretreated for 1 hr followed by substrate addition and measured at 1 min interval by fluorescence assay2019Journal of medicinal chemistry, 05-09, Volume: 62, Issue:9
Development of Novel Epoxyketone-Based Proteasome Inhibitors as a Strategy To Overcome Cancer Resistance to Carfilzomib and Bortezomib.
AID1219236Time-dependent inhibition of CYP3A in human liver microsomes assessed as testosterone 6-hydroxylation using testosterone as substrate measured after 25-fold diution by LC-MS/MS analysis in presence of NADPH2013Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1
Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib.
AID1597899Intrinsic clearance in monkey liver microsomes at 1 uM pre-incubated for 5 min followed by NADP+ addition and measured up to 20 mins by LC-MS analysis
AID1325773Inhibition of chymotrypsin like activity of mouse spleen 20S proteasome beta5i subunit using Suc-Leu-Leu-Val-Tyr-AMC as substrate preincubated for 15 mins followed by substrate addition measured after 2 hrs by fluorescence-based assay
AID1595608Cytotoxicity against human RPMI8226/Cfzr cells after 72 hrs by CellTiter 96 AQueous one solution cell proliferation assay2019Journal of medicinal chemistry, 05-09, Volume: 62, Issue:9
Development of Novel Epoxyketone-Based Proteasome Inhibitors as a Strategy To Overcome Cancer Resistance to Carfilzomib and Bortezomib.
AID1624025Inhibition of human 20S proteasome preincubated for 15 mins followed by substrate addition2019European journal of medicinal chemistry, Feb-15, Volume: 164Covalent docking modelling-based discovery of tripeptidyl epoxyketone proteasome inhibitors composed of aliphatic-heterocycles.
AID1252356Antiproliferative activity against human TOV21G cells after 72 hrs by oxyluciferin luminescence assay2015Bioorganic & medicinal chemistry letters, Nov-01, Volume: 25, Issue:21
Structure-activity relationship study of syringolin A as a potential anticancer agent.
AID1219178Half life in human patient with relapsed solid tumor at 20 mg/m'2, iv administered on days 1, 2, 8, 9, 15 and 16 of 28-day cycle over 2 to 10 mins measured on day 1 of cycle 1 by LC-MS/MS analysis2013Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1
Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib.
AID1198171Metabolic stability in human liver microsomes2015Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4
Proteasome inhibitors with pyrazole scaffolds from structure-based virtual screening.
AID1597897Intrinsic clearance in BALB/c mouse liver microsomes at 1 uM pre-incubated for 5 mins followed by NADP+ addition and measured up to 20 mins by LC-MS analysis
AID1612370Half life in Sprague-Dawley rat at 2 to 9 mg/kg, iv administered as bolus dose by LC/MS-MS analysis2018Journal of medicinal chemistry, 12-27, Volume: 61, Issue:24
Required Immunoproteasome Subunit Inhibition Profile for Anti-Inflammatory Efficacy and Clinical Candidate KZR-616 ((2 S,3 R)- N-(( S)-3-(Cyclopent-1-en-1-yl)-1-(( R)-2-methyloxiran-2-yl)-1-oxopropan-2-yl)-3-hydroxy-3-(4-methoxyphenyl)-2-(( S)-2-(2-morpho
AID1690825Covalent binding affinity to human 20S proteasome beta5 subunit assessed as compound-tryptic digest TTTLAFKFR peptide adduct formation at 10 uM incubated for 2 hrs measured after overnight incubation with trypsin by LC-MS/MS analysis
AID1219174Plasma protein binding in iv dosed human multiple myeloma patient at 15 mg/m'2 in first cycle and escalated to 20 mg/m'2 thereafter administered on days 1, 2, 8, 9, 15 and 16 of 28-day cycle over 2 to 10 mins by LC-MS/MS analysis2013Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1
Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib.
AID1687100Inhibition of Plasmodium falciparum 20S proteasome beta 5 subunit chymotrypsin-like activity using fluorogenic peptide Ac-WLA-AMC as substrate in presence of PA28alpha at 0.8 uM measured over 5 hrs by fluorescence microplate reader assay2018Journal of medicinal chemistry, 11-21, Volume: 61, Issue:22
Target Validation and Identification of Novel Boronate Inhibitors of the Plasmodium falciparum Proteasome.
AID353780Selectivity for chymotrypsin-like activity over tyrosine-like activity of human 20S proteasome2009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
Design and synthesis of an orally bioavailable and selective peptide epoxyketone proteasome inhibitor (PR-047).
AID1895436Inhibition of human 20S immunoproteasome beta-2i subunit using Ac-RLR-AMC as substrate preincubated for 2 hrs followed by substrate addition and measured after 1 hr by fluorescence intensity assay2021Journal of medicinal chemistry, 07-22, Volume: 64, Issue:14
Structure-Based Optimization and Discovery of M3258, a Specific Inhibitor of the Immunoproteasome Subunit LMP7 (β5i).
AID1613994Inhibition of human hepatic cell derived 20s constitutive proteasome beta5 chymotrypsin-like activity using Suc-WLA-AMC as substrate preincubated for 15 mins followed by substrate addition and measured after 60 mins by fluorescence assay2019European journal of medicinal chemistry, Feb-15, Volume: 164Exploration of novel macrocyclic dipeptide N-benzyl amides as proteasome inhibitors.
AID1624057Inhibition of human 20S proteasome at 1 nM preincubated for 30 mins followed by substrate addition relative to control2019European journal of medicinal chemistry, Feb-15, Volume: 164Covalent docking modelling-based discovery of tripeptidyl epoxyketone proteasome inhibitors composed of aliphatic-heterocycles.
AID706732Ratio of Kinact to Ki for human 20S proteasome subunit beta12012Journal of medicinal chemistry, Dec-13, Volume: 55, Issue:23
Molecular mechanisms of acquired proteasome inhibitor resistance.
AID1690821Antitumour activity against human HCT-116 cells xenografted in BALB/c athymic nude mouse assessed as reduction in tumour growth at 5 mg/kg, iv administered twice a week for 28 days by caliper analysis
AID1325770Inhibition of chymotrypsin like activity of rabbit 20S proteasome using Suc-Leu-Leu-Val-Tyr-AMC as substrate preincubated for 15 mins followed by substrate addition measured after 2 hrs by fluorescence-based assay
AID354004Antitumor activity against mouse CT26 cells xenografted in BALB/c mouse assessed as time to achieve significant decrease in tumor volume at 5 mg/kg, iv administered on day 3 post tumor challenge for weekly qdx2 schedule2009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
Design and synthesis of an orally bioavailable and selective peptide epoxyketone proteasome inhibitor (PR-047).
AID353776Metabolic stability in human liver microsomes assessed as extraction ratio at 1 uM2009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
Design and synthesis of an orally bioavailable and selective peptide epoxyketone proteasome inhibitor (PR-047).
AID1436349Inhibition of chymotrypsin-like activity of human 20S proteasome pretreated for 15 mins followed by Suc-Leu-Leu-Val-Tyr-AMC substrate addition by fluorescence assay2017European journal of medicinal chemistry, Jan-27, Volume: 126Exploration of novel piperazine or piperidine constructed non-covalent peptidyl derivatives as proteasome inhibitors.
AID1624036Antiproliferative activity against human MM1R cells after 72 hrs by MTS assay2019European journal of medicinal chemistry, Feb-15, Volume: 164Covalent docking modelling-based discovery of tripeptidyl epoxyketone proteasome inhibitors composed of aliphatic-heterocycles.
AID354016Toxicity in iv dosed BNX mouse xenografted with human RL cells assessed as maximum tolerated dose2009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
Design and synthesis of an orally bioavailable and selective peptide epoxyketone proteasome inhibitor (PR-047).
AID1325792Terminal half life in human plasma at 20 mg/m2 iv, administered for 2 to 10 mins after dexamethasone addition by LC-MS/MS analysis
AID1299917Inhibition of human liver cathepsin B using Cbz-RR-AMC as substrate at 100 uM by fluorometric assay2016ACS medicinal chemistry letters, Mar-10, Volume: 7, Issue:3
Synthesis and Evaluation of Macrocyclic Peptide Aldehydes as Potent and Selective Inhibitors of the 20S Proteasome.
AID1436352Inhibition of chymotrypsin-like activity of 20S proteasome in mouse blood at 2.5 uM pretreated for 40 mins followed by Suc-Leu-Leu-Val-Tyr-AMC substrate addition by fluorescence assay relative to control2017European journal of medicinal chemistry, Jan-27, Volume: 126Exploration of novel piperazine or piperidine constructed non-covalent peptidyl derivatives as proteasome inhibitors.
AID1408290Inhibition of human immunoproteasome beta5 subunit using Suc-RLR-AMC as substrate pretreated for 30 mins followed by substrate addition and measured after 60 mins by fluorescence assay2018European journal of medicinal chemistry, Sep-05, Volume: 157Design, synthesis, and evaluation of cystargolide-based β-lactones as potent proteasome inhibitors.
AID354011Ratio of Kinact to Ki for chymotrypsin-like activity of human 26S proteasome by spectrophotometry2009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
Design and synthesis of an orally bioavailable and selective peptide epoxyketone proteasome inhibitor (PR-047).
AID1408284Cytotoxicity against human RPMI8226 cells after 48 hrs by MTT assay2018European journal of medicinal chemistry, Sep-05, Volume: 157Design, synthesis, and evaluation of cystargolide-based β-lactones as potent proteasome inhibitors.
AID1219202Drug excretion in urine of iv dosed human patient with relapsed and refractory hematological malignancies assessed as morpholino-hPhe-Leu-Phe-Leu-diol metabolite formation administered on days 1, 2, 8, 9, 15 and 16 of 28-day cycle over 2 to 10 mins by LC-2013Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1
Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib.
AID1325784Cytotoxicity against human MCF10A cells harboring wild type p53 assessed as reduction in cell viability after 48 hrs by 7AAD-staining based FACS analysis
AID1408279Inhibition of yeast 20S proteasome beta1 subunit using fluorescent substrate pretreated for 30 mins followed by substrate addition and measured after 60 mins by fluorescence assay2018European journal of medicinal chemistry, Sep-05, Volume: 157Design, synthesis, and evaluation of cystargolide-based β-lactones as potent proteasome inhibitors.
AID1770085Inhibition of human 20S proteasome chymotrypsin-like activity in human RPMI-8226 cells using Suc-LLVY-AMC as fluorogenic substrate incubated for 3 hrs by fluorescence assay2021Journal of medicinal chemistry, 08-12, Volume: 64, Issue:15
Macrocyclic Immunoproteasome Inhibitors as a Potential Therapy for Alzheimer's Disease.
AID1436348In vivo inhibition of chymotrypsin-like activity of 20S proteasome in blood cell of BALB/c mouse at 5 mg/kg, iv after 2 hrs using Suc-Leu-Leu-Val-Tyr-AMC substrate measured by fluorescence assay2017European journal of medicinal chemistry, Jan-27, Volume: 126Exploration of novel piperazine or piperidine constructed non-covalent peptidyl derivatives as proteasome inhibitors.
AID1690811Cmax in Sprague-Dawley rat at 4 mg/kg, iv measured up to 48 hrs by LC-MS/MS analysis
AID1624037Antiproliferative activity against human NCI-H929 cells after 72 hrs by MTS assay2019European journal of medicinal chemistry, Feb-15, Volume: 164Covalent docking modelling-based discovery of tripeptidyl epoxyketone proteasome inhibitors composed of aliphatic-heterocycles.
AID1219247Decrease in CYP1A2 activity in human hepatocytes assessed as acetaminophenol formation using phenacetin as substrate at 2.5 uM incubated for 3 days prior to substrate challenge for 60 mins by LC-MS/MS analysis2013Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1
Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib.
AID1299911Inhibition of PGPH-like activity of rabbit 20S proteasome using Cbz-LLE-AMC substrate incubated at 37 degC by fluorometric assay2016ACS medicinal chemistry letters, Mar-10, Volume: 7, Issue:3
Synthesis and Evaluation of Macrocyclic Peptide Aldehydes as Potent and Selective Inhibitors of the 20S Proteasome.
AID354018Toxicity in iv dosed BALB/c mouse xenografted with mouse CT26 cells assessed as maximum tolerated dose2009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
Design and synthesis of an orally bioavailable and selective peptide epoxyketone proteasome inhibitor (PR-047).
AID1252354Antiproliferative activity against human HCT116 cells after 72 hrs by oxyluciferin luminescence assay2015Bioorganic & medicinal chemistry letters, Nov-01, Volume: 25, Issue:21
Structure-activity relationship study of syringolin A as a potential anticancer agent.
AID1219209Decrease in CYP1A2 gene expression in human hepatocytes at 2.5 uM after 3 days by qPCR analysis2013Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1
Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib.
AID353770Inhibition of chymotrypsin-like activity of 20S proteasome in BALB/c mouse adrenal gland 40 mg/kg, po after 1 hr2009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
Design and synthesis of an orally bioavailable and selective peptide epoxyketone proteasome inhibitor (PR-047).
AID1219196Drug metabolism in pooled human hepatocytes assessed as disapperance rate at 1 uM by LC-MS/MS analysis in presence of 10 uM CYP2C9 inhibitor sulfaphenazole2013Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1
Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib.
AID1219197Drug metabolism in pooled human hepatocytes assessed as disapperance rate at 1 uM by LC-MS/MS analysis in presence of 30 uM CYP2C8 inhibitor montelukast2013Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1
Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib.
AID1895440Inhibition of human 20S proteasome beta5 subunit using Suc-LLVY-AMC as substrate preincubated for 2 hrs followed by substrate addition and measured after 1 hr by fluorescence intensity assay2021Journal of medicinal chemistry, 07-22, Volume: 64, Issue:14
Structure-Based Optimization and Discovery of M3258, a Specific Inhibitor of the Immunoproteasome Subunit LMP7 (β5i).
AID1219187Inhibition of CYP2C8 in human liver microsomes using amodiaquine as substrate after 5 mins by LC-MS/MS analysis2013Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1
Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib.
AID1613997Antiproliferative activity against human MM1S cells after 72 hrs by MTS assay2019European journal of medicinal chemistry, Feb-15, Volume: 164Exploration of novel macrocyclic dipeptide N-benzyl amides as proteasome inhibitors.
AID1683212Induction of apoptosis in human RPMI-8226 cells at 10 nM measured after 48 hrs by DAPI staining based fluorescence microscopy analysis (Rvb = 3.1 +/- 0.85 %)2021Bioorganic & medicinal chemistry, 01-01, Volume: 29Optimization of piperidine constructed peptidyl derivatives as proteasome inhibitors.
AID1595605Cytotoxicity against human NCI-H727 cells after 72 hrs by CellTiter 96 AQueous one solution cell proliferation assay2019Journal of medicinal chemistry, 05-09, Volume: 62, Issue:9
Development of Novel Epoxyketone-Based Proteasome Inhibitors as a Strategy To Overcome Cancer Resistance to Carfilzomib and Bortezomib.
AID1624039Antiproliferative activity against human PC3 cells after 72 hrs by MTS assay2019European journal of medicinal chemistry, Feb-15, Volume: 164Covalent docking modelling-based discovery of tripeptidyl epoxyketone proteasome inhibitors composed of aliphatic-heterocycles.
AID1219177Half life in human patient with relapsed solid tumor at 20 mg/m'2, iv administered on days 1, 2, 8, 9, 15 and 16 of 28-day cycle over 2 to 10 mins measured on day 16 of cycle 1 by LC-MS/MS analysis2013Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1
Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib.
AID706733Ratio of Kinact to Ki for human 20S proteasome subunit beta52012Journal of medicinal chemistry, Dec-13, Volume: 55, Issue:23
Molecular mechanisms of acquired proteasome inhibitor resistance.
AID1299914Inhibition of chymotrypsin (unknown origin) using Suc-LLVY-AMC as substrate at 100 uM by fluorometric assay2016ACS medicinal chemistry letters, Mar-10, Volume: 7, Issue:3
Synthesis and Evaluation of Macrocyclic Peptide Aldehydes as Potent and Selective Inhibitors of the 20S Proteasome.
AID1597904Cytotoxicity against human U266B1 cells assessed as cell viability measured after 72 hrs by celltiter96 aqueous cell proliferation assay
AID1597900Intrinsic clearance in human liver microsomes at 1 uM pre-incubated for 5 min followed by NADP+ addition and measured up to 20 mins by LC-MS analysis
AID1532131Inhibition of human caspase-like activity of 20S constitutive proteasome preincubated for 15 mins followed by substrate addition by fluorescence assay2019European journal of medicinal chemistry, Jan-01, Volume: 161Design, synthesis, and biological evaluation of novel phenol ether derivatives as non-covalent proteasome inhibitors.
AID1624053Toxicity in human RPMI8226 cells xenografted CB17 NOD/SCID mouse assessed as body weight loss at 4 mg/kg, iv administered for 18 days through regimen of twice weekly for three weeks on days 1 and 22019European journal of medicinal chemistry, Feb-15, Volume: 164Covalent docking modelling-based discovery of tripeptidyl epoxyketone proteasome inhibitors composed of aliphatic-heterocycles.
AID1325781Cytotoxicity against human MDA-MB-468 cells harboring mutant p53 assessed as reduction in cell viability after 48 hrs by 7AAD-staining based FACS analysis
AID1597892Half life in monkey liver microsomes at 1 uM pre-incubated for 5 mins followed by NADP+ addition and measured up to 20 mins by LC-MS analysis
AID1597905Inhibition of human ERG in HEK293 cells assessed as effect on QT interval
AID1436350Cytotoxicity against human RPMI8226 cells measured after 72 hrs by MTS assay2017European journal of medicinal chemistry, Jan-27, Volume: 126Exploration of novel piperazine or piperidine constructed non-covalent peptidyl derivatives as proteasome inhibitors.
AID1687099Inhibition of Plasmodium falciparum 20S proteasome beta 2 subunit trypsin-like activity using fluorogenic peptide Ac-WLR-AMC as substrate in presence of PA28alpha at 0.8 uM measured over 5 hrs by fluorescence microplate reader assay2018Journal of medicinal chemistry, 11-21, Volume: 61, Issue:22
Target Validation and Identification of Novel Boronate Inhibitors of the Plasmodium falciparum Proteasome.
AID1219191Drug metabolism in plasma of human multiple myeloma patient assessed as morpholino-hPhe-Leu metabolite formation at 15 mg/m'2, iv administered as single dose measured within first 30 mins after end of drug infusion by LC-MS/MS analysis2013Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1
Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib.
AID1436347Inhibition of chymotrypsin-like activity of 20S proteasome in mouse blood at 0.5 uM pretreated for 40 mins followed by Suc-Leu-Leu-Val-Tyr-AMC substrate addition by fluorescence assay2017European journal of medicinal chemistry, Jan-27, Volume: 126Exploration of novel piperazine or piperidine constructed non-covalent peptidyl derivatives as proteasome inhibitors.
AID1604188Selectivity index, ratio of IC50 for 20S proteasome beta 1c (unknown origin) to IC50 for 20S proteasome beta 1i (unknown origin)2019European journal of medicinal chemistry, Nov-15, Volume: 182Immunoproteasome-selective inhibitors: An overview of recent developments as potential drugs for hematologic malignancies and autoimmune diseases.
AID1683220Antiproliferative activity against human RPMI-8226 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay2021Bioorganic & medicinal chemistry, 01-01, Volume: 29Optimization of piperidine constructed peptidyl derivatives as proteasome inhibitors.
AID354001Antitumor activity against human RL cells xenografted BNX mouse assessed as time to achieve significant decrease in tumor volume at 5 mg/kg, iv administered as weekly qdx2 schedule2009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
Design and synthesis of an orally bioavailable and selective peptide epoxyketone proteasome inhibitor (PR-047).
AID1597896Intrinsic clearance in rat liver microsomes at 1 uM pre-incubated for 5 mins followed by NADP+ addition and measured up to 20 mins by LC-MS analysis
AID1624032Inhibition of Caspase-3 (unknown origin) at 10 ug/mL using AC-DEVD-AMC as substrate by fluorescence assay relative to control2019European journal of medicinal chemistry, Feb-15, Volume: 164Covalent docking modelling-based discovery of tripeptidyl epoxyketone proteasome inhibitors composed of aliphatic-heterocycles.
AID1770087Selectivity index, ratio of IC50 for inhibition of human 20S proteasome chymotrypsin-like activity in human RPMI-8226 cells overexpressing ABCB1 to IC50 for inhibition of human 20S proteasome chymotrypsin-like activity in human RPMI-8226 cells2021Journal of medicinal chemistry, 08-12, Volume: 64, Issue:15
Macrocyclic Immunoproteasome Inhibitors as a Potential Therapy for Alzheimer's Disease.
AID1219245Decrease in CYP3A activity in human hepatocytes assessed as 6-betahydroxytestosterone formation using testosterone as substrate incubated for 3 days prior to substrate challenge for 30 mins by LC-MS/MS analysis2013Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1
Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib.
AID1219246Decrease in CYP3A4 activity in human hepatocytes assessed as 6-betahydroxytestosterone formation using testosterone as substrate at 2.5 uM incubated for 3 days prior to substrate challenge for 30 mins by LC-MS/MS analysis2013Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1
Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib.
AID1624047Volume of distribution at steady state in ICR mouse at 5 mg/kg, iv by LC-MS/MS analysis2019European journal of medicinal chemistry, Feb-15, Volume: 164Covalent docking modelling-based discovery of tripeptidyl epoxyketone proteasome inhibitors composed of aliphatic-heterocycles.
AID1613996Antiproliferative activity against human RPMI8226 cells after 72 hrs by MTS assay2019European journal of medicinal chemistry, Feb-15, Volume: 164Exploration of novel macrocyclic dipeptide N-benzyl amides as proteasome inhibitors.
AID1219204Drug excretion in urine of iv dosed human patient with relapsed and refractory hematological malignancies assessed as morpholino-hPhe metabolite formation administered on days 1, 2, 8, 9, 15 and 16 of 28-day cycle over 2 to 10 mins by LC-MS/MS analysis2013Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1
Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib.
AID1532129Inhibition of human chymotrypsin-like activity of 20S constitutive proteasome using Suc-LLVY-AMC as substrate preincubated for 15 mins followed by substrate addition by fluorescence assay2019European journal of medicinal chemistry, Jan-01, Volume: 161Design, synthesis, and biological evaluation of novel phenol ether derivatives as non-covalent proteasome inhibitors.
AID1604189Selectivity index, ratio of IC50 for 20S proteasome beta 2c (unknown origin) to IC50 for 20S proteasome beta 2i (unknown origin)2019European journal of medicinal chemistry, Nov-15, Volume: 182Immunoproteasome-selective inhibitors: An overview of recent developments as potential drugs for hematologic malignancies and autoimmune diseases.
AID1219184Cmax in human patient with relapsed solid tumor at 20 mg/m'2, iv administered on days 1, 2, 8, 9 15 and 16 of 28-day cycle over 2 to 10 mins measured on day 1 of cycle 1 by LC-MS/MS analysis2013Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1
Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib.
AID1219175Plasma clearance in human patient with relapsed solid tumor at 20 mg/m'2, iv administered on days 1, 2, 8, 9, 15 and 16 of 28-day cycle over 2 to 10 mins measured on day 16 of cycle 1 by LC-MS/MS analysis2013Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1
Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib.
AID1325790Inhibition of 26S proteasome in human MDA-MB-468 cells assessed as accumulation of high molecular weight polyubiquitin-conjugated proteins at 35 nM after 4 hrs by Western blot analysis
AID1624029Inhibition of thrombin (unknown origin) at 10 ug/mL using substrate 3 relative to control2019European journal of medicinal chemistry, Feb-15, Volume: 164Covalent docking modelling-based discovery of tripeptidyl epoxyketone proteasome inhibitors composed of aliphatic-heterocycles.
AID1597893Half life in BALB/c mouse liver microsomes at 1 uM pre-incubated for 5 mins followed by NADP+ addition and measured up to 20 mins by LC-MS analysis
AID1325782Cytotoxicity against human NCI-H929 cells harboring wild type p53 assessed as reduction in cell viability after 48 hrs by 7AAD-staining based FACS analysis
AID353771Cytotoxicity against human MESSA cells assessed as cell viability after 72 hrs by CellTiter-Glo luminescent assay2009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
Design and synthesis of an orally bioavailable and selective peptide epoxyketone proteasome inhibitor (PR-047).
AID1408282Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay2018European journal of medicinal chemistry, Sep-05, Volume: 157Design, synthesis, and evaluation of cystargolide-based β-lactones as potent proteasome inhibitors.
AID1219244Time-dependent inhibition of CYP3A in human liver microsomes preincubated for 30 mins with carfilzomib by LC-MS/MS analysis2013Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1
Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib.
AID1325783Cytotoxicity against human U266 cells harboring mutant p53 assessed as reduction in cell viability after 48 hrs by 7AAD-staining based FACS analysis
AID1604190Selectivity index, ratio of IC50 for 20S proteasome beta 5c (unknown origin) to IC50 for 20S proteasome beta 5i (unknown origin)2019European journal of medicinal chemistry, Nov-15, Volume: 182Immunoproteasome-selective inhibitors: An overview of recent developments as potential drugs for hematologic malignancies and autoimmune diseases.
AID1219240Time-dependent inhibition of CYP3A in human liver microsomes assessed as midazolam 1'-hydroxylation using midazolam as substrate by LC-MS/MS analysis2013Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1
Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib.
AID1624033Inhibition of trypsin (unknown origin) at 10 ug/mL relative to control2019European journal of medicinal chemistry, Feb-15, Volume: 164Covalent docking modelling-based discovery of tripeptidyl epoxyketone proteasome inhibitors composed of aliphatic-heterocycles.
AID1624046Clearance in ICR mouse at 5 mg/kg, iv by LC-MS/MS analysis2019European journal of medicinal chemistry, Feb-15, Volume: 164Covalent docking modelling-based discovery of tripeptidyl epoxyketone proteasome inhibitors composed of aliphatic-heterocycles.
AID1219192Drug metabolism in plasma of human multiple myeloma patient assessed as morpholino-hPhe metabolite formation at 15 mg/m'2, iv administered as single dose measured within first 30 mins after end of drug infusion by LC-MS/MS analysis2013Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1
Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib.
AID1219182AUC last in human patient with relapsed solid tumor at 20 mg/m'2, iv administered on days 1, 2, 8, 9, 15 and 16 of 28-day cycle over 2 to 10 mins measured on day 1 of cycle 1 by LC-MS/MS analysis2013Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1
Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib.
AID1687101Inhibition of Plasmodium falciparum 20S proteasome beta 1 subunit caspase-like activity using fluorogenic peptide Ac-nLPnLD-AMC as substrate in presence of PA28alpha at 0.8 uM measured over 5 hrs by fluorescence microplate reader assay2018Journal of medicinal chemistry, 11-21, Volume: 61, Issue:22
Target Validation and Identification of Novel Boronate Inhibitors of the Plasmodium falciparum Proteasome.
AID1219186Inhibition of CYP1A2 in human liver microsomes using phenacetin as substrate after 5 mins by LC-MS/MS analysis2013Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1
Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib.
AID353774Chemical stability in simulated intestinal fluid assessed as compound remaining at 4 uM after 15 mins2009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
Design and synthesis of an orally bioavailable and selective peptide epoxyketone proteasome inhibitor (PR-047).
AID1408278Inhibition of 20S proteasome beta5 subunit in human Jurkat cell lysate using Suc-LLVY-AMC as substrate pretreated for 30 mins followed by substrate addition and measured after 60 mins by fluorescence assay2018European journal of medicinal chemistry, Sep-05, Volume: 157Design, synthesis, and evaluation of cystargolide-based β-lactones as potent proteasome inhibitors.
AID1299909Inhibition of chymotrypsin-like activity of rabbit 20S proteasome using Suc-LLVY-AMC substrate incubated at 37 degC by fluorometric assay2016ACS medicinal chemistry letters, Mar-10, Volume: 7, Issue:3
Synthesis and Evaluation of Macrocyclic Peptide Aldehydes as Potent and Selective Inhibitors of the 20S Proteasome.
AID1624048In vivo inhibition of 20S proteasome chymotrypsin-like activity in BALB/c mouse at 1.25 to 10 mg/kg, iv using LLV-YAMC as substrate measured after 1 to 96 hrs2019European journal of medicinal chemistry, Feb-15, Volume: 164Covalent docking modelling-based discovery of tripeptidyl epoxyketone proteasome inhibitors composed of aliphatic-heterocycles.
AID1325162Antiproliferative activity against human RPMI8226 cells measured after 72 hrs by MTS assay2016Bioorganic & medicinal chemistry, 12-01, Volume: 24, Issue:23
Design, synthesis and biological evaluation of novel non-covalent piperidine-containing peptidyl proteasome inhibitors.
AID1384570Inhibition of GSTO1-1 (unknown origin) pre-incubated for 1 hr before GSH addition by CDNB-GSH conjugation assay2018Journal of medicinal chemistry, 09-13, Volume: 61, Issue:17
Reviewing Hit Discovery Literature for Difficult Targets: Glutathione Transferase Omega-1 as an Example.
AID1219193Drug metabolism in pooled human hepatocytes assessed as disapperance rate at 1 uM by LC-MS/MS analysis in presence of 10 uM CYP3A inhibitor ketoconazole2013Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1
Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib.
AID353998Selectivity for chymotrypsin-like activity over caspase-like activity of human 20S proteasome2009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
Design and synthesis of an orally bioavailable and selective peptide epoxyketone proteasome inhibitor (PR-047).
AID1690815Half life in Sprague-Dawley rat at 4 mg/kg, iv measured up to 48 hrs by LC-MS/MS analysis
AID1252358Antiproliferative activity against human RPMI8266 cells after 72 hrs by oxyluciferin luminescence assay2015Bioorganic & medicinal chemistry letters, Nov-01, Volume: 25, Issue:21
Structure-activity relationship study of syringolin A as a potential anticancer agent.
AID1624038Antiproliferative activity against human HCT116 cells after 72 hrs by MTS assay2019European journal of medicinal chemistry, Feb-15, Volume: 164Covalent docking modelling-based discovery of tripeptidyl epoxyketone proteasome inhibitors composed of aliphatic-heterocycles.
AID1597890Inhibition of human chymotrypsin-like activity of 20S proteasome using Suc-LLVY-AMC as substrate pre-incubated for 10 mins followed by substrate addition and measured after 1 hr by spectrofluorimetry
AID1597902Antitumour activity against human ARH77 cells xenografted in nude mouse assessed as tumor growth at 5mg/kg, iv dosed at day 14, 811, 15 and 18 for 3 weeks and measured every 2 days by caliper method relative to control
AID1219207Decrease in CYP3A activity in rifampin-treated human hepatocytes assessed as 6-betahydroxytestosterone formation using testosterone as substrate at 2.5 uM after 30 mins by LC-MS/MS analysis2013Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1
Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib.
AID1604183Inhibition of 20S proteasome beta 1i (unknown origin) after 1 hr by fluorescence based assay2019European journal of medicinal chemistry, Nov-15, Volume: 182Immunoproteasome-selective inhibitors: An overview of recent developments as potential drugs for hematologic malignancies and autoimmune diseases.
AID1683218Antiproliferative activity against human MM1.S cells assessed as cell growth inhibition measured after 72 hrs by MTT assay2021Bioorganic & medicinal chemistry, 01-01, Volume: 29Optimization of piperidine constructed peptidyl derivatives as proteasome inhibitors.
AID1219180AUC infinity in human patient with relapsed solid tumor at 20 mg/m'2, iv administered over 2 to 10 mins on days 1, 2, 8, 9, 15 and 16 of 28-day cycle measured on day 1 of cycle 1 by LC-MS/MS analysis2013Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1
Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib.
AID1832020Inhibition of intracellular 20S proteasome activity in Mycobacterium tuberculosis assessed as accumulation of pupylated protein at 50 uM incubated for 48 hrs2021Journal of medicinal chemistry, 05-13, Volume: 64, Issue:9
Macrocyclic Peptides that Selectively Inhibit the
AID353769Inhibition of chymotrypsin-like activity of 20S proteasome in BALB/c mouse blood at 40 mg/kg, po after 1 hr2009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
Design and synthesis of an orally bioavailable and selective peptide epoxyketone proteasome inhibitor (PR-047).
AID1325774Inhibition of bovine alpha chymotrypsin using Ala-Ala-Phe-7-AMC as substrate measured for 10 mins by spectrophotometric analysis
AID1198176Toxicity in human LNCAP cells xenografted nude mouse assessed as body weight loss at 5 mg/kg, ip twice a week for 4 weeks2015Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4
Proteasome inhibitors with pyrazole scaffolds from structure-based virtual screening.
AID1299918Inhibition of m-calpain (unknown origin) using Suc-LY-AMC as substrate at 100 uM by fluorometric assay2016ACS medicinal chemistry letters, Mar-10, Volume: 7, Issue:3
Synthesis and Evaluation of Macrocyclic Peptide Aldehydes as Potent and Selective Inhibitors of the 20S Proteasome.
AID1595606Selectivity ratio of IC50 for human NCI-H727 cells to IC50 for human NCI-H23 cells2019Journal of medicinal chemistry, 05-09, Volume: 62, Issue:9
Development of Novel Epoxyketone-Based Proteasome Inhibitors as a Strategy To Overcome Cancer Resistance to Carfilzomib and Bortezomib.
AID1624031Inhibition of DPP4 (unknown origin) at 10 ug/mL using Ala-Pro-AMC as substrate by fluorometric analysis relative to control2019European journal of medicinal chemistry, Feb-15, Volume: 164Covalent docking modelling-based discovery of tripeptidyl epoxyketone proteasome inhibitors composed of aliphatic-heterocycles.
AID1624056Inhibition of human 20S proteasome at 100 nM preincubated for 30 mins followed by substrate addition relative to control2019European journal of medicinal chemistry, Feb-15, Volume: 164Covalent docking modelling-based discovery of tripeptidyl epoxyketone proteasome inhibitors composed of aliphatic-heterocycles.
AID1325779Cytotoxicity against p53 deficient human SKOV3 cells assessed as reduction in cell viability after 48 hrs by 7AAD-staining based FACS analysis
AID1252357Antiproliferative activity against human CCRF-CEM cells after 72 hrs by oxyluciferin luminescence assay2015Bioorganic & medicinal chemistry letters, Nov-01, Volume: 25, Issue:21
Structure-activity relationship study of syringolin A as a potential anticancer agent.
AID1219237Time-dependent inhibition of CYP3A in human liver microsomes assessed as midazolam 1'-hydroxylation using midazolam as substrate by LC-MS/MS analysis in presence of NADPH2013Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1
Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib.
AID1219231Time-dependent inhibition of CYP3A in human liver microsomes assessed as testosterone 6-hydroxylation using testosterone as substrate by LC-MS/MS analysis in presence of NADPH2013Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1
Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib.
AID1882258Inhibition of proteasome (unknown origin)2022European journal of medicinal chemistry, Feb-05, Volume: 229A review on the treatment of multiple myeloma with small molecular agents in the past five years.
AID1219214Inhibition of CYP2D6 in human liver microsomes using dextromethorphan as substrate after 5 mins by LC-MS/MS analysis2013Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1
Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib.
AID353766Inhibition of chymotrypsin-like activity of human 20S proteasome by spectrofluorimetry2009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
Design and synthesis of an orally bioavailable and selective peptide epoxyketone proteasome inhibitor (PR-047).
AID1624041Antiproliferative activity against human A549 cells after 72 hrs by MTS assay2019European journal of medicinal chemistry, Feb-15, Volume: 164Covalent docking modelling-based discovery of tripeptidyl epoxyketone proteasome inhibitors composed of aliphatic-heterocycles.
AID1325776Cytotoxicity against human WE68 cells harboring wild type p53 assessed as reduction in cell viability after 48 hrs by 7AAD-staining based FACS analysis
AID353999Inhibition of chymotrypsin-like activity of human 20S proteasome beta 5 subunit by proteasome active site ELISA2009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
Design and synthesis of an orally bioavailable and selective peptide epoxyketone proteasome inhibitor (PR-047).
AID1325787Cytotoxicity against human LCL cells harboring wild type p53 assessed as reduction in cell viability after 48 hrs by 7AAD-staining based FACS analysis
AID1408280Inhibition of yeast 20S proteasome beta2 subunit using SUC-RLR-AMC as substrate pretreated for 30 mins followed by substrate addition and measured after 60 mins by fluorescence assay2018European journal of medicinal chemistry, Sep-05, Volume: 157Design, synthesis, and evaluation of cystargolide-based β-lactones as potent proteasome inhibitors.
AID1325166Inhibition of chymotrypsin-like activity of 20S proteasome in mouse blood at 0.5 to 12.5 uM preincubated for 40 mins followed by addition of Suc-Leu-Leu-Val-Tyr-AMC as substrate relative to control2016Bioorganic & medicinal chemistry, 12-01, Volume: 24, Issue:23
Design, synthesis and biological evaluation of novel non-covalent piperidine-containing peptidyl proteasome inhibitors.
AID1895438Inhibition of human 20S immunoproteasome beta1 subunit using Ac-nLPnLD-AMC as substrate preincubated for 2 hrs followed by substrate addition and measured after 1 hr by fluorescence intensity assay2021Journal of medicinal chemistry, 07-22, Volume: 64, Issue:14
Structure-Based Optimization and Discovery of M3258, a Specific Inhibitor of the Immunoproteasome Subunit LMP7 (β5i).
AID1683216Induction of apoptosis in human RPMI-8226 cells assessed as increase in PARP cleavage at 10 nM measured after 48 hrs by Western blot analysis2021Bioorganic & medicinal chemistry, 01-01, Volume: 29Optimization of piperidine constructed peptidyl derivatives as proteasome inhibitors.
AID1219230Inhibition of CYP3A in human liver microsomes assessed as substrate metabolite formation using testosterone as substrate preincubated with microsomes for 30 mins prior to substrate addition measured after 5 mins by LC-MS/MS analysis2013Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1
Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib.
AID1219176Plasma clearance in human patient with relapsed solid tumor at 20 mg/m'2, iv administered over 2 to 10 mins on days 1, 2, 8, 9, 15 and 16 of 28-day cycle measured on day 1 of cycle 1 by LC-MS/MS analysis2013Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1
Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib.
AID1219190Drug metabolism in plasma of human multiple myeloma patient assessed as morpholino-hPhe-Leu-Phe-Leu-diol metabolite formation at 15 mg/m'2, iv administered as single dose measured within first 30 mins after end of drug infusion by LC-MS/MS analysis2013Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1
Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib.
AID1219183Cmax in human patient with relapsed solid tumor at 20 mg/m'2, iv administered on days 1, 2, 8, 9, 15 and 16 of 28-day cycle over 2 to 10 mins measured on day 16 of cycle 1 by LC-MS/MS analysis2013Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1
Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib.
AID1252353Antiproliferative activity against human A431 cells after 72 hrs by oxyluciferin luminescence assay2015Bioorganic & medicinal chemistry letters, Nov-01, Volume: 25, Issue:21
Structure-activity relationship study of syringolin A as a potential anticancer agent.
AID1624034Antiproliferative activity against human RPMI8226 cells after 72 hrs by MTS assay2019European journal of medicinal chemistry, Feb-15, Volume: 164Covalent docking modelling-based discovery of tripeptidyl epoxyketone proteasome inhibitors composed of aliphatic-heterocycles.
AID1595604Cytotoxicity against human NCI-H23 cells after 72 hrs by CellTiter 96 AQueous one solution cell proliferation assay2019Journal of medicinal chemistry, 05-09, Volume: 62, Issue:9
Development of Novel Epoxyketone-Based Proteasome Inhibitors as a Strategy To Overcome Cancer Resistance to Carfilzomib and Bortezomib.
AID1325772Inhibition of caspase like activity of rabbit 20S proteasome using Ac-nLPnLD-AMC as substrate preincubated for 15 mins followed by substrate addition measured after 2 hrs by fluorescence-based assay
AID1645848NCATS Kinetic Aqueous Solubility Profiling2019Bioorganic & medicinal chemistry, 07-15, Volume: 27, Issue:14
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.
AID1347414qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: Secondary screen by immunofluorescence2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347412qHTS assay to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: Counter screen cell viability and HiBit confirmation2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347415qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: tertiary screen by RT-qPCR2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID180049820S proteasome chymotrypsin-like inhibition assay from Article 10.1111/cbdd.12342: \\Design, Synthesis and Biological Evaluation of Peptidyl Epoxyketone Proteasome Inhibitors Composed of ??????-amino Acids.\\2014Chemical biology & drug design, Nov, Volume: 84, Issue:5
Design, synthesis and biological evaluation of peptidyl epoxyketone proteasome inhibitors composed of β-amino acids.
AID1745855NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1745854NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (736)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's13 (1.77)29.6817
2010's464 (63.04)24.3611
2020's259 (35.19)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 69.75

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index69.75 (24.57)
Research Supply Index6.77 (2.92)
Research Growth Index6.74 (4.65)
Search Engine Demand Index118.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (69.75)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials121 (16.18%)5.53%
Reviews129 (17.25%)6.00%
Case Studies71 (9.49%)4.05%
Observational7 (0.94%)0.25%
Other420 (56.15%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
dinitrochlorobenzene
Dinitrochlorobenzene: A skin irritant that may cause dermatitis of both primary and allergic types. Contact sensitization with DNCB has been used as a measure of cellular immunity. DNCB is also used as a reagent for the detection and determination of pyridine compounds.. 1-chloro-2,4-dinitrobenzene : A C-nitro compound that is chlorobenzene carrying a nitro substituent at each of the 2- and 4-positions.		3.2710C-nitro compound;
monochlorobenzenes		allergen;
epitope;
sensitiser
aminolevulinic acid
Aminolevulinic Acid: A compound produced from succinyl-CoA and GLYCINE as an intermediate in heme synthesis. It is used as a PHOTOCHEMOTHERAPY for actinic KERATOSIS.. 5-aminolevulinic acid : The simplest delta-amino acid in which the hydrogens at the gamma position are replaced by an oxo group. It is metabolised to protoporphyrin IX, a photoactive compound which accumulates in the skin. Used (in the form of the hydrochloride salt)in combination with blue light illumination for the treatment of minimally to moderately thick actinic keratosis of the face or scalp.		2.6104-oxo monocarboxylic acid;
amino acid zwitterion;
delta-amino acid		antineoplastic agent;
dermatologic drug;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
photosensitizing agent;
plant metabolite;
prodrug;
Saccharomyces cerevisiae metabolite
adenine
[no description available]		6.171036-aminopurines;
purine nucleobase		Daphnia magna metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
benzene
[no description available]		4.811aromatic annulene;
benzenes;
volatile organic compound		carcinogenic agent;
environmental contaminant;
non-polar solvent
coumarin
2H-chromen-2-one: coumarin derivative		2.610coumarinsfluorescent dye;
human metabolite;
plant metabolite
salicylic acid
Scalp: The outer covering of the calvaria. It is composed of several layers: SKIN; subcutaneous connective tissue; the occipitofrontal muscle which includes the tendinous galea aponeurotica; loose connective tissue; and the pericranium (the PERIOSTEUM of the SKULL).		2.610monohydroxybenzoic acidalgal metabolite;
antifungal agent;
antiinfective agent;
EC 1.11.1.11 (L-ascorbate peroxidase) inhibitor;
keratolytic drug;
plant hormone;
plant metabolite
dimethyl sulfoxide
Dimethyl Sulfoxide: A highly polar organic liquid, that is used widely as a chemical solvent. Because of its ability to penetrate biological membranes, it is used as a vehicle for topical application of pharmaceuticals. It is also used to protect tissue during CRYOPRESERVATION. Dimethyl sulfoxide shows a range of pharmacological activity including analgesia and anti-inflammation.. dimethyl sulfoxide : A 2-carbon sulfoxide in which the sulfur atom has two methyl substituents.		2.110sulfoxide;
volatile organic compound		alkylating agent;
antidote;
Escherichia coli metabolite;
geroprotector;
MRI contrast agent;
non-narcotic analgesic;
polar aprotic solvent;
radical scavenger
glycine
[no description available]		10.02361alpha-amino acid;
amino acid zwitterion;
proteinogenic amino acid;
serine family amino acid		EC 2.1.2.1 (glycine hydroxymethyltransferase) inhibitor;
fundamental metabolite;
hepatoprotective agent;
micronutrient;
neurotransmitter;
NMDA receptor agonist;
nutraceutical
thioctic acid
Thioctic Acid: An octanoic acid bridged with two sulfurs so that it is sometimes also called a pentanoic acid in some naming schemes. It is biosynthesized by cleavage of LINOLEIC ACID and is a coenzyme of oxoglutarate dehydrogenase (KETOGLUTARATE DEHYDROGENASE COMPLEX). It is used in DIETARY SUPPLEMENTS.		2.610dithiolanes;
heterocyclic fatty acid;
thia fatty acid		fundamental metabolite;
geroprotector
nickel
Nickel: A trace element with the atomic symbol Ni, atomic number 28, and atomic weight 58.69. It is a cofactor of the enzyme UREASE.. nickel ion : A nickel atom having a net electric charge.. nickel atom : Chemical element (nickel group element atom) with atomic number 28.		4.811metal allergen;
nickel group element atom		epitope;
micronutrient
nitroxyl
nitroxyl: hydroxamic acid oxidized to nitroxyl free radical. nitroxyl : A nitrogen oxoacid consisting of an oxygen atom double-bonded to an NH group.		4.811nitrogen oxoacid
phosphorylcholine
Phosphorylcholine: Calcium and magnesium salts used therapeutically in hepatobiliary dysfunction.. phosphocholine : The phosphate of choline; and the parent compound of the phosphocholine family.		5.2140phosphocholinesallergen;
epitope;
hapten;
human metabolite;
mouse metabolite
picolinic acid
picolinic acid: iron-chelating agent that inhibits DNA synthesis; may interfere with iron-dependent production of stable free organic radical which is essential for ribonucleotide reductase formation of deoxyribonucleotides; RN given refers to parent cpd; structure in Merck Index, 9th ed, #7206. picolinic acid : A pyridinemonocarboxylic acid in which the carboxy group is located at position 2. It is an intermediate in the metabolism of tryptophan.		2.610pyridinemonocarboxylic acidhuman metabolite;
MALDI matrix material
succinic acid
Succinic Acid: A water-soluble, colorless crystal with an acid taste that is used as a chemical intermediate, in medicine, the manufacture of lacquers, and to make perfume esters. It is also used in foods as a sequestrant, buffer, and a neutralizing agent. (Hawley's Condensed Chemical Dictionary, 12th ed, p1099; McGraw-Hill Dictionary of Scientific and Technical Terms, 4th ed, p1851). succinic acid : An alpha,omega-dicarboxylic acid resulting from the formal oxidation of each of the terminal methyl groups of butane to the corresponding carboxy group. It is an intermediate metabolite in the citric acid cycle.		4.811alpha,omega-dicarboxylic acid;
C4-dicarboxylic acid		anti-ulcer drug;
fundamental metabolite;
micronutrient;
nutraceutical;
radiation protective agent
thiamine
thiamine(1+) : A primary alcohol that is 1,3-thiazol-3-ium substituted by (4-amino-2-methylpyrimidin-5-yl)methyl, methyl and 2-hydroxyethyl groups at positions 3, 4 and 5, respectively.		2.610primary alcohol;
vitamin B1		Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
toluene
methylbenzene : Any alkylbenzene that is benzene substituted with one or more methyl groups.		4.811methylbenzene;
toluenes;
volatile organic compound		cholinergic antagonist;
fuel additive;
neurotoxin;
non-polar solvent
uric acid
Uric Acid: An oxidation product, via XANTHINE OXIDASE, of oxypurines such as XANTHINE and HYPOXANTHINE. It is the final oxidation product of purine catabolism in humans and primates, whereas in most other mammals URATE OXIDASE further oxidizes it to ALLANTOIN.. uric acid : An oxopurine that is the final oxidation product of purine metabolism.. 6-hydroxy-1H-purine-2,8(7H,9H)-dione : A tautomer of uric acid having oxo groups at C-2 and C-8 and a hydroxy group at C-6.. 7,9-dihydro-1H-purine-2,6,8(3H)-trione : An oxopurine in which the purine ring is substituted by oxo groups at positions 2, 6, and 8.		5.321uric acidEscherichia coli metabolite;
human metabolite;
mouse metabolite
urea
pseudourea: clinical use; structure. isourea : A carboximidic acid that is the imidic acid tautomer of urea, H2NC(=NH)OH, and its hydrocarbyl derivatives.		4.811isourea;
monocarboxylic acid amide;
one-carbon compound		Daphnia magna metabolite;
Escherichia coli metabolite;
fertilizer;
flour treatment agent;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
b 844-39
[no description available]		2.1510diarylmethane
pk 11195
PK-11195 : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 1-(2-chlorophenyl)isoquinoline-3-carboxylic acid with the amino group of sec-butylmethylamine		3.0740aromatic amide;
isoquinolines;
monocarboxylic acid amide;
monochlorobenzenes		antineoplastic agent
pd 173074
[no description available]		2.0810aromatic amine;
biaryl;
dimethoxybenzene;
pyridopyrimidine;
tertiary amino compound;
ureas		antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
fibroblast growth factor receptor antagonist
3-aminobenzamide
[no description available]		2.610benzamides;
substituted aniline		EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor
pleconaril
WIN 63843: structure given in first source		2.610
4-(2-aminoethyl)benzenesulfonylfluoride
[no description available]		2.610
jtv519
[no description available]		2.8930
phenytoin
[no description available]		2.610imidazolidine-2,4-dioneanticonvulsant;
drug allergen;
sodium channel blocker;
teratogenic agent
abt 702
[no description available]		2.0810bipyridines
acetaminophen
Acetaminophen: Analgesic antipyretic derivative of acetanilide. It has weak anti-inflammatory properties and is used as a common analgesic, but may cause liver, blood cell, and kidney damage.. paracetamol : A member of the class of phenols that is 4-aminophenol in which one of the hydrogens attached to the amino group has been replaced by an acetyl group.		7.1510acetamides;
phenols		antipyretic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
cyclooxygenase 3 inhibitor;
environmental contaminant;
ferroptosis inducer;
geroprotector;
hepatotoxic agent;
human blood serum metabolite;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
xenobiotic
acetazolamide
Acetazolamide: One of the CARBONIC ANHYDRASE INHIBITORS that is sometimes effective against absence seizures. It is sometimes useful also as an adjunct in the treatment of tonic-clonic, myoclonic, and atonic seizures, particularly in women whose seizures occur or are exacerbated at specific times in the menstrual cycle. However, its usefulness is transient often because of rapid development of tolerance. Its antiepileptic effect may be due to its inhibitory effect on brain carbonic anhydrase, which leads to an increased transneuronal chloride gradient, increased chloride current, and increased inhibition. (From Smith and Reynard, Textbook of Pharmacology, 1991, p337)		2.610monocarboxylic acid amide;
sulfonamide;
thiadiazoles		anticonvulsant;
diuretic;
EC 4.2.1.1 (carbonic anhydrase) inhibitor
albendazole
[no description available]		4.811aryl sulfide;
benzimidazoles;
benzimidazolylcarbamate fungicide;
carbamate ester		anthelminthic drug;
microtubule-destabilising agent;
tubulin modulator
alprazolam
Alprazolam: A triazolobenzodiazepine compound with antianxiety and sedative-hypnotic actions, that is efficacious in the treatment of PANIC DISORDERS, with or without AGORAPHOBIA, and in generalized ANXIETY DISORDERS. (From AMA Drug Evaluations Annual, 1994, p238). alprazolam : A member of the class of triazolobenzodiazepines that is 4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine carrying methyl, phenyl and chloro substituents at positions 1, 6 and 8 respectively. Alprazolam is only found in individuals that have taken this drug.		2.8930organochlorine compound;
triazolobenzodiazepine		anticonvulsant;
anxiolytic drug;
GABA agonist;
muscle relaxant;
sedative;
xenobiotic
alprenolol
Alprenolol: One of the ADRENERGIC BETA-ANTAGONISTS used as an antihypertensive, anti-anginal, and anti-arrhythmic agent.. alprenolol : A secondary alcohol that is propan-2-ol substituted by a 2-allylphenoxy group at position 1 and an isopropylamino group at position 3. It is a beta-adrenergic antagonist used as a antihypertensive, anti-arrhythmia and a sympatholytic agent.		2.610secondary alcohol;
secondary amino compound		anti-arrhythmia drug;
antihypertensive agent;
beta-adrenergic antagonist;
sympatholytic agent
amantadine
amant: an antiviral compound consisting of an adamantane derivative chemically linked to a water-solube polyanioic matrix; structure in first source		2.610adamantanes;
primary aliphatic amine		analgesic;
antiparkinson drug;
antiviral drug;
dopaminergic agent;
NMDA receptor antagonist;
non-narcotic analgesic
p-aminohippuric acid
p-Aminohippuric Acid: The glycine amide of 4-aminobenzoic acid. Its sodium salt is used as a diagnostic aid to measure effective renal plasma flow (ERPF) and excretory capacity.. p-aminohippurate : A hippurate that is the conjugate base of p-aminohippuric acid, arising from deprotonation of the carboxy group.. p-aminohippuric acid : An N-acylglycine that is the 4-amino derivative of hippuric acid; used as a diagnostic agent in the measurement of renal plasma flow.		2.2510N-acylglycineDaphnia magna metabolite
2-aminothiazole
2-aminothiazole: RN given refers to parent cpd; structure. 1,3-thiazol-2-amine : A primary amino compound that is 1,3-thiazole substituted by an amino group at position 2.		2.6101,3-thiazoles;
primary amino compound
amiodarone
Amiodarone: An antianginal and class III antiarrhythmic drug. It increases the duration of ventricular and atrial muscle action by inhibiting POTASSIUM CHANNELS and VOLTAGE-GATED SODIUM CHANNELS. There is a resulting decrease in heart rate and in vascular resistance.. amiodarone : A member of the class of 1-benzofurans that is 1-benzofuran substituted by a butyl group at position 2 and a 4-[2-(diethylamino)ethoxy]-3,5-diiodobenzoyl group at position 3. It is a cardiovascular drug used for the treatment of cardiac dysrhythmias.		3.18101-benzofurans;
aromatic ketone;
organoiodine compound;
tertiary amino compound		cardiovascular drug
dan 2163
[no description available]		2.8930aromatic amide;
aromatic amine;
benzamides;
pyrrolidines;
sulfone		environmental contaminant;
second generation antipsychotic;
xenobiotic
amlexanox
amlexanox: SRA-A antagonist;structure given in first source. amlexanox : A pyridochromene-derived monocarboxylic acid having an amino substituent at the 2-position, an oxo substituent at the 5-position and an isopropyl substituent at the 7-position.		2.8930monocarboxylic acid;
pyridochromene		anti-allergic agent;
anti-ulcer drug;
non-steroidal anti-inflammatory drug
amodiaquine
Amodiaquine: A 4-aminoquinoline compound with anti-inflammatory properties.. amodiaquine : A quinoline having a chloro group at the 7-position and an aryl amino group at the 4-position.		2.610aminoquinoline;
organochlorine compound;
phenols;
secondary amino compound;
tertiary amino compound		anticoronaviral agent;
antimalarial;
drug allergen;
EC 2.1.1.8 (histamine N-methyltransferase) inhibitor;
non-steroidal anti-inflammatory drug;
prodrug
aspirin
Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5). acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.. acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.		7.920benzoic acids;
phenyl acetates;
salicylates		anticoagulant;
antipyretic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
drug allergen;
EC 1.1.1.188 (prostaglandin-F synthase) inhibitor;
geroprotector;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
plant activator;
platelet aggregation inhibitor;
prostaglandin antagonist;
teratogenic agent
astemizole
Astemizole: Antihistamine drug now withdrawn from the market in many countries because of rare but potentially fatal side effects.. astemizole : A piperidine compound having a 2-(4-methoxyphenyl)ethyl group at the 1-position and an N-[(4-fluorobenzyl)benzimidazol-2-yl]amino group at the 4-position.		2.8930benzimidazoles;
piperidines		anti-allergic agent;
anticoronaviral agent;
H1-receptor antagonist
baclofen
[no description available]		2.610amino acid zwitterion;
gamma-amino acid;
monocarboxylic acid;
monochlorobenzenes;
primary amino compound		central nervous system depressant;
GABA agonist;
muscle relaxant
benzamide
benzamide : An aromatic amide that consists of benzene bearing a single carboxamido substituent. The parent of the class of benzamides.		2.610benzamides
benzbromarone
Benzbromarone: Uricosuric that acts by increasing uric acid clearance. It is used in the treatment of gout.. benzbromarone : 1-Benzofuran substituted at C-2 and C-3 by an ethyl group and a 3,5-dibromo-4-hydroxybenzoyl group respectively. An inhibitor of CYP2C9, it is used as an anti-gout medication.		2.89301-benzofurans;
aromatic ketone		uricosuric drug
bicalutamide
bicalutamide: approved for treatment of advanced prostate cancer. N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanamide : A member of the class of (trifluoromethyl)benzenes that is 4-amino-2-(trifluoromethyl)benzonitrile in which one of the amino hydrogens is substituted by a 3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanoyl group.. bicalutamide : A racemate comprising of equal amounts of (R)-bicalutamide and (S)-bicalutamide. It is an oral non-steroidal antiandrogen used in the treatment of prostate cancer and hirsutism.		2.0810(trifluoromethyl)benzenes;
monocarboxylic acid amide;
monofluorobenzenes;
nitrile;
sulfone;
tertiary alcohol
bisindolylmaleimide i
bisindolylmaleimide I: a bis(indolyl)maleimide		2.8930
bufexamac
Bufexamac: A benzeneacetamide with anti-inflammatory, analgesic, and antipyretic action. It is administered topically, orally, or rectally.. bufexamac : A hydroxamic acid derived from phenylacetamide in which the benzene moiety is substituted at C-4 by a butoxy group. It has anti-inflammatory, analgesic, and antipyretic properties.		2.8930aromatic ether;
hydroxamic acid		antipyretic;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
cadralazine
cadralazine: structure given in first source		2.8930organic molecular entity
verapamil
Verapamil: A calcium channel blocker that is a class IV anti-arrhythmia agent.. verapamil : A racemate comprising equimolar amounts of dexverapamil and (S)-verapamil. An L-type calcium channel blocker of the phenylalkylamine class, it is used (particularly as the hydrochloride salt) in the treatment of hypertension, angina pectoris and cardiac arrhythmia, and as a preventive medication for migraine.. 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile : A tertiary amino compound that is 3,4-dimethoxyphenylethylamine in which the hydrogens attached to the nitrogen are replaced by a methyl group and a 4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl group.		2.4820aromatic ether;
nitrile;
polyether;
tertiary amino compound
camostat
camostat : A benzoate ester resulting from the formal condensation of the carboxy group of 4-guanidinobenzoic acid with the hydroxy group of 2-(dimethylamino)-2-oxoethyl (4-hydroxyphenyl)acetate. It is a potent inhibitor of the human transmembrane protease serine 2 (TMPRSS2) and its mesylate salt is currently under investigation for its effectiveness in COVID-19 patients.		2.610benzoate ester;
carboxylic ester;
diester;
guanidines;
tertiary carboxamide		anti-inflammatory agent;
anticoronaviral agent;
antifibrinolytic drug;
antihypertensive agent;
antineoplastic agent;
antiviral agent;
serine protease inhibitor
camphor, (+-)-isomer
[no description available]		2.610bornane monoterpenoid;
cyclic monoterpene ketone		plant metabolite
candesartan
candesartan: a nonpeptide angiotensin II receptor antagonist. candesartan : A benzimidazolecarboxylic acid that is 1H-benzimidazole-7-carboxylic acid substituted by an ethoxy group at position 2 and a ({2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl}methyl) group at position 1. It is a angiotensin receptor antagonist used for the treatment of hypertension.		2.610benzimidazolecarboxylic acid;
biphenylyltetrazole		angiotensin receptor antagonist;
antihypertensive agent;
environmental contaminant;
xenobiotic
carmustine
Carmustine: A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed). carmustine : A member of the class of N-nitrosoureas that is 1,3-bis(2-chloroethyl)urea in which one of the nitrogens is substituted by a nitroso group.		2.2510N-nitrosoureas;
organochlorine compound		alkylating agent;
antineoplastic agent
carvedilol
[no description available]		2.6320carbazoles;
secondary alcohol;
secondary amino compound		alpha-adrenergic antagonist;
antihypertensive agent;
beta-adrenergic antagonist;
cardiovascular drug;
vasodilator agent
celecoxib
[no description available]		2.0810organofluorine compound;
pyrazoles;
sulfonamide;
toluenes		cyclooxygenase 2 inhibitor;
geroprotector;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
cetirizine
Cetirizine: A potent second-generation histamine H1 antagonist that is effective in the treatment of allergic rhinitis, chronic urticaria, and pollen-induced asthma. Unlike many traditional antihistamines, it does not cause drowsiness or anticholinergic side effects.. cetirizine : A member of the class of piperazines that is piperazine in which the hydrogens attached to nitrogen are replaced by a (4-chlorophenyl)(phenyl)methyl and a 2-(carboxymethoxy)ethyl group respectively.		2.6320ether;
monocarboxylic acid;
monochlorobenzenes;
piperazines		anti-allergic agent;
environmental contaminant;
H1-receptor antagonist;
xenobiotic
cetylpyridinium
Cetylpyridinium: Cationic bactericidal surfactant used as a topical antiseptic for skin, wounds, mucous membranes, instruments, etc.; and also as a component in mouthwash and lozenges.		2.610pyridinium ion
chelerythrine
chelerythrine : A benzophenanthridine alkaloid isolated from the root of Zanthoxylum simulans, Chelidonium majus L., and other Papaveraceae.		2.0810benzophenanthridine alkaloid;
organic cation		antibacterial agent;
antineoplastic agent;
EC 2.7.11.13 (protein kinase C) inhibitor
chlorcyclizine
chlorcyclizine: was heading 1964-94 (Prov 1964-73); CHLOROCYCLIZINE & HISTACHLORAZINE were see CHLORCYCLIZINE 1977-94; use PIPERAZINES to search CHLORCYCLIZINE 1966-94; histamine H1-blocker used both orally and topically in allergies and also for the prevention of motion sickness		2.8930diarylmethane
chloroquine
Chloroquine: The prototypical antimalarial agent with a mechanism that is not well understood. It has also been used to treat rheumatoid arthritis, systemic lupus erythematosus, and in the systemic therapy of amebic liver abscesses.. chloroquine : An aminoquinoline that is quinoline which is substituted at position 4 by a [5-(diethylamino)pentan-2-yl]amino group at at position 7 by chlorine. It is used for the treatment of malaria, hepatic amoebiasis, lupus erythematosus, light-sensitive skin eruptions, and rheumatoid arthritis.		11.0341aminoquinoline;
organochlorine compound;
secondary amino compound;
tertiary amino compound		anticoronaviral agent;
antimalarial;
antirheumatic drug;
autophagy inhibitor;
dermatologic drug
chloroxylenol
chloroxylenol: topical antiseptic; RN given refers to parent cpd; structure. 4-chloro-3,5-dimethylphenol : A member of the class of phenols that is 3,5-xylenol which is substituted at position 4 by chlorine. It is bactericidal against most Gram-positive bacteria but less effective against Staphylococci and Gram-negative bacteria, and often inactive against Pseudomonas species. It is ineffective against bacterial spores.		2.610monochlorobenzenes;
phenols		antiseptic drug;
disinfectant;
molluscicide
chlorpromazine
Chlorpromazine: The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking DOPAMINE RECEPTORS. Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the treatment of intractable hiccup.. chlorpromazine : A substituted phenothiazine in which the ring nitrogen at position 10 is attached to C-3 of an N,N-dimethylpropanamine moiety.		2.610organochlorine compound;
phenothiazines;
tertiary amine		anticoronaviral agent;
antiemetic;
dopaminergic antagonist;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
phenothiazine antipsychotic drug
chlorpropamide
Chlorpropamide: A sulfonylurea hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. (From Martindale, The Extra Pharmacopoeia, 30th ed, p277). chlorpropamide : An N-sulfonylurea that is urea in which a hydrogen attached to one of the nitrogens is substituted by 4-chlorobenzenesulfonyl group and a hydrogen attached to the other nitrogen is substituted by propyl group. Chlorpropamide is a hypoglycaemic agent used in the treatment of type 2 (non-insulin-dependent) diabetes mellitus not responding to dietary modification.		2.1510monochlorobenzenes;
N-sulfonylurea		hypoglycemic agent;
insulin secretagogue
ci 994
tacedinaline: oral cytostatic drug with impressive differential activity against leukemic cells & normal stem-cells. tacedinaline : A benzamide obtained by formal condensation of the carboxy group of 4-acetamidobenzoic acid with one of the amino groups of 1,2-phenylenediamine. An oral cytostatic drug with impressive differential activity against leukemic cells and normal stem-cells. Also used in combination therapy for selected tumors including non-smoll cell lung, pancreatic, breast, and colorectal cancers.		2.8930acetamides;
benzamides;
substituted aniline		antineoplastic agent;
EC 3.5.1.98 (histone deacetylase) inhibitor
ciprofibrate
[no description available]		2.610cyclopropanes;
monocarboxylic acid;
organochlorine compound		antilipemic drug
clioquinol
Clioquinol: A potentially neurotoxic 8-hydroxyquinoline derivative long used as a topical anti-infective, intestinal antiamebic, and vaginal trichomonacide. The oral preparation has been shown to cause subacute myelo-optic neuropathy and has been banned worldwide.. 5-chloro-7-iodoquinolin-8-ol : A monohydroxyquinoline that is quinolin-8-ol in which the hydrogens at positions 5 and 7 are replaced by chlorine and iodine, respectively. It has antibacterial and atifungal properties, and is used in creams for the treatment of skin infections. It has also been investigated as a chelator of copper and zinc ions for the possible treatment of Alzheimer's disease.		3.1610monohydroxyquinoline;
organochlorine compound;
organoiodine compound		antibacterial agent;
antifungal agent;
antimicrobial agent;
antineoplastic agent;
antiprotozoal drug;
chelator;
copper chelator
clomipramine
Clomipramine: A tricyclic antidepressant similar to IMIPRAMINE that selectively inhibits the uptake of serotonin in the brain. It is readily absorbed from the gastrointestinal tract and demethylated in the liver to form its primary active metabolite, desmethylclomipramine.. clomipramine : A dibenzoazepine that is 10,11-dihydro-5H-dibenzo[b,f]azepine which is substituted by chlorine at position 3 and in which the hydrogen attached to the nitrogen is replaced by a 3-(dimethylamino)propyl group. One of the more sedating tricyclic antidepressants, it is used as the hydrochloride salt for the treatment of depression as well as obsessive-compulsive disorder and phobias.		2.610dibenzoazepineanticoronaviral agent;
antidepressant;
EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor;
serotonergic antagonist;
serotonergic drug;
serotonin uptake inhibitor
cyclosporine
cyclosporin A : A cyclic nonribosomal peptide of eleven amino acids; an immunosuppressant drug widely used in post-allogeneic organ transplant to reduce the activity of the patient's immune system, and therefore the risk of organ rejection. Also causes reversible inhibition of immunocompetent lymphocytes in the G0- and G1-phase of the cell cycle.		2.5920
danthron
danthron: structure. chrysazin : A dihydroxyanthraquinone that is anthracene-9,10-dione substituted by hydroxy groups at positions 1 and 8.		2.610dihydroxyanthraquinoneapoptosis inducer;
plant metabolite
deferiprone
Deferiprone: A pyridone derivative and iron chelator that is used in the treatment of IRON OVERLOAD in patients with THALASSEMIA.. deferiprone : A member of the class of 4-pyridones that is pyridin-4(1H)-one substituted at positions 1 and 2 by methyl groups and at position 3 by a hydroxy group. A lipid-soluble iron-chelator used for treatment of thalassaemia.		2.6104-pyridonesiron chelator;
protective agent
dipyridamole
Dipyridamole: A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752). dipyridamole : A pyrimidopyrimidine that is 2,2',2'',2'''-(pyrimido[5,4-d]pyrimidine-2,6-diyldinitrilo)tetraethanol substituted by piperidin-1-yl groups at positions 4 and 8 respectively. A vasodilator agent, it inhibits the formation of blood clots.		2.610piperidines;
pyrimidopyrimidine;
tertiary amino compound;
tetrol		adenosine phosphodiesterase inhibitor;
EC 3.5.4.4 (adenosine deaminase) inhibitor;
platelet aggregation inhibitor;
vasodilator agent
disulfiram
[no description available]		2.6620organic disulfide;
organosulfur acaricide		angiogenesis inhibitor;
antineoplastic agent;
apoptosis inducer;
EC 1.2.1.3 [aldehyde dehydrogenase (NAD(+))] inhibitor;
EC 3.1.1.1 (carboxylesterase) inhibitor;
EC 3.1.1.8 (cholinesterase) inhibitor;
EC 5.99.1.2 (DNA topoisomerase) inhibitor;
ferroptosis inducer;
fungicide;
NF-kappaB inhibitor
valproic acid
Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.. valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.		2.610branched-chain fatty acid;
branched-chain saturated fatty acid		anticonvulsant;
antimanic drug;
EC 3.5.1.98 (histone deacetylase) inhibitor;
GABA agent;
neuroprotective agent;
psychotropic drug;
teratogenic agent
doxazosin
Doxazosin: A prazosin-related compound that is a selective alpha-1-adrenergic blocker.. doxazosin : A member of the class of quinazolines that is quinazoline substituted by an amino group at position 4, methoxy groups at positions 6 and 7 and a piperazin-1-yl group at position 2 which in turn is substituted by a 2,3-dihydro-1,4-benzodioxin-2-ylcarbonyl group at position 4. An antihypertensive agent, it is used in the treatment of high blood pressure.		2.610aromatic amine;
benzodioxine;
monocarboxylic acid amide;
N-acylpiperazine;
N-arylpiperazine;
quinazolines		alpha-adrenergic antagonist;
antihyperplasia drug;
antihypertensive agent;
antineoplastic agent;
vasodilator agent
ebselen
ebselen : A benzoselenazole that is 1,2-benzoselenazol-3-one carrying an additional phenyl substituent at position 2. Acts as a mimic of glutathione peroxidase.		2.610benzoselenazoleanti-inflammatory drug;
antibacterial agent;
anticoronaviral agent;
antifungal agent;
antineoplastic agent;
antioxidant;
apoptosis inducer;
EC 1.13.11.33 (arachidonate 15-lipoxygenase) inhibitor;
EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor;
EC 1.3.1.8 [acyl-CoA dehydrogenase (NADP(+))] inhibitor;
EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor;
EC 2.5.1.7 (UDP-N-acetylglucosamine 1-carboxyvinyltransferase) inhibitor;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
EC 3.1.3.25 (inositol-phosphate phosphatase) inhibitor;
EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor;
EC 3.5.4.1 (cytosine deaminase) inhibitor;
EC 5.1.3.2 (UDP-glucose 4-epimerase) inhibitor;
enzyme mimic;
ferroptosis inhibitor;
genotoxin;
hepatoprotective agent;
neuroprotective agent;
radical scavenger
ethacrynic acid
Ethacrynic Acid: A compound that inhibits symport of sodium, potassium, and chloride primarily in the ascending limb of Henle, but also in the proximal and distal tubules. This pharmacological action results in excretion of these ions, increased urinary output, and reduction in extracellular fluid. This compound has been classified as a loop or high ceiling diuretic.. etacrynic acid : An aromatic ether that is phenoxyacetic acid in which the phenyl ring is substituted by chlorines at positions 2 and 3, and by a 2-methylidenebutanoyl group at position 4. It is a loop diuretic used to treat high blood pressure resulting from diseases such as congestive heart failure, liver failure, and kidney failure. It is also a glutathione S-transferase (EC 2.5.1.18) inhibitor.		3.2710aromatic ether;
aromatic ketone;
dichlorobenzene;
monocarboxylic acid		EC 2.5.1.18 (glutathione transferase) inhibitor;
ion transport inhibitor;
loop diuretic
etidronate
Etidronic Acid: A diphosphonate which affects calcium metabolism. It inhibits ectopic calcification and slows down bone resorption and bone turnover.. etidronic acid : A 1,1-bis(phosphonic acid) that is (ethane-1,1-diyl)bis(phosphonic acid) having a hydroxy substituent at the 1-position. It inhibits the formation, growth, and dissolution of hydroxyapatite crystals by chemisorption to calcium phosphate surfaces.		2.6101,1-bis(phosphonic acid)antineoplastic agent;
bone density conservation agent;
chelator
2-hexyloxybenzamide
2-hexyloxybenzamide: structure		2.610aromatic ether;
benzamides		antifungal agent
brl 42810
[no description available]		2.6102-aminopurines;
acetate ester		antiviral drug;
prodrug
fenbendazole
Fenbendazole: Antinematodal benzimidazole used in veterinary medicine.. fenbendazole : A member of the class of benzimidazoles that is 1H-benzimidazole which is substituted at positons 2 and 5 by (methoxycarbonyl)amino and phenylsulfanediyl groups, respectively. A broad-spectrum anthelmintic, it is used, particularly in veterinary medicine, for the treatment of nematodal infections.		2.8930aryl sulfide;
benzimidazoles;
carbamate ester		antinematodal drug
berotek
Fenoterol: A synthetic adrenergic beta-2 agonist that is used as a bronchodilator and tocolytic.. fenoterol : A member of the class resorcinols that is 5-(1-hydroxyethyl)benzene-1,3-diol in which one of the methyl hydrogens is replaced by a 1-(4-hydroxyphenyl)propan-2-amino group. A beta2-adrenergic agonist, it is used (as the hydrobromide salt) as a bronchodilator in the management of reversible airway obstruction.		2.1510resorcinols;
secondary alcohol;
secondary amino compound		beta-adrenergic agonist;
bronchodilator agent;
sympathomimetic agent;
tocolytic agent
fluphenazine
[no description available]		2.610N-alkylpiperazine;
organofluorine compound;
phenothiazines		anticoronaviral agent;
dopaminergic antagonist;
phenothiazine antipsychotic drug
fluorouracil
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.. 5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.		2.610nucleobase analogue;
organofluorine compound		antimetabolite;
antineoplastic agent;
environmental contaminant;
immunosuppressive agent;
radiosensitizing agent;
xenobiotic
furosemide
Furosemide: A benzoic-sulfonamide-furan. It is a diuretic with fast onset and short duration that is used for EDEMA and chronic RENAL INSUFFICIENCY.. furosemide : A chlorobenzoic acid that is 4-chlorobenzoic acid substituted by a (furan-2-ylmethyl)amino and a sulfamoyl group at position 2 and 5 respectively. It is a diuretic used in the treatment of congestive heart failure.		2.0810chlorobenzoic acid;
furans;
sulfonamide		environmental contaminant;
loop diuretic;
xenobiotic
gabexate
Gabexate: A serine proteinase inhibitor used therapeutically in the treatment of pancreatitis, disseminated intravascular coagulation (DIC), and as a regional anticoagulant for hemodialysis. The drug inhibits the hydrolytic effects of thrombin, plasmin, and kallikrein, but not of chymotrypsin and aprotinin.		2.610benzoate ester
glutaral
Glutaral: One of the protein CROSS-LINKING REAGENTS that is used as a disinfectant for sterilization of heat-sensitive equipment and as a laboratory reagent, especially as a fixative.. glutaraldehyde : A dialdehyde comprised of pentane with aldehyde functions at C-1 and C-5.		2.610dialdehydecross-linking reagent;
disinfectant;
fixative
go 6976
[no description available]		2.8930indolocarbazole;
organic heterohexacyclic compound		EC 2.7.11.13 (protein kinase C) inhibitor
gossypol
Gossypol: A dimeric sesquiterpene found in cottonseed (GOSSYPIUM). The (-) isomer is active as a male contraceptive (CONTRACEPTIVE AGENTS, MALE) whereas toxic symptoms are associated with the (+) isomer.		2.0810
fasudil
fasudil: intracellular calcium antagonist; structure in first source. fasudil : An isoquinoline substituted by a (1,4-diazepan-1-yl)sulfonyl group at position 5. It is a Rho-kinase inhibitor and its hydrochloride hydrate form is approved for the treatment of cerebral vasospasm and cerebral ischemia.		2.5820isoquinolines;
N-sulfonyldiazepane		antihypertensive agent;
calcium channel blocker;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor;
geroprotector;
neuroprotective agent;
nootropic agent;
vasodilator agent
haloperidol
Haloperidol: A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279). haloperidol : A compound composed of a central piperidine structure with hydroxy and p-chlorophenyl substituents at position 4 and an N-linked p-fluorobutyrophenone moiety.		3.1640aromatic ketone;
hydroxypiperidine;
monochlorobenzenes;
organofluorine compound;
tertiary alcohol		antidyskinesia agent;
antiemetic;
dopaminergic antagonist;
first generation antipsychotic;
serotonergic antagonist
miltefosine
miltefosine: hexadecyl phosphocholine derivative of cisplatin; did not substantially activate HIV long terminal repeat; less toxic than cisplatin. miltefosine : A phospholipid that is the hexadecyl monoester of phosphocholine.		2.610phosphocholines;
phospholipid		anti-inflammatory agent;
anticoronaviral agent;
antifungal agent;
antineoplastic agent;
antiprotozoal drug;
apoptosis inducer;
immunomodulator;
protein kinase inhibitor
hexylresorcinol
[no description available]		2.610resorcinols
beta-thujaplicin
beta-thujaplicin: structure. beta-thujaplicin : A monoterpenoid that is cyclohepta-2,4,6-trien-1-one substituted by a hydroxy group at position 2 and an isopropyl group at position 4. Isolated from Thuja plicata and Chamaecyparis obtusa, it exhibits antimicrobial activities.		2.610cyclic ketone;
enol;
monoterpenoid		antibacterial agent;
antifungal agent;
antineoplastic agent;
antiplasmodial drug;
plant metabolite
homochlorocyclizine
homochlorocyclizine: RN given refers to parent cpd		2.8930diarylmethane
hycanthone
Hycanthone: Potentially toxic, but effective antischistosomal agent, it is a metabolite of LUCANTHONE.. hycanthone : A thioxanthen-9-one compound having a hydroxymethyl substituent at the 1-position and a 2-[(diethylamino)ethyl]amino substituent at the 4-position. It was formerly used (particularly as the monomethanesulfonic acid salt) as a schistosomicide for individual or mass treatement of infection with Schistosoma haematobium and S. mansoni, but due to its toxicity and concern about possible carcinogenicity, it has been replaced by other drugs such as praziquantel.		2.610thioxanthenesmutagen;
schistosomicide drug
hydrochlorothiazide
Hydrochlorothiazide: A thiazide diuretic often considered the prototypical member of this class. It reduces the reabsorption of electrolytes from the renal tubules. This results in increased excretion of water and electrolytes, including sodium, potassium, chloride, and magnesium. It is used in the treatment of several disorders including edema, hypertension, diabetes insipidus, and hypoparathyroidism.. hydrochlorothiazide : A benzothiadiazine that is 3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxide substituted by a chloro group at position 6 and a sulfonamide at 7. It is diuretic used for the treatment of hypertension and congestive heart failure.		2.610benzothiadiazine;
organochlorine compound;
sulfonamide		antihypertensive agent;
diuretic;
environmental contaminant;
xenobiotic
hydroxychloroquine
Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970). hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.		7.1310aminoquinoline;
organochlorine compound;
primary alcohol;
secondary amino compound;
tertiary amino compound		anticoronaviral agent;
antimalarial;
antirheumatic drug;
dermatologic drug
hydroxyurea
[no description available]		2.610one-carbon compound;
ureas		antimetabolite;
antimitotic;
antineoplastic agent;
DNA synthesis inhibitor;
EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor;
genotoxin;
immunomodulator;
radical scavenger;
teratogenic agent
hydroxyzine
Hydroxyzine: A histamine H1 receptor antagonist that is effective in the treatment of chronic urticaria, dermatitis, and histamine-mediated pruritus. Unlike its major metabolite CETIRIZINE, it does cause drowsiness. It is also effective as an antiemetic, for relief of anxiety and tension, and as a sedative.. hydroxyzine : A N-alkylpiperazine that is piperzine in which the nitrogens atoms are substituted by 2-(2-hydroxyethoxy)ethyl and (4-chlorophenyl)(phenyl)methyl groups respectively.		2.8930hydroxyether;
monochlorobenzenes;
N-alkylpiperazine		anticoronaviral agent;
antipruritic drug;
anxiolytic drug;
dermatologic drug;
H1-receptor antagonist
ibuprofen
Midol: combination of cinnamedrine, phenacetin, aspirin & caffeine		2.610monocarboxylic acidantipyretic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
drug allergen;
environmental contaminant;
geroprotector;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
radical scavenger;
xenobiotic
ifenprodil
ifenprodil: NMDA receptor antagonist		2.8930piperidines
ifosfamide
[no description available]		4.9522ifosfamidesalkylating agent;
antineoplastic agent;
environmental contaminant;
immunosuppressive agent;
xenobiotic
indirubin-3'-monoxime
indirubin-3'-monoxime: has antiangiogenic activity. indirubin-3'-monoxime : A member of the class of biindoles that is indirubin in which the keto group at position 3' has undergone condensation with hydroxylamine to form the corresponding oxime.		2.0810
indomethacin
Indomethacin: A non-steroidal anti-inflammatory agent (NSAID) that inhibits CYCLOOXYGENASE, which is necessary for the formation of PROSTAGLANDINS and other AUTACOIDS. It also inhibits the motility of POLYMORPHONUCLEAR LEUKOCYTES.. indometacin : A member of the class of indole-3-acetic acids that is indole-3-acetic acid in which the indole ring is substituted at positions 1, 2 and 5 by p-chlorobenzoyl, methyl, and methoxy groups, respectively. A non-steroidal anti-inflammatory drug, it is used in the treatment of musculoskeletal and joint disorders including osteoarthritis, rheumatoid arthritis, gout, bursitis and tendinitis.		2.610aromatic ether;
indole-3-acetic acids;
monochlorobenzenes;
N-acylindole		analgesic;
drug metabolite;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
environmental contaminant;
gout suppressant;
non-steroidal anti-inflammatory drug;
xenobiotic metabolite;
xenobiotic
avapro
Irbesartan: A spiro compound, biphenyl and tetrazole derivative that acts as an angiotensin II type 1 receptor antagonist. It is used in the management of HYPERTENSION, and in the treatment of kidney disease.. irbesartan : A biphenylyltetrazole that is an angiotensin II receptor antagonist used mainly for the treatment of hypertension.		2.610azaspiro compound;
biphenylyltetrazole		angiotensin receptor antagonist;
antihypertensive agent;
environmental contaminant;
xenobiotic
itraconazole
[no description available]		2.610piperazines
1-(2-naphthalenyl)-3-[(phenylmethyl)-propan-2-ylamino]-1-propanone
ZM39923: structure in first source		2.8930naphthalenes
ketamine
Ketamine: A cyclohexanone derivative used for induction of anesthesia. Its mechanism of action is not well understood, but ketamine can block NMDA receptors (RECEPTORS, N-METHYL-D-ASPARTATE) and may interact with sigma receptors.. ketamine : A member of the class of cyclohexanones in which one of the hydrogens at position 2 is substituted by a 2-chlorophenyl group, while the other is substituted by a methylamino group.		2.8930cyclohexanones;
monochlorobenzenes;
secondary amino compound		analgesic;
environmental contaminant;
intravenous anaesthetic;
neurotoxin;
NMDA receptor antagonist;
xenobiotic
ketoprofen
Ketoprofen: An IBUPROFEN-type anti-inflammatory analgesic and antipyretic. It is used in the treatment of rheumatoid arthritis and osteoarthritis.. ketoprofen : An oxo monocarboxylic acid that consists of propionic acid substituted by a 3-benzoylphenyl group at position 2.		2.8930benzophenones;
oxo monocarboxylic acid		antipyretic;
drug allergen;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
environmental contaminant;
non-steroidal anti-inflammatory drug;
xenobiotic
kojic acid
[no description available]		2.6104-pyranones;
enol;
primary alcohol		Aspergillus metabolite;
EC 1.10.3.1 (catechol oxidase) inhibitor;
EC 1.10.3.2 (laccase) inhibitor;
EC 1.13.11.24 (quercetin 2,3-dioxygenase) inhibitor;
EC 1.14.18.1 (tyrosinase) inhibitor;
EC 1.4.3.3 (D-amino-acid oxidase) inhibitor;
NF-kappaB inhibitor;
skin lightening agent
lapachol
lapachol : A hydroxy-1,4-naphthoquinone that is 1,4-naphthoquinone substituted by hydroxy and 3-methylbut-2-en-1-yl groups at positions 2 and 3, respectively. It is a natural compound that exhibits antibacterial and anticancer properties, first isolated in 1882 from the bark of Tabebuia avellanedae.		2.610
leflunomide
Leflunomide: An isoxazole derivative that inhibits dihydroorotate dehydrogenase, the fourth enzyme in the pyrimidine biosynthetic pathway. It is used an immunosuppressive agent in the treatment of RHEUMATOID ARTHRITIS and PSORIATIC ARTHRITIS.. leflunomide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-methyl-1,2-oxazole-4-carboxylic acid with the anilino group of 4-(trifluoromethyl)aniline. The prodrug of teriflunomide.		2.0810(trifluoromethyl)benzenes;
isoxazoles;
monocarboxylic acid amide		antineoplastic agent;
antiparasitic agent;
EC 1.3.98.1 [dihydroorotate oxidase (fumarate)] inhibitor;
EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor;
hepatotoxic agent;
immunosuppressive agent;
non-steroidal anti-inflammatory drug;
prodrug;
pyrimidine synthesis inhibitor;
tyrosine kinase inhibitor
letrozole
[no description available]		2.0810nitrile;
triazoles		antineoplastic agent;
EC 1.14.14.14 (aromatase) inhibitor
lg 100268
LG 100268: a retinoid X receptor (RXR) selective compound; structure given in first source		2.0810
loperamide
Loperamide: One of the long-acting synthetic ANTIDIARRHEALS; it is not significantly absorbed from the gut, and has no effect on the adrenergic system or central nervous system, but may antagonize histamine and interfere with acetylcholine release locally.. loperamide : A synthetic piperidine derivative, effective against diarrhoea resulting from gastroenteritis or inflammatory bowel disease.		2.610monocarboxylic acid amide;
monochlorobenzenes;
piperidines;
tertiary alcohol		anticoronaviral agent;
antidiarrhoeal drug;
mu-opioid receptor agonist
loratadine
Loratadine: A second-generation histamine H1 receptor antagonist used in the treatment of allergic rhinitis and urticaria. Unlike most classical antihistamines (HISTAMINE H1 ANTAGONISTS) it lacks central nervous system depressing effects such as drowsiness.. loratadine : A benzocycloheptapyridine that is 6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridine substituted by a chloro group at position 8 and a 1-(ethoxycarbonyl)piperidin-4-ylidene group at position 11. It is a H1-receptor antagonist commonly employed in the treatment of allergic disorders.		2.610benzocycloheptapyridine;
ethyl ester;
N-acylpiperidine;
organochlorine compound;
tertiary carboxamide		anti-allergic agent;
cholinergic antagonist;
geroprotector;
H1-receptor antagonist
losartan
Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.. losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position		2.610biphenylyltetrazole;
imidazoles		angiotensin receptor antagonist;
anti-arrhythmia drug;
antihypertensive agent;
endothelin receptor antagonist
4-(dimethylamino)-n-(7-(hydroxyamino)-7-oxoheptyl)benzamide
4-(dimethylamino)-N-(7-(hydroxyamino)-7-oxoheptyl)benzamide: structure in first source. 4-(dimethylamino)-N-[7-(hydroxyamino)-7-oxoheptyl]benzamide : A benzamide resulting from the formal condensation of the carboxy group of 4-(dimethylamino)benzoic acid with the amino group of 7-amino-N-hydroxyheptanamide. It is a potent inhibitor of histone deacetylases and induces cell cycle arrest and apoptosis in several human cancer cell lines.		2.610benzamides;
hydroxamic acid;
secondary carboxamide;
tertiary amino compound		antineoplastic agent;
apoptosis inducer;
EC 3.5.1.98 (histone deacetylase) inhibitor
mafenide
Mafenide: A sulfonamide that inhibits the enzyme CARBONIC ANHYDRASE and is used as a topical anti-bacterial agent, especially in burn therapy.		2.610aromatic amine
mebendazole
Mebendazole: A benzimidazole that acts by interfering with CARBOHYDRATE METABOLISM and inhibiting polymerization of MICROTUBULES.. mebendazole : A carbamate ester that is methyl 1H-benzimidazol-2-ylcarbamate substituted by a benzoyl group at position 5.		2.8930aromatic ketone;
benzimidazoles;
carbamate ester		antinematodal drug;
microtubule-destabilising agent;
tubulin modulator
mephenesin
Mephenesin: A centrally acting muscle relaxant with a short duration of action.. 1-(2-methylphenyl)glycerol : A glycerol ether in which a single 2-methylphenyl group is attached at position 1 of glycerol via an ether linkage.		2.8930aromatic ether;
glycerol ether
metformin
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289). metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.		5.9461guanidinesenvironmental contaminant;
geroprotector;
hypoglycemic agent;
xenobiotic
methazolamide
Methazolamide: A carbonic anhydrase inhibitor that is used as a diuretic and in the treatment of glaucoma.		2.610sulfonamide;
thiadiazoles
methocarbamol
Methocarbamol: A centrally acting muscle relaxant whose mode of action has not been established. It is used as an adjunct in the symptomatic treatment of musculoskeletal conditions associated with painful muscle spasm. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1206). methocarbamol : A racemate comprising equimolar amounts of (R)- and (S)-methocarbamol. A centrally acting skeletal muscle relaxant, it is used as an adjunct in the short-term symptomatic treatment of painful muscle spasm. The (R)-enantiomer is more active than the (S)-enantiomer.. 2-hydroxy-3-(2-methoxyphenoxy)propyl carbamate : A carbamate ester that is glycerol in which one of the primary alcohol groups has been converted to its 2-methoxyphenyl ether while the other has been converted to the corresponding carbamate ester.		2.610aromatic ether;
carbamate ester;
secondary alcohol
midazolam
Midazolam: A short-acting hypnotic-sedative drug with anxiolytic and amnestic properties. It is used in dentistry, cardiac surgery, endoscopic procedures, as preanesthetic medication, and as an adjunct to local anesthesia. The short duration and cardiorespiratory stability makes it useful in poor-risk, elderly, and cardiac patients. It is water-soluble at pH less than 4 and lipid-soluble at physiological pH.. midazolam : An imidazobenzodiazepine that is 4H-imidazo[1,5-a][1,4]benzodiazepine which is substituted by a methyl, 2-fluorophenyl and chloro groups at positions 1, 6 and 8, respectively.		3.4711imidazobenzodiazepine;
monofluorobenzenes;
organochlorine compound		anticonvulsant;
antineoplastic agent;
anxiolytic drug;
apoptosis inducer;
central nervous system depressant;
GABAA receptor agonist;
general anaesthetic;
muscle relaxant;
sedative
mitotane
Mitotane: A derivative of the insecticide DICHLORODIPHENYLDICHLOROETHANE that specifically inhibits cells of the adrenal cortex and their production of hormones. It is used to treat adrenocortical tumors and causes CNS damage, but no bone marrow depression.		2.1310diarylmethane
mitoxantrone
Mitoxantrone: An anthracenedione-derived antineoplastic agent.. mitoxantrone : A dihydroxyanthraquinone that is 1,4-dihydroxy-9,10-anthraquinone which is substituted by 6-hydroxy-1,4-diazahexyl groups at positions 5 and 8.		2.5820dihydroxyanthraquinoneanalgesic;
antineoplastic agent
entinostat
[no description available]		2.5820benzamides;
carbamate ester;
primary amino compound;
pyridines;
substituted aniline		antineoplastic agent;
apoptosis inducer;
EC 3.5.1.98 (histone deacetylase) inhibitor
ethylmaleimide
Ethylmaleimide: A sulfhydryl reagent that is widely used in experimental biochemical studies.		2.610maleimidesanticoronaviral agent;
EC 1.3.1.8 [acyl-CoA dehydrogenase (NADP(+))] inhibitor;
EC 2.1.1.122 [(S)-tetrahydroprotoberberine N-methyltransferase] inhibitor;
EC 2.7.1.1 (hexokinase) inhibitor
nabumetone
Nabumetone: A butanone non-steroidal anti-inflammatory drug and cyclooxygenase-2 (COX2) inhibitor that is used in the management of pain associated with OSTEOARTHRITIS and RHEUMATOID ARTHRITIS.. nabumetone : A methyl ketone that is 2-butanone in which one of the methyl hydrogens at position 4 is replaced by a 6-methoxy-2-naphthyl group. A prodrug that is converted to the active metabolite, 6-methoxy-2-naphthylacetic acid, following oral administration. It is shown to have a slightly lower risk of gastrointestinal side effects than most other non-steroidal anti-inflammatory drugs.		2.610methoxynaphthalene;
methyl ketone		cyclooxygenase 2 inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
prodrug
nafamostat
nafamostat: inhibitor of trypsin, plasmin, pancreatic kallikrein, plasma kallikrein & thrombin; strongly inhibits esterolytic activities of C1r & C1 esterase complement-mediated hemolysis; antineoplastic		2.610benzoic acids;
guanidines
nevirapine
Nevirapine: A potent, non-nucleoside reverse transcriptase inhibitor used in combination with nucleoside analogues for treatment of HIV INFECTIONS and AIDS.. nevirapine : A dipyridodiazepine that is 5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepine which is substituted by methyl, oxo, and cyclopropyl groups at positions 4, 6, and 11, respectively. A non-nucleoside reverse transcriptase inhibitor with activity against HIV-1, it is used in combination with other antiretrovirals for the treatment of HIV infection.		2.610cyclopropanes;
dipyridodiazepine		antiviral drug;
HIV-1 reverse transcriptase inhibitor
niclosamide
Niclosamide: An antihelmintic that is active against most tapeworms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p48). niclosamide : A secondary carboxamide resulting from the formal condensation of the carboxy group of 5-chlorosalicylic acid with the amino group of 2-chloro-4-nitroaniline. It is an oral anthelmintic drug approved for use against tapeworm infections.		2.8930benzamides;
C-nitro compound;
monochlorobenzenes;
salicylanilides;
secondary carboxamide		anthelminthic drug;
anticoronaviral agent;
antiparasitic agent;
apoptosis inducer;
molluscicide;
piscicide;
STAT3 inhibitor
nimodipine
Nimodipine: A calcium channel blockader with preferential cerebrovascular activity. It has marked cerebrovascular dilating effects and lowers blood pressure.. nimodipine : A dihydropyridine that is 1,4-dihydropyridine which is substituted by methyl groups at positions 2 and 6, a (2-methoxyethoxy)carbonyl group at position 3, a m-nitrophenyl group at position 4, and an isopropoxycarbonyl group at position 5. An L-type calcium channel blocker, it acts particularly on cerebral circulation, and is used both orally and intravenously for the prevention and treatment of subarachnoid hemorrhage from ruptured intracranial aneurysm.		2.13102-methoxyethyl ester;
C-nitro compound;
dicarboxylic acids and O-substituted derivatives;
diester;
dihydropyridine;
isopropyl ester		antihypertensive agent;
calcium channel blocker;
cardiovascular drug;
vasodilator agent
nitroglycerin
Nitroglycerin: A volatile vasodilator which relieves ANGINA PECTORIS by stimulating GUANYLATE CYCLASE and lowering cytosolic calcium. It is also sometimes used for TOCOLYSIS and explosives.. nitroglycerol : A nitrate ester that is glycerol in which nitro group(s) replace the hydrogen(s) attached to one or more of the hydroxy groups.. nitroglycerin : A nitroglycerol that is glycerol in which the hydrogen atoms of all three hydroxy groups are replaced by nitro groups. It acts as a prodrug, releasing nitric oxide to open blood vessels and so alleviate heart pain.		2.1510nitroglycerolexplosive;
muscle relaxant;
nitric oxide donor;
prodrug;
tocolytic agent;
vasodilator agent;
xenobiotic
ofloxacin
Ofloxacin: A synthetic fluoroquinolone antibacterial agent that inhibits the supercoiling activity of bacterial DNA GYRASE, halting DNA REPLICATION.. 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid : An oxazinoquinoline that is 2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinolin-7-one substituted by methyl, carboxy, fluoro, and 4-methylpiperazin-1-yl groups at positions 3, 6, 9, and 10, respectively.. ofloxacin : A racemate comprising equimolar amounts of levofloxacin and dextrofloxacin. It is a synthetic fluoroquinolone antibacterial agent which inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication.		4.8113-oxo monocarboxylic acid;
N-arylpiperazine;
N-methylpiperazine;
organofluorine compound;
oxazinoquinoline
olprinone
olprinone: RN refers to HCl; structure given in first source		2.0810bipyridines
omeprazole
Omeprazole: A 4-methoxy-3,5-dimethylpyridyl, 5-methoxybenzimidazole derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits an H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS.. omeprazole : A racemate comprising equimolar amounts of (R)- and (S)-omeprazole.. 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole : A member of the class of benzimidazoles that is 1H-benzimidazole which is substituted by a [4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl group at position 2 and a methoxy group at position 5.		3.9730aromatic ether;
benzimidazoles;
pyridines;
sulfoxide
osalmide
osalmide: structure		2.610organic molecular entity
oxethazaine
[no description available]		2.610amino acid amide
oxibendazole
oxibendazole: structure		2.8930benzimidazoles;
carbamate ester
4-(2'-methoxyphenyl)-1-(2'-(n-(2''-pyridinyl)-4-iodobenzamido)ethyl)piperazine
4-(2'-methoxyphenyl)-1-(2'-(N-(2''-pyridinyl)-4-iodobenzamido)ethyl)piperazine: a 5-HT(1A) ligand; structure in first source		2.8930
palmidrol
palmidrol: a cannabinoid receptor-inactive eCB-related molecule used as prophylactic in helping to prevent respiratory viral infection. palmitoyl ethanolamide : An N-(long-chain-acyl)ethanolamine that is the ethanolamide of palmitic (hexadecanoic) acid.		2.610endocannabinoid;
N-(long-chain-acyl)ethanolamine;
N-(saturated fatty acyl)ethanolamine		anti-inflammatory drug;
anticonvulsant;
antihypertensive agent;
neuroprotective agent
papaverine
Papaverine: An alkaloid found in opium but not closely related to the other opium alkaloids in its structure or pharmacological actions. It is a direct-acting smooth muscle relaxant used in the treatment of impotence and as a vasodilator, especially for cerebral vasodilation. The mechanism of its pharmacological actions is not clear, but it apparently can inhibit phosphodiesterases and it may have direct actions on calcium channels.. papaverine : A benzylisoquinoline alkaloid that is isoquinoline substituted by methoxy groups at positions 6 and 7 and a 3,4-dimethoxybenzyl group at position 1. It has been isolated from Papaver somniferum.		2.610benzylisoquinoline alkaloid;
dimethoxybenzene;
isoquinolines		antispasmodic drug;
vasodilator agent
pentoxifylline
[no description available]		2.610oxopurine
perhexiline
Perhexiline: 2-(2,2-Dicyclohexylethyl)piperidine. Coronary vasodilator used especially for angina of effort. It may cause neuropathy and hepatitis.		2.610piperidinescardiovascular drug
perphenazine
Perphenazine: An antipsychotic phenothiazine derivative with actions and uses similar to those of CHLORPROMAZINE.. perphenazine : A phenothiazine derivative in which the phenothiazine tricycle carries a chloro substituent at the 2-position and a 3-[4-(2-hydroxyethyl)piperazin-1-yl]propyl group at N-10.		2.8930N-(2-hydroxyethyl)piperazine;
N-alkylpiperazine;
organochlorine compound;
phenothiazines		antiemetic;
dopaminergic antagonist;
phenothiazine antipsychotic drug
phenazopyridine
Phenazopyridine: A local anesthetic that has been used in urinary tract disorders. Its use is limited by problems with toxicity (primarily blood disorders) and potential carcinogenicity.. phenazopyridine : A diaminopyridine that is 2,6-diaminopyridine substituted at position 3 by a phenylazo group. A local anesthetic that has topical analgesic effect on mucosa lining of the urinary tract. Its use is limited by problems with toxicity (primarily blood disorders) and potential carcinogenicity.		2.610diaminopyridine;
monoazo compound		anticoronaviral agent;
carcinogenic agent;
local anaesthetic;
non-narcotic analgesic
4-phenylbutyric acid
4-phenylbutyric acid: RN refers to the parent cpd. 4-phenylbutyric acid : A monocarboxylic acid the structure of which is that of butyric acid substituted with a phenyl group at C-4. It is a histone deacetylase inhibitor that displays anticancer activity. It inhibits cell proliferation, invasion and migration and induces apoptosis in glioma cells. It also inhibits protein isoprenylation, depletes plasma glutamine, increases production of foetal haemoglobin through transcriptional activation of the gamma-globin gene and affects hPPARgamma activation.		2.610monocarboxylic acidantineoplastic agent;
apoptosis inducer;
EC 3.5.1.98 (histone deacetylase) inhibitor;
prodrug
phenylmethylsulfonyl fluoride
Phenylmethylsulfonyl Fluoride: An enzyme inhibitor that inactivates IRC-50 arvin, subtilisin, and the fatty acid synthetase complex.. phenylmethanesulfonyl fluoride : An acyl fluoride with phenylmethanesulfonyl as the acyl group.		2.610acyl fluorideserine proteinase inhibitor
pimobendan
pimobendan: produces arterial & venous dilatation in dogs; structure given in first source		3.1640benzimidazoles;
pyridazinone		cardiotonic drug;
EC 3.1.4.* (phosphoric diester hydrolase) inhibitor;
vasodilator agent
pioglitazone
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.. pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.		2.0810aromatic ether;
pyridines;
thiazolidinediones		antidepressant;
cardioprotective agent;
EC 2.7.1.33 (pantothenate kinase) inhibitor;
EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor;
ferroptosis inhibitor;
geroprotector;
hypoglycemic agent;
insulin-sensitizing drug;
PPARgamma agonist;
xenobiotic
piracetam
Piracetam: A compound suggested to be both a nootropic and a neuroprotective agent.		2.1310organonitrogen compound;
organooxygen compound
pj-34
PJ34 : A member of the class of phenanthridines that is 5,6-dihydrophenanthridine substituted at positions 2 and 6 by (N,N-dimethylglycyl)amino and oxo groups, respectively. It is a potent inhibitor of poly(ADP-ribose) polymerases PARP1 and PARP2 (IC50 of 110 nM and 86 nM, respectively) and exhibits anti-cancer, cardioprotective and neuroprotective properties.		2.610phenanthridines;
secondary carboxamide;
tertiary amino compound		angiogenesis inhibitor;
anti-inflammatory agent;
antiatherosclerotic agent;
antineoplastic agent;
apoptosis inducer;
cardioprotective agent;
EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor;
neuroprotective agent
ag 1879
3-(4-chlorophenyl)-1-(1,1-dimethylethyl)-1H-pyrazolo(3,4-d)pyrimidin-4-amine: Fyn kinase inhibitor		2.8930aromatic amine;
monochlorobenzenes;
pyrazolopyrimidine		beta-adrenergic antagonist;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor;
geroprotector
praziquantel
azinox: Russian drug		2.610isoquinolines
probenecid
Probenecid: The prototypical uricosuric agent. It inhibits the renal excretion of organic anions and reduces tubular reabsorption of urate. Probenecid has also been used to treat patients with renal impairment, and, because it reduces the renal tubular excretion of other drugs, has been used as an adjunct to antibacterial therapy.. probenecid : A sulfonamide in which the nitrogen of 4-sulfamoylbenzoic acid is substituted with two propyl groups.		2.610benzoic acids;
sulfonamide		uricosuric drug
probucol
Probucol: A drug used to lower LDL and HDL cholesterol yet has little effect on serum-triglyceride or VLDL cholesterol. (From Martindale, The Extra Pharmacopoeia, 30th ed, p993).. probucol : A dithioketal that is propane-2,2-dithiol in which the hydrogens attached to both sulfur atoms are replaced by 3,5-di-tert-butyl-4-hydroxyphenyl groups. An anticholesteremic drug with antioxidant and anti-inflammatory properties, it is used to treat high levels of cholesterol in blood.		2.610dithioketal;
polyphenol		anti-inflammatory drug;
anticholesteremic drug;
antilipemic drug;
antioxidant;
cardiovascular drug
promazine
Promazine: A phenothiazine with actions similar to CHLORPROMAZINE but with less antipsychotic activity. It is primarily used in short-term treatment of disturbed behavior and as an antiemetic.. promazine : A phenothiazine deriative in which the phenothiazine tricycle has a 3-(dimethylaminopropyl) group at the N-10 position.		2.610phenothiazines;
tertiary amine		antiemetic;
dopaminergic antagonist;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
H1-receptor antagonist;
muscarinic antagonist;
phenothiazine antipsychotic drug;
serotonergic antagonist
promethazine
Promethazine: A phenothiazine derivative with histamine H1-blocking, antimuscarinic, and sedative properties. It is used as an antiallergic, in pruritus, for motion sickness and sedation, and also in animals.. promethazine : A tertiary amine that is a substituted phenothiazine in which the ring nitrogen at position 10 is attached to C-3 of an N,N-dimethylpropan-2-amine moiety.		2.610phenothiazines;
tertiary amine		anti-allergic agent;
anticoronaviral agent;
antiemetic;
antipruritic drug;
H1-receptor antagonist;
local anaesthetic;
sedative
propranolol
Propranolol: A widely used non-cardioselective beta-adrenergic antagonist. Propranolol has been used for MYOCARDIAL INFARCTION; ARRHYTHMIA; ANGINA PECTORIS; HYPERTENSION; HYPERTHYROIDISM; MIGRAINE; PHEOCHROMOCYTOMA; and ANXIETY but adverse effects instigate replacement by newer drugs.. propranolol : A propanolamine that is propan-2-ol substituted by a propan-2-ylamino group at position 1 and a naphthalen-1-yloxy group at position 3.		2.610naphthalenes;
propanolamine;
secondary amine		anti-arrhythmia drug;
antihypertensive agent;
anxiolytic drug;
beta-adrenergic antagonist;
environmental contaminant;
human blood serum metabolite;
vasodilator agent;
xenobiotic
pyrimethamine
Maloprim: contains above 2 cpds		4.811aminopyrimidine;
monochlorobenzenes		antimalarial;
antiprotozoal drug;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor
3-[(3,5-dibromo-4-hydroxyphenyl)methylidene]-5-iodo-1H-indol-2-one
[no description available]		2.8330indoles
raloxifene
raloxifene : A member of the class of 1-benzothiophenes that is 1-benzothiophene in which the hydrogens at positions 2, 3, and 6 have been replaced by p-hydroxyphenyl, p-[2-(piperidin-1-yl)ethoxy]benzoyl, and hydroxy groups, respectively.		2.21101-benzothiophenes;
aromatic ketone;
N-oxyethylpiperidine;
phenols		bone density conservation agent;
estrogen antagonist;
estrogen receptor modulator
riluzole
Riluzole: A glutamate antagonist (RECEPTORS, GLUTAMATE) used as an anticonvulsant (ANTICONVULSANTS) and to prolong the survival of patients with AMYOTROPHIC LATERAL SCLEROSIS.		2.0810benzothiazoles
rimantadine
Rimantadine: An RNA synthesis inhibitor that is used as an antiviral agent in the prophylaxis and treatment of influenza.		2.610alkylamine
ro 31-8220
Ro 31-8220: a protein kinase C inhibitor		2.8930imidothiocarbamic ester;
indoles;
maleimides		EC 2.7.11.13 (protein kinase C) inhibitor
rolipram
[no description available]		2.610pyrrolidin-2-onesantidepressant;
EC 3.1.4.* (phosphoric diester hydrolase) inhibitor
ropinirole
[no description available]		2.8930indolones;
tertiary amine		antidyskinesia agent;
antiparkinson drug;
central nervous system drug;
dopamine agonist
sb 206553
SB 206553: a high-affinity 5-HT(2C/2B) antagonist; structure given in first source		2.0810pyrroloindole
sb 220025
SB 220025: inhibits p38 mitogen-activated protein kinase; structure in first source. SB220025 : Am member of the class of imidazoles carrying piperidin-4-yl, 4-fluophenyl and 2-aminopyrimidin-4-yl substituents at posiitons 1, 4 and 5 respectively.		2.0810aminopyrimidine;
imidazoles;
organofluorine compound;
piperidines		angiogenesis inhibitor;
anti-inflammatory agent;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
sb 202190
4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole: structure given in first source; inhibits p38 MAP kinase		2.0810imidazoles;
organofluorine compound;
phenols;
pyridines		apoptosis inducer;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
scriptaid
scriptide: provokes translocation of GLUT4 to increase glucose uptake; structure in first source		2.610isoquinolines
sebacic acid
sebacic acid : An alpha,omega-dicarboxylic acid that is the 1,8-dicarboxy derivative of octane.		2.610alpha,omega-dicarboxylic acid;
dicarboxylic fatty acid		human metabolite;
plant metabolite
sk&f 86002
6-(4-fluorophenyl)-2,3-dihydro-5-(4-pyridinyl)imidazo(2,1-b)thiazole: inhibits p38 MAP kinase		2.0810imidazoles
sodium fluoride
[no description available]		4.811fluoride saltmutagen
fenofibrate
[no description available]		2.610benzochromenone;
delta-lactone;
naphtho-alpha-pyrone		platelet aggregation inhibitor;
Sir2 inhibitor
imatinib
[no description available]		2.5820aromatic amine;
benzamides;
N-methylpiperazine;
pyridines;
pyrimidines		antineoplastic agent;
apoptosis inducer;
tyrosine kinase inhibitor
vorinostat
Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.. vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).		8.6183dicarboxylic acid diamide;
hydroxamic acid		antineoplastic agent;
apoptosis inducer;
EC 3.5.1.98 (histone deacetylase) inhibitor
sulfasalazine
Sulfasalazine: A drug that is used in the management of inflammatory bowel diseases. Its activity is generally considered to lie in its metabolic breakdown product, 5-aminosalicylic acid (see MESALAMINE) released in the colon. (From Martindale, The Extra Pharmacopoeia, 30th ed, p907). sulfasalazine : An azobenzene consisting of diphenyldiazene having a carboxy substituent at the 4-position, a hydroxy substituent at the 3-position and a 2-pyridylaminosulphonyl substituent at the 4'-position.		2.4920
suprofen
Suprofen: An IBUPROFEN-type anti-inflammatory analgesic and antipyretic. It inhibits prostaglandin synthesis and has been proposed as an anti-arthritic.. suprofen : An aromatic ketone that is thiophene substituted at C-2 by a 4-(1-carboxyethyl)benzoyl group.		2.610aromatic ketone;
monocarboxylic acid;
thiophenes		antirheumatic drug;
drug allergen;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
peripheral nervous system drug
2-[4-(1,2-diphenylbut-1-enyl)phenoxy]-N,N-dimethylethanamine
[no description available]		2.0810stilbenoid
temozolomide
[no description available]		4.811imidazotetrazine;
monocarboxylic acid amide;
triazene derivative		alkylating agent;
antineoplastic agent;
prodrug
thalidomide
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.. thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.. 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.		19.1112128phthalimides;
piperidones
ticlopidine
Ticlopidine: An effective inhibitor of platelet aggregation commonly used in the placement of STENTS in CORONARY ARTERIES.. ticlopidine : A thienopyridine that is 4,5,6,7-tetrahydrothieno[3,2-c]pyridine in which the hydrogen attached to the nitrogen is replaced by an o-chlorobenzyl group.		2.610monochlorobenzenes;
thienopyridine		anticoagulant;
fibrin modulating drug;
hematologic agent;
P2Y12 receptor antagonist;
platelet aggregation inhibitor
2-[4-(4-chloro-1,2-diphenylbut-1-enyl)phenoxy]-N,N-dimethylethanamine
[no description available]		2.5920stilbenoid
triamterene
Triamterene: A pteridinetriamine compound that inhibits SODIUM reabsorption through SODIUM CHANNELS in renal EPITHELIAL CELLS.. triamterene : Pteridine substituted at positions 2, 4 and 7 with amino groups and at position 6 with a phenyl group. A sodium channel blocker, it is used as a diuretic in the treatment of hypertension and oedema.		2.610pteridinesdiuretic;
sodium channel blocker
trifluoperazine
[no description available]		2.610N-alkylpiperazine;
N-methylpiperazine;
organofluorine compound;
phenothiazines		antiemetic;
calmodulin antagonist;
dopaminergic antagonist;
EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor;
EC 5.3.3.5 (cholestenol Delta-isomerase) inhibitor;
phenothiazine antipsychotic drug
trifluperidol
Trifluperidol: A butyrophenone with general properties similar to those of HALOPERIDOL. It is used in the treatment of PSYCHOSES including MANIA and SCHIZOPHRENIA. (From Martindale, The Extra Pharmacopoeia, 30th ed, p621)		2.1510aromatic ketone
triflupromazine
Triflupromazine: A phenothiazine used as an antipsychotic agent and as an antiemetic.. triflupromazine : A member of the class of phenothiazines that is 10H-phenothiazine having a trifluoromethyl subsitituent at the 2-position and a 3-(dimethylamino)propyl group at the N-10 position.		2.610organofluorine compound;
phenothiazines;
tertiary amine		anticoronaviral agent;
antiemetic;
dopaminergic antagonist;
first generation antipsychotic
trigonelline
trigonelline: in hydra among other organisms; RN given refers to hydroxide inner salt; structure. N-methylnicotinic acid : A pyridinium ion consisting of nicotinic acid having a methyl substituent on the pyridine nitrogen.. N-methylnicotinate : An iminium betaine that is the conjugate base of N-methylnicotinic acid, arising from deprotonation of the carboxy group.		2.610alkaloid;
iminium betaine		food component;
human urinary metabolite;
plant metabolite
trimethobenzamide
trimethobenzamide: major descriptor (64-84); on-line search BENZAMIDES (64-84); Index Medicus search TRIMETHOBENZAMIDE (64-84); RN given refers to parent cpd. trimethobenzamide : The amide obtained by formal condensation of 3,4,5-trihydroxybenzoic acid with 4-[2-(N,N-dimethylamino)ethoxy]benzylamine. It is used to prevent nausea and vomitting in humans.		2.610benzamides;
tertiary amino compound		antiemetic
trimethoprim
Trimethoprim: A pyrimidine inhibitor of dihydrofolate reductase, it is an antibacterial related to PYRIMETHAMINE. It is potentiated by SULFONAMIDES and the TRIMETHOPRIM, SULFAMETHOXAZOLE DRUG COMBINATION is the form most often used. It is sometimes used alone as an antimalarial. TRIMETHOPRIM RESISTANCE has been reported.. trimethoprim : An aminopyrimidine antibiotic whose structure consists of pyrimidine 2,4-diamine and 1,2,3-trimethoxybenzene moieties linked by a methylene bridge.		2.610aminopyrimidine;
methoxybenzenes		antibacterial drug;
diuretic;
drug allergen;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor;
environmental contaminant;
xenobiotic
troglitazone
Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.		2.0810chromanes;
thiazolidinone		anticoagulant;
anticonvulsant;
antineoplastic agent;
antioxidant;
EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor;
ferroptosis inhibitor;
hypoglycemic agent;
platelet aggregation inhibitor;
vasodilator agent
tyrphostin a9
[no description available]		2.610alkylbenzenegeroprotector
delavirdine
Delavirdine: A potent, non-nucleoside reverse transcriptase inhibitor with activity specific for HIV-1.. delavirdine : The amide resulting from the formal condensation of 5-[(methylsulfonyl)amino]-1H-indole-2-carboxylic acid and 4-amino group of 1-[3-(isopropylamino)pyridin-2-yl]piperazine, delavirdine is a non-nucleoside reverse transcriptase inhibitor with activity specific for HIV-1. Viral resistance emerges rapidly when delavirdine is used alone, so it is therefore used (as the methanesulfonic acid salt) with other antiretrovirals for combination therapy of HIV infection.		2.610aminopyridine;
indolecarboxamide;
N-acylpiperazine;
sulfonamide		antiviral drug;
HIV-1 reverse transcriptase inhibitor
vesnarinone
[no description available]		2.610organic molecular entity
3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole
3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole: antineoplastic; activates platelet guanylate cyclase; a radiosensitizing agent and guanylate cyclase activator; structure in first source. lificiguat : A member of the class of indazoles that is 1H-indazole which is substituted by a benzyl group at position 1 and a 5-(hydroxymethyl)-2-furyl group at position 3. It is an activator of soluble guanylate cyclase and inhibits platelet aggregation.		2.8930aromatic primary alcohol;
furans;
indazoles		antineoplastic agent;
apoptosis inducer;
platelet aggregation inhibitor;
soluble guanylate cyclase activator;
vasodilator agent
zotepine
zotepine: structure		2.8930dibenzothiepine;
tertiary amino compound		alpha-adrenergic drug;
second generation antipsychotic;
serotonergic drug
prednisone
Prednisone: A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.. prednisone : A synthetic glucocorticoid drug that is particularly effective as an immunosuppressant, and affects virtually all of the immune system. Prednisone is a prodrug that is converted by the liver into prednisolone (a beta-hydroxy group instead of the oxo group at position 11), which is the active drug and also a steroid.		11.424111-oxo steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(1),Delta(4)-steroid;
C21-steroid;
glucocorticoid;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone		adrenergic agent;
anti-inflammatory drug;
antineoplastic agent;
immunosuppressive agent;
prodrug
idoxuridine
[no description available]		2.610organoiodine compound;
pyrimidine 2'-deoxyribonucleoside		antiviral drug;
DNA synthesis inhibitor
diethylnitrosamine
Diethylnitrosamine: A nitrosamine derivative with alkylating, carcinogenic, and mutagenic properties.. N-nitrosodiethylamine : A nitrosamine that is N-ethylethanamine substituted by a nitroso group at the N-atom.		2.110nitrosaminecarcinogenic agent;
hepatotoxic agent;
mutagen
chloramphenicol
Amphenicol: Chloramphenicol and its derivatives.		2.610C-nitro compound;
carboxamide;
diol;
organochlorine compound		antibacterial drug;
antimicrobial agent;
Escherichia coli metabolite;
geroprotector;
Mycoplasma genitalium metabolite;
protein synthesis inhibitor
glutamine
Glutamine: A non-essential amino acid present abundantly throughout the body and is involved in many metabolic processes. It is synthesized from GLUTAMIC ACID and AMMONIA. It is the principal carrier of NITROGEN in the body and is an important energy source for many cells.. L-glutamine : An optically active form of glutamine having L-configuration.. glutamine : An alpha-amino acid that consists of butyric acid bearing an amino substituent at position 2 and a carbamoyl substituent at position 4.		5.221amino acid zwitterion;
glutamine family amino acid;
glutamine;
L-alpha-amino acid;
polar amino acid zwitterion;
proteinogenic amino acid		EC 1.14.13.39 (nitric oxide synthase) inhibitor;
Escherichia coli metabolite;
human metabolite;
metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
Saccharomyces cerevisiae metabolite
lysine
Lysine: An essential amino acid. It is often added to animal feed.. lysine : A diamino acid that is caproic (hexanoic) acid bearing two amino substituents at positions 2 and 6.. L-lysine : An L-alpha-amino acid; the L-isomer of lysine.		2.610aspartate family amino acid;
L-alpha-amino acid zwitterion;
L-alpha-amino acid;
lysine;
organic molecular entity;
proteinogenic amino acid		algal metabolite;
anticonvulsant;
Escherichia coli metabolite;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
plant metabolite;
Saccharomyces cerevisiae metabolite
carbostyril
Quinolones: A group of derivatives of naphthyridine carboxylic acid, quinoline carboxylic acid, or NALIDIXIC ACID.. quinolin-2(1H)-one : A quinolone that is 1,2-dihydroquinoline substituted by an oxo group at position 2.		3.1810monohydroxyquinoline;
quinolone		bacterial xenobiotic metabolite
phenylethyl alcohol
Phenylethyl Alcohol: An antimicrobial, antiseptic, and disinfectant that is used also as an aromatic essence and preservative in pharmaceutics and perfumery.. 2-phenylethanol : A primary alcohol that is ethanol substituted by a phenyl group at position 2.		2.610benzenes;
primary alcohol		Aspergillus metabolite;
fragrance;
plant growth retardant;
plant metabolite;
Saccharomyces cerevisiae metabolite
tyrosine
Tyrosine: A non-essential amino acid. In animals it is synthesized from PHENYLALANINE. It is also the precursor of EPINEPHRINE; THYROID HORMONES; and melanin.. tyrosine : An alpha-amino acid that is phenylalanine bearing a hydroxy substituent at position 4 on the phenyl ring.		4.811amino acid zwitterion;
erythrose 4-phosphate/phosphoenolpyruvate family amino acid;
L-alpha-amino acid;
proteinogenic amino acid;
tyrosine		EC 1.3.1.43 (arogenate dehydrogenase) inhibitor;
fundamental metabolite;
micronutrient;
nutraceutical
zoxazolamine
Zoxazolamine: A uricosuric and muscle relaxant. Zoxazolamine acts centrally as a muscle relaxant, but the mechanism of its action is not understood.		2.610benzoxazole
colchicine
(S)-colchicine : A colchicine that has (S)-configuration. It is a secondary metabolite, has anti-inflammatory properties and is used to treat gout, crystal-induced joint inflammation, familial Mediterranean fever, and many other conditions.		2.8930alkaloid;
colchicine		anti-inflammatory agent;
gout suppressant;
mutagen
cycloheximide
Cycloheximide: Antibiotic substance isolated from streptomycin-producing strains of Streptomyces griseus. It acts by inhibiting elongation during protein synthesis.. cycloheximide : A dicarboximide that is 4-(2-hydroxyethyl)piperidine-2,6-dione in which one of the hydrogens attached to the carbon bearing the hydroxy group is replaced by a 3,5-dimethyl-2-oxocyclohexyl group. It is an antibiotic produced by the bacterium Streptomyces griseus.		2.6620antibiotic fungicide;
cyclic ketone;
dicarboximide;
piperidine antibiotic;
piperidones;
secondary alcohol		anticoronaviral agent;
bacterial metabolite;
ferroptosis inhibitor;
neuroprotective agent;
protein synthesis inhibitor
ficusin
Ficusin: A naturally occurring furocoumarin, found in PSORALEA. After photoactivation with UV radiation, it binds DNA via single and double-stranded cross-linking.. psoralen : The simplest member of the class of psoralens that is 7H-furo[3,2-g]chromene having a keto group at position 7. It has been found in plants like Psoralea corylifolia and Ficus salicifolia.		2.610psoralensplant metabolite
benziodarone
benziodarone: minor descriptor (75-89); on-line & INDEX MEDICUS search BENZOFURANS (68-89) & IODOBENZOATES (74)		2.8930aromatic ketone
tubercidin
Tubercidin: An antibiotic purine ribonucleoside that readily substitutes for adenosine in the biological system, but its incorporation into DNA and RNA has an inhibitory effect on the metabolism of these nucleic acids.. tubercidin : An N-glycosylpyrrolopyrimidine that is adenosine in which the in the 5-membered ring that is not attached to the ribose moiety is replaced by a carbon. Tubercidin is produced in the culture broth of Streptomyces tubericidus.		2.610antibiotic antifungal agent;
N-glycosylpyrrolopyrimidine;
ribonucleoside		antimetabolite;
antineoplastic agent;
bacterial metabolite
cytarabine
[no description available]		2.2510beta-D-arabinoside;
monosaccharide derivative;
pyrimidine nucleoside		antimetabolite;
antineoplastic agent;
antiviral agent;
immunosuppressive agent
trifluridine
Trifluridine: An antiviral derivative of THYMIDINE used mainly in the treatment of primary keratoconjunctivitis and recurrent epithelial keratitis due to HERPES SIMPLEX virus. (From Martindale, The Extra Pharmacopoeia, 30th ed, p557). trifluridine : A pyrimidine 2'-deoxyribonucleoside compound having 5-trifluoromethyluracil as the nucleobase. An antiviral drug used mainly in the treatment of primary keratoconjunctivitis and recurrent epithelial keratitis.		2.610nucleoside analogue;
organofluorine compound;
pyrimidine 2'-deoxyribonucleoside		antimetabolite;
antineoplastic agent;
antiviral drug;
EC 2.1.1.45 (thymidylate synthase) inhibitor
threonine
Threonine: An essential amino acid occurring naturally in the L-form, which is the active form. It is found in eggs, milk, gelatin, and other proteins.. threonine : An alpha-amino acid in which one of the hydrogens attached to the alpha-carbon of glycine is substituted by a 1-hydroxyethyl group.		6.21100amino acid zwitterion;
aspartate family amino acid;
L-alpha-amino acid;
proteinogenic amino acid;
threonine		algal metabolite;
Escherichia coli metabolite;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
plant metabolite;
Saccharomyces cerevisiae metabolite
phencyclidine
Phencyclidine: A hallucinogen formerly used as a veterinary anesthetic, and briefly as a general anesthetic for humans. Phencyclidine is similar to KETAMINE in structure and in many of its effects. Like ketamine, it can produce a dissociative state. It exerts its pharmacological action through inhibition of NMDA receptors (RECEPTORS, N-METHYL-D-ASPARTATE). As a drug of abuse, it is known as PCP and Angel Dust.. phencyclidine : A member of the class of piperidines that is piperidine in which the nitrogen is substituted with a 1-phenylcyclohexyl group. Formerly used as an anaesthetic agent, it exhibits both hallucinogenic and neurotoxic effects.		4.811benzenes;
piperidines		anaesthetic;
neurotoxin;
NMDA receptor antagonist;
psychotropic drug
divinyl sulfone
divinyl sulfone: cross-linking reagent for agarose gels. divinyl sulfone : A sulfone compound having two S-vinyl substituents.		2.0510sulfonecross-linking reagent
quinic acid
(-)-quinic acid : The (-)-enantiomer of quinic acid.		7.2510
acrylic acid
acrylic acid: RN given refers to parent cpd. acrylic acid : A alpha,beta-unsaturated monocarboxylic acid that is ethene substituted by a carboxy group.		4.811alpha,beta-unsaturated monocarboxylic acidmetabolite
rhodamine b
rhodamine B: RN & N1 from 9th CI Form Index; RN given refers to parent cpd; structure in Merck Index, 9th ed, #7973; TETRAETHYLRHODAMINE was see RHODAMINES 1975-93; use RHODAMINES to search TETRAETHYLRHODAMINE 1975-93. rhodamine B : An organic chloride salt having N-[9-(2-carboxyphenyl)-6-(diethylamino)-3H-xanthen-3-ylidene]-N-ethylethanaminium as the counterion. An amphoteric dye commonly used as a fluorochrome.		4.811organic chloride salt;
xanthene dye		fluorescent probe;
fluorochrome;
histological dye
cyclizine
Cyclizine: A histamine H1 antagonist given by mouth or parenterally for the control of postoperative and drug-induced vomiting and in motion sickness. (From Martindale, The Extra Pharmacopoeia, 30th ed, p935). cyclizine : An N-alkylpiperazine in which one nitrogen of the piperazine ring is substituted by a methyl group, while the other is substituted by a diphenylmethyl group.		2.2110N-alkylpiperazineantiemetic;
central nervous system depressant;
cholinergic antagonist;
H1-receptor antagonist;
local anaesthetic
methylprednisolone
Methylprednisolone: A PREDNISOLONE derivative with similar anti-inflammatory action.. 6alpha-methylprednisolone : The 6alpha-stereoisomer of 6-methylprednisolone.		2.41106-methylprednisolone;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone		adrenergic agent;
anti-inflammatory drug;
antiemetic;
environmental contaminant;
neuroprotective agent;
xenobiotic
9,10-anthraquinone
9,10-anthraquinone : An anthraquinone that is anthracene in which positions 9 and 10 have been oxidised to carbonyls.		2.610anthraquinone
salicylanilide
salicylanilide: RN given refers to parent cpd. salicylanilide : An amide of salicylic acid and of aniline; it is therefore both a salicylamide and an anilide.		2.610benzanilide fungicide;
salicylamides;
salicylanilides
gramine
gramine : An aminoalkylindole that is indole carrying a dimethylaminomethyl substituent at postion 3.		2.610aminoalkylindole;
indole alkaloid;
tertiary amino compound		antibacterial agent;
antiviral agent;
plant metabolite;
serotonergic antagonist
n-vinyl-2-pyrrolidinone
N-vinyl-2-pyrrolidinone: monomer of POVIDONE; structure given in first source		4.811pyrrolidin-2-ones
aminacrine
Aminacrine: A highly fluorescent anti-infective dye used clinically as a topical antiseptic and experimentally as a mutagen, due to its interaction with DNA. It is also used as an intracellular pH indicator.. 9-aminoacridine : An aminoacridine that is acridine in which the hydrogen at position 9 is replaced by an amino group. A fluorescent dyd and topical antiseptic agent, it is used (usually as the hydrochloride salt) in eye drops for the treatment of superficial eye infections.		2.610aminoacridines;
primary amino compound		acid-base indicator;
antiinfective agent;
antiseptic drug;
fluorescent dye;
MALDI matrix material;
mutagen
trehalose
alpha,alpha-trehalose : A trehalose in which both glucose residues have alpha-configuration at the anomeric carbon.		2.8930trehaloseEscherichia coli metabolite;
geroprotector;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
methyl gallate
methyl gallate: has both immunosuppressive and phytogenic antineoplastic activities; isolated from Acer saccharinum. methyl 3,4,5-trihydroxybenzoate : A gallate ester obtained by the formal condensation of gallic acid with methanol. It exhibits anti-oxidant, anti-tumor, anti-microbial and anti-inflammatory properties.		2.610gallate esteranti-inflammatory agent;
antioxidant;
plant metabolite
ethylbenzene
[no description available]		4.811alkylbenzene
quinuclidines
Quinuclidines: A class of organic compounds which contain two rings that share a pair of bridgehead carbon atoms and contains an amine group.		3.6120quinuclidines;
saturated organic heterobicyclic parent
triclocarban
triclocarban: bacteriostat; antiseptic in soaps & other cleansing solns; germicide; structure. triclocarban : A member of the class of phenylureas that is urea substituted by a 4-chlorophenyl group and a 3,4-dichlorophenyl group at positions 1 and 3 respectively.		2.8930dichlorobenzene;
monochlorobenzenes;
phenylureas		antimicrobial agent;
antiseptic drug;
disinfectant;
environmental contaminant;
xenobiotic
monobenzone
monobenzone: structure. monobenzone : The monobenzyl ether of hydroquinone. It is used as a topical drug for medical depigmentation.		2.610benzyl etherallergen;
dermatologic drug;
melanin synthesis inhibitor
pyrroles
1H-pyrrole : A tautomer of pyrrole that has the double bonds at positions 2 and 4.. pyrrole : A five-membered monocyclic heteroarene comprising one NH and four CH units which forms the parent compound of the pyrrole group of compounds. Its five-membered ring structure has three tautomers. A 'closed class'.. azole : Any monocyclic heteroarene consisting of a five-membered ring containing nitrogen. Azoles can also contain one or more other non-carbon atoms, such as nitrogen, sulfur or oxygen.		8.14150pyrrole;
secondary amine
thiophenes
Thiophenes: A monocyclic heteroarene furan in which the oxygen atom is replaced by a sulfur.. thiophenes : Compounds containing at least one thiophene ring.		3.1910mancude organic heteromonocyclic parent;
monocyclic heteroarene;
thiophenes;
volatile organic compound		non-polar solvent
framycetin
Framycetin: A component of NEOMYCIN that is produced by Streptomyces fradiae. On hydrolysis it yields neamine and neobiosamine B. (From Merck Index, 11th ed). framycetin : A tetracyclic antibacterial agent derived from neomycin, being a glycoside ester of neamine and neobiosamine B.		4.811aminoglycosideallergen;
antibacterial drug;
Escherichia coli metabolite
4-tert-octylphenol
4-tert-octylphenol: structure given in first source		2.8930alkylbenzene
ditiocarb
Ditiocarb: A chelating agent that has been used to mobilize toxic metals from the tissues of humans and experimental animals. It is the main metabolite of DISULFIRAM.. diethyldithiocarbamic acid : A member of the class of dithiocarbamic acids that is diethylcarbamic acid in which both of the oxygens are replaced by sulfur.		2.610dithiocarbamic acidschelator;
copper chelator
catechin
Catechin: An antioxidant flavonoid, occurring especially in woody plants as both (+)-catechin and (-)-epicatechin (cis) forms.. catechin : Members of the class of hydroxyflavan that have a flavan-3-ol skeleton and its substituted derivatives.. rac-catechin : A racemate comprising equimolar amounts of (+)- and (-)-catechin. (+)-catechin : The (+)-enantiomer of catechin and a polyphenolic antioxidant plant metabolite.		2.610catechinantioxidant;
plant metabolite
quinazolines
Quinazolines: A group of aromatic heterocyclic compounds that contain a bicyclic structure with two fused six-membered aromatic rings, a benzene ring and a pyrimidine ring.. quinazoline : A mancude organic heterobicyclic parent that is naphthalene in which the carbon atoms at positions 1 and 3 have been replaced by nitrogen atoms.. quinazolines : Any organic heterobicyclic compound based on a quinazoline skeleton and its substituted derivatives.		2.5720azaarene;
mancude organic heterobicyclic parent;
ortho-fused heteroarene;
quinazolines
indazoles
Indazoles: A group of heterocyclic aromatic organic compounds consisting of the fusion of BENZENE and PYRAZOLES.		4.811indazole
cyclopentane
Cyclopentanes: A group of alicyclic hydrocarbons with the general formula R-C5H9.. cyclopentanes : Cyclopentane and its derivatives formed by substitution.		2.6320cycloalkane;
cyclopentanes;
volatile organic compound		non-polar solvent
thiazoles
[no description available]		7.21811,3-thiazoles;
mancude organic heteromonocyclic parent;
monocyclic heteroarene
pyrazines
Pyrazines: A heterocyclic aromatic organic compound with the chemical formula C4H4N2.. pyrazine : A diazine that is benzene in which the carbon atoms at positions 1 and 4 have been replaced by nitrogen atoms.		15.96759diazine;
pyrazines		Daphnia magna metabolite
hydrazine
diamine : Any polyamine that contains two amino groups.		8.0383azane;
hydrazines		EC 4.3.1.10 (serine-sulfate ammonia-lyase) inhibitor
ethamivan
ethamivan: minor descriptor (65-72); major descriptor (73-86); on-line search BENZAMIDES (66-86); INDEX MEDICUS search BENZAMIDES (65-72); ETHAMIVAN (73-86). etamivan : Phenol substituted at C-2 and C-4 by a methoxy group and an N,N-diethylaminocarbonyl group respectively. A respiratory stimulant drug related to nikethamide, it has now fallen largely into disuse.		2.8930methoxybenzenes;
phenols
dexamethasone 21-phosphate
dexamethasone 21-phosphate: has anti-inflammatory activity. dexamethasone phosphate : A steroid phosphate that is the 21-O-phospho derivative of dexamethasone.		2.171011beta-hydroxy steroid;
17-hydroxy steroid;
3-oxo-Delta(4) steroid;
fluorinated steroid;
steroid phosphate;
tertiary alpha-hydroxy ketone		glucocorticoid receptor agonist
azacitidine
Azacitidine: A pyrimidine analogue that inhibits DNA methyltransferase, impairing DNA methylation. It is also an antimetabolite of cytidine, incorporated primarily into RNA. Azacytidine has been used as an antineoplastic agent.. 5-azacytidine : An N-glycosyl-1,3,5-triazine that is 4-amino-1,3,5-triazin-2(1H)-one substituted by a beta-D-ribofuranosyl residue via an N-glycosidic linkage. An antineoplastic agent, it is used in the treatment of myeloid leukaemia.		2.8530N-glycosyl-1,3,5-triazine;
nucleoside analogue		antineoplastic agent
methysergide
Methysergide: An ergot derivative that is a congener of LYSERGIC ACID DIETHYLAMIDE. It antagonizes the effects of serotonin in blood vessels and gastrointestinal smooth muscle, but has few of the properties of other ergot alkaloids. Methysergide is used prophylactically in migraine and other vascular headaches and to antagonize serotonin in the carcinoid syndrome.. methysergide : A synthetic ergot alkaloid, structurally related to the oxytocic agent methylergonovine and to the potent hallucinogen LSD and used prophylactically to reduce the frequency and intensity of severe vascular headaches.		2.8930ergoline alkaloid
hydantoins
Hydantoins: Compounds based on imidazolidine dione. Some derivatives are ANTICONVULSANTS.. imidazolidine-2,4-dione : An imidazolidinone with oxo groups at position 2 and 4.		4.811imidazolidine-2,4-dione
lucanthone
Lucanthone: One of the SCHISTOSOMICIDES, it has been replaced largely by HYCANTHONE and more recently PRAZIQUANTEL. (From Martindale The Extrapharmacopoeia, 30th ed., p46). lucanthone : A thioxanthen-9-one compound having a methyl substituent at the 1-position and a 2-[(diethylamino)ethyl]amino substituent at the 4-position. Formerly used for the treatment of schistosomiasis. It is a prodrug, being metabolised to hycanthone.		2.610thioxanthenesadjuvant;
antineoplastic agent;
EC 5.99.1.2 (DNA topoisomerase) inhibitor;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
mutagen;
photosensitizing agent;
prodrug;
schistosomicide drug
cepharanthine
cepharanthine: isoquinoline alkaloid from tubers of STEPHANIA; stimulates recovery of immunologic function in lymphatic system after administration of antineoplastic agents or x-irradiation. cepharanthine : A bisbenzylisoquinoline alkaloid from tubers of Stephania; stimulates recovery of immunologic function in lymphatic system after administration of antineoplastic agents or x-irradiation.		2.610bisbenzylisoquinoline alkaloid;
isoquinolines
aloe emodin
aloe emodin: structure distinct from emodin; this does not mean emodin from aloe. Aloe emodin : A dihydroxyanthraquinone that is chrysazin carrying a hydroxymethyl group at position 3. It has been isolated from plant species of the genus Aloe.		2.610aromatic primary alcohol;
dihydroxyanthraquinone		antineoplastic agent;
plant metabolite
chrysophanic acid
chrysophanic acid: RN given refers to parent cpd; structure in Merck, 9th ed, #2260. chrysophanol : A trihydroxyanthraquinone that is chrysazin with a methyl substituent at C-3. It has been isolated from Aloe vera and exhibits antiviral and anti-inflammatory activity.		2.610dihydroxyanthraquinoneanti-inflammatory agent;
antiviral agent;
plant metabolite
emetine
Emetine: The principal alkaloid of ipecac, from the ground roots of Uragoga (or Cephaelis) ipecacuanha or U. acuminata, of the Rubiaceae. It is used as an amebicide in many different preparations and may cause serious cardiac, hepatic, or renal damage and violent diarrhea and vomiting. Emetine inhibits protein synthesis in EUKARYOTIC CELLS but not PROKARYOTIC CELLS.. emetine : A pyridoisoquinoline comprising emetam having methoxy substituents at the 6'-, 7'-, 10- and 11-positions. It is an antiprotozoal agent and emetic. It inhibits SARS-CoV2, Zika and Ebola virus replication and displays antimalarial, antineoplastic and antiamoebic properties.		3.1640isoquinoline alkaloid;
pyridoisoquinoline		antiamoebic agent;
anticoronaviral agent;
antiinfective agent;
antimalarial;
antineoplastic agent;
antiprotozoal drug;
antiviral agent;
autophagy inhibitor;
emetic;
expectorant;
plant metabolite;
protein synthesis inhibitor
osthol
osthol: from Cnidium monnieri and Angelica pubescens (both Apiaceae); structure given in first source		2.610botanical anti-fungal agent;
coumarins		metabolite
flavanone
flavanone: RN given refers to cpd with unspecified isomeric designation; structure in first source. flavanone : The simplest member of the class of flavanones that consists of flavan bearing an oxo substituent at position 4.		2.610flavanones
thymoquinone
thymoquinone: constituent of cedarwood; can cause dermatitis; structure. thymoquinone : A member of the class of 1,4-benzoquinones that is 1,4-bezoquinone in which the hydrogens at positions 2 and 5 are replaced by methyl and isopropyl groups, respectively. It is a natural compound isolated from Nigella sativa which has demonstrated promising chemotherapeutic activity.		7.6101,4-benzoquinonesadjuvant;
anti-inflammatory agent;
antidepressant;
antineoplastic agent;
antioxidant;
cardioprotective agent;
plant metabolite
phloretic acid
phloretic acid: structure. N-hydroxysuccinimide ester : An ester of N-hydroxysuccinimide.. phloretic acid : A hydroxy monocarboxylic acid consisting of propionic acid having a 4-hydroxyphenyl group at the 3-position.		2.610hydroxy monocarboxylic acidplant metabolite
oleanolic acid
[no description available]		2.610hydroxy monocarboxylic acid;
pentacyclic triterpenoid		plant metabolite
podophyllotoxin
Podophyllum: A genus of poisonous American herbs, family BERBERIDACEAE. The roots yield PODOPHYLLOTOXIN and other pharmacologically important agents. The plant was formerly used as a cholagogue and cathartic. It is different from the European mandrake, MANDRAGORA.		3.0740furonaphthodioxole;
lignan;
organic heterotetracyclic compound		antimitotic;
antineoplastic agent;
keratolytic drug;
microtubule-destabilising agent;
plant metabolite;
tubulin modulator
angelicin
angelicin: used as tranquillizer; sedative; or anticonvulsant; structure		2.610furanocoumarin
diperodon
diperodon: RN given refers to parent cpd; structure given in first source		2.610carbamate ester
formestane
[no description available]		2.081017-oxo steroid;
3-oxo-Delta(4) steroid;
enol;
hydroxy steroid		antineoplastic agent;
EC 1.14.14.14 (aromatase) inhibitor
megestrol acetate
[no description available]		2.61020-oxo steroid;
3-oxo-Delta(4) steroid;
acetate ester;
steroid ester		antineoplastic agent;
appetite enhancer;
contraceptive drug;
progestin;
synthetic oral contraceptive
toyocamycin
Toyocamycin: 4-Amino-5-cyano-7-(D-ribofuranosyl)-7H- pyrrolo(2,3-d)pyrimidine. Antibiotic antimetabolite isolated from Streptomyces toyocaensis cultures. It is an analog of adenosine, blocks RNA synthesis and ribosome function, and is used mainly as a tool in biochemistry.. toyocamycin : An N-glycosylpyrrolopyrimidine that is tubercidin in which the hydrogen at position 5 of the pyrrolopyrimidine moiety has been replaced by a cyano group.		3.1910antibiotic antifungal agent;
N-glycosylpyrrolopyrimidine;
nitrile;
ribonucleoside		antimetabolite;
antineoplastic agent;
apoptosis inducer;
bacterial metabolite
acetylcysteine
N-acetyl-L-cysteine : An N-acetyl-L-amino acid that is the N-acetylated derivative of the natural amino acid L-cysteine.		2.6120acetylcysteine;
L-cysteine derivative;
N-acetyl-L-amino acid		antidote to paracetamol poisoning;
antiinfective agent;
antioxidant;
antiviral drug;
ferroptosis inhibitor;
geroprotector;
human metabolite;
mucolytic;
radical scavenger;
vulnerary
hydroxychloroquine sulfate
[no description available]		2.5820
levonorgestrel
Levonorgestrel: A synthetic progestational hormone with actions similar to those of PROGESTERONE and about twice as potent as its racemic or (+-)-isomer (NORGESTREL). It is used for contraception, control of menstrual disorders, and treatment of endometriosis.		4.81117beta-hydroxy steroid;
3-oxo-Delta(4) steroid;
terminal acetylenic compound		contraceptive drug;
female contraceptive drug;
progestin;
synthetic oral contraceptive
etonitazene
etonitazene: was heading 1979-94 (see under BENZIMIDAZOLES 1979-90); ETONITAZIN was see ETONITAZENE 1979-94; use BENZIMIDAZOLES to search ETONITAZENE 1979-94; narcotic analgesic similar to morphine in action; used mainly to study narcotic habituation, tolerance, and withdrawal in laboratory animals		2.8930
ethambutol
Ethambutol: An antitubercular agent that inhibits the transfer of mycolic acids into the cell wall of the tubercle bacillus. It may also inhibit the synthesis of spermidine in mycobacteria. The action is usually bactericidal, and the drug can penetrate human cell membranes to exert its lethal effect. (From Smith and Reynard, Textbook of Pharmacology, 1992, p863). ethambutol : An ethylenediamine derivative that is ethane-1,2-diamine in which one hydrogen attached to each of the nitrogens is sutstituted by a 1-hydroxybutan-2-yl group (S,S-configuration). It is a bacteriostatic antimycobacterial drug, effective against Mycobacterium tuberculosis and some other mycobacteria. It is used (as the dihydrochloride salt) in combination with other antituberculous drugs in the treatment of pulmonary and extrapulmonary tuberculosis; resistant strains of M. tuberculosis are readily produced if ethambutol is used alone.		2.610ethanolamines;
ethylenediamine derivative		antitubercular agent;
environmental contaminant;
xenobiotic
metformin hydrochloride
metformin hydrochloride : A hydrochloride resulting from the reaction of metformin with one molar equivalent of hydrogen chloride.		2.610hydrochlorideenvironmental contaminant;
hypoglycemic agent;
xenobiotic
calcium peroxide
[no description available]		4.811calcium oxides
manganese dioxide
[no description available]		4.811manganese molecular entity;
metal oxide
zinc oxide
Zinc Oxide: A mild astringent and topical protectant with some antiseptic action. It is also used in bandages, pastes, ointments, dental cements, and as a sunblock.		4.811zinc molecular entity
arsenic trioxide
Arsenic Trioxide: An inorganic compound with the chemical formula As2O3 that is used for the treatment of ACUTE PROMYELOCYTIC LEUKEMIA in patients who have relapsed from, or are resistant to, conventional drug therapy.		2.3110
antimycin a
[no description available]		2.610benzamides;
formamides;
macrodiolide;
phenols		antifungal agent;
mitochondrial respiratory-chain inhibitor;
piscicide
d-alpha tocopherol
Vitamin E: A generic descriptor for all TOCOPHEROLS and TOCOTRIENOLS that exhibit ALPHA-TOCOPHEROL activity. By virtue of the phenolic hydrogen on the 2H-1-benzopyran-6-ol nucleus, these compounds exhibit varying degree of antioxidant activity, depending on the site and number of methyl groups and the type of ISOPRENOIDS.. tocopherol : A collective name for a group of closely related lipids that contain a chroman-6-ol nucleus substituted at position 2 by a methyl group and by a saturated hydrocarbon chain consisting of three isoprenoid units. They are designated as alpha-, beta-, gamma-, and delta-tocopherol depending on the number and position of additional methyl substituents on the aromatic ring. Tocopherols occur in vegetable oils and vegetable oil products, almost exclusively with R,R,R configuration. Tocotrienols differ from tocopherols only in having three double bonds in the hydrocarbon chain.. vitamin E : Any member of a group of fat-soluble chromanols that exhibit biological activity against vitamin E deficiency. The vitamers in this class consists of a chroman-6-ol core which is substituted at position 2 by a methyl group and (also at position 2) either a saturated or a triply-unsaturated hydrocarbon chain consisting of three isoprenoid units. The major function of vitamin E is to act as a natural antioxidant by scavenging free radicals and molecular oxygen.. (R,R,R)-alpha-tocopherol : An alpha-tocopherol that has R,R,R configuration. The naturally occurring stereoisomer of alpha-tocopherol, it is found particularly in sunflower and olive oils.		3.2710alpha-tocopherolalgal metabolite;
antiatherogenic agent;
anticoagulant;
antioxidant;
antiviral agent;
EC 2.7.11.13 (protein kinase C) inhibitor;
immunomodulator;
micronutrient;
nutraceutical;
plant metabolite
tocopherols
[no description available]		2.4110
5,5'-dimethyl-2,2'-bipyridyl
5,5'-dimethyl-2,2'-bipyridyl: structure in first source		2.610bipyridines
dichlorobenzyl alcohol
2,4-dichlorobenzyl alcohol : A member of the class of benzyl alcohols that is benzyl alcohol in which the hydrogens at positions 2 and 4 are replaced by chlorines.		2.610benzyl alcohols;
dichlorobenzene		antiseptic drug
amiloride hydrochloride, anhydrous
amiloride hydrochloride : A hydrochloride obtained by combining amiloride with one molar equivalent of hydrochloric acid.		2.0810hydrochloridediuretic;
sodium channel blocker
clothiapine
clothiapine: was heading 1975-94 (was see under DIBENZOTHIAZEPINES 1975-90); CLOTIAPINE was see CLOTHIAPINE 1978-94; use DIBENZOTHIAZEPINES to search CLOTHIAPINE 1975-94; antipsychotic similar to clozapine		2.8930dibenzothiazepine
benperidol
Benperidol: A butyrophenone with general properties similar to those of HALOPERIDOL. It has been used in the treatment of aberrant sexual behavior. (From Martindale, The Extra Pharmacopoeia, 30th ed, p567)		2.8930aromatic ketone
7-hydroxychlorpromazine
7-hydroxychlorpromazine: RN given refers to parent cpd		2.8930phenothiazines
acadesine
[no description available]		2.08101-ribosylimidazolecarboxamide;
aminoimidazole;
nucleoside analogue		antineoplastic agent;
platelet aggregation inhibitor
stavudine
Stavudine: A dideoxynucleoside analog that inhibits reverse transcriptase and has in vitro activity against HIV.. stavudine : A nucleoside analogue obtained by formal dehydration across positions 2 and 3 of thymidine. An inhibitor of HIV-1 reverse transcriptase		2.610dihydrofuran;
nucleoside analogue;
organic molecular entity		antimetabolite;
antiviral agent;
EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor
nitroxoline
nitroxoline: structure in Merck Index, 9th ed, #6475; RN given refers to parent cpd. nitroxoline : A monohydroxyquinoline in which the hydroxy group is positioned at C-8 with a nitro group trans to it at C-5.		3.5110C-nitro compound;
monohydroxyquinoline		antifungal agent;
antiinfective agent;
antimicrobial agent;
renal agent
dideoxyadenosine
Dideoxyadenosine: A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is an inhibitor of HIV replication, acting as a chain-terminator of viral DNA by binding to reverse transcriptase. Its principal side effect is nephrotoxicity. In vivo, dideoxyadenosine is rapidly metabolized to DIDANOSINE (ddI) by enzymatic deamination; ddI is then converted to dideoxyinosine monophosphate and ultimately to dideoxyadenosine triphosphate, the putative active metabolite.		2.610adenosines;
purine 2',3'-dideoxyribonucleoside		EC 3.5.4.4 (adenosine deaminase) inhibitor;
EC 4.6.1.1 (adenylate cyclase) inhibitor
cladribine
[no description available]		2.520organochlorine compound;
purine 2'-deoxyribonucleoside		antineoplastic agent;
immunosuppressive agent
alpha-tocopherol succinate
[no description available]		3.2710hemisuccinate;
tocol
vidarabine
adenine arabinoside : A purine nucleoside in which adenine is attached to arabinofuranose via a beta-N(9)-glycosidic bond.		3.9730beta-D-arabinoside;
purine nucleoside		antineoplastic agent;
bacterial metabolite;
nucleoside antibiotic
3-deazaadenosine
3-deazaadenosine: RN given refers to parent cpd.		2.610
manganese
Manganese: A trace element with atomic symbol Mn, atomic number 25, and atomic weight 54.94. It is concentrated in cell mitochondria, mostly in the pituitary gland, liver, pancreas, kidney, and bone, influences the synthesis of mucopolysaccharides, stimulates hepatic synthesis of cholesterol and fatty acids, and is a cofactor in many enzymes, including arginase and alkaline phosphatase in the liver. (From AMA Drug Evaluations Annual 1992, p2035). manganese(4+) : A manganese cation that is monoatomic and has a formal charge of +4.		4.811elemental manganese;
manganese group element atom		Escherichia coli metabolite;
micronutrient
mercury
Mercury: A silver metallic element that exists as a liquid at room temperature. It has the atomic symbol Hg (from hydrargyrum, liquid silver), atomic number 80, and atomic weight 200.59. Mercury is used in many industrial applications and its salts have been employed therapeutically as purgatives, antisyphilitics, disinfectants, and astringents. It can be absorbed through the skin and mucous membranes which leads to MERCURY POISONING. Because of its toxicity, the clinical use of mercury and mercurials is diminishing.. mercury(0) : Elemental mercury of oxidation state zero.		4.811elemental mercury;
zinc group element atom		neurotoxin
molybdenum
Molybdenum: A metallic element with the atomic symbol Mo, atomic number 42, and atomic weight 95.95. It is an essential trace element, being a component of the enzymes xanthine oxidase, aldehyde oxidase, and nitrate reductase.		4.811chromium group element atommicronutrient
platinum
Platinum: A heavy, soft, whitish metal, resembling tin, with atomic number 78, atomic weight 195.084, symbol Pt. It is used in manufacturing equipment for laboratory and industrial use. It occurs as a black powder (platinum black) and as a spongy substance (spongy platinum) and may have been known in Pliny's time as alutiae.		8.6411elemental platinum;
nickel group element atom;
platinum group metal atom
silver
Silver: An element with the atomic symbol Ag, atomic number 47, and atomic weight 107.87. It is a soft metal that is used medically in surgical instruments, dental prostheses, and alloys. Long-continued use of silver salts can lead to a form of poisoning known as ARGYRIA.		5.0621copper group element atom;
elemental silver		Escherichia coli metabolite
titanium
Titanium: A dark-gray, metallic element of widespread distribution but occurring in small amounts with atomic number, 22, atomic weight, 47.867 and symbol, Ti; specific gravity, 4.5; used for fixation of fractures.		5.2521titanium group element atom
gold
Gold: A yellow metallic element with the atomic symbol Au, atomic number 79, and atomic weight 197. It is used in jewelry, goldplating of other metals, as currency, and in dental restoration. Many of its clinical applications, such as ANTIRHEUMATIC AGENTS, are in the form of its salts.		5.2521copper group element atom;
elemental gold
zalcitabine
Zalcitabine: A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication at low concentrations, acting as a chain-terminator of viral DNA by binding to reverse transcriptase. Its principal toxic side effect is axonal degeneration resulting in peripheral neuropathy.. zalcitabine : A pyrimidine 2',3'-dideoxyribonucleoside compound having cytosine as the nucleobase.		2.610pyrimidine 2',3'-dideoxyribonucleosideantimetabolite;
antiviral drug;
HIV-1 reverse transcriptase inhibitor
galactosamine
2-amino-2-deoxy-D-galactopyranose : The pyranose form of D-galactosamine.. D-galactosamine : The D-stereoisomer of galactosamine.		4.811D-galactosamine;
primary amino compound		toxin
camptothecin
NSC 100880: carboxylate (opened lactone) form of camptothecin; RN refers to (S)-isomer; structure given in first source		3.0840delta-lactone;
pyranoindolizinoquinoline;
quinoline alkaloid;
tertiary alcohol		antineoplastic agent;
EC 5.99.1.2 (DNA topoisomerase) inhibitor;
genotoxin;
plant metabolite
zinc sulfate
Zinc Sulfate: A compound given in the treatment of conditions associated with zinc deficiency such as acrodermatitis enteropathica. Externally, zinc sulfate is used as an astringent in lotions and eye drops. (Reynolds JEF(Ed): Martindale: The Extra Pharmacopoeia (electronic version). Micromedex, Inc, Englewood, CO, 1995). zinc sulfate : A metal sulfate compound having zinc(2+) as the counterion.		4.811metal sulfate;
zinc molecular entity		fertilizer
tricalcium phosphate
tricalcium phosphate: a form of tricalcium phosphate used as bioceramic bone replacement material; see also records for alpha-tricalcium phosphate, beta-tricalcium phosphate, calcium phosphate; apatitic tricalcium phosphate Ca9(HPO4)(PO4)5(OH) is the calcium orthophosphate leading to beta tricalcium phosphate Ca3(PO4)2 (b-TCP). calcium phosphate : A calcium salt composed of calcium and phosphate/diphosphate ions; present in milk and used for the mineralisation of calcified tissues.		4.811calcium phosphate
ancitabine
Ancitabine: Congener of CYTARABINE that is metabolized to cytarabine and thereby maintains a more constant antineoplastic action.. ancitabine : An organic heterotricyclic compound resulting from the formal condensation of the oxo group of cytidine to the 2' position with loss of water to give the corresponding cyclic ether. A prodrug, it is metabolised to the antineoplastic agent cytarabine, so is used to maintain a more constant antineoplastic action.		2.610diol;
organic heterotricyclic compound		antimetabolite;
antineoplastic agent;
prodrug
chloropyramine
chloropyramine: RN given refers to parent cpd; structure		2.610aminopyridine
titanium dioxide
titanium dioxide: used medically as protectant against externally caused irritation & sunlight; high concentrations of dust may cause irritation to respiratory tract; RN given refers to titanium oxide (TiO2); structure. titanium dioxide : A titanium oxide with the formula TiO2. A naturally occurring oxide sourced from ilmenite, rutile and anatase, it has a wide range of applications.		4.811titanium oxidesfood colouring
levamisole
Levamisole: An antihelminthic drug that has been tried experimentally in rheumatic disorders where it apparently restores the immune response by increasing macrophage chemotaxis and T-lymphocyte function. Paradoxically, this immune enhancement appears to be beneficial in rheumatoid arthritis where dermatitis, leukopenia, and thrombocytopenia, and nausea and vomiting have been reported as side effects. (From Smith and Reynard, Textbook of Pharmacology, 1991, p435-6). levamisole : A 6-phenyl-2,3,5,6-tetrahydroimidazo[2,1-b][1,3]thiazole that has S configuration. It is used (generally as the monohydrochloride salt) to treat parasitic worm infections in pigs, sheep and cattle and was formerly used in humans as an adjuvant to chemotherapy for the treatment of various cancers. It is also widely used as an adulterant to coccaine.		2.6106-phenyl-2,3,5,6-tetrahydroimidazo[2,1-b][1,3]thiazoleantinematodal drug;
antirheumatic drug;
EC 3.1.3.1 (alkaline phosphatase) inhibitor;
immunological adjuvant;
immunomodulator
thenalidine
thenalidine: antihistaminic, antipruritic; RN in Chemline for thenalidine calcium: 67250-62-8; structure		2.8930dialkylarylamine;
tertiary amino compound
n'-nitrosonornicotine
N'-nitrosonornicotine: structure; a potent carcinogen in laboratory animals		2.610pyridines;
pyrrolidines
daunorubicin
Daunorubicin: A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of LEUKEMIA and other NEOPLASMS.. anthracycline : Anthracyclines are polyketides that have a tetrahydronaphthacenedione ring structure attached by a glycosidic linkage to the amino sugar daunosamine.. daunorubicin : A natural product found in Actinomadura roseola.		2.7220aminoglycoside antibiotic;
anthracycline;
p-quinones;
tetracenequinones		antineoplastic agent;
bacterial metabolite
bromocriptine
Bromocriptine: A semisynthetic ergotamine alkaloid that is a dopamine D2 agonist. It suppresses prolactin secretion.		2.8930indole alkaloidantidyskinesia agent;
antiparkinson drug;
dopamine agonist;
hormone antagonist
zingerone
zingerone: pungent principle of ginger; structure. zingerone : A methyl ketone that is 4-phenylbutan-2-one in which the phenyl ring is substituted at positions 3 and 4 by methoxy and hydroxy groups respectively. The major pungent component in ginger.		7.4110methyl ketone;
monomethoxybenzene;
phenols		anti-inflammatory agent;
antiemetic;
antioxidant;
flavouring agent;
fragrance;
plant metabolite;
radiation protective agent
phenyl acetate
phenyl acetate: The ester formed between phenol and acetic acid. Don't confuse with phenylacetic acid derivatives listed under PHENYLACETATES.. phenyl acetate : An acetate ester obtained by the formal condensation of phenol with acetic acid.		2.2110benzenes;
phenyl acetates
alkenes
[no description available]		2.3110
dexchlorpheniramine
dexchlorpheniramine: RN given refers to parent cpd(S)-isomer		2.8930chlorphenamine
dv 1006
[no description available]		2.8930
zidovudine
Zidovudine: A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia.. zidovudine : A pyrimidine 2',3'-dideoxyribonucleoside compound having a 3'-azido substituent and thymine as the nucleobase.		2.5820azide;
pyrimidine 2',3'-dideoxyribonucleoside		antimetabolite;
antiviral drug;
HIV-1 reverse transcriptase inhibitor
paclitaxel
Taxus: Genus of coniferous yew trees or shrubs, several species of which have medicinal uses. Notable is the Pacific yew, Taxus brevifolia, which is used to make the anti-neoplastic drug taxol (PACLITAXEL).		7.3110taxane diterpenoid;
tetracyclic diterpenoid		antineoplastic agent;
human metabolite;
metabolite;
microtubule-stabilising agent
etoposide
[no description available]		5.0532beta-D-glucoside;
furonaphthodioxole;
organic heterotetracyclic compound		antineoplastic agent;
DNA synthesis inhibitor
ribavirin
Rebetron: Rebetron is tradename		2.6101-ribosyltriazole;
aromatic amide;
monocarboxylic acid amide;
primary carboxamide		anticoronaviral agent;
antiinfective agent;
antimetabolite;
antiviral agent;
EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor
climbazole
1-(4-chlorophenoxy)-1-(1H-imidazol-1-yl)-3,3-dimethylbutan-2-one : A ketone that is butan-2-one substituted by a 4-chlorophenoxy and a 1H-imidazol-1-yl group at position 1 and 2 methyl groups at position 3.		2.8930aromatic ether;
hemiaminal ether;
imidazoles;
ketone;
monochlorobenzenes
pyridoxal phosphate
[no description available]		2.610pyridinecarbaldehyde
lonidamine
lonidamine: structure. lonidamine : A member of the class of indazoles that is 1H-indazole that is substituted at positions 1 and 3 by 2,4-dichlorobenzyl and carboxy groups, respectively.		2.0810dichlorobenzene;
indazoles;
monocarboxylic acid		antineoplastic agent;
antispermatogenic agent;
EC 2.7.1.1 (hexokinase) inhibitor;
geroprotector
triadimenol
triadimenol : A member of the class of triazoles that is 3,3-dimethyl-1-(1,2,4-triazol-1-yl)butane-1,2-diol substituted at position O1 by a 4-chlorophenyl group. A fungicide for cereals, beet and brassicas used to control a range of diseases including powdery mildew, rusts, bunts and smuts.		2.8930aromatic ether;
conazole fungicide;
hemiaminal ether;
monochlorobenzenes;
secondary alcohol;
triazole fungicide		antifungal agrochemical;
EC 1.14.13.70 (sterol 14alpha-demethylase) inhibitor;
xenobiotic metabolite
nitazoxanide
nitazoxanide: a 5-nitrothiazolyl derivative used for a broad range of intestinal parasitic infections including CRYPTOSPORIDIUM and GIARDIA; it is a redox-active nitrothiazolyl-salicylamide prodrug		2.610benzamides;
carboxylic ester
captopril
Captopril: A potent and specific inhibitor of PEPTIDYL-DIPEPTIDASE A. It blocks the conversion of ANGIOTENSIN I to ANGIOTENSIN II, a vasoconstrictor and important regulator of arterial blood pressure. Captopril acts to suppress the RENIN-ANGIOTENSIN SYSTEM and inhibits pressure responses to exogenous angiotensin.. captopril : A L-proline derivative in which L-proline is substituted on nitrogen with a (2S)-2-methyl-3-sulfanylpropanoyl group. It is used as an anti-hypertensive ACE inhibitor drug.		2.610alkanethiol;
L-proline derivative;
N-acylpyrrolidine;
pyrrolidinemonocarboxylic acid		antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
oltipraz
oltipraz : A 1,2-dithiole that is 3H-1,2-dithiole-3-thione substituted at positions 4 and 5 by methyl and pyrazin-2-yl groups respectively.		2.6101,2-dithiole;
pyrazines		angiogenesis modulating agent;
antimutagen;
antineoplastic agent;
antioxidant;
EC 3.1.3.48 (protein-tyrosine-phosphatase) inhibitor;
neurotoxin;
protective agent;
schistosomicide drug
fiacitabine
fiacitabine: anti-herpes virus agent which also inhibits growth of certain human tumor cell lines in vitro.		2.610
amonafide
xanafide: salt formulation of amonafide; DNA-intercalating agent and topoisomerase II inhibitor		2.8930isoquinolines
flupirtine
flupirtine: RN given refers to parent cpd without isomeric designation		2.8930aminopyridine
chaetochromin
chaetochromin: from Chaetomium spp.; RN given refers to chaetochromin A		2.8930
enoximone
Enoximone: A selective phosphodiesterase inhibitor with vasodilating and positive inotropic activity that does not cause changes in myocardial oxygen consumption. It is used in patients with CONGESTIVE HEART FAILURE.		2.8930aromatic ketone
simvastatin
Simvastatin: A derivative of LOVASTATIN and potent competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase (HYDROXYMETHYLGLUTARYL COA REDUCTASES), which is the rate-limiting enzyme in cholesterol biosynthesis. It may also interfere with steroid hormone production. Due to the induction of hepatic LDL RECEPTORS, it increases breakdown of LDL CHOLESTEROL.. simvastatin : A member of the class of hexahydronaphthalenes that is lovastatin in which the 2-methylbutyrate ester moiety has been replaced by a 2,2-dimethylbutyrate ester group. It is used as a cholesterol-lowering and anti-cardiovascular disease drug.		2.0810delta-lactone;
fatty acid ester;
hexahydronaphthalenes;
statin (semi-synthetic)		EC 1.1.1.34/EC 1.1.1.88 (hydroxymethylglutaryl-CoA reductase) inhibitor;
EC 3.4.24.83 (anthrax lethal factor endopeptidase) inhibitor;
ferroptosis inducer;
geroprotector;
prodrug
itraconazole
Itraconazole: A triazole antifungal agent that inhibits cytochrome P-450-dependent enzymes required for ERGOSTEROL synthesis.. itraconazole : An N-arylpiperazine that is cis-ketoconazole in which the imidazol-1-yl group is replaced by a 1,2,4-triazol-1-yl group and in which the actyl group attached to the piperazine moiety is replaced by a p-[(+-)1-sec-butyl-5-oxo-1,5-dihydro-4H-1,2,4-triazol-4-yl]phenyl group. A potent P-glycoprotein and CYP3A4 inhibitor, it is used as an antifungal drug for the treatment of various fungal infections, including aspergillosis, blastomycosis, candidiasis, chromoblastomycosis, coccidioidomycosis, cryptococcosis, histoplasmosis, and sporotrichosis.		2.0810aromatic ether;
conazole antifungal drug;
cyclic ketal;
dichlorobenzene;
dioxolane;
N-arylpiperazine;
triazole antifungal drug;
triazoles		EC 3.6.3.44 (xenobiotic-transporting ATPase) inhibitor;
Hedgehog signaling pathway inhibitor;
P450 inhibitor
pravadoline
[no description available]		2.0810
salmeterol xinafoate
Salmeterol Xinafoate: A selective ADRENERGIC BETA-2 RECEPTOR agonist that functions as a BRONCHODILATOR when administered by inhalation. It is used to manage the symptoms of ASTHMA and CHRONIC OBSTRUCTIVE PULMONARY DISEASE.		4.811naphthoic acid
ranolazine
Ranolazine: An acetanilide and piperazine derivative that functions as a SODIUM CHANNEL BLOCKER and prevents the release of enzymes during MYOCARDIAL ISCHEMIA. It is used in the treatment of ANGINA PECTORIS.. N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl}acetamide : An aromatic amide obtained by formal condensation of the carboxy group of 2-{4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl}acetic acid with the amino group of 2,6-dimethylaniline.. ranolazine : A racemate comprising equal amounts of (R)- and (S)-ranolazine. Used for treatment of chronic angina.		2.610aromatic amide;
monocarboxylic acid amide;
monomethoxybenzene;
N-alkylpiperazine;
secondary alcohol
brequinar
brequinar : A quinolinemonocarboxylic acid that is quinoline substituted by 2'-fluoro[1,1'-biphenyl]-4-yl, methyl, carboxy and fluoro groups at positions 2, 3, 4, and 6, respectively. It is an inhibitor of dihydroorotate dehydrogenase, an enzyme that is required for de novo pyrimidine biosynthesis. The compound exhibits antineoplastic and antiviral properties.		2.610biphenyls;
monocarboxylic acid;
monofluorobenzenes;
quinolinemonocarboxylic acid		anticoronaviral agent;
antimetabolite;
antineoplastic agent;
antiviral agent;
EC 1.3.5.2 [dihydroorotate dehydrogenase (quinone)] inhibitor;
immunosuppressive agent;
pyrimidine synthesis inhibitor
imiquimod
Imiquimod: A topically-applied aminoquinoline immune modulator that induces interferon production. It is used in the treatment of external genital and perianal warts, superficial CARCINOMA, BASAL CELL; and ACTINIC KERATOSIS.. imiquimod : An imidazoquinoline fused [4,5-c] carrying isobutyl and amino substituents at N-1 and C-4 respectively. A prescription medication, it acts as an immune response modifier and is used to treat genital warts, superficial basal cell carcinoma, and actinic keratosis.		2.610imidazoquinolineantineoplastic agent;
interferon inducer
adefovir
adefovir: inhibitor of African swine fever virus. adefovir(1-) : A organophosphonate oxoanion obtained by removal of a proton from the phosphonate group of adefovir, a nucleoside reverse transcriptase inhibitor. It is the major microspecies at pH 7.3 (according to Marvin v 6.2.0.).. adefovir : A member of the class of phosphonic acids that is methylphosphonic acid in which one of the methyl hydrogens has been replaced by a 2-(6-amino-9H-purin-9-yl)ethoxy group. An inhibitor of HIV-1 reverse transcriptase, the bis(t-butoxycarbonyloxymethyl) ester (dipivoxil ester) prodrug is used to treat chronic hepatitis B viral infection.		2.6106-aminopurines;
ether;
phosphonic acids		antiviral drug;
DNA synthesis inhibitor;
drug metabolite;
HIV-1 reverse transcriptase inhibitor;
nephrotoxic agent
zileuton
[no description available]		2.08101-benzothiophenes;
ureas		anti-asthmatic drug;
EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor;
ferroptosis inhibitor;
leukotriene antagonist;
non-steroidal anti-inflammatory drug
niguldipine
[no description available]		2.0810diarylmethane
cidofovir anhydrous
Cidofovir: An acyclic nucleoside phosphonate that acts as a competitive inhibitor of viral DNA polymerases. It is used in the treatment of RETINITIS caused by CYTOMEGALOVIRUS INFECTIONS and may also be useful for treating HERPESVIRUS INFECTIONS.. cidofovir anhydrous : Cytosine substituted at the 1 position by a 3-hydroxy-2-(phosphonomethoxy)propyl group (S configuration). A nucleoside analogue, it is an injectable antiviral used for the treatment of cytomegalovirus (CMV) retinitis in AIDS patients.		2.610phosphonic acids;
pyrimidone		anti-HIV agent;
antineoplastic agent;
antiviral drug;
photosensitizing agent
topotecan
Topotecan: An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA TOPOISOMERASES, TYPE I.. topotecan : A pyranoindolizinoquinoline used as an antineoplastic agent. It is a derivative of camptothecin and works by binding to the topoisomerase I-DNA complex and preventing religation of these 328 single strand breaks.		2.0810pyranoindolizinoquinolineantineoplastic agent;
EC 5.99.1.2 (DNA topoisomerase) inhibitor
eliprodil
1-(4-chlorophenyl)-2-[4-(4-fluorobenzyl)piperidin-1-yl]ethanol : A member of the class of piperidines that is piperidine substituted by a 2-(4-chlorophenyl)-2-hydroxyethyl group at position 1 and by a 4-fluorobenzyl group at position 4.		2.0810monochlorobenzenes;
monofluorobenzenes;
piperidines;
secondary alcohol;
tertiary amino compound
celgosivir
celgosivir: inhibits glycoprotein processing & the growth of HIVs		2.610
gemcitabine
gemcitabine : A 2'-deoxycytidine having geminal fluoro substituents in the 2'-position. An inhibitor of ribonucleotide reductase, gemcitabine is used in the treatment of various carcinomas, particularly non-small cell lung cancer, pancreatic cancer, bladder cancer and breast cancer.		2.5820organofluorine compound;
pyrimidine 2'-deoxyribonucleoside		antimetabolite;
antineoplastic agent;
antiviral drug;
DNA synthesis inhibitor;
EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor;
environmental contaminant;
immunosuppressive agent;
photosensitizing agent;
prodrug;
radiosensitizing agent;
xenobiotic
aripiprazole
Aripiprazole: A piperazine and quinolone derivative that is used primarily as an antipsychotic agent. It is a partial agonist of SEROTONIN RECEPTOR, 5-HT1A and DOPAMINE D2 RECEPTORS, where it also functions as a post-synaptic antagonist, and an antagonist of SEROTONIN RECEPTOR, 5-HT2A. It is used for the treatment of SCHIZOPHRENIA and BIPOLAR DISORDER, and as an adjunct therapy for the treatment of depression.. aripiprazole : An N-arylpiperazine that is piperazine substituted by a 4-[(2-oxo-1,2,3,4-tetrahydroquinolin-7-yl)oxy]butyl group at position 1 and by a 2,3-dichlorophenyl group at position 4. It is an antipsychotic drug used for the treatment of Schizophrenia, and other mood disorders.		4.1740aromatic ether;
delta-lactam;
dichlorobenzene;
N-alkylpiperazine;
N-arylpiperazine;
quinolone		drug metabolite;
H1-receptor antagonist;
second generation antipsychotic;
serotonergic agonist
lamivudine
[no description available]		2.610monothioacetal;
nucleoside analogue;
oxacycle;
primary alcohol		allergen;
anti-HBV agent;
antiviral drug;
EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor;
HIV-1 reverse transcriptase inhibitor;
prodrug
irinotecan
[no description available]		8.9421carbamate ester;
delta-lactone;
N-acylpiperidine;
pyranoindolizinoquinoline;
ring assembly;
tertiary alcohol;
tertiary amino compound		antineoplastic agent;
apoptosis inducer;
EC 5.99.1.2 (DNA topoisomerase) inhibitor;
prodrug
valsartan
Valsartan: A tetrazole derivative and ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKER that is used to treat HYPERTENSION.. valsartan : A monocarboxylic acid amide consisting of L-valine in which the amino hydrogens have been replaced by a pentanoyl and a [2'-(1H-tetrazol-5-yl)biphenyl]-4-yl]methyl group. It exhibits antihypertensive activity.		2.610biphenylyltetrazole;
monocarboxylic acid amide;
monocarboxylic acid		angiotensin receptor antagonist;
antihypertensive agent;
environmental contaminant;
xenobiotic
ziprasidone
ziprasidone: a benzisothiazoylpiperazine derivative; has combined dopamine and serotonin receptor antagonist activity; structurally related to tiospirone. ziprasidone : A piperazine compound having 1,2-benzothiazol-3-yl- and 2-(6-chloro-1,3-dihydro-2-oxindol-5-yl)ethyl substituents attached to the nitrogen atoms.		3.18101,2-benzisothiazole;
indolones;
organochlorine compound;
piperazines		antipsychotic agent;
dopaminergic antagonist;
histamine antagonist;
muscarinic antagonist;
psychotropic drug;
serotonergic antagonist
zanamivir
Zanamivir: A guanido-neuraminic acid that is used to inhibit NEURAMINIDASE.		2.610guanidinesantiviral agent;
EC 3.2.1.18 (exo-alpha-sialidase) inhibitor
adefovir dipivoxil
bis(pivaloyloxymethyl)-9-(2-phosphonylmethoxyethyl)adenine: structure given in first source. adefovir pivoxil : An organic phosphonate that is the dipivoxil ester of adefovir. A prodrug for adefovir, an HIV-1 reverse transcriptase inhibitor, adefovir pivoxil is used to treat chronic hepatitis B viral infection.		2.6106-aminopurines;
carbonate ester;
ether;
organic phosphonate		antiviral drug;
DNA synthesis inhibitor;
HIV-1 reverse transcriptase inhibitor;
nephrotoxic agent;
prodrug
emtricitabine
Emtricitabine: A deoxycytidine analog and REVERSE TRANSCRIPTASE INHIBITOR with antiviral activity against HIV-1 and HEPATITIS B viruses. It is used to treat HIV INFECTIONS.. emtricitabine : An organofluorine compound that is 5-fluorocytosine substituted at the 1 position by a 2-(hydroxymethyl)-1,3-oxathiolan-5-yl group (2R,5S configuration). It is used in combination therapy for the treatment of HIV-1 infection.		2.610monothioacetal;
nucleoside analogue;
organofluorine compound;
pyrimidone		antiviral drug;
HIV-1 reverse transcriptase inhibitor
adenosine
quinquefolan B: isolated from roots of Panax quinquefolium L.; RN not in Chemline 10/87; RN from Toxlit		4.811adenosines;
purines D-ribonucleoside		analgesic;
anti-arrhythmia drug;
fundamental metabolite;
human metabolite;
vasodilator agent
octyl gallate
[no description available]		2.610gallate esterfood antioxidant;
hypoglycemic agent;
plant metabolite
verapamil hydrochloride
verapamil hydrochloride : A racemate comprising equimolar amounts of dexverapamil hydrochloride and (S)-verapamil hydrochloride.		2.0810
efavirenz
efavirenz: HIV-1 reverse transcriptase inhibitor. efavirenz : 1,4-Dihydro-2H-3,1-benzoxazin-2-one substituted at the 4 position by cyclopropylethynyl and trifluoromethyl groups (S configuration) and at the 6 position by chlorine. A non-nucleoside reverse transcriptase inhibitor with activity against HIV, it is used with other antiretrovirals for combination therapy of HIV infection.		2.5820acetylenic compound;
benzoxazine;
cyclopropanes;
organochlorine compound;
organofluorine compound		antiviral drug;
HIV-1 reverse transcriptase inhibitor
nelfinavir
Nelfinavir: A potent HIV protease inhibitor. It is used in combination with other antiviral drugs in the treatment of HIV in both adults and children.. nelfinavir : An aryl sulfide that is used (as its mesylate salt) for treatment of HIV and also exhibits some anticancer properties.		3.0430aryl sulfide;
benzamides;
organic heterobicyclic compound;
phenols;
secondary alcohol;
tertiary amino compound		antineoplastic agent;
HIV protease inhibitor
glucose, (beta-d)-isomer
beta-D-glucose : D-Glucopyranose with beta configuration at the anomeric centre.. (1->4)-beta-D-glucan : A beta-D-glucan in which the glucose units are connected by (1->4) linkages.. (1->3)-beta-D-glucan : A beta-D-glucan in which the glucose units are connected by (1->3) linkages.		4.811D-glucopyranoseepitope;
mouse metabolite
betulinic acid
[no description available]		2.610hydroxy monocarboxylic acid;
pentacyclic triterpenoid		anti-HIV agent;
anti-inflammatory agent;
antimalarial;
antineoplastic agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
plant metabolite
arctigenin
arctigenin: precursor to catechols; in many plants		2.610lignan
baicalin
[no description available]		2.610dihydroxyflavone;
glucosiduronic acid;
glycosyloxyflavone;
monosaccharide derivative		antiatherosclerotic agent;
antibacterial agent;
anticoronaviral agent;
antineoplastic agent;
antioxidant;
cardioprotective agent;
EC 2.7.7.48 (RNA-directed RNA polymerase) inhibitor;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
ferroptosis inhibitor;
neuroprotective agent;
non-steroidal anti-inflammatory drug;
plant metabolite;
prodrug
plerixafor
plerixafor: a bicyclam derivate, highly potent & selective inhibitor of HIV-1 & HIV-2. plerixafor : An azamacrocycle consisting of two cyclam rings connected by a 1,4-phenylenebis(methylene) linker. It is a CXCR4 chemokine receptor antagonist and a hematopoietic stem cell mobilizer. It is used in combination with grulocyte-colony stimulating factor (G-CSF) to mobilize hematopoietic stem cells to the perpheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin's lymphoma and multiple myeloma.		5.6240azacycloalkane;
azamacrocycle;
benzenes;
crown amine;
secondary amino compound;
tertiary amino compound		anti-HIV agent;
antineoplastic agent;
C-X-C chemokine receptor type 4 antagonist;
immunological adjuvant
amprenavir
[no description available]		2.610carbamate ester;
sulfonamide;
tetrahydrofuryl ester		antiviral drug;
HIV protease inhibitor
oseltamivir
Oseltamivir: An acetamido cyclohexene that is a structural homolog of SIALIC ACID and inhibits NEURAMINIDASE.. oseltamivir : A cyclohexenecarboxylate ester that is the ethyl ester of oseltamivir acid. An antiviral prodrug (it is hydrolysed to the active free carboxylic acid in the liver), it is used to slow the spread of influenza.		2.610acetamides;
amino acid ester;
cyclohexenecarboxylate ester;
primary amino compound		antiviral drug;
EC 3.2.1.18 (exo-alpha-sialidase) inhibitor;
environmental contaminant;
prodrug;
xenobiotic
epigallocatechin gallate
epigallocatechin gallate: a steroid 5alpha-reductase inhibitor and antimutagen in green tea (Camellia sinensis). (-)-epigallocatechin 3-gallate : A gallate ester obtained by the formal condensation of gallic acid with the (3R)-hydroxy group of (-)-epigallocatechin.		2.610flavans;
gallate ester;
polyphenol		antineoplastic agent;
antioxidant;
apoptosis inducer;
geroprotector;
Hsp90 inhibitor;
neuroprotective agent;
plant metabolite
salvin
salvin: a biocyclic diterpenoid; from sage and rosemary (Lamiaceae)		3.2710abietane diterpenoid;
carbotricyclic compound;
catechols;
monocarboxylic acid		angiogenesis modulating agent;
anti-inflammatory agent;
antineoplastic agent;
antioxidant;
apoptosis inducer;
food preservative;
HIV protease inhibitor;
plant metabolite
1,2,3,4,6-pentakis-O-galloyl-beta-D-glucose
pentagalloylglucose: pentahydroxy gallic acid ester of glucose; a phytogenic antineoplastic agent and antibacterial agent. 1,2,3,4,6-pentakis-O-galloyl-beta-D-glucose : A galloyl-beta-D-glucose compound having five galloyl groups in the 1-, 2-, 3-, 4- and 6-positions.		2.610gallate ester;
galloyl beta-D-glucose		anti-inflammatory agent;
antineoplastic agent;
geroprotector;
hepatoprotective agent;
plant metabolite;
radiation protective agent;
radical scavenger
cephalotaxine
[no description available]		2.610benzazepine alkaloid fundamental parent;
benzazepine alkaloid;
cyclic acetal;
enol ether;
organic heteropentacyclic compound;
secondary alcohol;
tertiary amino compound
desipramine hydrochloride
desipramine hydrochloride : The hydrochloride salt of desipramine.		2.610hydrochloridedrug allergen
mefloquine hydrochloride
[no description available]		2.610hydrochloride
bendamustine
[no description available]		2.0810benzimidazoles
aloxistatin
aloxistatin: a membrane-permeable cysteine protease inhibitor. aloxistatin : An L-leucine derivative that is the amide obtained by formal condensation of the carboxy group of (2S,3S)-3-(ethoxycarbonyl)oxirane-2-carboxylic acid with the amino group of N-(3-methylbutyl)-L-leucinamide.		2.7220epoxide;
ethyl ester;
L-leucine derivative;
monocarboxylic acid amide		anticoronaviral agent;
cathepsin B inhibitor
propazole
propazole: RN given refers to parent cpd; structure		2.610benzimidazoles
caroverine
caroverine: structure		2.0810quinoxaline derivative
indocate
[no description available]		2.8930
cgs 9343b
[no description available]		2.0810benzimidazoles
prulifloxacin
prulifloxacin: structure given in first source		2.610fluoroquinolone antibiotic;
quinolone antibiotic
telmisartan
Telmisartan: A biphenyl compound and benzimidazole derivative that acts as an angiotensin II type 1 receptor antagonist. It is used in the management of HYPERTENSION.. telmisartan : A member of the class of benzimidazoles used widely in the treatment of hypertension.		2.5820benzimidazoles;
biphenyls;
carboxybiphenyl		angiotensin receptor antagonist;
antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
environmental contaminant;
xenobiotic
bergenin
bergenin: RN refers to (2R-(2alpha,3beta,4alpha,4aalpha,10bbeta))-isomer; structure		2.610trihydroxybenzoic acidmetabolite
2-methoxyestradiol
2-methoxy-17beta-estradiol : A 17beta-hydroxy steroid, being 17beta-estradiol methoxylated at C-2.		2.081017beta-hydroxy steroid;
3-hydroxy steroid		angiogenesis modulating agent;
antimitotic;
antineoplastic agent;
human metabolite;
metabolite;
mouse metabolite
N(4)-acetylsulfathiazole
N(4)-acetylsulfathiazole : A sulfonamide that is benzenesulfonamide substituted by an acetylamino group at position 4 and a 1,3-thiazol-2-yl group at the nitrogen atom. It is a metabolite of sulfathiazole.		2.89301,3-thiazoles;
acetamides;
sulfonamide		marine xenobiotic metabolite
triazoles
Triazoles: Heterocyclic compounds containing a five-membered ring with two carbon atoms and three nitrogen atoms with the molecular formula C2H3N3.. triazoles : An azole in which the five-membered heterocyclic aromatic skeleton contains three N atoms and two C atoms.		7.931121,2,3-triazole
cyclizine hydrochloride
[no description available]		2.5920
2,3-trimethylene-4-quinazolone
2,3-trimethylene-4-quinazolone: structure in first source		2.8930quinazolines
fluorodeoxyglucose f18
Fluorodeoxyglucose F18: The compound is given by intravenous injection to do POSITRON-EMISSION TOMOGRAPHY for the assessment of cerebral and myocardial glucose metabolism in various physiological or pathological states including stroke and myocardial ischemia. It is also employed for the detection of malignant tumors including those of the brain, liver, and thyroid gland. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1162)		4.8112-deoxy-2-((18)F)fluoro-D-glucose;
2-deoxy-2-fluoro-aldehydo-D-glucose
zoledronic acid
Zoledronic Acid: An imidobisphosphonate inhibitor of BONE RESORPTION that is used for the treatment of malignancy-related HYPERCALCEMIA; OSTEITIS DEFORMANS; and OSTEOPOROSIS.. zoledronic acid : An imidazole compound having a 2,2-bis(phosphono)-2-hydroxyethane-1-yl substituent at the 1-position.		2.61201,1-bis(phosphonic acid);
imidazoles		bone density conservation agent
artemisinin
(+)-artemisinin : A sesquiterpene lactone obtained from sweet wormwood, Artemisia annua, which is used as an antimalarial for the treatment of multi-drug resistant strains of falciparum malaria.		2.610organic peroxide;
sesquiterpene lactone		antimalarial;
plant metabolite
brinzolamide
brinzolamide: an antiglaucoma agent		2.610sulfonamide;
thienothiazine		antiglaucoma drug;
EC 4.2.1.1 (carbonic anhydrase) inhibitor
1,3-dimethyluric acid
1,3-dimethyluric acid : An oxopurine that is 7,9-dihydro-1H-purine-2,6,8(3H)-trionesubstituted by methyl groups at N-1 and N-3.		2.8930oxopurinemetabolite
dipropylacetamide
dipropylacetamide: structure. valpromide : A fatty amide derived from valproic acid.		2.610fatty amidegeroprotector;
metabolite;
teratogenic agent
oxprenolol hydrochloride
[no description available]		2.610
danofloxacin
[no description available]		2.8930quinolines
dexrazoxane
Dexrazoxane: The (+)-enantiomorph of razoxane.		7.1310razoxaneantineoplastic agent;
cardiovascular drug;
chelator;
immunosuppressive agent
opipramol hydrochloride
[no description available]		2.610
voriconazole
Voriconazole: A triazole antifungal agent that specifically inhibits STEROL 14-ALPHA-DEMETHYLASE and CYTOCHROME P-450 CYP3A.. voriconazole : A triazole-based antifungal agent used for the treatment of esophageal candidiasis, invasive pulmonary aspergillosis, and serious fungal infections caused by Scedosporium apiospermum and Fusarium spp. It is an inhibitor of cytochrome P450 2C9 (CYP2C9) and CYP3A4.		3.1810conazole antifungal drug;
difluorobenzene;
pyrimidines;
tertiary alcohol;
triazole antifungal drug		P450 inhibitor
moroxydine
[no description available]		2.610biguanides
nitrefazole
[no description available]		2.8930imidazoles
alacepril
[no description available]		2.0810dipeptide;
thioacetate ester		EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
thioxolone
tioxolone : A 1,3-benzoxathiole having a hydroxy substituent at the 6-position.		2.610benzoxathioleantiseborrheic
ubenimex
ubenimex: growth inhibitor		2.0810
methotrimeprazine
Methotrimeprazine: A phenothiazine with pharmacological activity similar to that of both CHLORPROMAZINE and PROMETHAZINE. It has the histamine-antagonist properties of the antihistamines together with CENTRAL NERVOUS SYSTEM effects resembling those of chlorpromazine. (From Martindale, The Extra Pharmacopoeia, 30th ed, p604). methotrimeprazine : A member of the class of phenothiazines that is 10H-phenothiazine substituted by a (2R)-3-(dimethylamino)-2-methylpropyl group and a methoxy group at positions 10 and 2 respectively.		2.8930phenothiazines;
tertiary amine		anticoronaviral agent;
cholinergic antagonist;
dopaminergic antagonist;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
non-narcotic analgesic;
phenothiazine antipsychotic drug;
serotonergic antagonist
honokiol
[no description available]		3.1640biphenyls
nobiletin
nobiletin : A methoxyflavone that is flavone substituted by methoxy groups at positions 5, 6, 7, 8, 3' and 4' respectively.		2.610methoxyflavoneantineoplastic agent;
plant metabolite
lycorine
lycorine: from bulbs of LYCORIS & other plants; RN given refers to (1 alpha,2 beta)-isomer; structure in Merck Index, 9th ed, #5444. lycorine : An indolizidine alkaloid that is 3,12-didehydrogalanthan substituted by hydroxy groups at positions and 2 and a methylenedioxy group across positions 9 and 10. Isolated from Crinum asiaticum, it has been shown to exhibit antimalarial activity.		2.610indolizidine alkaloidanticoronaviral agent;
antimalarial;
plant metabolite;
protein synthesis inhibitor
leupeptin
[no description available]		2.610aldehyde;
tripeptide		bacterial metabolite;
calpain inhibitor;
cathepsin B inhibitor;
EC 3.4.21.4 (trypsin) inhibitor;
serine protease inhibitor
9-methoxyellipticine
9-methoxyellipticine: RN given refers to parent cpd		2.8930
3-aminophenoxazone
3-aminophenoxazone: also inhibits sulfatase; structure		2.8930phenoxazine
tetrandrine
tetrandrine: a bisbenzylisoquinoline that exhibits antifibrogenic activity		2.610bisbenzylisoquinoline alkaloid;
isoquinolines
3-deazaneplanocin
3-deazaneplanocin: S-adenosylhomocysteine hydrolase antagonist		2.8930
calpeptin
[no description available]		2.610amino acid amide
fangchinoline
[no description available]		2.610aromatic ether;
bisbenzylisoquinoline alkaloid;
macrocycle		anti-HIV-1 agent;
anti-inflammatory agent;
antineoplastic agent;
antioxidant;
neuroprotective agent;
plant metabolite
tryptanthrine
tryptanthrine: minor constituent of traditional Chinese medicine qing dai		2.8930alkaloid antibiotic;
organic heterotetracyclic compound;
organonitrogen heterocyclic compound
maslinic acid
(2Alpha,3beta)-2,3-dihydroxyolean-12-en-28-oic acid: from Luehea divaricata and Agrimonia eupatoria		2.610dihydroxy monocarboxylic acid;
pentacyclic triterpenoid		anti-inflammatory agent;
antineoplastic agent;
antioxidant;
plant metabolite
atovaquone
Atovaquone: A hydroxynaphthoquinone that has antimicrobial activity and is being used in antimalarial protocols.. atovaquone : A naphthoquinone compound having a 4-(4-chlorophenyl)cyclohexyl group at the 2-position and a hydroxy substituent at the 3-position.		2.610hydroxy-1,2-naphthoquinone
2-chlorodiazepam
[no description available]		2.8930
bendamustine hydrochloride
[no description available]		9.27104
Polycartine B
[no description available]		2.8930phenazines
aminoquinuride dihydrochloride
[no description available]		2.8930
gamma-glutamine-4-nitroanilide
gamma-glutamine-4-nitroanilide: substrate for glutaminase B.; RN given refers to (L)-isomer		2.3110
clarithromycin
Clarithromycin: A semisynthetic macrolide antibiotic derived from ERYTHROMYCIN that is active against a variety of microorganisms. It can inhibit PROTEIN SYNTHESIS in BACTERIA by reversibly binding to the 50S ribosomal subunits. This inhibits the translocation of aminoacyl transfer-RNA and prevents peptide chain elongation.. clarithromycin : The 6-O-methyl ether of erythromycin A, clarithromycin is a macrolide antibiotic used in the treatment of respiratory-tract, skin and soft-tissue infections. It is also used to eradicate Helicobacter pylori in the treatment of peptic ulcer disease. It prevents bacteria from growing by interfering with their protein synthesis.		8.711macrolide antibioticantibacterial drug;
environmental contaminant;
protein synthesis inhibitor;
xenobiotic
loganin
[no description available]		2.610beta-D-glucoside;
cyclopentapyran;
enoate ester;
iridoid monoterpenoid;
methyl ester;
monosaccharide derivative;
secondary alcohol		anti-inflammatory agent;
EC 3.1.1.7 (acetylcholinesterase) inhibitor;
EC 3.2.1.20 (alpha-glucosidase) inhibitor;
EC 3.4.23.46 (memapsin 2) inhibitor;
neuroprotective agent;
plant metabolite
fibrinogen
Fibrinogen: Plasma glycoprotein clotted by thrombin, composed of a dimer of three non-identical pairs of polypeptide chains (alpha, beta, gamma) held together by disulfide bonds. Fibrinogen clotting is a sol-gel change involving complex molecular arrangements: whereas fibrinogen is cleaved by thrombin to form polypeptides A and B, the proteolytic action of other enzymes yields different fibrinogen degradation products.. D-iditol : The D-enantiomer of iditol.		4.811iditolfungal metabolite
moexipril
[no description available]		2.610peptide
aucubin
[no description available]		2.610organic molecular entitymetabolite
catalpol
[no description available]		2.610organic molecular entitymetabolite
thioproperazine mesylate
[no description available]		2.8930phenothiazines
n(6)-(delta(2)-isopentenyl)adenine
N(6)-dimethylallyladenine : A 6-isopentenylaminopurine in which has the isopentenyl double bond is located between the 2 and 3 positions of the isopentenyl group.		2.89306-isopentenylaminopurinecytokinin
lekoptin
(S)-verapamil : A 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile that has S configuration.		2.6102-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile
lopinavir
[no description available]		2.6620amphetamines;
dicarboxylic acid diamide		anticoronaviral agent;
antiviral drug;
HIV protease inhibitor
titanium nitride (tin)
titanium nitride: RN given refers to unspecified MF		2.4110
alpha-tocopherol phosphate
alpha-tocopherol phosphate: RN given refers to (2R*(4R*,8R*))-(+-)-isomer		3.2710
4-methyl-N-(phenylmethyl)benzenesulfonamide
[no description available]		2.8930sulfonamide
zpck
ZPCK: alkylates histidine residue at active center of bovine chymotrypsin		2.6320
n-methyladenosine
N-methyladenosine: is a inhibitor of cell differentiation. N(6)-methyladenosine : A methyladenosine compound with one methyl group attached to N(6) of the adenine nucleobase.		2.610methyladenosine
cobalt
Cobalt: A trace element that is a component of vitamin B12. It has the atomic symbol Co, atomic number 27, and atomic weight 58.93. It is used in nuclear weapons, alloys, and pigments. Deficiency in animals leads to anemia; its excess in humans can lead to erythrocytosis.. cobalt(1+) : A monovalent inorganic cation obtained from cobalt.. cobalt atom : A cobalt group element atom that has atomic number 27.		2.2510cobalt group element atom;
metal allergen		micronutrient
fulvestrant
Fulvestrant: An estradiol derivative and estrogen receptor antagonist that is used for the treatment of estrogen receptor-positive, locally advanced or metastatic breast cancer.. fulvestrant : A 3-hydroxy steroid that is 17beta-estradiol in which the 7alpha hydrogen has been replaced by a nonyl group in which one of the hydrogens of the terminal methyl has been replaced by a (4,4,5,5,5-pentafluoropentyl)sulfinyl group. An estrogen receptor antagonist, it is used in the treatment of breast cancer.		2.211017beta-hydroxy steroid;
3-hydroxy steroid;
organofluorine compound;
sulfoxide		antineoplastic agent;
estrogen antagonist;
estrogen receptor antagonist
sr141716
[no description available]		2.8930amidopiperidine;
carbohydrazide;
dichlorobenzene;
monochlorobenzenes;
pyrazoles		anti-obesity agent;
appetite depressant;
CB1 receptor antagonist
vinpocetine
[no description available]		2.0810
(6R)-7-[4-(dimethylamino)phenyl]-N-hydroxy-4,6-dimethyl-7-oxohepta-2,4-dienamide
[no description available]		2.5920aromatic ketone
sivelestat
sivelestat: inhibitor of neutrophil elastase; structure given in first source		2.610N-acylglycine;
pivalate ester
pyronaridine
[no description available]		2.610aminoquinoline
geniposide
[no description available]		2.610terpene glycoside
deguelin
deguelin: a natural product from Mundulea sericea; RN refers to (7aS-cis)-isomer; structure given in first source. deguelin : A rotenone that is 13,13a-dihydro-3H-chromeno[3,4-b]pyrano[2,3-h]chromen-7(7aH)-one substituted by methoxy groups at positions 9 and 10, and by two methyl groups at position 3 (the 7aS,13aS-stereoisomer). It exists in abundant quantities in the bark, roots, and leaves of the Leguminosae family of plants and reported to exert anti-tumour effects in various cancers.		2.0810aromatic ether;
diether;
organic heteropentacyclic compound;
rotenones		angiogenesis inhibitor;
anti-inflammatory agent;
antineoplastic agent;
antiviral agent;
apoptosis inducer;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor;
mitochondrial NADH:ubiquinone reductase inhibitor;
plant metabolite
fingolimod
fingolimod : An aminodiol that consists of propane-1,3-diol having amino and 2-(4-octylphenyl)ethyl substituents at the 2-position. It is a sphingosine 1-phosphate receptor modulator used for the treatment of relapsing-remitting multiple sclerosis. A prodrug, fingolimod is phosphorylated by sphingosine kinase to active metabolite fingolimod-phosphate, a structural analogue of sphingosine 1-phosphate.		2.8930aminodiol;
primary amino compound		antineoplastic agent;
CB1 receptor antagonist;
immunosuppressive agent;
prodrug;
sphingosine-1-phosphate receptor agonist
daidzin
daidzin: a potent, selective, and reversible inhibitor of human mitochondrial aldehyde dehydrogenase. daidzein 7-O-beta-D-glucoside : A glycosyloxyisoflavone that is daidzein attached to a beta-D-glucopyranosyl residue at position 7 via a glycosidic linkage. It is used in the treatment of alcohol dependency (antidipsotropic).		2.6107-hydroxyisoflavones 7-O-beta-D-glucoside;
hydroxyisoflavone;
monosaccharide derivative		plant metabolite
triptolide
[no description available]		2.0810diterpenoid;
epoxide;
gamma-lactam;
organic heteroheptacyclic compound		antispermatogenic agent;
plant metabolite
tesmilifene
[no description available]		2.8930diarylmethane
ecteinascidin 743
[no description available]		3.2310acetate ester;
azaspiro compound;
bridged compound;
hemiaminal;
isoquinoline alkaloid;
lactone;
organic heteropolycyclic compound;
organic sulfide;
oxaspiro compound;
polyphenol;
tertiary amino compound		alkylating agent;
angiogenesis modulating agent;
anti-inflammatory agent;
antineoplastic agent;
marine metabolite
homoorientin
homoorientin: isolated from Swertia japonica; structure given in first source		4.811flavone C-glycoside;
tetrahydroxyflavone		antineoplastic agent;
radical scavenger
sophocarpine
[no description available]		2.610
marimastat
marimastat: a matrix metalloproteinase inhibitor active in patients with advanced carcinoma of the pancreas, prostate, or ovary. marimastat : A secondary carboxamide resulting from the foraml condensation of the carboxy group of (2R)-2-[(1S)-1-hydroxy-2-(hydroxyamino)-2-oxoethyl]-4-methylpentanoic acid with the alpha-amino group of N,3-dimethyl-L-valinamide.		2.610hydroxamic acid;
secondary carboxamide		antineoplastic agent;
matrix metalloproteinase inhibitor
clofarabine
[no description available]		3.2110adenosines;
organofluorine compound		antimetabolite;
antineoplastic agent
sr 48692
SR 48692: structure in first source; a neurotensin receptor-1 antagonist		2.0810N-acyl-amino acid
elacridar
Elacridar: inhibitor of MDR1 PROTEIN; structure given in first source		2.5820
sr 27897
SR 27897: structure given in first source; a CCK(A) receptor antagonist		2.8930indolyl carboxylic acid
5-chloromethylfluorescein diacetate
[no description available]		3.2710acetate esterfluorochrome
celastrol
[no description available]		2.610monocarboxylic acid;
pentacyclic triterpenoid		anti-inflammatory drug;
antineoplastic agent;
antioxidant;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
Hsp90 inhibitor;
metabolite
imatinib mesylate
imatinib methanesulfonate : A methanesulfonate (mesylate) salt that is the monomesylate salt of imatinib. Used for treatment of chronic myelogenous leukemia and gastrointestinal stromal tumours.		2.6920methanesulfonate saltanticoronaviral agent;
antineoplastic agent;
apoptosis inducer;
tyrosine kinase inhibitor
gefitinib
[no description available]		2.0810aromatic ether;
monochlorobenzenes;
monofluorobenzenes;
morpholines;
quinazolines;
secondary amino compound;
tertiary amino compound		antineoplastic agent;
epidermal growth factor receptor antagonist
n-(n-(3-carboxyoxirane-2-carbonyl)leucyl)isoamylamine
N-(N-(3-carboxyoxirane-2-carbonyl)leucyl)isoamylamine: inhibits calcium-activated neutral protease; see also record for E-64; RN given refers to (2-S-(2alpha,3beta)(R*)-isomer)		3.1640leucine derivative
bay x 1005
2-(4-(quinolin-2-yl-methoxy)phenyl)-2-cyclopentylacetic acid: inhibits synthesis of leukotriene B4 and 5-hydroxyeicosatetraenoic acid; inhibits five-lipoxygenase activating protein(FLAP)and leukotriene A4 hydrolase(LTA4H); structure given in first source;		2.0810
norketamine
norketamine: metabolite of ketamine; RN given refers to cpd without isomeric designation		2.8930organochlorine compound
vadimezan
vadimezan : A monocarboxylic acid that is acetic acid in which one of the methyl hydrogens is replaced by a 5,6-dimethyl-9-oxoxanthen-4-yl group.		2.610monocarboxylic acid;
xanthones		antineoplastic agent
e 64
E 64: cysteine protease inhibitor of microbial origin, which inhibits cathepsin B (EC 3.4.22.1) and cathepsin L (EC 3.4.22.-)		2.610dicarboxylic acid monoamide;
epoxy monocarboxylic acid;
guanidines;
L-leucine derivative;
zwitterion		antimalarial;
antiparasitic agent;
protease inhibitor
indatraline
indatraline: RN given for (trans)-isomer; structure in first source		2.6320indanes
gyki 53655
GYKI 53655: an AMPA (alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate) receptor antagonist		2.0810
methotrexate
[no description available]		10.350dicarboxylic acid;
monocarboxylic acid amide;
pteridines		abortifacient;
antimetabolite;
antineoplastic agent;
antirheumatic drug;
dermatologic drug;
DNA synthesis inhibitor;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor;
immunosuppressive agent
salvinorin a
salvinorin A: from the herb, Salvia divinorum		2.2110organic heterotricyclic compound;
organooxygen compound		metabolite;
oneirogen
umifenovir
umifenovir: an antiviral agent		2.610indolyl carboxylic acid
4-diethoxyphosphorylmethyl-n-(4-bromo-2-cyanophenyl)benzamide
4-diethoxyphosphorylmethyl-N-(4-bromo-2-cyanophenyl)benzamide: increases lipoprotein lipase activity with resulting elevation of high density lipoprotein cholesterol		2.8930
safinamide
safinamide: short-acting inhibitor of MOA-B; FCE 26743 is (S)-isomer, FCE 28073 is (R)-isomer; structure in first source		2.610amino acid amide
n,n-di-n-hexyl-2-(4-fluorophenyl)indole-3-acetamide
N,N-di-n-hexyl-2-(4-fluorophenyl)indole-3-acetamide: binds with high affinity to glial mitochondrial diazepam binding inhibitor receptors & increases mitochondrial steroidogenesis		2.8930phenylindole
ilomastat
CS 610: matrix metalloproteinase inhibitor; structure in first source. ilomastat : An N-acyl-amino acid obtained by formal condensation of the carboxy group of (2R)-2-[2-(hydroxyamino)-2-oxoethyl]-4-methylpentanoic acid with the amino group of N-methyl-L-tryptophanamide. A cell permeable broad-spectrum matrix metalloproteinase (MMP) inhibitor		2.610hydroxamic acid;
L-tryptophan derivative;
N-acyl-amino acid		anti-inflammatory agent;
antibacterial agent;
antineoplastic agent;
EC 3.4.24.24 (gelatinase A) inhibitor;
neuroprotective agent
ml-3000
[no description available]		2.0810
l 741626
3-(4-(4-chlorophenyl-4-hydroxypiperidino)methyl)indole: structure in first source		2.8930piperidines
pomalidomide
3-aminophthalimidoglutarimide: structure in first source		14.89546aromatic amine;
dicarboximide;
isoindoles;
piperidones		angiogenesis inhibitor;
antineoplastic agent;
immunomodulator
cd 437
CD 437: selective for retinoic acid receptors gamma. CD437 : A naphthoic acid that is 6-phenylnaphthylene-2-carboxyic acid in which the phenyl substituent has been substituted at positions 3 and 4 by adamant-1-yl and hydroxy groups, respectively. It acts as a selective agonist of retinoic acid receptor (RAR)gamma and induces cell cycle arrest and apoptosis in various cancer cells.		2.0810adamantanes;
monocarboxylic acid;
naphthoic acid;
phenols		apoptosis inducer;
retinoic acid receptor gamma agonist
docetaxel anhydrous
Docetaxel: A semisynthetic analog of PACLITAXEL used in the treatment of locally advanced or metastatic BREAST NEOPLASMS and NON-SMALL CELL LUNG CANCER.. docetaxel anhydrous : A tetracyclic diterpenoid that is paclitaxel with the N-benzyloxycarbonyl group replaced by N-tert-butoxycarbonyl, and the acetoxy group at position 10 replaced by a hydroxy group.		2.5120secondary alpha-hydroxy ketone;
tetracyclic diterpenoid		antimalarial;
antineoplastic agent;
photosensitizing agent
perifosine
[no description available]		5.3950ammonium betaine;
phospholipid		EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor
atazanavir
atazanavir : A heavily substituted carbohydrazide that is an antiretroviral drug of the protease inhibitor (PI) class used to treat infection of human immunodeficiency virus (HIV).		2.610carbohydrazideantiviral drug;
HIV protease inhibitor
tariquidar
[no description available]		2.1510benzamides
dx 8951
[no description available]		2.8930pyranoindolizinoquinoline
mk 767
5-((2,4-dioxo-5-thiazolidinyl)methyl)-2-methoxy-N-((4-(trifluoromethyl)phenyl)methyl)benzamide: an antihyperlipidemic agent that also functions as an insulin sensitizer, PPARalpha agonist, and PPARgamma agonist; structure in first source		2.0810
vx 497
N-3-(3-(3-methoxy-4-oxazol-5-ylphenyl)ureido)benzylcarbamic acid tetrahydrofuran-3-yl ester: structure in first source		2.610
bcx 1812
[no description available]		2.6103-hydroxy monocarboxylic acid;
acetamides;
cyclopentanols;
guanidines		antiviral drug;
EC 3.2.1.18 (exo-alpha-sialidase) inhibitor
bazedoxifene acetate
[no description available]		2.0810
naproxen
Naproxen: An anti-inflammatory agent with analgesic and antipyretic properties. Both the acid and its sodium salt are used in the treatment of rheumatoid arthritis and other rheumatic or musculoskeletal disorders, dysmenorrhea, and acute gout.. naproxen : A methoxynaphthalene that is 2-methoxynaphthalene substituted by a carboxy ethyl group at position 6. Naproxen is a non-steroidal anti-inflammatory drug commonly used for the reduction of pain, fever, inflammation and stiffness caused by conditions such as osteoarthritis, kidney stones, rheumatoid arthritis, psoriatic arthritis, gout, ankylosing spondylitis, menstrual cramps, tendinitis, bursitis, and for the treatment of primary dysmenorrhea. It works by inhibiting both the COX-1 and COX-2 enzymes.		2.610methoxynaphthalene;
monocarboxylic acid		antipyretic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
drug allergen;
environmental contaminant;
gout suppressant;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
xenobiotic
canertinib
[no description available]		2.0810monochlorobenzenes;
morpholines;
organofluorine compound;
quinazolines		antineoplastic agent;
tyrosine kinase inhibitor
birb 796
[no description available]		2.0810aromatic ether;
morpholines;
naphthalenes;
pyrazoles;
ureas		EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor;
immunomodulator
olmesartan
olmesartan: an active metabolite of CS 866		2.7220biphenylyltetrazoleangiotensin receptor antagonist;
antihypertensive agent
telbivudine
[no description available]		2.610pyrimidine 2'-deoxyribonucleosideantiviral drug;
EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor
tipifarnib
[no description available]		3.0740imidazoles;
monochlorobenzenes;
primary amino compound;
quinolone		antineoplastic agent;
apoptosis inducer;
EC 2.5.1.58 (protein farnesyltransferase) inhibitor
celastrol methyl ester
celastrol methyl ester: isolated from Tripterygium wilfordii; potent inhibitory activity on both Kir2.1 and ERG1 potassium channels, leading to LONG QT SYNDROME		2.610carboxylic ester
resiquimod
S 28463: structure given in first source		2.610imidazoquinoline
cyc 202
seliciclib : 2,6-Diaminopurine carrying benzylamino, (2R)-1-hydroxybutan-2-yl and isopropyl substituents at C-6, C-2-N and N-9 respectively. It is an experimental drug candidate in the family of pharmacological cyclin-dependent kinase (CDK) inhibitors.		3.07402,6-diaminopurinesantiviral drug;
EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
tanshinone ii a
tashinone IIA: a cardiovascular agent with antineoplastic activity; isolated from Salvia miltiorrhiza; structure in first source		2.610abietane diterpenoid
avasimibe
[no description available]		2.8930monoterpenoid
anacardic acid
anacardic acid: isolated from Anacardium occidentale; monophenol monooxygenase inhibitor. anacardic acid : A hydroxybenzoic acid that is salicylic acid substituted by a pentadecyl group at position 6. It is a major component of cashew nut shell liquid and exhibits an extensive range of bioactivities.		2.610hydroxy monocarboxylic acid;
hydroxybenzoic acid		anti-inflammatory agent;
antibacterial agent;
anticoronaviral agent;
apoptosis inducer;
EC 2.3.1.48 (histone acetyltransferase) inhibitor;
EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor;
neuroprotective agent;
plant metabolite
angiotensin ii
Giapreza: injectable form of angiotensin II used to increase blood pressure in adult patients with septic or other distributive shock. Ile(5)-angiotensin II : An angiotensin II that acts on the central nervous system (PDB entry: 1N9V).		4.811amino acid zwitterion;
angiotensin II		human metabolite
migalastat
migalastat: a potent inhibitor of glycolipid biosynthesis		2.610piperidines
sb 203580
[no description available]		2.0810imidazoles;
monofluorobenzenes;
pyridines;
sulfoxide		EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor;
geroprotector;
Hsp90 inhibitor;
neuroprotective agent
enzastaurin
[no description available]		2.0810indoles;
maleimides
erlotinib
[no description available]		2.5820aromatic ether;
quinazolines;
secondary amino compound;
terminal acetylenic compound		antineoplastic agent;
epidermal growth factor receptor antagonist;
protein kinase inhibitor
piboserod
Serotonin 5-HT4 Receptor Antagonists: Drugs that bind to but do not activate SEROTONIN 5-HT4 RECEPTORS, thereby blocking the actions of SEROTONIN or SEROTONIN RECEPTOR AGONISTS.		2.0810
organophosphonates
hydrogenphosphite : A divalent inorganic anion resulting from the removal of a proton from two of the hydroxy groups of phosphorous acid.		4.811divalent inorganic anion;
phosphite ion
l 163191
[no description available]		3.0740
limonin
[no description available]		2.610epoxide;
furans;
hexacyclic triterpenoid;
lactone;
limonoid;
organic heterohexacyclic compound		inhibitor;
metabolite;
volatile oil component
dizocilpine
[no description available]		2.8930secondary amino compound;
tetracyclic antidepressant		anaesthetic;
anticonvulsant;
neuroprotective agent;
nicotinic antagonist;
NMDA receptor antagonist
scutellarin
scutellarin: see scutellarein for aglycone. scutellarin : The glycosyloxyflavone which is the 7-O-glucuronide of scutellarein.		2.610glucosiduronic acid;
glycosyloxyflavone;
monosaccharide derivative;
trihydroxyflavone		antineoplastic agent;
proteasome inhibitor
dioxiram
dioxiram: structure given in first source		3.2710
bd 1047
N-(2-(3,4-Dichlorphenyl)ethyl)-N,N',N'-trimethyl-1,2-ethandiamin: sigma receptor ligand; putative sigma receptor antagonist with antidystonic activity		2.0810primary amine
s-benzylcysteine
[no description available]		2.8930S-aryl-L-cysteine zwitterion
etravirine
[no description available]		2.610aminopyrimidine;
aromatic ether;
dinitrile;
organobromine compound		antiviral agent;
HIV-1 reverse transcriptase inhibitor
chelidonine
chelidonine: benzophenanthridine derived from scoulerine from Chelidonium majus; RN given refers to parent cpd (chelidonine, (5bR-(5balpha,6beta,12alpha))-isomer)		3.1640alkaloid antibiotic;
alkaloid fundamental parent;
benzophenanthridine alkaloid
maropitant
maropitant: neurokinin-1 receptor antagonist for treatment and prevention of emesis		3.1810
4-n-butylresorcinol
4-n-butylresorcinol: structure in first source		2.610resorcinols
lapatinib
[no description available]		3.0740furans;
organochlorine compound;
organofluorine compound;
quinazolines		antineoplastic agent;
tyrosine kinase inhibitor
darunavir
Darunavir: An HIV PROTEASE INHIBITOR that is used in the treatment of AIDS and HIV INFECTIONS. Due to the emergence of ANTIVIRAL DRUG RESISTANCE when used alone, it is administered in combination with other ANTI-HIV AGENTS.. darunavir : An N,N-disubstituted benzenesulfonamide bearing an unsubstituted amino group at the 4-position, used for the treatment of HIV infection. A second-generation HIV protease inhibitor, darunavir was designed to form robust interactions with the protease enzyme from many strains of HIV, including those from treatment-experienced patients with multiple resistance mutations to other protease inhibitors.		2.610carbamate ester;
furofuran;
sulfonamide		antiviral drug;
HIV protease inhibitor
dapivirine
Dapivirine: effectively prevented human immunodeficiency virus (HIV) infection in cocultures of monocyte-derived dendritic cells and T cells, representing primary targets in sexual transmission		2.610
sorafenib
[no description available]		7.5220(trifluoromethyl)benzenes;
aromatic ether;
monochlorobenzenes;
phenylureas;
pyridinecarboxamide		angiogenesis inhibitor;
anticoronaviral agent;
antineoplastic agent;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor;
ferroptosis inducer;
tyrosine kinase inhibitor
lenalidomide
[no description available]		19.5714146aromatic amine;
dicarboximide;
isoindoles;
piperidones		angiogenesis inhibitor;
antineoplastic agent;
immunomodulator
N-[4-(3-chloro-4-fluoroanilino)-3-cyano-7-ethoxy-6-quinolinyl]-4-(dimethylamino)-2-butenamide
[no description available]		2.0810aminoquinoline
roxindole
[no description available]		2.8930indolesalpha-adrenergic antagonist;
serotonergic drug
sr 142806
[no description available]		2.0810
conidendrin
[no description available]		2.8930
Porfiromycine
[no description available]		2.8930mitomycin
nsc 74859
NSC 74859: inhibits Stat3 binding activity; structure in first source. S3I-201 : An amidobenzoic acid obtained by formal condensation of the carboxy group of [(4-methylbenzene-1-sulfonyl)oxy]acetic acid with the amino group of 4-amino-2-hydroxybenzoic acid.		2.610amidobenzoic acid;
monohydroxybenzoic acid;
tosylate ester		STAT3 inhibitor
nsc 95397
[no description available]		2.89301,4-naphthoquinones
4-methyl-2-quinazolinamine
4-methyl-2-quinazolinamine: from Streptomyces of TCM plant; structure in first source		2.8930
berbamine
[no description available]		2.610bisbenzylisoquinoline alkaloid;
isoquinolines
2-glycineamide-5-chlorophenyl-2-pyrryl ketone
[no description available]		2.8930
homoharringtonine
Homoharringtonine: Semisynthetic derivative of harringtonine that acts as a protein synthesis inhibitor and induces APOPTOSIS in tumor cells. It is used in the treatment of MYELOID LEUKEMIA, CHRONIC.. omacetaxine mepesuccinate : A cephalotaxine-derived alkaloid ester obtained from Cephalotaxus harringtonia; used for the treatment of chronic or accelerated phase chronic myeloid leukaemia.		2.610alkaloid ester;
enol ether;
organic heteropentacyclic compound;
tertiary alcohol		anticoronaviral agent;
antineoplastic agent;
apoptosis inducer;
protein synthesis inhibitor
elesclomol
[no description available]		2.0810carbohydrazide;
thiocarbonyl compound		antineoplastic agent;
apoptosis inducer
u-104
SLC-0111: a carbonic anhydrase inhibitor; structure in first source		2.610
niguldipine hydrochloride
[no description available]		2.6320
7-hydroxy-5-methyl-2-(2-oxopropyl)-8-[3,4,5-trihydroxy-6-(hydroxymethyl)-2-oxanyl]-1-benzopyran-4-one
[no description available]		2.610glycoside
2,5-bis(5-hydroxymethyl-2-thienyl)furan
[no description available]		2.8930thiophenes
nsc 663284
NSC 663284: structure in first source		2.0810quinolone
bortezomib
[no description available]		19.8422926amino acid amide;
L-phenylalanine derivative;
pyrazines		antineoplastic agent;
antiprotozoal drug;
protease inhibitor;
proteasome inhibitor
ritonavir
Ritonavir: An HIV protease inhibitor that works by interfering with the reproductive cycle of HIV. It also inhibits CYTOCHROME P-450 CYP3A.. ritonavir : An L-valine derivative that is L-valinamide in which alpha-amino group has been acylated by a [(2-isopropyl-1,3-thiazol-4-yl)methyl]methylcarbamoyl group and in which a hydrogen of the carboxamide amino group has been replaced by a (2R,4S,5S)-4-hydroxy-1,6-diphenyl-5-{[(1,3-thiazol-5-ylmethoxy)carbonyl]amino}hexan-2-yl group. A CYP3A inhibitor and antiretroviral drug from the protease inhibitor class used to treat HIV infection and AIDS, it is often used as a fixed-dose combination with another protease inhibitor, lopinavir. Also used in combination with dasabuvir sodium hydrate, ombitasvir and paritaprevir (under the trade name Viekira Pak) for treatment of chronic hepatitis C virus genotype 1 infection as well as cirrhosis of the liver.		8.36501,3-thiazoles;
carbamate ester;
carboxamide;
L-valine derivative;
ureas		antiviral drug;
environmental contaminant;
HIV protease inhibitor;
xenobiotic
tizoxanide
tizoxanide: major metabolite of nitazoxanide; structure in first source		2.610salicylamides
bardoxolone methyl
methyl 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oate: structure in first source		2.5320cyclohexenones
nsc 23766
[no description available]		2.0810aminopyrimidine;
aminoquinoline;
primary amino compound;
secondary amino compound;
tertiary amino compound		antiviral agent;
apoptosis inducer;
EC 3.6.5.2 (small monomeric GTPase) inhibitor;
muscarinic antagonist
5-amino-8-hydroxyquinoline
5-amino-8-hydroxyquinoline: structure in first source		3.1610
gant 61
GANT 61: a sonic hedgehog pathway inhibitor and Gli inhibitor; structure in first source. GANT61 : An aminal that is hexahydropyrimidine which is substituted on each nitrogen by a 2-(dimethylamino)benzyl group, and at the aminal carbon by a pyridin-4-yl group. A Hedgehog signaling pathway and Gli protein inhibitor.		3.5110aminal;
dialkylarylamine;
pyridines;
substituted aniline;
tertiary amino compound		antineoplastic agent;
apoptosis inducer;
glioma-associated oncogene inhibitor;
Hedgehog signaling pathway inhibitor
leupeptins
Leupeptins: A group of acylated oligopeptides produced by Actinomycetes that function as protease inhibitors. They have been known to inhibit to varying degrees trypsin, plasmin, KALLIKREINS, papain and the cathepsins.		3.5370
carboplatin
[no description available]		5.1842
Destruxin B
[no description available]		2.8930cyclodepsipeptide
tosylphenylalanyl chloromethyl ketone
Tosylphenylalanyl Chloromethyl Ketone: An inhibitor of Serine Endopeptidases. Acts as alkylating agent and is known to interfere with the translation process.. N-tosyl-L-phenylalanyl chloromethyl ketone : The N-tosyl derivative of L-phenylalanyl chloromethyl ketone.		2.8930alpha-chloroketone;
sulfonamide		alkylating agent;
serine proteinase inhibitor
pentostatin
Pentostatin: A potent inhibitor of ADENOSINE DEAMINASE. The drug induces APOPTOSIS of LYMPHOCYTES, and is used in the treatment of many lymphoproliferative malignancies, particularly HAIRY CELL LEUKEMIA. It is also synergistic with some other antineoplastic agents and has immunosuppressive activity.. pentostatin : A member of the class of coformycins that is coformycin in which the hydroxy group at position 2' is replaced with a hydrogen. It is a drug used for the treatment of hairy cell leukaemia.		3.2310coformycinsantimetabolite;
antineoplastic agent;
Aspergillus metabolite;
bacterial metabolite;
EC 3.5.4.4 (adenosine deaminase) inhibitor
arbutin
hydroquinone O-beta-D-glucopyranoside : A monosaccharide derivative that is hydroquinone attached to a beta-D-glucopyranosyl residue at position 4 via a glycosidic linkage.		2.610beta-D-glucoside;
monosaccharide derivative		Escherichia coli metabolite;
plant metabolite
quinidine
Quinidine: An optical isomer of quinine, extracted from the bark of the CHINCHONA tree and similar plant species. This alkaloid dampens the excitability of cardiac and skeletal muscles by blocking sodium and potassium currents across cellular membranes. It prolongs cellular ACTION POTENTIALS, and decreases automaticity. Quinidine also blocks muscarinic and alpha-adrenergic neurotransmission.. quinidine : A cinchona alkaloid consisting of cinchonine with the hydrogen at the 6-position of the quinoline ring substituted by methoxy.		2.610cinchona alkaloidalpha-adrenergic antagonist;
anti-arrhythmia drug;
antimalarial;
drug allergen;
EC 1.14.13.181 (13-deoxydaunorubicin hydroxylase) inhibitor;
EC 3.6.3.44 (xenobiotic-transporting ATPase) inhibitor;
muscarinic antagonist;
P450 inhibitor;
potassium channel blocker;
sodium channel blocker
conessine
conessine : A steroid alkaloid that is con-5-enine substituted by a N,N-dimethylamino group at position 3. It has been isolated from the plant species of the family Apocynaceae.		2.610steroid alkaloid;
tertiary amino compound		antibacterial agent;
antimalarial;
H3-receptor antagonist;
plant metabolite
saquinavir
Saquinavir: An HIV protease inhibitor which acts as an analog of an HIV protease cleavage site. It is a highly specific inhibitor of HIV-1 and HIV-2 proteases, and also inhibits CYTOCHROME P-450 CYP3A.. saquinavir : An aspartic acid derivative obtained by formal condensation of the primary amino group of (2S,3R)-4-[(3S,4aS,8aS)-3-(tert-butylcarbamoyl)octahydroisoquinolin-2(1H)-yl]-3-hydroxy-1-phenylbutan-2-ylamine with the carboxy group of N(2)(-quinolin-2-ylcarbonyl)-L-asparagine. An inhibitor of HIV-1 protease.		2.610L-asparagine derivative;
quinolines		antiviral drug;
HIV protease inhibitor
abacavir
abacavir: a carbocyclic nucleoside with potent selective anti-HIV activity. abacavir : A 2,6-diaminopurine that is (1S)-cyclopent-2-en-1-ylmethanol in which the pro-R hydrogen at the 4-position is substituted by a 2-amino-6-(cyclopropylamino)-9H-purin-9-yl group. A nucleoside analogue reverse transcriptase inhibitor (NRTI) with antiretroviral activity against HIV, it is used (particularly as the sulfate) with other antiretrovirals in combination therapy of HIV infection.		2.6102,6-diaminopurinesantiviral drug;
drug allergen;
HIV-1 reverse transcriptase inhibitor
linezolid
[no description available]		2.610acetamides;
morpholines;
organofluorine compound;
oxazolidinone		antibacterial drug;
protein synthesis inhibitor
cephaelin
cephaelin: do not confuse with cephalin of brain; after emetine this is the most important alkaloid of ipecac; protein synthesis inhibitor. cephaeline : A pyridoisoquinoline comprising emetam having a hydroxy group at the 6'-position and methoxy substituents at the 7'-, 10- and 11-positions.		2.610pyridoisoquinoline
(-)-usnic acid
(-)-usnic acid : The (-)-enantiomer of usnic acid.		2.610usnic acidEC 1.13.11.27 (4-hydroxyphenylpyruvate dioxygenase) inhibitor
acetylleucyl-leucyl-norleucinal
acetylleucyl-leucyl-norleucinal: a proteasome inhibitor. acetylleucyl-leucyl-norleucinal : A tripeptide composed of N-acetylleucyl, leucyl and norleucinal residues joined in sequence.		2.7620aldehyde;
tripeptide		cysteine protease inhibitor
betadex
beta-Cyclodextrins: Cyclic GLUCANS consisting of seven (7) glucopyranose units linked by 1,4-glycosidic bonds.		3.1810cyclodextrin
trichostatin a
trichostatin A: chelates zinc ion in the active site of histone deacetylases, resulting in preventing histone unpacking so DNA is less available for transcription; do not confuse with TRICHOSANTHIN which is a protein; found in STREPTOMYCES		2.5720antibiotic antifungal agent;
hydroxamic acid;
trichostatin		bacterial metabolite;
EC 3.5.1.98 (histone deacetylase) inhibitor;
geroprotector
resveratrol
trans-resveratrol : A resveratrol in which the double bond has E configuration.		2.610resveratrolantioxidant;
phytoalexin;
plant metabolite;
quorum sensing inhibitor;
radical scavenger
tacrolimus
Tacrolimus: A macrolide isolated from the culture broth of a strain of Streptomyces tsukubaensis that has strong immunosuppressive activity in vivo and prevents the activation of T-lymphocytes in response to antigenic or mitogenic stimulation in vitro.. tacrolimus (anhydrous) : A macrolide lactam containing a 23-membered lactone ring, originally isolated from the fermentation broth of a Japanese soil sample that contained the bacteria Streptomyces tsukubaensis.		2.610macrolide lactambacterial metabolite;
immunosuppressive agent
lycopene
[no description available]		2.610acyclic caroteneantioxidant;
plant metabolite
zithromax
Azithromycin: A semi-synthetic macrolide antibiotic structurally related to ERYTHROMYCIN. It has been used in the treatment of Mycobacterium avium intracellulare infections, toxoplasmosis, and cryptosporidiosis.. azithromycin : A macrolide antibiotic useful for the treatment of bacterial infections.		2.610macrolide antibioticantibacterial drug;
environmental contaminant;
xenobiotic
gw 3965
GW 3965: a liver X receptor ligand		2.0810diarylmethane
y 27632
Y 27632: RN given for di-HCl salt; inhibits Rho-associated protein kinase; inhibits calcium sensitization to affect smooth muscle relaxation; structure in first source. Y-27632 : A monocarboxylic acid amide that is trans-[(1R)-1-aminoethyl]cyclohexanecarboxamide in which one of the nitrogens of the aminocarbony group is substituted by a pyridine nucleus. It has been shown to exhibit inhibitory activity against Rho-associated protein kinase (ROCK) enzyme.		2.0810aromatic amide
6-bromoindirubin-3'-oxime
6-bromoindirubin-3'-oxime: structure in first source. 6-bromoindirubin-3'-oxime : A member of the class of biindoles that is indirubin substituted at position 6 by a bromo group and in which the keto group at position 3' has undergone condensation with hydroxylamine to form the corresponding oxime.		2.0810
purvalanol b
purvalanol B: protein kinase inhibitor; structure in first source		2.0810purvalanolprotein kinase inhibitor
y-700
[no description available]		2.0810
repsox
RepSox: inhibits TGF-beta signaling; structure in first source appears to be incorrect		2.0810pyrazolopyridine
roflumilast
[no description available]		2.610aromatic ether;
benzamides;
chloropyridine;
cyclopropanes;
organofluorine compound		anti-asthmatic drug;
phosphodiesterase IV inhibitor
L-cycloserine
L-cycloserine : A 4-amino-1,2-oxazolidin-3-one that has S configuration. An antibiotic isolated from Erwinia uredovora.		2.6104-amino-1,2-oxazolidin-3-oneanti-HIV agent;
anticonvulsant;
EC 2.3.1.50 (serine C-palmitoyltransferase) inhibitor
h 89
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide: structure given in first source. N-[2-(4-bromocinnamylamino)ethyl]isoquinoline-5-sulfonamide : A member of the class of isoquinolines that is the sulfonamide obtained by formal condensation of the sulfo group of isoquinoline-5-sulfonic acid with the primary amino group of N(1)-[3-(4-bromophenyl)prop-2-en-1-yl]ethane-1,2-diamine. It is a protein kinase A inhibitor.. (E)-N-[2-(4-bromocinnamylamino)ethyl]isoquinoline-5-sulfonamide : A N-[2-(4-bromocinnamylamino)ethyl]isoquinoline-5-sulfonamide in which the double bond adopts a trans-configuration.		2.610N-[2-(4-bromocinnamylamino)ethyl]isoquinoline-5-sulfonamide
bevirimat
bevirimat: an HIV inhibitor; disrupts late step in processing HIV Major Core Protein p24, preventing the capsid precursor p25 from being converted to mature capsid p24. bevirimat : A pentacyclic triterpenoid obtained by the formal condensation of 2,2-dimethylsuccinic acid with the 3-hydroxy group of betulinic acid. It is isolated from the Chinese herb Syzygium claviflorum. The first in the class of HIV-1 maturation inhibitors to be studied in humans, bevirimat was identified as a potent HIV drug candidate and several clinical trials were conducted, but development into a new drug was plagued by numerous resistance-related problems.		2.610dicarboxylic acid monoester;
monocarboxylic acid;
pentacyclic triterpenoid		HIV-1 maturation inhibitor;
metabolite
melphalan
Melphalan: An alkylating nitrogen mustard that is used as an antineoplastic in the form of the levo isomer - MELPHALAN, the racemic mixture - MERPHALAN, and the dextro isomer - MEDPHALAN; toxic to bone marrow, but little vesicant action; potential carcinogen.. melphalan : A phenylalanine derivative comprising L-phenylalanine having [bis(2-chloroethyl)amino group at the 4-position on the phenyl ring.		14.11111L-phenylalanine derivative;
nitrogen mustard;
non-proteinogenic L-alpha-amino acid;
organochlorine compound		alkylating agent;
antineoplastic agent;
carcinogenic agent;
drug allergen;
immunosuppressive agent
sitafloxacin
[no description available]		2.2110fluoroquinolone antibiotic;
quinolines;
quinolone antibiotic
benzyloxycarbonylleucyl-leucyl-leucine aldehyde
benzyloxycarbonylleucyl-leucyl-leucine aldehyde: proteasome inhibitor. N-benzyloxycarbonyl-L-leucyl-L-leucyl-L-leucinal : A tripeptide that is L-leucyl-L-leucyl-L-leucine in which the C-terminal carboxy group has been reduced to the corresponding aldehyde and the N-terminal amino group is protected as its benzyloxycarbonyl derivative.		3.87100amino aldehyde;
carbamate ester;
tripeptide		proteasome inhibitor
tenofovir
tenofovir (anhydrous) : A member of the class of phosphonic acids that is methylphosphonic acid in which one of the methyl hydrogens is replaced by a [(2R)-1-(6-amino-9H-purin-9-yl)propan-2-yl]oxy group. An inhibitor of HIV-1 reverse transcriptase, the bis(isopropyloxycarbonyloxymethyl) ester (disoproxil ester) prodrug is used as the fumaric acid salt in combination therapy for the treatment of HIV infection.		2.610nucleoside analogue;
phosphonic acids		antiviral drug;
drug metabolite;
HIV-1 reverse transcriptase inhibitor
posaconazole
[no description available]		2.610aromatic ether;
conazole antifungal drug;
N-arylpiperazine;
organofluorine compound;
oxolanes;
triazole antifungal drug;
triazoles		trypanocidal drug
gw 257406x
maribavir: has antiviral activity against human cytomegalovirus		2.610
shikonin
shikonin: a naphthazarin; has antineoplastic and angiogenesis inhibiting activities		2.610hydroxy-1,4-naphthoquinone
4,4-difluoro-N-[(1S)-3-[3-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl]-1-phenylpropyl]-1-cyclohexanecarboxamide
[no description available]		2.5820tropane alkaloid
cmx 001
[no description available]		2.610
amd 8664
[no description available]		2.610
bay 41-4109
BAY 41-4109: structure in first source		2.610
bay 57-1293
pritelivir: herpes simplex virus 1 helicase-primase inhibitor		2.610
2'-c-methylcytidine
2'-C-methylcytidine: structure in first source		3.1640
isoxanthohumol
isoxanthohumol: structure in first source		2.610flavanones
jp-1302
[no description available]		2.8930
4-(4-chloro-2-methylphenoxy)-n-hydroxybutanamide
4-(4-chloro-2-methylphenoxy)-N-hydroxybutanamide: a c-FLIP inhibitor; structure in first source		2.610aromatic ether
mecarbinate
[no description available]		2.610
7-chloro-5,10-dihydrothieno[3,4-b][1,5]benzodiazepin-4-one
[no description available]		2.8930benzodiazepine
artemisin
[no description available]		2.1710
tenatoprazole
Tenatoprazole: structure in first source		2.8930imidazopyridine
s 1033
[no description available]		3.2750(trifluoromethyl)benzenes;
imidazoles;
pyridines;
pyrimidines;
secondary amino compound;
secondary carboxamide		anticoronaviral agent;
antineoplastic agent;
tyrosine kinase inhibitor
acetyl-aspartyl-glutamyl-valyl-aspartal
acetyl-aspartyl-glutamyl-valyl-aspartal: a capase inhibitor. Ac-Asp-Glu-Val-Asp-H : A tetrapeptide consisting of two L-aspartic acid residues, an L-glutamyl residue and an L-valine residue with an acetyl group at the N-terminal and with the C-terminal carboxy group reduced to an aldehyde. It is an inhibitor of caspase-3/7.		2.610tetrapeptideprotease inhibitor
5-[(2-fluoroanilino)methyl]-8-quinolinol
[no description available]		2.8930hydroxyquinoline
benidipine hydrochloride
[no description available]		2.5920
benidipine
benidipine: RN refers to (R*,R*)-(+-)-isomer		2.2110
octotropine methylbromide
octotropine methylbromide: minor descriptor (65-86); on line & INDEX MEDICUS search TROPANES (69-86); RN given refers to endo-isomer. anisotropine methylbromide : A quaternary ammonium salt resulting from the reaction of the amino group of anisotropine with methyl bromide.		2.610
fludarabine
[no description available]		3.6220purine nucleoside
2-(1,3-benzoxazol-2-ylamino)-5-spiro[1,6,7,8-tetrahydroquinazoline-4,1'-cyclopentane]one
[no description available]		2.8930quinazolines
chlorprothixene
(E)-chlorprothixene : A chlorprothixene in which the double bond adopts an (E)-configuration.		2.8930chlorprothixene
mercaptopurine
Mercaptopurine: An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia.. purine-6-thiol : A thiol that is the tautomer of mercaptopurine.. mercaptopurine : A member of the class of purines that is 6,7-dihydro-1H-purine carrying a thione group at position 6. An adenine analogue, it is used in the treatment of acute lymphocytic leukemia (ALL), chronic myeloid leukemia (CML), Crohn's disease, and ulcerative colitis.		2.5820aryl thiol;
purines;
thiocarbonyl compound		anticoronaviral agent;
antimetabolite;
antineoplastic agent
jrf 12
N2,N4-dibenzylquinazoline-2,4-diamine: a selective, potent, reversible, and ATP-competitive p97 inhibitor		3.1640
3,4'-dihydroxyflavone
3,4'-dihydroxyflavone: an antioxidant; structure in first source		2.610
rg108
RG108: DNA methyltransferase inhibitor; structure in first source		2.0810indolyl carboxylic acid
3-(3,4-dimethoxyphenyl)propenoic acid
3-(3,4-dimethoxyphenyl)propenoic acid: structure given in first source; RN given refers to parent cpd. 3,4-dimethoxycinnamic acid : A methoxycinnamic acid that is trans-cinnamic acid substituted by methoxy groups at positions 3' and 4' respectively.		2.610methoxycinnamic acid
5-amino-3-(4-methoxyphenyl)-4-oxo-1-thieno[3,4-d]pyridazinecarboxylic acid ethyl ester
[no description available]		2.8930methoxybenzenes;
substituted aniline
stf 083010
[no description available]		2.0810
isoferulic acid
isoferulic acid: isomer of ferulic acid; structure. isoferulic acid : A ferulic acid consisting of trans-cinnamic acid bearing methoxy and hydroxy substituents at positions 4 and 3 respectively on the phenyl ring.		2.610ferulic acidsantioxidant;
biomarker;
metabolite
3-hydroxypyridine, sodium salt
[no description available]		2.8930
N-(3-cyano-4,5,6,7-tetrahydro-1-benzothiophen-2-yl)-1-naphthalenecarboxamide
[no description available]		3.0740naphthalenecarboxamide
cyclouridine
cyclouridine: structure given in third source		2.610
5-[(2-bromoanilino)methyl]-8-quinolinol
[no description available]		2.8930hydroxyquinoline
3-amino-n-(4-methoxybenzyl)-4,6-dimethylthieno(2,3-b)pyridine-2-carboxamide
3-amino-N-(4-methoxybenzyl)-4,6-dimethylthieno(2,3-b)pyridine-2-carboxamide: structure in first source		2.8930
N-[(2-methoxyphenyl)methyl]-4-(1-piperidinyl)aniline
[no description available]		2.8930aromatic amine
curcumin
Curcumin: A yellow-orange dye obtained from tumeric, the powdered root of CURCUMA longa. It is used in the preparation of curcuma paper and the detection of boron. Curcumin appears to possess a spectrum of pharmacological properties, due primarily to its inhibitory effects on metabolic enzymes.. curcumin : A beta-diketone that is methane in which two of the hydrogens are substituted by feruloyl groups. A natural dyestuff found in the root of Curcuma longa.		7.9330aromatic ether;
beta-diketone;
diarylheptanoid;
enone;
polyphenol		anti-inflammatory agent;
antifungal agent;
antineoplastic agent;
biological pigment;
contraceptive drug;
dye;
EC 1.1.1.205 (IMP dehydrogenase) inhibitor;
EC 1.1.1.21 (aldehyde reductase) inhibitor;
EC 1.1.1.25 (shikimate dehydrogenase) inhibitor;
EC 1.6.5.2 [NAD(P)H dehydrogenase (quinone)] inhibitor;
EC 1.8.1.9 (thioredoxin reductase) inhibitor;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor;
EC 3.5.1.98 (histone deacetylase) inhibitor;
flavouring agent;
food colouring;
geroprotector;
hepatoprotective agent;
immunomodulator;
iron chelator;
ligand;
lipoxygenase inhibitor;
metabolite;
neuroprotective agent;
nutraceutical;
radical scavenger
cct018159
CCT018159: structure in first source. CCT-018159 : A member of the class of pyrazoles that is 1H-pyrazole carrying 1,4-benzodioxane-6-yl and 5-ethyl-2,4-dihydroxyphenyl substituents at positions 4 and 5 respectively.		2.0810benzodioxine;
pyrazoles;
resorcinols		antineoplastic agent;
apoptosis inducer;
Hsp90 inhibitor
1-[4-(4-bromophenyl)-2-thiazolyl]-4-piperidinecarboxamide
[no description available]		2.8930piperidinecarboxamide
secinh3
SecinH3: a small molecule antagonist of cytohesins; structure in first source		2.0810triazoles
jk184
JK184: structure in first source		2.0810
5-[[2-(trifluoromethyl)anilino]methyl]-8-quinolinol
[no description available]		2.8930hydroxyquinoline
N-[3-[2-[(4-methyl-2-pyridinyl)amino]-4-thiazolyl]phenyl]acetamide
[no description available]		2.8930acetamides;
anilide
ptc-209
PTC-209: inhibits BMI-1 protein; structure in first source		2.1310
5-bromo-N-(5-cyclohexyl-1,3,4-thiadiazol-2-yl)-2-thiophenecarboxamide
[no description available]		2.8930aromatic amide;
thiophenes
6-amino-1-[2-(3,4-dimethoxyphenyl)ethyl]-2-sulfanylidene-4-pyrimidinone
[no description available]		2.8930dimethoxybenzene
N-[4-[(3,4-dimethyl-5-isoxazolyl)sulfamoyl]phenyl]-6,8-dimethyl-2-(2-pyridinyl)-4-quinolinecarboxamide
[no description available]		2.8930aromatic amide
thiohydantoins
Thiohydantoins: Sulfur analogs of hydantoins with one or both carbonyl groups replaced by thiocarbonyl groups.		4.811
N-[5-[(4-chlorophenoxy)methyl]-1,3,4-thiadiazol-2-yl]-5-methyl-3-phenyl-4-isoxazolecarboxamide
[no description available]		2.8930aromatic ether
3-chloro-1-(2,5-dimethoxyphenyl)-4-(1-piperidinyl)pyrrole-2,5-dione
[no description available]		2.8930maleimides
Src Inhibitor-1
Src Inhibitor-1 : A member of the class of quinazolines that is quinazoline which is substituted at position 4 by a p-phenoxyanilino group and at positions 6 and 7 by methoxy groups. It is a potent, competitive dual site (both the ATP- and peptide-binding) Src kinase inhibitor. Src Inhibitor-1 is one of the 'gold standards' for Src kinase inhibition that has been shown to use PP1 or PP2 in parallel with Src-I1 to inhbit Src family kinases.		2.8930aromatic ether;
polyether;
quinazolines;
secondary amino compound		EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor
1-[2-(3,4-dimethoxyphenyl)ethyl]-6-propyl-2-sulfanylidene-7,8-dihydro-5H-pyrimido[4,5-d]pyrimidin-4-one
[no description available]		2.8930dimethoxybenzene
zucapsaicin
[no description available]		2.610methoxybenzenes;
phenols
nbd 556
[no description available]		2.610
2-phenyl-N-[4-(2-thiazolylsulfamoyl)phenyl]-4-quinolinecarboxamide
[no description available]		2.8930quinolines
chlorogenic acid
caffeoylquinic acid: Antiviral Agent; structure in first source. chlorogenate : A monocarboxylic acid anion that is the conjugate base of chlorogenic acid; major species at pH 7.3.		4.811cinnamate ester;
tannin		food component;
plant metabolite
3-(2,5-dimethyl-1-phenyl-3-pyrrolyl)-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine
[no description available]		2.8930pyrroles
thioguanine anhydrous
Thioguanine: An antineoplastic compound which also has antimetabolite action. The drug is used in the therapy of acute leukemia.. tioguanine : A 2-aminopurine that is the 6-thiono derivative of 2-amino-1,9-dihydro-6H-purine. Incorporates into DNA and inhibits synthesis. Used in the treatment of leukaemia.		2.6102-aminopurinesanticoronaviral agent;
antimetabolite;
antineoplastic agent
thiourea
Thiourea: A photographic fixative used also in the manufacture of resins. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), this substance may reasonably be anticipated to be a carcinogen (Merck Index, 9th ed). Many of its derivatives are ANTITHYROID AGENTS and/or FREE RADICAL SCAVENGERS.. thiourea : The simplest member of the thiourea class, consisting of urea with the oxygen atom substituted by sulfur.		4.811one-carbon compound;
thioureas;
ureas		antioxidant;
chromophore
4,5,6,7-tetrachloroindan-1,3-dione
4,5,6,7-tetrachloroindan-1,3-dione: inhibits ubiquitin C-terminal hydrolase L1		2.610
tamoxifen citrate
[no description available]		2.0810citrate saltangiogenesis inhibitor;
anticoronaviral agent
tamoxifen
[no description available]		2.1710stilbenoid;
tertiary amino compound		angiogenesis inhibitor;
antineoplastic agent;
bone density conservation agent;
EC 1.2.3.1 (aldehyde oxidase) inhibitor;
EC 2.7.11.13 (protein kinase C) inhibitor;
estrogen antagonist;
estrogen receptor antagonist;
estrogen receptor modulator
hc-067047
HC-067047: a TRPA1 antagonist; structure in first source		2.0810
bi-78d3
[no description available]		3.0740aryl sulfide
srpin340
SRPIN340: Serine-Arginine-Rich Protein Kinase Inhibitor		2.610
gsk 3787
[no description available]		2.0810
pr-619
[no description available]		2.610
p5091
P5091: inhibits ubiquitin-specific protease 7; structure in first source		420
kartogenin
kartogenin: promotes chondrocyte differentiation; structure in first source		2.8930
methyl-thiohydantoin-tryptophan
methyl-thiohydantoin-tryptophan: structure in first source		2.0810organonitrogen compound;
organooxygen compound
ace-011
ACE-011: a dimeric fusion protein consisting of the extracellular domain of the human ActRIIA linked to the Fc portion of human IgG1 and may be an effective therapy in a variety of diseases involving bone loss		3.1910
2-[2-chloro-6-ethoxy-4-[(3-methyl-5-oxo-1-phenyl-4-pyrazolylidene)methyl]phenoxy]acetic acid methyl ester
[no description available]		2.0810monocarboxylic acid
4-(5-(4-methoxyphenyl)-3-phenyl-4,5-dihydro-1h-pyrazol-1-yl)benzenesulfonamide
[no description available]		2.0810sulfonamide
trovirdine
trovirdine: HIV-1 reverse transcriptase inhibitor		2.610
LSM-1318
[no description available]		2.0810oxa-steroid
fti 277
[no description available]		2.610
toremifene
Toremifene: A first generation selective estrogen receptor modulator (SERM). Like TAMOXIFEN, it is an estrogen agonist for bone tissue and cholesterol metabolism but is antagonistic on mammary and uterine tissue.		2.2110aromatic ether;
organochlorine compound;
tertiary amine		antineoplastic agent;
bone density conservation agent;
estrogen antagonist;
estrogen receptor modulator
u 0126
U 0126: protein kinase kinase inhibitor; structure in first source		2.610aryl sulfide;
dinitrile;
enamine;
substituted aniline		antineoplastic agent;
antioxidant;
apoptosis inducer;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor;
osteogenesis regulator;
vasoconstrictor agent
rwj 67657
RWJ 67657: inhibits p38 mitogen-activated protein kinase; structure in first source		2.0810
vicriviroc
vicriviroc: structure in first source		2.610(trifluoromethyl)benzenes
telaprevir
[no description available]		2.610cyclopentapyrrole;
cyclopropanes;
oligopeptide;
pyrazines		antiviral drug;
hepatitis C protease inhibitor;
peptidomimetic
6-methyl-2-(phenylethynyl)pyridine
6-methyl-2-(phenylethynyl)pyridine: an mGlu5 antagonist. 2-methyl-6-(phenylethynyl)pyridine : A methylpyridine that coinsists of 2-methylp[yridine bearing an additional phenylethynyl group at position 6. Potent and highly selective non-competitive antagonist at the mGlu5 receptor subtype (IC50 = 36 nM) and a positive allosteric modulator at mGlu4 receptors. Centrally active following systemic administration in vivo. Reverses mechanical hyperalgesia in the inflamed rat hind paw.		2.0810acetylenic compound;
methylpyridines		anxiolytic drug;
metabotropic glutamate receptor antagonist
bms 387032
N-(5-(((5-(1,1-dimethylethyl)-2-oxazolyl)methyl)thio)-2-thiazolyl)-4-piperidinecarboxamide: a CDK2 inhibitor with antineoplastic activity; structure in first source. N-(5-{[(5-tert-butyl-1,3-oxazol-2-yl)methyl]sulfanyl}-1,3-thiazol-2-yl)piperidine-4-carboxamide : A secondary carboxamide resulting from the formal condensation of the carboxy group of piperidine-4-carboxylic acid with the amino group of 5-{[(5-tert-butyl-1,3-oxazol-2-yl)methyl]sulfanyl}-1,3-thiazol-2-amine. It is an ATP-competitive inhibitor of CDK2, CDK7 and CDK9 kinases and exhibits anti-cancer properties.		2.08101,3-oxazoles;
1,3-thiazoles;
organic sulfide;
piperidinecarboxamide;
secondary carboxamide		angiogenesis inhibitor;
antineoplastic agent;
apoptosis inducer;
EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
cobaltous chloride
cobaltous chloride: RN given refers to unlabeled cpd; RN in Chemline for cobalt trichloride: 10241-04-0; RN for 60-labeled cpd: 14543-09-0; RN for 57-labeled cpd: 164113-89-1; RN for 58-labeled cpd: 29377-09-1; structure. cobalt dichloride : A cobalt salt in which the cobalt metal is in the +2 oxidation state and the counter-anion is chloride. It is used as an indicator for water in desiccants.		2.2510cobalt salt;
inorganic chloride		allergen;
calcium channel blocker;
sensitiser;
two-colour indicator
orlistat
Orlistat: A lactone derivative of LEUCINE that acts as a pancreatic lipase inhibitor to limit the absorption of dietary fat; it is used in the management of obesity.. orlistat : A carboxylic ester resulting from the formal condensation of the carboxy group of N-formyl-L-leucine with the hydroxy group of (3S,4S)-3-hexyl-4-[(2S)-2-hydroxytridecyl]oxetan-2-one. A pancreatic lipase inhibitor, it is used as an anti-obesity drug.		2.610beta-lactone;
carboxylic ester;
formamides;
L-leucine derivative		anti-obesity agent;
bacterial metabolite;
EC 2.3.1.85 (fatty acid synthase) inhibitor;
EC 3.1.1.3 (triacylglycerol lipase) inhibitor
tandutinib
[no description available]		2.0810aromatic ether;
N-arylpiperazine;
N-carbamoylpiperazine;
phenylureas;
piperidines;
quinazolines;
tertiary amino compound		antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
vx-745
[no description available]		3.0740aryl sulfide;
dichlorobenzene;
difluorobenzene;
pyrimidopyridazine		anti-inflammatory drug;
apoptosis inducer;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
corlanor
ivabradine hydrochloride : A hydrochloride obtained by combining ivabradine with one molar equivalent of hydrochloric acid. Used to treat patients with angina who have intolerance to beta blockers and/or heart failure.		2.0810hydrochloridecardiotonic drug
dasatinib
N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-yl)amino)-1,3-thiazole-5-carboxamide: a dasatinib prodrug; structure in first source. dasatinib (anhydrous) : An aminopyrimidine that is 2-methylpyrimidine which is substituted at position 4 by the primary amino group of 2-amino-1,3-thiazole-5-carboxylic acid and at position 6 by a 4-(2-hydroxyethyl)piperazin-1-yl group, and in which the carboxylic acid group has been formally condensed with 2-chloro-6-methylaniline to afford the corresponding amide. A multi-targeted kinase inhibitor, it is used, particularly as the monohydrate, for the treatment of chronic, accelerated, or myeloid or lymphoid blast phase chronic myeloid leukemia. Note that the name 'dasatinib' is used to refer to the monohydrate (USAN) as well as to anhydrous dasatinib (INN).		3.28501,3-thiazoles;
aminopyrimidine;
monocarboxylic acid amide;
N-(2-hydroxyethyl)piperazine;
N-arylpiperazine;
organochlorine compound;
secondary amino compound;
tertiary amino compound		anticoronaviral agent;
antineoplastic agent;
tyrosine kinase inhibitor
zd 6474
CH 331: structure in first source		3.0740aromatic ether;
organobromine compound;
organofluorine compound;
piperidines;
quinazolines;
secondary amine		antineoplastic agent;
tyrosine kinase inhibitor
N-[2-(diethylamino)ethyl]-5-[(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
[no description available]		2.6320indoles
compound 968
compound 968: a glutaminase inhibitor. 5-[3-bromo-4-(dimethylamino)phenyl]-2,2-dimethyl-2,3,5,6-tetrahydrobenzo[a]phenanthridin-4(1H)-one : A partially hydrogenated benzophenanthridine carrying an oxo group at C-4, geminal methyl groups at C-2 and a 3-bromo-4-(dimethylamino)phenyl group at C-5.		2.0810benzophenanthridineEC 3.5.1.2 (glutaminase) inhibitor
yya-021
YYA-021: an HIV entry inhibitor; structure in first source		2.610
nih-12848
NIH-12848: inhibits phosphatidylinositol 5-phosphate 4-kinase gamma; structure in first source		2.8930
2,4-dioxo-3-pentyl-N-[3-(1-piperidinyl)propyl]-1H-quinazoline-7-carboxamide
[no description available]		2.8930quinazolines
[1-(3-methylphenyl)-5-benzimidazolyl]-(1-piperidinyl)methanone
[no description available]		2.8930benzimidazoles
2-[[(6-bromo-1H-imidazo[4,5-b]pyridin-2-yl)thio]methyl]benzonitrile
[no description available]		2.8930imidazopyridine
3-[(3-fluorophenyl)methyl]-8-[4-(4-fluorophenyl)-4-oxobutyl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one
[no description available]		2.8930aromatic ketone
sb-224289
SB 224289 : A member of the class of benzamides obtained by formal condensation of the carboxy group of 2'-methyl-4'-(5-methyl-1,2,4-oxadiazol-3-yl)biphenyl-4-carboxylic acid with the secondary amino group of 1'-methyl-6,7-dihydro-5H-spiro[furo[2,3-f]indole-3,4'-piperidine]. Selective 5-HT1B receptor antagonist (pKi = 8.2). Displays >60-fold selectivity over 5-HT1D, 5-HT1A, 5-HT1E, 5-HT1F, 5-HT2A and 5-HT2C receptors in radioligand binding and functional assays. Centrally active following oral administration in vivo.		2.08101,2,4-oxadiazole;
azaspiro compound;
benzamides;
organic heterotetracyclic compound		serotonergic antagonist
4-[[7-[(4-fluorophenyl)methyl]-1,3-dimethyl-2,6-dioxo-8-purinyl]methyl]-1-piperazinecarboxylic acid ethyl ester
[no description available]		2.8930oxopurine
gw 7647
GW 7647: a PPAR-alpha agonist; structure in first source. GW 7647 : A monocarboxylic acid that is 2-(phenylsulfanyl)isobutyric acid in which the phenyl group is substituted at the para- position by a 3-aza-7-cyclohexylhept-1-yl group in which the nitrogen is acylated by a (cyclohexylamino)carbonyl group.		2.0810aryl sulfide;
monocarboxylic acid;
ureas		PPARalpha agonist
N,N-dimethylcarbamodithioic acid (1-acetamido-2,2,2-trichloroethyl) ester
[no description available]		2.8930organonitrogen compound;
organosulfur compound
6-bromo-2-(4-methylphenyl)-N-[(1-methyl-4-pyrazolyl)methyl]-4-quinolinecarboxamide
[no description available]		2.8930quinolines
l 663536
MK-886: orally active leukotriene biosynthesis inhibitor. 3-[3-(tert-butylsulfanyl)-1-(4-chlorobenzyl)-5-(propan-2-yl)-1H-indol-2-yl]-2,2-dimethylpropanoic acid : A member of the class of indoles that is 1H-indole substituted by a isopropyl group at position 5, a tert-butylsulfanediyl group at position 3, a 4-chlorobenzyl group at position 1 and a 2-carboxy-2-methylpropyl group at position 2. It acts as an inhibitor of arachidonate 5-lipoxygenase.		2.0810aryl sulfide;
indoles;
monocarboxylic acid;
monochlorobenzenes		antineoplastic agent;
EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor;
leukotriene antagonist
LSM-1924
[no description available]		2.8930organic heterotricyclic compound;
organooxygen compound
1-[6-(4-chlorophenyl)-5-imidazo[2,1-b]thiazolyl]-N-[(3,4-dichlorophenyl)methoxy]methanimine
[no description available]		2.0810imidazoles
N4-ethyl-N6,1,2-trimethyl-N4-phenylpyrimidin-1-ium-4,6-diamine
[no description available]		2.0810aromatic amine;
tertiary amino compound
alpha-chymotrypsin
Chymotrypsin: A serine endopeptidase secreted by the pancreas as its zymogen, CHYMOTRYPSINOGEN and carried in the pancreatic juice to the duodenum where it is activated by TRYPSIN. It selectively cleaves aromatic amino acids on the carboxyl side.		4.8370
ferrostatin-1
ferrostatin-1: inhibits ferroptosis, an iron-dependent form of nonapoptotic cell death; structure in first source. ferrostatin-1 : An ethyl ester resulting from the formal condensation of the carboxy group of 3-amino-4-(cyclohexylamino)benzoic acid with ethanol. It is a potent inhibitor of ferroptosis, a distinct non-apoptotic form of cell death caused by lipid peroxidation. It is also a radical-trapping antioxidant and has the ability to reduce the accumulation of lipid peroxides and chain-carrying peroxyl radicals.		2.8930ethyl ester;
primary arylamine;
substituted aniline		antifungal agent;
antioxidant;
ferroptosis inhibitor;
neuroprotective agent;
radiation protective agent;
radical scavenger
2-[[2-[2-(2,3-dihydro-1,4-benzodioxin-6-ylamino)-2-oxoethyl]-1-oxo-5-isoquinolinyl]oxy]propanoic acid ethyl ester
[no description available]		2.0810isoquinolines
sb 415286
3-(3-chloro-4-hydroxyphenylamino)-4-(4-nitrophenyl)-1H-pyrrole-2,5-dione: a glycogen synthase kinase-3 inhibitor; structure in first source		2.610C-nitro compound;
maleimides;
monochlorobenzenes;
phenols;
secondary amino compound;
substituted aniline		antioxidant;
apoptosis inducer;
EC 2.7.11.26 (tau-protein kinase) inhibitor;
neuroprotective agent
naphthoquinones
Naphthoquinones: Naphthalene rings which contain two ketone moieties in any position. They can be substituted in any position except at the ketone groups.		2.2510
N-[3-(N-(2-chloro-1-oxoethyl)-4-nitroanilino)propyl]-2,2,2-trifluoroacetamide
[no description available]		3.2710C-nitro compound;
secondary carboxamide;
tertiary carboxamide;
trifluoroacetamide
sch 79797
[no description available]		2.0810quinazolines
6-(2-methyl-1-piperidinyl)-5-nitro-4-pyrimidinamine
[no description available]		2.8930C-nitro compound
sitagliptin
sitagliptin : A triazolopyrazine that exhibits hypoglycemic activity.		2.610triazolopyrazine;
trifluorobenzene		EC 3.4.14.5 (dipeptidyl-peptidase IV) inhibitor;
environmental contaminant;
hypoglycemic agent;
serine proteinase inhibitor;
xenobiotic
osteoprotegerin
Osteoprotegerin: A secreted member of the TNF receptor superfamily that negatively regulates osteoclastogenesis. It is a soluble decoy receptor of RANK LIGAND that inhibits both CELL DIFFERENTIATION and function of OSTEOCLASTS by inhibiting the interaction between RANK LIGAND and RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B.		2.1110long-chain fatty acid
2-(N-(2-chloro-1-oxoethyl)-4-fluoroanilino)-N-cyclohexyl-2-(3-pyridinyl)acetamide
[no description available]		3.2710organonitrogen compound;
organooxygen compound
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1h-imidazol-2-yl)benzamide
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide: a TGF-beta type I receptor kinase activity inhibitor		2.0810benzamides;
benzodioxoles;
imidazoles;
pyridines		EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
rabeprazole(1-)
[no description available]		2.6320organic nitrogen anion
1-(4-Fluorophenyl)-3-(3-(4-fluorophenyl)-3-hydroxypropyl)-4-(4-hydroxyphenyl)azetidin-2-one
[no description available]		2.0810monobactam
imd 0354
N-(3,5-bis(trifluoromethyl)phenyl)-5-chloro-2-hydroxybenzamide: a cardioprotective agent that inhibits IkappaB kinase beta (IKKbeta); structure in first source		2.0810benzamides
ex 527
6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide: structure in first source. 6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide : A member of the class of carbazoles that is 2,3,4,9-tetrahydro-1H-carbazole which is substituted at position 1 by an aminocarbohyl group and at position 6 by a chlorine.		2.0810carbazoles;
monocarboxylic acid amide;
organochlorine compound
ncgc00099374
[no description available]		2.8930
2-nitro-4-[(6-nitro-4-quinolinyl)amino]-N-[4-(pyridin-4-ylamino)phenyl]benzamide
[no description available]		2.8930benzamides
tak-220
TAK-220: structure in first source		2.610
jtk-303
[no description available]		2.610aromatic ether;
monochlorobenzenes;
organofluorine compound;
quinolinemonocarboxylic acid;
quinolone		HIV-1 integrase inhibitor
nbd 557
[no description available]		2.610
quercetin
[no description available]		2.08107-hydroxyflavonol;
pentahydroxyflavone		antibacterial agent;
antineoplastic agent;
antioxidant;
Aurora kinase inhibitor;
chelator;
EC 1.10.99.2 [ribosyldihydronicotinamide dehydrogenase (quinone)] inhibitor;
geroprotector;
phytoestrogen;
plant metabolite;
protein kinase inhibitor;
radical scavenger
dinoprost
Dinoprost: A naturally occurring prostaglandin that has oxytocic, luteolytic, and abortifacient activities. Due to its vasocontractile properties, the compound has a variety of other biological actions.. prostaglandin F2alpha : A prostaglandins Falpha that is prosta-5,13-dien-1-oic acid substituted by hydroxy groups at positions 9, 11 and 15. It is a naturally occurring prostaglandin used to induce labor.		2.2510monocarboxylic acid;
prostaglandins Falpha		human metabolite;
mouse metabolite
luteolin
[no description available]		5.62413'-hydroxyflavonoid;
tetrahydroxyflavone		angiogenesis inhibitor;
anti-inflammatory agent;
antineoplastic agent;
apoptosis inducer;
c-Jun N-terminal kinase inhibitor;
EC 2.3.1.85 (fatty acid synthase) inhibitor;
immunomodulator;
nephroprotective agent;
plant metabolite;
radical scavenger;
vascular endothelial growth factor receptor antagonist
5'-o-caffeoylquinic acid
trans-5-O-caffeoyl-D-quinic acid : A cinnamate ester obtained by formal condensation of the carboxy group of trans-caffeic acid with the 5-hydroxy group of quinic acid.		2.610cinnamate ester;
cyclitol carboxylic acid		plant metabolite
luteolin-7-glucoside
luteolin-7-glucoside: has both antiasthmatic and antineoplastic activities; has 3C protease inhibitory activity; isolated from Ligustrum lucidum. luteolin 7-O-beta-D-glucoside : A glycosyloxyflavone that is luteolin substituted by a beta-D-glucopyranosyl moiety at position 7 via a glycosidic linkage.		2.610beta-D-glucoside;
glycosyloxyflavone;
monosaccharide derivative;
trihydroxyflavone		antioxidant;
plant metabolite
cyclosporine
[no description available]		2.7220
rutin
Hydroxyethylrutoside: Monohydroxyethyl derivative of rutin. Peripheral circulation stimulant used in treatment of venous disorders.		2.5820disaccharide derivative;
quercetin O-glucoside;
rutinoside;
tetrahydroxyflavone		antioxidant;
metabolite
kaempferol
[no description available]		2.89307-hydroxyflavonol;
flavonols;
tetrahydroxyflavone		antibacterial agent;
geroprotector;
human blood serum metabolite;
human urinary metabolite;
human xenobiotic metabolite;
plant metabolite
harmine
Harmine: Alkaloid isolated from seeds of PEGANUM HARMALA; ZYGOPHYLLACEAE. It is identical to banisterine, or telepathine, from Banisteria caapi and is one of the active ingredients of hallucinogenic drinks made in the western Amazon region from related plants. It has no therapeutic use, but (as banisterine) was hailed as a cure for postencephalitic PARKINSON DISEASE in the 1920's.. harmine : A harmala alkaloid in which the harman skeleton is methoxy-substituted at C-7.		2.610harmala alkaloidanti-HIV agent;
EC 1.4.3.4 (monoamine oxidase) inhibitor;
metabolite
genistein
[no description available]		3.07407-hydroxyisoflavonesantineoplastic agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
geroprotector;
human urinary metabolite;
phytoestrogen;
plant metabolite;
tyrosine kinase inhibitor
eprosartan
eprosartan: angiotensin II receptor antagonist. eprosartan : A member of the class of imidazoles and thiophenes that is an angiotensin II receptor antagonist used for the treatment of high blood pressure.		2.610dicarboxylic acid;
imidazoles;
thiophenes		angiotensin receptor antagonist;
antihypertensive agent;
environmental contaminant;
xenobiotic
montelukast
montelukast: a leukotriene D4 receptor antagonist		7.2110aliphatic sulfide;
monocarboxylic acid;
quinolines		anti-arrhythmia drug;
anti-asthmatic drug;
leukotriene antagonist
mycophenolate mofetil
mycophenolate mofetil : A carboxylic ester resulting from the formal condensation between the carboxylic acid group of mycophenolic acid and the hydroxy group of 2-(morpholin-4-yl)ethanol. In the liver, it is metabolised to mycophenolic acid, an immunosuppressant for which it is a prodrug. It is widely used to prevent tissue rejection following organ transplants as well as for the treatment of certain autoimmune diseases.		3.1640carboxylic ester;
ether;
gamma-lactone;
phenols;
tertiary amino compound		anticoronaviral agent;
EC 1.1.1.205 (IMP dehydrogenase) inhibitor;
immunosuppressive agent;
prodrug
entacapone
entacapone: structure given in first source. entacapone : A monocarboxylic acid amide that is N,N-diethylprop-2-enamide in which the hydrogen at position 2 is substituted by a cyano group and the hydrogen at the 3E position is substituted by a 3,4-dihydroxy-5-nitrophenyl group.		2.6102-nitrophenols;
catechols;
monocarboxylic acid amide;
nitrile		antidyskinesia agent;
antiparkinson drug;
central nervous system drug;
EC 2.1.1.6 (catechol O-methyltransferase) inhibitor
bruceantin
[no description available]		2.8930triterpenoid
amentoflavone
[no description available]		2.610biflavonoid;
hydroxyflavone;
ring assembly		angiogenesis inhibitor;
antiviral agent;
cathepsin B inhibitor;
P450 inhibitor;
plant metabolite
baicalein
[no description available]		2.610trihydroxyflavoneangiogenesis inhibitor;
anti-inflammatory agent;
antibacterial agent;
anticoronaviral agent;
antifungal agent;
antineoplastic agent;
antioxidant;
apoptosis inducer;
EC 1.13.11.31 (arachidonate 12-lipoxygenase) inhibitor;
EC 1.13.11.33 (arachidonate 15-lipoxygenase) inhibitor;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor;
EC 4.1.1.17 (ornithine decarboxylase) inhibitor;
ferroptosis inhibitor;
geroprotector;
hormone antagonist;
plant metabolite;
prostaglandin antagonist;
radical scavenger
chrysin
chrysin : A dihydroxyflavone in which the two hydroxy groups are located at positions 5 and 7.		2.89307-hydroxyflavonol;
dihydroxyflavone		anti-inflammatory agent;
antineoplastic agent;
antioxidant;
EC 2.7.11.18 (myosin-light-chain kinase) inhibitor;
hepatoprotective agent;
plant metabolite
genkwanin
genkwanin: structure. genkwanin : A monomethoxyflavone that is apigenin in which the hydroxy group at position 7 is methylated.		2.610dihydroxyflavone;
monomethoxyflavone		metabolite
hyperoside
quercetin 3-O-beta-D-galactopyranoside : A quercetin O-glycoside that is quercetin with a beta-D-galactosyl residue attached at position 3. Isolated from Artemisia capillaris, it exhibits hepatoprotective activity.		2.610beta-D-galactoside;
monosaccharide derivative;
quercetin O-glycoside;
tetrahydroxyflavone		hepatoprotective agent;
plant metabolite
mangostin
mangostin: xanthone from rind of Garcinia mangostana Linn. fruit. alpha-mangostin : A member of the class of xanthones that is 9H-xanthene substituted by hydroxy group at positions 1, 3 and 6, a methoxy group at position 7, an oxo group at position 9 and prenyl groups at positions 2 and 8. Isolated from the stems of Cratoxylum cochinchinense, it exhibits antioxidant, antimicrobial and antitumour activities.		2.610aromatic ether;
phenols;
xanthones		antimicrobial agent;
antineoplastic agent;
antioxidant;
plant metabolite
3-methylquercetin
isorhamnetin : A monomethoxyflavone that is quercetin in which the hydroxy group at position 3' is replaced by a methoxy group.		2.6107-hydroxyflavonol;
monomethoxyflavone;
tetrahydroxyflavone		anticoagulant;
EC 1.14.18.1 (tyrosinase) inhibitor;
metabolite
kaempferide
kaempferide: structure in first source. kaempferide : A monomethoxyflavone that is the 4'-O-methyl derivative of kaempferol.		2.6107-hydroxyflavonol;
monomethoxyflavone;
trihydroxyflavone		antihypertensive agent;
metabolite
orientin
orientin: structure given in first source; RN given refers to the (D-glucopyranosyl)-isomer. orientin : A C-glycosyl compound that is luteolin substituted by a beta-D-glucopyranosyl moiety at position 8.		2.6103'-hydroxyflavonoid;
C-glycosyl compound;
tetrahydroxyflavone		antioxidant;
metabolite
scutellarein
scutellarein: aglycone of scutellarin from Scutellaria baicalensis; carthamidin is 2S isomer of scutellarein; do not confuse with isoscutellarein and/or isocarthamidin which are respective regioisomers, or with the scutelarin protein. scutellarein : Flavone substituted with hydroxy groups at C-4', -5, -6 and -7.		2.610tetrahydroxyflavonemetabolite
daidzein
[no description available]		2.89307-hydroxyisoflavonesantineoplastic agent;
EC 2.7.7.7 (DNA-directed DNA polymerase) inhibitor;
EC 3.2.1.20 (alpha-glucosidase) inhibitor;
phytoestrogen;
plant metabolite
trans-2,3',4,5'-tetrahydroxystilbene
trans-2,3',4,5'-tetrahydroxystilbene: hydroxystilbene oxyresveratrol		2.610stilbenoid
polydatin
trans-piceid : A stilbenoid that is trans-resveratrol substituted at position 3 by a beta-D-glucosyl residue.		2.610beta-D-glucoside;
monosaccharide derivative;
polyphenol;
stilbenoid		anti-arrhythmia drug;
antioxidant;
geroprotector;
hepatoprotective agent;
metabolite;
nephroprotective agent;
potassium channel modulator
chicoric acid
chicoric acid: inhibits HIV-1 integrase		2.610organooxygen compoundgeroprotector;
HIV-1 integrase inhibitor
acteoside
acteoside: a protein kinase C inhibitor with hepatoprotective, anti-asthmatic, and analgesic activities; a phenylethanoid glycoside related to isoacteoside; from leaves of Lippia multiflora (Verbenaceae). acteoside : A glycoside that is the alpha-L-rhamnosyl-(1->3)-beta-D-glucoside of hydroxytyrosol in which the hydroxy group at position 4 of the glucopyranosyl moiety has undergone esterification by formal condensation with trans-caffeic acid.		2.610catechols;
cinnamate ester;
disaccharide derivative;
glycoside;
polyphenol		anti-inflammatory agent;
antibacterial agent;
antileishmanial agent;
neuroprotective agent;
plant metabolite
neticonazole
neticonazole: RN refers to (E)-isomer. neticonazole : An enamine that is ethene which is substituted at positions 1, 1, and 2 by o-pentoxyphenyl, 1H-imidazol-1-yl, and methylthio groups, respectively (the E isomer). An inhibitor of P450-dependent C-14alpha-demethylation of lanosterol (preventing conversion to ergosterol and inhibiting cell wall synthesis in fungi), it is used in Japan (generally as the corresponding hydrochloride salt) as an antifungal drug for the treatment of superficial skin infections.		2.8930aromatic ether;
benzenes;
conazole antifungal drug;
enamine;
imidazole antifungal drug;
imidazoles;
methyl sulfide		antifungal drug;
EC 1.14.13.70 (sterol 14alpha-demethylase) inhibitor
N-(4Z,7Z,10Z,13Z,16Z,19Z)-docosahexaenoylethanolamine
synaptamide: structurally similar to the endocannabinoid N-arachidonoylethanolamine (anandamide). N-(4Z,7Z,10Z,13Z,16Z,19Z)-docosahexaenoylethanolamine : An N-acylethanolamine 22:6 that is the ethanolamide of (4Z,7Z,10Z,13Z,16Z,19Z)-docosahexaenoic acid.		2.8930endocannabinoid;
N-acylethanolamine 22:6
n-oleoylethanolamine
N-oleoylethanolamine: ceramidase inhibitor. oleoyl ethanolamide : An N-(long-chain-acyl)ethanolamine that is the ethanolamide of oleic acid. The monounsaturated analogue of the endocannabinoid anandamide.		2.8930endocannabinoid;
N-(long-chain-acyl)ethanolamine;
N-acylethanolamine 18:1		EC 3.5.1.23 (ceramidase) inhibitor;
geroprotector;
PPARalpha agonist
dorzolamide
dorzolamide: topically effective ocular hypotensive carbonic anhydrase inhibitor; RN refers to mono-HCl (4S-trans)-isomer. dorzolamide : 5,6-Dihydro-4H-thieno[2,3-b]thiopyran-2-sulfonamide 7,7-dioxide in which hydrogens at the 4 and 6 positions are substituted by ethylamino and methyl groups, respectively (4S, trans-configuration). A carbonic anhydrase inhibitor, it is used as the hydrochloride in ophthalmic solutions to lower increased intraocular pressure in the treatment of open-angle glaucoma and ocular hypertension.		2.610sulfonamide;
thiophenes		antiglaucoma drug;
antihypertensive agent;
EC 4.2.1.1 (carbonic anhydrase) inhibitor
levetiracetam
Levetiracetam: A pyrrolidinone and acetamide derivative that is used primarily for the treatment of SEIZURES and some movement disorders, and as a nootropic agent.. levetiracetam : A pyrrolidinone and carboxamide that is N-methylpyrrolidin-2-one in which one of the methyl hydrogens is replaced by an aminocarbonyl group, while another is replaced by an ethyl group (the S enantiomer). An anticonvulsant, it is used for the treatment of epilepsy in both human and veterinary medicine.		2.1310pyrrolidin-2-onesanticonvulsant;
environmental contaminant;
xenobiotic
sirolimus
Sirolimus: A macrolide compound obtained from Streptomyces hygroscopicus that acts by selectively blocking the transcriptional activation of cytokines thereby inhibiting cytokine production. It is bioactive only when bound to IMMUNOPHILINS. Sirolimus is a potent immunosuppressant and possesses both antifungal and antineoplastic properties.. sirolimus : A macrolide lactam isolated from Streptomyces hygroscopicus consisting of a 29-membered ring containing 4 trans double bonds, three of which are conjugated. It is an antibiotic, immunosupressive and antineoplastic agent.		4.4130antibiotic antifungal drug;
cyclic acetal;
cyclic ketone;
ether;
macrolide lactam;
organic heterotricyclic compound;
secondary alcohol		antibacterial drug;
anticoronaviral agent;
antineoplastic agent;
bacterial metabolite;
geroprotector;
immunosuppressive agent;
mTOR inhibitor
topiramate
Topiramate: A sulfamate-substituted fructose analog that was originally identified as a hypoglycemic agent. It is used for the treatment of EPILEPSY and MIGRAINE DISORDERS, and may also promote weight loss.. topiramate : A hexose derivative that is 2,3:4,5-di-O-isopropylidene-beta-D-fructopyranose in which the hydroxy group has been converted to the corresponding sulfamate ester. It blocks voltage-dependent sodium channels and is used as an antiepileptic and for the prevention of migraine.		2.610cyclic ketal;
ketohexose derivative;
sulfamate ester		anticonvulsant;
sodium channel blocker
alpha-zearalenol
[no description available]		2.8930macrolide
fenretinide
Fenretinide: A synthetic retinoid that is used orally as a chemopreventive against prostate cancer and in women at risk of developing contralateral breast cancer. It is also effective as an antineoplastic agent.. 4-hydroxyphenyl retinamide : A retinoid obtained by formal condensation of the carboxy group of all-trans retinoic acid and the anilino group of 4-hydroxyaniline. Synthetic retinoid agonist. Antiproliferative, antioxidant and anticancer agent with a long half-life in vivo. Apoptotic effects appear to be mediated by a mechanism distinct from that of 'classical' retinoids.		2.0810monocarboxylic acid amide;
retinoid		antineoplastic agent;
antioxidant
su 9516
[no description available]		2.8930
N-(4-bromo-3-methylphenyl)-2,5-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine
[no description available]		2.8930triazolopyrimidines
ter 199
[no description available]		2.0810
arachidonylcyclopropylamide
arachidonylcyclopropylamide: a potent and selective agonist of neuronal cannabinoid receptor; structure in first source		2.0810
sb 277011
SB 277011: structure in first source		2.8930
fluticasone
Fluticasone: A STEROID with GLUCOCORTICOID RECEPTOR activity that is used to manage the symptoms of ASTHMA; ALLERGIC RHINITIS, and ATOPIC DERMATITIS.. fluticasone : A trifluorinated corticosteroid used in the form of its propionate ester for treatment of allergic rhinitis.		4.81111beta-hydroxy steroid;
17alpha-hydroxy steroid;
3-oxo-Delta(4) steroid;
corticosteroid;
fluorinated steroid;
thioester		anti-allergic agent;
anti-asthmatic drug
benzyloxycarbonyl-phe-ala-fluormethylketone
cathepsin B inhibitor : A cysteine protease inhibitor which inhibits cathepsin B (EC 3.4.22.1).		2.610
ly 320135
LY 320135: cannabinoid receptor antagonist; structure in first source		2.0810benzofurans
n-(n-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester
DAPT : A dipeptide consisting of alanylphenylglycine derivatised as a 3,5-difluorophenylacetamide at the amino terminal and a tert-butyl ester at the carboxy terminal. A gamma-secretase inhibitor.		2.610carboxylic ester;
difluorobenzene;
dipeptide;
tert-butyl ester		EC 3.4.23.46 (memapsin 2) inhibitor
pd 166285
[no description available]		2.0810
sb 223412
SB 223412: SB-223412 is the (S)-(-)-isomer; RN given for (S)-isomer; structure in first source		2.8930
sr 59230a
[no description available]		2.8930tetralins
3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide
[no description available]		2.8930pyrimidines
kn 62
KN 62: inhibitor of Ca/calmodulin-dependent protein kinase II		3.0740piperazines
su 6656
SU 6656: a c-Src kinase inhibitor; used to probe growth signaling; structure in first source. SU6656 : A member of the class of oxindoles that is 3-methyleneoxindole in which the hydrogeh at position 5 has been replaced by a dimethylaminosulfonyl group and in which one of the hydrogens of the methylene group has been replaced by a 4,5,6,7-tetrahydro-indol-2-yl group. It is a specific inhibitor of Src family kinase.		2.0810
casticin
casticin: from fruit of Vitex rotundifolia; structure in second source. casticin : A tetramethoxyflavone that consists of quercetagetin in which the hydroxy groups at positions 3, 6, 7 and 4' have been replaced by methoxy groups. It has been isolated from Eremophila mitchellii.		2.610dihydroxyflavone;
tetramethoxyflavone		apoptosis inducer;
plant metabolite
MeJA
[no description available]		2.8930Jasmonate derivatives
5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one
5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one: isolated from the Chinese herb Scutellariae radix. oroxylin A : A dihydroxy- and monomethoxy-flavone in which the hydroxy groups are positioned at C-5 and C-7 and the methoxy group is at C-6.		2.610dihydroxyflavone;
monomethoxyflavone		antineoplastic agent;
EC 1.14.13.39 (nitric oxide synthase) inhibitor
(E)-2,3,5,4'-tetrahydroxystilbene-2-O-beta-D-glucoside
2,3,5,4'-tetrahydroxystilbene-2-O-beta-D-glucopyranoside: Tyrosinase inhibitor from Polygonum multiflorum; structure in first source. (E)-2,3,5,4'-tetrahydroxystilbene-2-O-beta-D-glucoside : A stilbenoid that is trans-stilbene which has been substituted by hydroxy groups at positions 2, 3, 5, and 4', and in which the hydroxy group at positon 2 has then been converted to the corresponding the beta-D-glucoside.		2.610beta-D-glucoside;
resorcinols;
stilbenoid		anti-inflammatory agent;
antioxidant;
apoptosis inhibitor;
cardioprotective agent;
cyclooxygenase 2 inhibitor;
platelet aggregation inhibitor
1h-pyrrole-2,5-dione, 3-(1-methyl-1h-indol-3-yl)-4-(1-methyl-6-nitro-1h-indol-3-yl)-
1H-pyrrole-2,5-dione, 3-(1-methyl-1H-indol-3-yl)-4-(1-methyl-6-nitro-1H-indol-3-yl)-: structure in first source		2.8930
pd 161570
PD 161570: structure in first source		2.8930
tyrphostin ag 555
[no description available]		2.610
bosutinib
4-((2,4-dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methyl-1-piperazinyl)propoxy)-3-quinolinecarbonitrile: a Src kinase inhibitor; structure in first source		2.3110aminoquinoline;
aromatic ether;
dichlorobenzene;
N-methylpiperazine;
nitrile;
tertiary amino compound		antineoplastic agent;
tyrosine kinase inhibitor
semaxinib
semaxanib : An oxindole that is 3-methyleneoxindole in which one of the hydrogens of the methylene group is replaced by a 3,5-dimethylpyrrol-2-yl group.		2.0810olefinic compound;
oxindoles;
pyrroles		angiogenesis modulating agent;
antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
vascular endothelial growth factor receptor antagonist
su 11248
[no description available]		2.5220monocarboxylic acid amide;
pyrroles		angiogenesis inhibitor;
antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
immunomodulator;
neuroprotective agent;
vascular endothelial growth factor receptor antagonist
palbociclib
[no description available]		3.0740aminopyridine;
aromatic ketone;
cyclopentanes;
piperidines;
pyridopyrimidine;
secondary amino compound;
tertiary amino compound		antineoplastic agent;
EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
jnj-7706621
[no description available]		3.0740sulfonamide
pd 151746
[no description available]		2.610
strontium
Strontium: An element of the alkaline earth family of metals. It has the atomic symbol Sr, atomic number 38, and atomic weight 87.62.		4.811alkaline earth metal atom
bismuth
Bismuth: A metallic element that has the atomic symbol Bi, and atomic number 83. Its principal isotope is Bismuth 209.		4.811metal atom;
pnictogen
lisinopril
Lisinopril: One of the ANGIOTENSIN-CONVERTING ENZYME INHIBITORS (ACE inhibitors), orally active, that has been used in the treatment of hypertension and congestive heart failure.		2.610dipeptideEC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
verteporfin
(2R,2(1)S)-8-ethenyl-2(1),2(2)-bis(methoxycarbonyl)-17-(3-methoxy-3-oxopropyl)-2,7,12,18-tetramethyl-2,2(1)-dihydrobenzo[b]porphyrin-13-propanoic acid : The 2(1),2(2),17-trimethyl ester of (2R,2(1)S)-2(1),2(2)-dicarboxy-8-ethenyl-2,7,12,18-tetramethyl-2,2(1)-dihydrobenzo[b]porphyrin-13,17-dipropanoic acid.		2.610
batimastat
batimastat: structure given in first source; a synthetic matrix metalloproteinase inhibitor. batimastat : A secondary carboxamide resulting from the formal condensation of the carboxy group of (2S,3R)-5-methyl-3-{[(2S)-1-(methylamino)-1-oxo-3-phenylpropan-2-yl]carbamoyl}-2-[(thiophen-2-ylsulfanyl)methyl]hexanoic acid with the amino group of hydroxylamine. It a broad-spectrum matrix metalloprotease inhibitor.		2.610hydroxamic acid;
L-phenylalanine derivative;
organic sulfide;
secondary carboxamide;
thiophenes;
triamide		angiogenesis inhibitor;
antineoplastic agent;
matrix metalloproteinase inhibitor
indinavir sulfate
Indinavir: A potent and specific HIV protease inhibitor that appears to have good oral bioavailability.		2.610dicarboxylic acid diamide;
N-(2-hydroxyethyl)piperazine;
piperazinecarboxamide		HIV protease inhibitor
sulfur
Sulfur: An element that is a member of the chalcogen family. It has an atomic symbol S, atomic number 16, and atomic weight [32.059; 32.076]. It is found in the amino acids cysteine and methionine.		4.811chalcogen;
nonmetal atom		macronutrient
virginiamycin factor s1
virginiamycin factor S1: a component of VIRGINIAMYCIN; was EP to VIRGINIAMYCIN 1992-2001. virginiamycin S1 : A cyclodepsipeptide that is N-(3-hydroxypicolinoyl)-L-threonyl-D-alpha-aminobutyryl-L-prolyl-N-methyl-L-phenylalanyl-4-oxo-L-pipecoloyl-L-2-phenylglycine in which the carboxy group of the 2-phenylglycine moiety has undergone formal intramolecular condensation with the hydroxy group of the N-(3-hydroxypicolinoyl)-L-threonyl to give the corresponding 19-membered ring lactone. It is one of the two major components of the antibacterial drug virginiamycin, produced by Streptomyces virginiae, S. loidensis, S. mitakaensis, S. pristina-spiralis, S. ostreogriseus, and others.		2.8930cyclodepsipeptide;
macrolide antibiotic		antibacterial drug;
bacterial metabolite
cisplatin
[no description available]		2.0810diamminedichloroplatinumantineoplastic agent;
apoptosis inducer;
cross-linking reagent;
ferroptosis inducer;
genotoxin;
mutagen;
nephrotoxin;
photosensitizing agent
cysteine
Cysteine: A thiol-containing non-essential amino acid that is oxidized to form CYSTINE.. L-cysteinium : The L-enantiomer of cysteinium.. cysteine : A sulfur-containing amino acid that is propanoic acid with an amino group at position 2 and a sulfanyl group at position 3.		2.110cysteiniumfundamental metabolite
solanesol
solanesol : A nonaprenol that is hexatriaconta-2,6,10,14,18,22,26,30,34-nonaen-1-ol substituted by 9 methyl groups at positions 3, 7, 11, 15, 19, 23, 27, 31 and 35 (the all-trans0stereoisomer).		2.610nonaprenol;
primary alcohol		plant metabolite
pepstatin
pepstatin: inhibits the aspartic protease endothiapepsin		2.610pentapeptide;
secondary carboxamide		bacterial metabolite;
EC 3.4.23.* (aspartic endopeptidase) inhibitor
l 685458
L 685458: a gamma-secretase inhibitor; structure in first source. L-685,458 : A peptide and carboxamide that is L-leucyl-L-phenylalaninamide, L-Leu-L-Phe-NH2, which has been acylated on the N-terminus by a Phe-Phe hydroxyethylene dipeptide isotere, 2R-benzyl-5S-tert-butoxycarbonylamino-4R-hydroxy-6-phenylhexanoic acid. Compounds based on the structure of L-685,458 are potent inhibitors of gamma-secretase, which mediates the final catalytic step that generates the amyloid beta-peptide (Abeta), which assembles into the neurotoxic aggregates in the brains of sufferers of Alzheimer's disease.		2.610carbamate ester;
monocarboxylic acid amide;
peptide;
secondary alcohol		EC 3.4.23.46 (memapsin 2) inhibitor;
peptidomimetic
vx680
[no description available]		2.0810N-arylpiperazine
bms 806
BMS 806: prevents entry of HIV into cells by binding HIV envelope protein gp120; no further info available 4/2002		2.610
benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone
[no description available]		2.610
fenoterol
fenoterol hydrobromide : The hydrobromide salt of fenoterol. A beta2-adrenergic agonist, it is used as a bronchodilator in the management of reversible airway obstruction.		2.6320hydrobromidebeta-adrenergic agonist;
bronchodilator agent;
sympathomimetic agent
tulobuterol hydrochloride
[no description available]		2.610organic molecular entity
xib 4035
XIB 4035: a GFRalpha-1 agonist; structure in first source		2.8930
salubrinal
salubrinal: prevents dephosphorylation of eIF2alpha; structure in first source. salubrinal : A member of the class of quinolines that is a mixed aminal resulting from the formal condensation oftrichloroacetaldehyde with the amide nitrogen of trans-cinnamamide and the primary amino group of 1-quinolin-8-ylthiourea. It is a selective inhibitor of cellular complexes that dephosphorylate eukaryotic translation initiation factor 2 subunit alpha (eIF2alpha).		2.610aminal;
organochlorine compound;
quinolines;
secondary carboxamide;
thioureas
gw-5074
[no description available]		2.2110
d 4476
[no description available]		2.0810imidazoles
cyc 116
4-methyl-5-(2-(4-morpholinophenylamino)pyrimidin-4-yl)thiazol-2-amine: an aurora kinase inhibitor; structure in first source		2.0810
bay 19-8004
BAY 19-8004: a PDE4 inhibitor; structure in first source		2.0810
bafilomycin a1
bafilomycin A1: from Streptomyces griseus; structure given in first source. bafilomycin A1 : The most used of the bafilomycins, a family of toxic macrolide antibiotics derived from Streptomyces griseus.		2.1310cyclic hemiketal;
macrolide antibiotic;
oxanes		apoptosis inducer;
autophagy inhibitor;
bacterial metabolite;
EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor;
EC 3.6.3.14 (H(+)-transporting two-sector ATPase) inhibitor;
ferroptosis inhibitor;
fungicide;
potassium ionophore;
toxin
germacrone
germacrone: isolated from Curcuma wenyujin		2.610germacrane sesquiterpenoid;
olefinic compound		androgen antagonist;
anti-inflammatory agent;
antifeedant;
antifungal agent;
antimicrobial agent;
antineoplastic agent;
antioxidant;
antitussive;
antiviral agent;
apoptosis inducer;
autophagy inducer;
hepatoprotective agent;
insecticide;
neuroprotective agent;
plant metabolite;
volatile oil component
(2e,4e,6e,10e)-3,7,11,15-tetramethyl-2,4,6,10,14-hexadecapentaenoic acid
(2E,4E,6E,10E)-3,7,11,15-tetramethyl-2,4,6,10,14-hexadecapentaenoic acid: an acyclic retinoid that suppresses hepatocellular carcinoma recurrence; structure in first source		2.610
lithospermic acid
[no description available]		2.610
everolimus
[no description available]		4.4230cyclic acetal;
cyclic ketone;
ether;
macrolide lactam;
primary alcohol;
secondary alcohol		anticoronaviral agent;
antineoplastic agent;
geroprotector;
immunosuppressive agent;
mTOR inhibitor
laq824
LAQ824: Histone deacetylase inhibitor		2.610
ixabepilone
[no description available]		7.6101,3-thiazoles;
beta-hydroxy ketone;
epoxide;
lactam;
macrocycle		antineoplastic agent;
microtubule-destabilising agent
ekb 569
EKB 569: an EGF receptor kinase inhibitor		2.610aminoquinoline;
monocarboxylic acid amide;
monochlorobenzenes;
nitrile		protein kinase inhibitor
axitinib
[no description available]		2.0810aryl sulfide;
benzamides;
indazoles;
pyridines		antineoplastic agent;
tyrosine kinase inhibitor;
vascular endothelial growth factor receptor antagonist
pai 039
tiplaxtinin: inhibitor of plasminogen activator inhibitor-1		2.0810indole-3-acetic acids
rilpivirine
[no description available]		2.610aminopyrimidine;
nitrile		EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor;
HIV-1 reverse transcriptase inhibitor
belotecan
belotecan: structure in first source		2.8930pyranoindolizinoquinoline
(1Ar,7aS,10aS,10bS)-1a,5-dimethyl-8-methylidene-2,3,6,7,7a,8,10a,10b-octahydrooxireno[9,10]cyclodeca[1,2-b]furan-9(1aH)-one
[no description available]		2.610germacranolide
4,5-di-O-caffeoylquinic acid
[no description available]		2.610quinic acid
indigo carmine
3,5-di-O-(E)-caffeoylquinic acid: from roots of Lychnophora ericoides; structure in first source. 3,5-di-O-caffeoyl quinic acid : A carboxylic ester that is the diester obtained by the condensation of the hydroxy groups at positions 3 and 5 of (-)-quinic acid with the carboxy group of trans-caffeic acid. Isolated from Brazilian propolis and Suaeda glauca, it exhibits hepatoprotective and cytotoxic activities.		2.610
tanespimycin
CP 127374: analog of herbimycin A		3.16101,4-benzoquinones;
ansamycin;
carbamate ester;
organic heterobicyclic compound;
secondary amino compound		antineoplastic agent;
apoptosis inducer;
Hsp90 inhibitor
norgestimate
[no description available]		2.8930ketoxime;
steroid ester;
terminal acetylenic compound		contraceptive drug;
progestin;
synthetic oral contraceptive
b 43
RK-24466 : A member of the class of pyrrolopyrimidines that is 7H-pyrrolo[2,3-d]pyrimidine substituted by amino, 4-phenoxyphenyl, and cyclopentyl groups at positions 4, 5 and 7, respectively. It is a potent inhibitor of Lck that inhibits Lck (64-509) and LckCD isoforms (IC50 of less than 1 and 2 nM, respectively).		2.8930aromatic amine;
aromatic ether;
cyclopentanes;
primary amino compound;
pyrrolopyrimidine		EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor;
geroprotector
gw2974
GW2974: quinazoline derivative, which is able to block the activation of both the EGFR and erbB2		2.0810pyridopyrimidine
4-(2' methoxyphenyl)-1-(2'-(n-(2''-pyridinyl)-4-fluorobenzamido)ethyl)piperazine
[no description available]		2.8930
methiazole
methiazole: a parasitostatic agent		2.8930benzimidazoles;
carbamate ester
sb 218795
SB 218795: structure in first source		2.8930quinolines
bvt.948
[no description available]		2.8930
lactacystin
[no description available]		2.8130lactam;
S-substituted L-cysteine
ispinesib
[no description available]		2.0810benzamides
fk 866
N-(4-(1-benzoylpiperidin-4-yl)butyl)-3-(pyridin-3-yl)acrylamide: inhibits nicotinamide phosphoribosyltransferase; structure in first source		2.2110benzamides;
N-acylpiperidine
a 38503
[no description available]		2.8930
artesunate
artesunic acid: RN given for (3R-(3alpha,5abeta,6beta,8abeta,9alpha,10alpha,12beta,(2aR*))-isomer; succinic ester of artemether		2.610artemisinin derivative;
cyclic acetal;
dicarboxylic acid monoester;
hemisuccinate;
semisynthetic derivative;
sesquiterpenoid		antimalarial;
antineoplastic agent;
ferroptosis inducer
temsirolimus
[no description available]		2.0810macrolide lactam
(3S,6S,9S,12R)-3-[(2S)-Butan-2-yl]-6-[(1-methoxyindol-3-yl)methyl]-9-(6-oxooctyl)-1,4,7,10-tetrazabicyclo[10.4.0]hexadecane-2,5,8,11-tetrone
[no description available]		2.610oligopeptide
pd 184352
2-(2-chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamide: inhibits MAP kinase kinase; structure in first source		2.0810aminobenzoic acid
bibx 1382bs
BIBX 1382BS: an ErbB receptor kinase inhibitor; no further information available 4/2001		2.0810substituted aniline
vildagliptin
[no description available]		2.610amino acid amide
belinostat
[no description available]		2.610hydroxamic acid;
olefinic compound;
sulfonamide		antineoplastic agent;
EC 3.5.1.98 (histone deacetylase) inhibitor
pep005
3-ingenyl angelate: protein kinase C agonist and antineoplastic; structure in first source		3.2310
panobinostat
Panobinostat: An indole and hydroxamic acid derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used as an antineoplastic agent in combination with BORTEZOMIB and DEXAMETHASONE for the treatment of MULTIPLE MYELOMA.. panobinostat : A hydroxamic acid obtained by formal condensation of the carboxy group of (2E)-3-[4-({[2-(2-methylindol-3-yl)ethyl]amino}methyl)phenyl]prop-2-enoic acid with the amino group of hydroxylamine. A histone deacetylase inhibitor used (as its lactate salt) in combination with bortezomib and dexamethasone for the treatment of multiple myeloma.		10.48153cinnamamides;
hydroxamic acid;
methylindole;
secondary amino compound		angiogenesis modulating agent;
antineoplastic agent;
EC 3.5.1.98 (histone deacetylase) inhibitor
hdac-42
HDAC-42: structure in first source		2.5820amidobenzoic acid
parthenolide
[no description available]		2.5820sesquiterpene lactonedrug allergen;
inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
peripheral nervous system drug
krn 633
N-(2-chloro-4-((6,7-dimethoxy-4-quinazolinyl)oxy)phenyl)-N'-propylurea: a VEGF receptor-2 tyrosine kinase inhibitor; structure in first source		2.8930
[4-[[4-(1-benzothiophen-2-yl)-2-pyrimidinyl]amino]phenyl]-[4-(1-pyrrolidinyl)-1-piperidinyl]methanone
[no description available]		2.0810benzamides;
N-acylpiperidine
chlorhexidine
Chlorhexidine: A disinfectant and topical anti-infective agent used also as mouthwash to prevent oral plaque.. chlorhexidine : A bisbiguanide compound with a structure consisting of two (p-chlorophenyl)guanide units linked by a hexamethylene bridge.		2.610biguanides;
monochlorobenzenes		antibacterial agent;
antiinfective agent
gs-7340
tenofovir alafenamide: component of Biktarvy. tenofovir alafenamide : An L-alanine derivative that is isopropyl L-alaninate in which one of the amino hydrogens is replaced by an (S)-({[(2R)-1-(6-amino-9H-purin-9-yl)propan-2-yl]oxy}methyl)(phenoxy)phosphoryl group. A prodrug for tenofovir, it is used (as the fumarate salt) in combination therapy for the treatment of HIV-1 infection.		2.6106-aminopurines;
ether;
isopropyl ester;
L-alanine derivative;
phosphoramidate ester		antiviral drug;
HIV-1 reverse transcriptase inhibitor;
prodrug
clasto-lactacystin beta-lactone
clasto-lactacystin beta-lactone: active metabolite of lactacystin; inhibits 20 S proteasome; structure in first source		2.0810
5-amino-4-oxo-3-phenyl-1-thieno[3,4-d]pyridazinecarboxylic acid
[no description available]		2.8930organonitrogen heterocyclic compound;
organosulfur heterocyclic compound
iniparib
[no description available]		2.5820carbonyl compound;
organohalogen compound
n-(2-amino-5-fluorobenzyl)-4-(n-(pyridine-3-acrylyl)aminomethyl)benzamide
[no description available]		2.610
pri-2205
[no description available]		2.610
mk 0752
[no description available]		2.5820
gw 501516
GW 501516: a selective PPARdelta agonist; structure in first source. GW 501516 : An aromatic ether that is phenoxyacetic acid in which the phenyl group is substituted at position 2 by a methyl group and at position 4 by a (1,3-thiazol-5-ylmethyl)sulfanediyl group, and in which the 1,3-thiazolyl group is substituted at positions 2 and 4 by p-trifluoromethylphenyl and methyl groups, respectively.		3.07401,3-thiazoles;
aromatic ether;
aryl sulfide;
monocarboxylic acid;
organofluorine compound		carcinogenic agent;
PPARbeta/delta agonist
givinostat
[no description available]		2.610carbamate ester
av 412
[no description available]		2.0810
ag-041r
AG-041R: structure in first source		2.0810
telatinib
[no description available]		2.0810
dolastatin 10
dolastatin 10: from mollusk Dolabella auricularia; contains four amino acids, dolavaline, dolaisoleucine, dolaproine, valine and the primary amine dolaphenine; deo-dolastatin 10 is a new dolastatin 10 chiral derivative with MW of 784. dolastatin 10 : A tetrapeptide that is isolated from the sea hare Dolabella auricularia. It is a potent anticancer agent which inhibits tubulin polymerization.		2.89301,3-thiazoles;
tetrapeptide		animal metabolite;
antineoplastic agent;
apoptosis inducer;
marine metabolite;
microtubule-destabilising agent
cp 547632
3-(4-bromo-2,6-difluorobenzyloxy)-5-(3-(4-pyrrolidin-1-ylbutyl)ureido)isothiazole-4-carboxylic acid amide: inhibits vascular endothelial growth factor receptor-2 tyrosine kinase; structure in first source		2.0810
pd 144418
[no description available]		2.610
spc-839
SPC-839: an inhibitor of activator protein 1; structure in first source		3.0740
bicyclol
bicyclol: an antihepatitis drug, on the metabolism and hepatotoxicity of aflatoxin B1 (AFB1) in rats.		2.610
lenvatinib
lenvatinib : A member of the class of quinolines that is the carboxamide of 4-{3-chloro-4-[(cyclopropylcarbamoyl)amino]phenoxy}-7-methoxyquinoline-6-carboxylic acid. A multi-kinase inhibitor and orphan drug used (as its mesylate salt) for the treatment of various types of thyroid cancer that do not respond to radioiodine.		2.0810aromatic amide;
aromatic ether;
cyclopropanes;
monocarboxylic acid amide;
monochlorobenzenes;
phenylureas;
quinolines		antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
fibroblast growth factor receptor antagonist;
orphan drug;
vascular endothelial growth factor receptor antagonist
andarine
[no description available]		2.0810acetamides;
anilide
gw843682x
[no description available]		2.0810(trifluoromethyl)benzenes
pd 0325901
mirdametinib: has antineoplastic activity; appears to be a MEK inhibitor. PD 0325901 : A hydroxamic acid ester that is benzhydroxamic acid (N-hydroxybenzamide) in which the hydroxamic acid group has been converted to the corresponding 2,3-dihydroxypropyl ester and in which the benzene ring has been substituted at position 2 by a (2-fluoro-4-iodophenyl)amino group and at positions 3 and 4 by fluorines (the R enantiomer).		2.0810difluorobenzene;
hydroxamic acid ester;
monofluorobenzenes;
organoiodine compound;
propane-1,2-diols;
secondary amino compound		antineoplastic agent;
EC 2.7.12.2 (mitogen-activated protein kinase kinase) inhibitor
midostaurin
midostaurin : An organic heterooctacyclic compound that is the N-benzoyl derivative of staurosporine.		3.2850benzamides;
gamma-lactam;
indolocarbazole;
organic heterooctacyclic compound		antineoplastic agent;
EC 2.7.11.13 (protein kinase C) inhibitor
pd 150606
PD 150606: a calpain inhibitor; structure given in first source. (Z)-3-(4-iodophenyl)-2-mercaptoacrylic acid : An organoiodine compound that is acrylic acid in which the vinylic hydrogens at positions 2 and 3 are replaced by mercapto and 4-iodophenyl groups respectively (the Z geoisomer).		2.2510cinnamic acids;
organoiodine compound;
thioenol		apoptosis inhibitor;
calpain inhibitor
ag 14361
[no description available]		2.0810benzimidazoles
sb 265610
[no description available]		2.0810
ly 450139
[no description available]		2.610peptide
valnemulin
[no description available]		2.6320
nu 7026
2-(morpholin-4-yl)benzo(h)chromen-4-one: a radiosensitizing agent that inhibits DNA-dependent protein kinase; structure in first source		2.8930organic heterotricyclic compound;
organooxygen compound
fr 148083
5Z-7-oxozeaenol : A macrolide that is the 7-oxo derivative of zeaenol (the 5Z stereoisomer). Isolated from Fungi, it exhibits cytotoxic, antibacterial and inhibitory activity against NF-kappaB.		2.0810aromatic ether;
macrolide;
phenols;
secondary alcohol;
secondary alpha-hydroxy ketone		antibacterial agent;
antineoplastic agent;
metabolite;
NF-kappaB inhibitor
mocetinostat
mocetinostat: undergoing phase II clinical trials for treatment of cancer. mocetinostat : A benzamide obtained by formal condensation of the carboxy group of 4-({[4-(pyridin-3-yl)pyrimidin-2-yl]amino}methyl)benzoic acid with one of the amino groups of benzene-1,2-diamine. It is an orally active and isotype-selective HDAC inhibitor which exhibits antitumour activity (IC50 = 0.15, 0.29, 1.66 and 0.59 muM for HDAC1, HDAC2, HDAC3 and HDAC11).		2.8830aminopyrimidine;
benzamides;
pyridines;
secondary amino compound;
secondary carboxamide;
substituted aniline		antineoplastic agent;
apoptosis inducer;
autophagy inducer;
cardioprotective agent;
EC 3.5.1.98 (histone deacetylase) inhibitor;
hepatotoxic agent
osi 930
OSI 930: inhibits both receptor tyrosine kinase Kit and kinase insert domain receptor; structure in first source		3.0740aromatic amide
ki 20227
[no description available]		2.0810
scio-469
SCIO-469: a small-molecule p38 mitogen-activated protein (MAP) kinase inhibitor for potential oral therapy for inflammatory disorders; in phase lib clinical trials for rheumatoid arthritis 4/2004. talmapimod : An indolecarboxamide obtained by formal condensation of the carboxy group of 6-chloro-3-[(dimethylamino)(oxo)acetyl]-1-methylindole-5-carboxylic acid with the secondary amino group of (2S,5R)-1-[(4-fluorophenyl)methyl]-2,5-dimethylpiperazine. It is a potent inhibitor of MAPK and exhibits anti-cancer properties.		2.0810aromatic amide;
aromatic ketone;
chloroindole;
dicarboxylic acid diamide;
indolecarboxamide;
monofluorobenzenes;
N-acylpiperazine;
N-alkylpiperazine		antineoplastic agent;
apoptosis inducer;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
ticagrelor
Ticagrelor: An adenosine triphosphate analogue and reversible P2Y12 PURINORECEPTOR antagonist that inhibits ADP-mediated PLATELET AGGREGATION. It is used for the prevention of THROMBOEMBOLISM by patients with ACUTE CORONARY SYNDROME or a history of MYOCARDIAL INFARCTION.. ticagrelor : A triazolopyrimidine that is an adenosine isostere; the cyclopentane ring is similar to ribose and the nitrogen-rich [1,2,3]triazolo[4,5-d]pyrimidine moiety resembles the nucleobase adenine. A platelet aggregation inhibitor which is used for prevention of thromboembolic events in patients with acute coronary syndrome.		2.8930aryl sulfide;
hydroxyether;
organofluorine compound;
secondary amino compound;
triazolopyrimidines		P2Y12 receptor antagonist;
platelet aggregation inhibitor
ssr 69071
SSR 69071: structure in first source		2.0810pyridopyrimidine
l 692585
[no description available]		2.8930peptide
rivaroxaban
Rivaroxaban: A morpholine and thiophene derivative that functions as a FACTOR XA INHIBITOR and is used in the treatment and prevention of DEEP-VEIN THROMBOSIS and PULMONARY EMBOLISM. It is also used for the prevention of STROKE and systemic embolization in patients with non-valvular ATRIAL FIBRILLATION, and for the prevention of atherothrombotic events in patients after an ACUTE CORONARY SYNDROME.. rivaroxaban : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-chlorothiophene-2-carboxylic acid with the amino group of 4-{4-[(5S)-5-(aminomethyl)-2-oxo-1,3-oxazolidin-3-yl]phenyl}morpholin-3-one. An anticoagulant used for prophylaxis of venous thromboembolism in patients with knee or hip replacement surgery.		2.610aromatic amide;
lactam;
monocarboxylic acid amide;
morpholines;
organochlorine compound;
oxazolidinone;
thiophenes		anticoagulant;
EC 3.4.21.6 (coagulation factor Xa) inhibitor
sb 3ct compound
SB 3CT compound: a matrix metalloproteinase-2 inhibitor; structure in first source		2.610aromatic ether
pi103
PI103: pyridofuropyrimidine antineoplastic; a potent inhibitor of class I phosphatidylinositide 3-kinases (PI3K); structure in first soruce		3.0740aromatic amine;
morpholines;
organic heterotricyclic compound;
phenols;
tertiary amino compound		antineoplastic agent;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor;
mTOR inhibitor
sb 210313
[no description available]		2.0810
gw 4064
[no description available]		2.0810stilbenoid
nnc 26-9100
NNC 26-9100: structure in first source		2.8930aminopyridine
ginsenoside rb1
[no description available]		2.610ginsenoside;
glycoside;
tetracyclic triterpenoid		anti-inflammatory drug;
anti-obesity agent;
apoptosis inhibitor;
neuroprotective agent;
plant metabolite;
radical scavenger
2-(3-chlorobenzyloxy)-6-(piperazin-1-yl)pyrazine
[no description available]		2.8930
sa 4503
[no description available]		2.0810
ic 87114
IC 87114: structure in first source		2.08106-aminopurines;
biaryl;
quinazolines		EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor
zibotentan
ZD4054: a potent endothelin receptor A antagonist that inhibits ovarian carcinoma cell proliferation		2.0810phenylpyridine
tivozanib
N-(2-chloro-4-((6,7-dimethoxy-4-quinolyl)oxy)phenyl)-N'-(5-methyl-3-isoxazolyl)urea: KNR-951 is the HCl, monohydrate salt; an antineoplastic agent; structure in first source		3.0740aromatic ether
hki 272
[no description available]		2.5320nitrile;
quinolines		antineoplastic agent;
tyrosine kinase inhibitor
tofacitinib
tofacitinib : A pyrrolopyrimidine that is pyrrolo[2,3-d]pyrimidine substituted at position 4 by an N-methyl,N-(1-cyanoacetyl-4-methylpiperidin-3-yl)amino moiety. Used as its citrate salt to treat moderately to severely active rheumatoid arthritis.		2.0810N-acylpiperidine;
nitrile;
pyrrolopyrimidine;
tertiary amino compound		antirheumatic drug;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor
bibr 1532
[no description available]		2.0810
n-(6-chloro-7-methoxy-9h-beta-carbolin-8-yl)-2-methylnicotinamide
[no description available]		3.0740
rucaparib
AG14447: Poly(ADP-ribose) polymerase inhibitor; structure in first source		2.5820azepinoindole;
caprolactams;
organofluorine compound;
secondary amino compound		antineoplastic agent;
EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor
cediranib
[no description available]		2.0810aromatic ether
tae226
TAE226: an adhesion kinase inhibitor, offers an attractive therapeutic approach in ovarian carcinoma; structure in first source		2.8930morpholines
gw0742
GW 610742: structure in first source		3.0740monocarboxylic acid
6h-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine-6-acetamide, 4-(4-chlorophenyl)-n-(4-hydroxyphenyl)-2,3,9-trimethyl-, (6s)-
[no description available]		2.8220organonitrogen heterocyclic compound;
organosulfur heterocyclic compound
reversin 121
reversin 121: high affinity peptide chemosensitizer		2.5420
ps1145
PS1145: IkappaB kinase inhibitor; structure in first source		2.0810beta-carbolines
cetilistat
cetilistat: lipase inhibitor in randomized, placebo-controlled study of weight reduction in obese patients (3/2007)		2.610benzoxazine
bay 41-8543
BAY 41-8543: structure in first source		2.0810pyrazolopyridine
u 18666a
3-beta-(2-(diethylamino)ethoxy)androst-5-en-17-one: inhibits cycloartenol synthase. 3beta-(2-diethylaminoethoxy)androst-5-en-17-one hydrochloride : A hydrochloride obtained by reaction of 3beta-(2-diethylaminoethoxy)androst-5-en-17-one with one equivalent of hydrochloric acid. It is a cholesterol synthesis and transport inhibitor.		2.8930hydrochlorideantiviral agent;
EC 1.3.1.72 (Delta(24)-sterol reductase) inhibitor;
Hedgehog signaling pathway inhibitor;
nicotinic antagonist;
sterol biosynthesis inhibitor
chir 99021
Chir 99021: structure in first source. CHIR 99021 : A member of the class of aminopyrimidines that is 2-aminopyrimidine substituted at positions N2, 5 and 6 by (5-cyanopyridin-2-yl)ethyl, 4-methylimidazol-2-yl and 2,4-dichlorophenyl groups respectively.		2.0810aminopyridine;
aminopyrimidine;
cyanopyridine;
diamine;
dichlorobenzene;
imidazoles;
secondary amino compound		EC 2.7.11.26 (tau-protein kinase) inhibitor
ym 201636
6-amino-N-(3-(4-(4-morpholinyl)pyrido(3',2'-4,5)furo(3,2-d)pyrimidin-2-yl)phenyl)-3-pyridinecarboxamide: an antiviral agent; structure in first source		2.610aromatic amide
benzyloxycarbonyl-isoleucyl-glutamyl(o-tert-butyl)-alanyl-leucinal
benzyloxycarbonyl-isoleucyl-glutamyl(O-tert-butyl)-alanyl-leucinal: inhibits chymotrypsin activity of the proteasome		2.0710
sb 525334
6-(2-tert-butyl-5-(6-methylpyridin-2-yl)-1H-imidazol-4-yl)quinoxaline: a TGF-betaR kinase inhibitor		3.0740quinoxaline derivative
aluminum oxide
Aluminum Oxide: An oxide of aluminum, occurring in nature as various minerals such as bauxite, corundum, etc. It is used as an adsorbent, desiccating agent, and catalyst, and in the manufacture of dental cements and refractories.		4.811
way-362450
[no description available]		2.0810indoles
masitinib
[no description available]		3.59201,3-thiazoles;
benzamides;
N-alkylpiperazine;
pyridines		antineoplastic agent;
antirheumatic drug;
tyrosine kinase inhibitor
bx795
BX795: structure in first source		3.0740ureas
halichondrin b
halichondrin B: from marine sponge Halichondria okadai; binds in the Vinca domain of tubulin		3.2310furopyran
linagliptin
Linagliptin: A purine and quinazoline derivative that functions as an INCRETIN and DIPEPTIDYL-PEPTIDASE IV INHIBTOR. It is used as a HYPOGLYCEMIC AGENT in the treatment of TYPE II DIABETES MELLITUS.. linagliptin : A xanthine that is 7H-xanthine bearing (4-methylquinazolin-2-yl)methyl, methyl, but-2-yn-1-yl and 3-aminopiperidin-1-yl substituents at positions 1, 3, 7 and 8 respectively (the R-enantiomer). Used for treatment of type II diabetes.		2.610aminopiperidine;
quinazolines		EC 3.4.14.5 (dipeptidyl-peptidase IV) inhibitor;
hypoglycemic agent
pazopanib
pazopanib: a protein kinase inhibitor. pazopanib : A pyrimidine that is 5-(pyrimidin-2-yl}amino-2-methylbenzenesulfonamide substituted at position 4 by a (2,3-dimethylindazol-6-yl)(methyl)amino group. Used as its hydrochloride salt for treatment of kidney cancer.		2.0810aminopyrimidine;
indazoles;
sulfonamide		angiogenesis modulating agent;
antineoplastic agent;
tyrosine kinase inhibitor;
vascular endothelial growth factor receptor antagonist
sepantronium
sepantronium: a survivin suppressant with antineoplastic activity. sepantronium : An organic cation that is 1-(2-methoxyethyl)-2-methyl-1H-naphtho[2,3-d]imidazole-4,9-dione in which the nitrogen at position 3 of the napthoimidazole moiety has been alkylated by a pyrazin-2-ylmethyl group.		2.5420organic cation
azd 6244
AZD 6244: a MEK inhibitor		3.2850benzimidazoles;
bromobenzenes;
hydroxamic acid ester;
monochlorobenzenes;
organofluorine compound;
secondary amino compound		anticoronaviral agent;
antineoplastic agent;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
odanacatib
odanacatib: a selective inhibitor of cathepsin K for the treatment of post-menopausal osteoporosis; structure in first source		2.610
1-(2-(1-adamantyl)ethyl)-1-pentyl-3-(3-(4-pyridyl)propyl)urea
1-(2-(1-adamantyl)ethyl)-1-pentyl-3-(3-(4-pyridyl)propyl)urea: structure in first source		3.0740
apilimod
[no description available]		2.610
apixaban
[no description available]		2.610aromatic ether;
lactam;
piperidones;
pyrazolopyridine		anticoagulant;
EC 3.4.21.6 (coagulation factor Xa) inhibitor
bibw 2992
[no description available]		2.2510aromatic ether;
enamide;
furans;
monochlorobenzenes;
organofluorine compound;
quinazolines;
secondary carboxamide;
tertiary amino compound		antineoplastic agent;
tyrosine kinase inhibitor
bay 61-3606
[no description available]		2.8930pyrimidines
N-(3-cyanophenyl)-2'-methyl-5'-(5-methyl-1,3,4-oxadiazol-2-yl)biphenyl-4-carboxamide
N-(3-cyanophenyl)-2'-methyl-5'-(5-methyl-1,3,4-oxadiazol-2-yl)biphenyl-4-carboxamide : A member of the class of biphenyls that is the amide obtained by formal condensation of the carboxy group of 2'-methyl-5'-(5-methyl-1,3,4-oxadiazol-2-yl)[1,1'-biphenyl]-4-carboxylic acid with the amino group of 3-cyanoaniline.		2.08101,3,4-oxadiazoles;
benzamides;
biphenyls;
nitrile		EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
ar c155858
AR C155858: an MCT1 inhibitor; structure in first source		2.0810
betrixaban
betrixaban: a highly potent, selective, and orally efficacious factor Xa inhibitor; structure in first source. betrixaban : A secondary carboxamide obtained by formal condensation of the carboxy group of 4-(N,N-dimethylcarbamimidoyl)benzoic acid with the amino group of 2-amino-N-(5-chloropyridin-2-yl)-5-methoxybenzamide. A synthetic anticoagulant compound that targets activated factor Xa in the coagulation cascade.		2.610benzamides;
guanidines;
monochloropyridine;
monomethoxybenzene;
secondary carboxamide		anticoagulant;
EC 3.4.21.6 (coagulation factor Xa) inhibitor
edoxaban
edoxaban : A monocarboxylic acid amide that is used (as its tosylate monohydrate) for the treatment of deep vein thrombosis and pulmonary embolism.		2.610chloropyridine;
monocarboxylic acid amide;
tertiary amino compound;
thiazolopyridine		anticoagulant;
EC 3.4.21.6 (coagulation factor Xa) inhibitor;
platelet aggregation inhibitor
aee 788
AEE 788: structure in first source		2.08106-{4-[(4-ethylpiperazin-1-yl)methyl]phenyl}-N-(1-phenylethyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amineangiogenesis inhibitor;
antineoplastic agent;
apoptosis inducer;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
epidermal growth factor receptor antagonist;
trypanocidal drug
saracatinib
[no description available]		2.5820aromatic ether;
benzodioxoles;
diether;
N-methylpiperazine;
organochlorine compound;
oxanes;
quinazolines;
secondary amino compound		anticoronaviral agent;
antineoplastic agent;
apoptosis inducer;
autophagy inducer;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor;
radiosensitizing agent
sd-208
[no description available]		3.0740
ko 143
[no description available]		2.3110beta-carbolines;
tert-butyl ester
n-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide
boceprevir : A synthetic tripeptide consisting of N-(tert-butylcarbamoyl)-3-methyl-L-valyl, a cyclopropyl-fused prolyl and 3-amino-4-cyclobutyl-2-oxobutanamide residues joined in sequence. Used for treatment of chronic hepatitis C virus genotype 1 infection.		2.610tripeptide;
ureas		antiviral drug;
hepatitis C protease inhibitor;
peptidomimetic
vx 702
VX 702: a p38 MAP kinase inhibitor		2.0810phenylpyridine
crenolanib
[no description available]		2.8930aminopiperidine;
aromatic ether;
benzimidazoles;
oxetanes;
quinolines;
tertiary amino compound		angiogenesis inhibitor;
antineoplastic agent;
apoptosis inducer;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
cj 033466
CJ 033466: structure in first source		2.8930
cc 401
CC 401: an anthrapyrazolone		2.8930pyrazoles;
ring assembly
ly 411575
[no description available]		2.610dibenzoazepine;
difluorobenzene;
lactam;
secondary alcohol		EC 3.4.23.46 (memapsin 2) inhibitor
galidesivir
[no description available]		2.610
volasertib
BI 6727: a polo-like kinase inhibitor with broad antitumor activity; structure in first source		2.0810
PB28
PB28 : A member of the class of tetralins that is tetralin that is substituted by 3-(4-cyclohexylpiperazin-1-yl)propyl and methoxy groups at positions 1 and 5, respectively. It is a sigma 2 (sigma2) receptor agonist (Ki = 0.68 nM) and exhibits antineoplastic and anti SARS-CoV-2 activities.		3.2850aromatic ether;
piperazines;
tetralins		anticoronaviral agent;
antineoplastic agent;
apoptosis inducer;
sigma-2 receptor agonist
arterolane
arterolane: a trioxolane with antimalarial activity; structure in first source. arterolane : An oxaspiro compound that is dispiro[cyclohexane-1,3'-[1,2,4]trioxolane-5',2''-tricyclo[3.3.1.1(3,7)]decane] substituted by a 2-[(2-amino-2-methylpropyl)amino]-2-oxoethyl group at position 4s. Its maleic acid salt is used as an antimalarial drug in combination with piperaquine.		2.8930
belactosin c
belactosin C: isolated from Streptomyces; structure in first source		2.1110
azd 7762
[no description available]		2.0810aromatic amide;
thiophenes
cariprazine
cariprazine: Structure in first source. cariprazine : An N-alkylpiperazine that is N,N-dimethyl-N'-{trans-4-[2-(piperazin-1-yl)ethyl]cyclohexyl}urea substituted at position 4 on the piperazine ring by a 2,3-dichlorophenyl group. Used (as the hydrochloride salt) for treatment of schizophrenia and bipolar disorder.		2.8930
krp-203
[no description available]		3.0740
mk 0354
[no description available]		2.0810
regorafenib
[no description available]		3.0740(trifluoromethyl)benzenes;
aromatic ether;
monochlorobenzenes;
monofluorobenzenes;
phenylureas;
pyridinecarboxamide		antineoplastic agent;
hepatotoxic agent;
tyrosine kinase inhibitor
at 7867
[no description available]		2.8930monochlorobenzenes;
piperidines;
pyrazoles		antineoplastic agent;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor
acetic acid 2-[4-methyl-8-(4-morpholinylsulfonyl)-1,3-dioxo-2-pyrrolo[3,4-c]quinolinyl]ethyl ester
[no description available]		3.0740pyrroloquinoline
6-[[5-fluoro-2-(3,4,5-trimethoxyanilino)-4-pyrimidinyl]amino]-2,2-dimethyl-4H-pyrido[3,2-b][1,4]oxazin-3-one
[no description available]		2.0810methoxybenzenes;
substituted aniline
ptc 124
[no description available]		2.8930oxadiazole;
ring assembly
degrasyn
degrasyn: a JAK2 kinase inhibitor that induces rapid degradation of c-Myc protein in MM-1 multiple myeloma and other tumor cell lines; structure in first source		2.9830
epoxomicin
[no description available]		10.570morpholines;
tripeptide		proteasome inhibitor
brivanib
[no description available]		2.0810aromatic ether;
diether;
fluoroindole;
pyrrolotriazine;
secondary alcohol		angiogenesis inhibitor;
antineoplastic agent;
apoptosis inducer;
drug metabolite;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
fibroblast growth factor receptor antagonist
icg 001
[no description available]		2.0810peptide
bms 477118
[no description available]		2.610adamantanes;
azabicycloalkane;
monocarboxylic acid amide;
nitrile;
tertiary alcohol		EC 3.4.14.5 (dipeptidyl-peptidase IV) inhibitor;
hypoglycemic agent
pha 680632
PHA 680632: Aurora kinase inhibitor with potent antitumoral activity; structure in first source		2.610
tmc 353121
[no description available]		2.610
amd 070
mavorixafor: a derivative of AMD3100; a CXCR4 blocker		2.610aminoquinoline
mp470
[no description available]		2.0810N-arylpiperazine
danoprevir
[no description available]		2.610
bms-626529
[no description available]		2.610
bms-663068
fostemsavir: an HIV-1 attachment inhibitor; structure in first source		2.610
nu 7441
8-dibenzothiophen-4-yl-2-morpholin-4-yl-chromen-4-one: structure in first source		2.0810dibenzothiophenes
at 7519
4-(2,6-dichlorobenzamido)-N-(piperidin-4-yl)-pyrazole-3-carboxamide : A member of the class of pryrazoles that is 4-amino-1H-pyrazole-3-carboxylic acid in which the primary amino group has been acylated by a 2,6-dichlorobenzoyl group and in which the carboxylic acid has been converted into a carboxamide by formal condensation with the primary amino group of 4-aminopiperidine.		2.0810dichlorobenzene;
piperidines;
pyrazoles;
secondary carboxamide		antineoplastic agent;
EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
marizomib
marizomib: a proteasome inhibitor from a marine bacterium Salinospora; structure in first source		8.29160beta-lactone;
gamma-lactam;
organic heterobicyclic compound;
organochlorine compound;
salinosporamide		antineoplastic agent;
proteasome inhibitor
er-086526
eribulin: a halichondrin B derivative that suppresses microtubule growth and acts as an antimitotic agent; structure in first source. eribulin : A fully synthetic macrocyclic ketone analogue of marine sponge natural products. Inhibits growth phase of microtubules via tubulin-based antimitotic mechanism, which leads to G2/M cell-cycle block, disruption of mitotic spindles, and, ultimately, apoptotic cell death after prolonged mitotic blockage		3.2310cyclic ketal;
cyclic ketone;
macrocycle;
polycyclic ether;
polyether;
primary amino compound		antineoplastic agent;
microtubule-destabilising agent
bi 2536
[no description available]		3.0740
amenamevir
ASP2151: a herpesvirus helicase-primase inhibitor, in a guinea pig model of genital herpes; structure in first source		2.610
vx 765
belnacasan: a NSAID		2.610dipeptide
Dihydrotanshinone I
dihydrotanshinone I: extracted from Radix Salviae		2.610abietane diterpenoidanticoronaviral agent
danusertib
[no description available]		2.0810piperazines
alogliptin
alogliptin: structure in first source. alogliptin : A piperidine that is 3-methyl-2,4-dioxo-3,4-dihydropyrimidine carrying additional 2-cyanobenzyl and 3-aminopiperidin-1-yl groups at positions 1 and 2 respectively (the R-enantiomer). Used in the form of its benzoate salt for treatment of type 2 diabetes.		2.610nitrile;
piperidines;
primary amino compound;
pyrimidines		EC 3.4.14.5 (dipeptidyl-peptidase IV) inhibitor;
hypoglycemic agent
N-[4-(2-tert-butylphenyl)sulfonylphenyl]-2,3,4-trihydroxy-5-[(2-propan-2-ylphenyl)methyl]benzamide
[no description available]		2.0810benzamides
N-[5-[[5-[(4-acetyl-1-piperazinyl)-oxomethyl]-4-methoxy-2-methylphenyl]thio]-2-thiazolyl]-4-[(3,3-dimethylbutan-2-ylamino)methyl]benzamide
[no description available]		2.0810benzamides
abt 869
[no description available]		2.0810aromatic amine;
indazoles;
phenylureas		angiogenesis inhibitor;
antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
fr 180204
FR 180204: structure in first source		2.610pyrazoles;
ring assembly
azd 1152
AZD-1152 : A member of the of quinazolines that is 4-aminoquinazolin-7-ol in which the amino group at position 4 has been substituted by a 5-[2-(3-fluoroanilino)-2-oxoethyl]-1H-pyrazol-3-yl group, while the hydroxy group at position 7 has been converted into the corresponding 3-[ethyl(2-hydroxyethyl)aminopropyl ether.		2.8930anilide;
monoalkyl phosphate;
monofluorobenzenes;
pyrazoles;
quinazolines;
secondary amino compound;
secondary carboxamide;
tertiary amino compound		antineoplastic agent;
Aurora kinase inhibitor;
prodrug
dorsomorphin
dorsomorphin: an AMPK inhibitor. dorsomorphin : A pyrazolopyrimidine that is pyrazolo[1,5-a]pyrimidine which is substituted at positions 3 and 6 by pyridin-4-yl and p-[2-(piperidin-1-yl)ethoxy]phenyl groups, respectively. It is a potent, selective, reversible, and ATP-competitive inhibitor of AMPK (AMP-activated protein kinase, EC 2.7.11.31) and a selective inhibitor of bone morphogenetic protein (BMP) signaling.		2.0810aromatic ether;
piperidines;
pyrazolopyrimidine;
pyridines		bone morphogenetic protein receptor antagonist;
EC 2.7.11.31 {[hydroxymethylglutaryl-CoA reductase (NADPH)] kinase} inhibitor
ac 261066
[no description available]		2.0810
quisinostat
[no description available]		2.610indoles
monomethyl auristatin e
[no description available]		2.2110
hcv 796
HCV 796: inhibits HCV RdRp; structure in first source		2.610
apremilast
[no description available]		2.5720aromatic ether;
N-acetylarylamine;
phthalimides;
sulfone		non-steroidal anti-inflammatory drug;
phosphodiesterase IV inhibitor
gw9508
GW9508: structure in first source		2.0810aromatic amine
jnj 26854165
[no description available]		2.0810
resminostat
resminostat: a histone deacetylase inhibitor; structure in first source		2.610
pf 573228
6-(4-(3-(methylsulfonyl)benzylamino)-5-(trifluoromethyl)pyrimidin-2-ylamino)-3,4-dihydroquinolin-2(1H)-one: structure in first source		2.0810quinolines
gw 2580
5-(3-methoxy-4-((4-methoxybenzyl)oxy)benzyl)pyrimidine-2,4-diamine: a cFMS kinase inhibitor; structure in first source		2.0810
idelalisib
idelalisib: an antineoplastic agent and p110delta inhibitor; structure in first source. idelalisib : A member of the class of quinazolines that is 5-fluoro-3-phenylquinazolin-4-one in which the hydrogen at position 2 is replaced by a (1S)-1-(3H-purin-6-ylamino)propyl group. used for for the treatment of refractory indolent non-Hodgkin's lymphoma and relapsed chronic lymphocytic leukemia.		3.0740aromatic amine;
organofluorine compound;
purines;
quinazolines;
secondary amino compound		antineoplastic agent;
apoptosis inducer;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor
crizotinib
Crizotinib: A piperidine and aminopyridine derivative that acts as an inhibitor of RECEPTOR PROTEIN-TYROSINE KINASES, including ANAPLASTIC LYMPHOMA KINASE (ALK) and HEPATOCYTE GROWTH FACTOR RECEPTOR (HGFR; c-Met). It is used in the treatment of NON-SMALL CELL LUNG CANCER.. crizotinib : A 3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[1-(piperidin-4-yl)pyrazol-4-yl]pyridin-2-amine that has R configuration at the chiral centre. The active enantiomer, it acts as a kinase inhibitor and is used for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC)		3.6203-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[1-(piperidin-4-yl)pyrazol-4-yl]pyridin-2-amineantineoplastic agent;
biomarker;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
5-(5,6-dimethoxy-1-benzimidazolyl)-3-[(2-methylsulfonylphenyl)methoxy]-2-thiophenecarbonitrile
[no description available]		2.0810benzimidazoles
4-[2-(2-chloro-4-fluoroanilino)-5-methyl-4-pyrimidinyl]-N-[(1S)-1-(3-chlorophenyl)-2-hydroxyethyl]-1H-pyrrole-2-carboxamide
Vx-11e: ERK1-2 inhibitor		2.0810aromatic amide;
heteroarene
osi 906
[no description available]		2.0810cyclobutanes;
quinolines
protoapigenone
protoapigenone: has antineoplastic activity; isolated from Thelypteris torresiana; structure in first source		3.2710
ly2109761
[no description available]		2.0810
chir-265
[no description available]		2.0810aromatic ether
motesanib
[no description available]		3.0740pyridinecarboxamide
az-628
AZ-628: a multikinase inhibitor; structure in first source		2.0810benzamides
zk 756326
2-(2-(4-(3-phenoxybenzyl)piperazin-1-yl)ethoxy)ethanol: a CC chemokine receptor CCR8 agonist; structure in first source		2.610aromatic ether
balapiravir
balapiravir: a prodrug of R1479; structure in first source		2.610
trametinib
[no description available]		2.5820acetamides;
aromatic amine;
cyclopropanes;
organofluorine compound;
organoiodine compound;
pyridopyrimidine;
ring assembly		anticoronaviral agent;
antineoplastic agent;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor;
geroprotector
pf-562,271
[no description available]		3.0740indoles
gliocladin c
gliocladin C: structure in first source		2.8930
deoxyarbutin
4-((tetrahydro-2H-pyran-2-yl)oxy)phenol: has antineoplastic activity; structure in first source		2.610
abexinostat
abexinostat: structure in first source		2.610benzofurans
silvestrol
silvestrol: isolated from the fruit and twig of Aglaia silvestris. silvestrol : An organic heterotricyclic compound that consists of a 2,3,3a,8b-tetrahydro-H-benzo[b]cyclopenta[d]furan framework substituted by hydroxy groups at positions C-1 and C-8b, a methoxycarbonyl group at C-2, a phenyl group at C-3, a 4-methoxyphenyl group at C-3a, a methoxy group at C-8 and a 1,4-dioxan-2-yloxy group at position C-6 which in turn is substituted by a methoxy group at position 3 and a 1,2-dihydroxyethyl group at position 6. Isolated from Aglaia silvestris, it exhibits antineoplastic activity.		2.610dioxanes;
ether;
methyl ester;
organic heterotricyclic compound		antineoplastic agent;
metabolite
sb 706504
[no description available]		2.8930
narlaprevir
narlaprevir: an antiviral agent that inhibits hepatitis C virus NS3 protease. narlaprevir : An azabicyclohexane that is (1R,5S)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane substituted by [(3S)-1-(cyclopropylamino)-1,2-dioxoheptan-3-yl]aminoacyl and N-({1-[(tert-butylsulfonyl)methyl]cyclohexyl}carbamoyl)-3-methyl-L-valyl groups at positions 2S and 3, respectively. It is a hepatitis C virus (HCV) NS3/4A serine protease inhibitor (Ki = 6 nM) that is used for the treatment of chronic hepatitis C.		2.610azabicyclohexane;
cyclopropanes;
pyrrolidinecarboxamide;
secondary carboxamide;
sulfone;
tertiary carboxamide;
ureas		anticoronaviral agent;
antiviral drug;
EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor;
hepatitis C protease inhibitor
empagliflozin
[no description available]		4.811aromatic ether;
C-glycosyl compound;
monochlorobenzenes;
tetrahydrofuryl ether		hypoglycemic agent;
sodium-glucose transport protein subtype 2 inhibitor
teneligliptin
[no description available]		2.610amino acid amide
dextrothyroxine
[no description available]		2.610
veliparib
[no description available]		2.5820benzimidazolesEC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor
ku-0060648
[no description available]		3.0740dibenzothiophenes
dactolisib
dactolisib: antineoplastic agent that inhibits both phosphatidylinositol 3-kinase and mTOR. dactolisib : An imidazoquinoline that is 3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]quinoline substituted at position 1 by a 4-(1-cyanoisopropyl)phenyl group and at position 8 by a quinolin-3-yl group. A dual PI3K/mTOR inhibitor used in cancer treatment.		2.0810imidazoquinoline;
nitrile;
quinolines;
ring assembly;
ureas		antineoplastic agent;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor;
mTOR inhibitor
bgt226
BGT226 free base : An imidazoquinoline that is 3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]quinoline substituted at position 1 by a 3-trifluoromethyl-4-(piperazin-1-yl)phenyl group and at position 8 by a 6-methoxypyridin-3-yl group. A dual PI3K/mTOR inhibitor.. BGT226 : The maleate salt of 8-(6-methoxypyridin-3-yl)-3-methyl-1-[4-(piperazin-1-yl)-3-(trifluoromethyl)phenyl]-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one. A dual PI3K/mTOR inhibitor.		2.8930aromatic ether;
imidazoquinoline;
N-arylpiperazine;
organofluorine compound;
pyridines		antineoplastic agent;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor;
mTOR inhibitor
palomid 529
[no description available]		2.0810
pf 03491390
[no description available]		2.610
alloin
[no description available]		2.610anthracenes;
C-glycosyl compound;
cyclic ketone;
phenols		laxative;
metabolite
n-desmethyldanofloxacin
N-desmethyldanofloxacin: structure given in first source		2.8930
rabeprazole sodium
[no description available]		2.1510organic sodium salt
tosedostat
[no description available]		2.0810carboxylic ester;
hydroxamic acid;
secondary carboxamide
nad
NAD(1-) : An anionic form of nicotinamide adenine dinucleotide arising from deprotonation of the two OH groups of the diphosphate moiety.		7.4110organophosphate oxoanioncofactor;
human metabolite;
hydrogen acceptor;
Saccharomyces cerevisiae metabolite
rrx-001
RRx-001: has antineoplastic activity; structure in first source		3.5110
mdv 3100
[no description available]		2.5820(trifluoromethyl)benzenes;
benzamides;
imidazolidinone;
monofluorobenzenes;
nitrile;
thiocarbonyl compound		androgen antagonist;
antineoplastic agent
ku 60019
[no description available]		2.0810
gsk 461364
GSK 461364: an antineoplastic agent that inhibits polo-like kinase 1		2.0810(trifluoromethyl)benzenes
n-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide
N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide: a MEK inhibitor; structure in first source		2.0810
azd 1152-hqpa
AZD2811: has antineoplastic activity; structure in first source		2.6320anilide;
monofluorobenzenes;
primary alcohol;
pyrazoles;
quinazolines;
secondary amino compound;
secondary carboxamide;
tertiary amino compound		antineoplastic agent;
Aurora kinase inhibitor
CDN1163
CDN1163: a SERCA2 activator with antidiabetic activity; structure in first source. CDN1163 : A secondary carboxamide resulting from the formal condensation of the carboxy group of 4-isopropoxybenzoic acid with the primary amino group of 2-methylquinolin-8-amine. An allosteric activator of sarco/endoplasmic reticulum Ca(2+)-ATPase (SERCA).		2.8930aromatic ether;
quinolines;
secondary carboxamide		SERCA activator
nvp-tae684
[no description available]		2.0810piperidines
bms-650032
asunaprevir: an NS3 protease inhibitor against hepatitis C virus		2.610oligopeptide
4-methyl-3-(2-(2-morpholinoethylamino)quinazolin-6-yl)-n-(3-(trifluoromethyl)phenyl)benzamide
4-methyl-3-(2-(2-morpholinoethylamino)quinazolin-6-yl)-N-(3-(trifluoromethyl)phenyl)benzamide: structure in first source		2.0810
gsk 269962a
[no description available]		3.0740
rg 7128
2'-fluoro-2'-methyl-3',5'-diisobutyryldeoxycytidine: inhibits HCV polymerase; structure in first source		2.610
tannins
Tannins: Polyphenolic compounds with molecular weights of around 500-3000 daltons and containing enough hydroxyl groups (1-2 per 100 MW) for effective cross linking of other compounds (ASTRINGENTS). The two main types are HYDROLYZABLE TANNINS and CONDENSED TANNINS. Historically, the term has applied to many compounds and plant extracts able to render skin COLLAGEN impervious to degradation. The word tannin derives from the Celtic word for OAK TREE which was used for leather processing.		2.2110
oritavancin
oritavancin : A semisynthetic glycopeptide used (as its bisphosphate salt) for the treatment of acute bacterial skin and skin structure infections caused or suspected to be caused by susceptible isolates of designated Gram-positive microorganisms including MRSA.		2.610disaccharide derivative;
glycopeptide;
semisynthetic derivative		antibacterial drug;
antimicrobial agent
ctce-9908
CTCE-9908: antineoplastic; a small peptide CXCR4 antagonist		3.2310
cellulose
DEAE-Cellulose: Cellulose derivative used in chromatography, as ion-exchange material, and for various industrial applications.		4.811glycoside
a-83-01
A-83-01: an ALK-5 inhibitor; structure in first source		2.0810
3-[(1-methyl-3-indolyl)methylidene]-1H-pyrrolo[3,2-b]pyridin-2-one
[no description available]		2.0810indoles
vx-770
ivacaftor: a CFTR potentiator; structure in first source. ivacaftor : An aromatic amide obtained by formal condensation of the carboxy group of 4-oxo-1,4-dihydroquinoline-3-carboxylic acid with the amino group of 5-amino-2,4-di-tert-butylphenol. Used for the treatment of cystic fibrosis.		2.0810aromatic amide;
monocarboxylic acid amide;
phenols;
quinolone		CFTR potentiator;
orphan drug
buparlisib
NVP-BKM120: a pan class I PI3 kinase inhibitor with antineoplastic activity; structure in first source		2.0810aminopyridine;
aminopyrimidine;
morpholines;
organofluorine compound		antineoplastic agent;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor
azd 1480
[no description available]		2.0810
pha 848125
N,1,4,4-tetramethyl-8-((4-(4-methylpiperazin-1-yl)phenyl)amino)-4,5-dihydro-1H-pyrazolo(4,3-h)quinazoline-3-carboxamide: a cyclin dependent kinase inhibitor		2.8930
pevonedistat
pevonedistat: a potent and selective inhibitor of NAE (NEDD8-activating enzyme). pevonedistat : A pyrrolopyrimidine that is 7H-pyrrolo[2,3-d]pyrimidine which is substituted by a (1S)-2,3-dihydro-1H-inden-1-ylnitrilo group at position 4 and by a (1S,3S,4S)-3-hydroxy-4-[(sulfamoyloxy)methyl]cyclopentyl group at position 7. It is a potent and selective NEDD8-activating enzyme inhibitor with an IC50 of 4.7 nM, and currently under clinical investigation for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndromes.		4.3340cyclopentanols;
indanes;
pyrrolopyrimidine;
secondary amino compound;
sulfamidate		antineoplastic agent;
apoptosis inducer
fedratinib
fedratinib: a selective small-molecule inhibitor of JAK2		2.0810sulfonamide
gsk690693
[no description available]		2.08101,2,5-oxadiazole;
acetylenic compound;
aromatic amine;
aromatic ether;
imidazopyridine;
piperidines;
primary amino compound;
tertiary alcohol		antineoplastic agent;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor
cnf 2024
[no description available]		2.08102-aminopurines;
aromatic ether;
organochlorine compound;
pyridines		antineoplastic agent;
Hsp90 inhibitor
ku 0063794
Ku 0063794: an mTOR inhibitor; structure in first source		2.0810benzyl alcohols;
monomethoxybenzene;
morpholines;
pyridopyrimidine;
tertiary amino compound		antineoplastic agent;
mTOR inhibitor
uk 453,061
UK 453,061: a reverse transcriptase inhibitor/anti-HIV agent; structure in first source		2.610aromatic ether
14-methyl-20-oxa-5,7,14,26-tetraazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaene
14-methyl-20-oxa-5,7,14,26-tetraazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaene: has antineoplastic activity; also inhibits Fms-like tyrosine kinase-3; structure in first source		2.1310
azd 7545
AZD 7545: an anilide tertiary carbinol; a pyruvate dehydrogenase kinase 2 inhibitor. AZD7545 : A sulfone that is benzene substituted by [4-(dimethylcarbamoyl)phenyl]sulfonyl, chloro and [(2R)-3,3,3-trifluoro-2-hydroxy-2-methylpropanoyl]amino groups at positions 1, 3 and 4, respectively. It is a potent and non-ATP-competitive inhibitor of pyruvate dehydrogenase kinase 2 (PDHK2) with IC50 of 6.4 nM and exhibits glucose-lowering activity. Also inhibits PDHK1 at higher levels (IC50 = 36.8 nM).		2.0810benzamides;
monochlorobenzenes;
organofluorine compound;
secondary carboxamide;
sulfone;
tertiary alcohol;
tertiary carboxamide		EC 2.7.11.2 - [pyruvate dehydrogenase (acetyl-transferring)] kinase inhibitor;
hypoglycemic agent
nvp-bhg712
[no description available]		2.8930benzamides
nutlin-3b
[no description available]		2.0810Nutlin;
piperazinone		anticoronaviral agent
boc-d-fmk
Boc-D-FMK: Caspase inhibitor and neuroprotective agent		2.0810
N-(2-aminophenyl)-2-pyrazinecarboxamide
[no description available]		2.610aromatic amide
pf 04217903
[no description available]		3.0740quinolines
gdc 0941
pictrelisib : A sulfonamide composed of indazole, morpholine, and methylsulfonyl-substituted piperazine rings bound to a thienopyrimidine ring.		2.0810indazoles;
morpholines;
piperazines;
sulfonamide;
thienopyrimidine		EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor
sm 164
SM 164: a bivalent Smac mimetic with antineoplastic activity; structure in first source		2.0810benzenes;
organic heterobicyclic compound;
secondary carboxamide;
triazoles		antineoplastic agent;
apoptosis inducer;
radiosensitizing agent
calpain
Calpain: Cysteine proteinase found in many tissues. Hydrolyzes a variety of endogenous proteins including NEUROPEPTIDES; CYTOSKELETAL PROTEINS; proteins from SMOOTH MUSCLE; CARDIAC MUSCLE; liver; platelets; and erythrocytes. Two subclasses having high and low calcium sensitivity are known. Removes Z-discs and M-lines from myofibrils. Activates phosphorylase kinase and cyclic nucleotide-independent protein kinase. This enzyme was formerly listed as EC 3.4.22.4.		2.2510
5-[[4-(4-acetylphenyl)-1-piperazinyl]sulfonyl]-1,3-dihydroindol-2-one
[no description available]		2.8930aromatic ketone
ph 797804
PH 797804: an NSAID; structure in first source. PH 797804 : A member of the class of benzamides obtained by formal condensation of the carboxy group of 3-{3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxopyridin-1-yl}-4-methylbenzoic acid with the amino group of methylamine.		3.0740aromatic ether;
benzamides;
organobromine compound;
organofluorine compound;
pyridone		anti-inflammatory agent;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
pha 408
PHA 408: an IKK-2 antagonist; structure in first source		2.0810
gsk 1016790a
GSK1016790A : A tertiary carboxamide that is piperazine in which one of the amino groups has undergone condensation with the carboxy group of N-[(2,4-dichlorophenyl)sulfonyl]-L-serine, while the other has undergone condensation with the carboxy group of N-(1-benzothiophen-2-ylcarbonyl)-L-leucine. It is a cell-permeable, potent and selective agonist of the TRPV4 (transient receptor potential vanilloid 4) channel.		2.08101-benzothiophenes;
aromatic primary alcohol;
dichlorobenzene;
N-acylpiperazine;
sulfonamide;
tertiary carboxamide		TRPV4 agonist
pr-957
[no description available]		2.5320
tegobuvir
tegobuvir: a non-structural protein 5B polymerase inhibitor		2.610
pf-429242
PF-429242: a subtilisin kexin isozyme-1/site-1 protease inhibitor		2.610
deoxycholic acid, monosodium salt
[no description available]		3.2710bile acid salt
chiniofon
Hydroxyquinolines: The 8-hydroxy derivatives inhibit various enzymes and their halogenated derivatives, though neurotoxic, are used as topical anti-infective agents, among other uses.		3.1610
arginine
Teniposide: A semisynthetic derivative of PODOPHYLLOTOXIN that exhibits antitumor activity. Teniposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent cells from entering into the mitotic phase of the cell cycle, and lead to cell death. Teniposide acts primarily in the G2 and S phases of the cycle.. teniposide : A furonaphthodioxole that is a synthetic derivative of podophyllotoxin with anti-tumour activity; causes single- and double-stranded breaks in DNA and DNA-protein cross-links and prevents repair by topoisomerase II binding.		2.110
olaparib
[no description available]		2.5820cyclopropanes;
monofluorobenzenes;
N-acylpiperazine;
phthalazines		antineoplastic agent;
apoptosis inducer;
EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor
srt1720
[no description available]		3.0740
plx 4720
PLX 4720: a B-Raf(V600E) kinase inhibitor; structure in first source		2.0810aromatic ketone;
difluorobenzene;
organochlorine compound;
pyrrolopyridine;
sulfonamide		antineoplastic agent;
B-Raf inhibitor
lcl161
[no description available]		2.17101,3-thiazoles;
aromatic ketone;
L-alanine derivative;
monofluorobenzenes;
N-acylpyrrolidine		antineoplastic agent;
apoptosis inducer
cx 4945
[no description available]		2.5820
pci 34051
PCI 34051: an HDAC8 inhibitor		2.610indolecarboxamide
cudc 101
7-(4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide: a histone deacetylase inhibitor; structure in first source		2.5120
purfalcamine
purfalcamine: a PfCDPK-1 inhibitor; structure in first source		2.8930
mln 8237
MLN 8237: an aurora kinase A inhibitor		2.0810benzazepine
lde225
sonidegib: specific Smoothened/Smo antagonist. sonidegib : A member of the classo of biphenyls that is the amide obtained by formal condensation of the carboxy group of 2-methyl-4'-(trifluoromethoxy)[1,1'-biphenyl]-3-carboxylic acid with the amino group of 6-(2,6-dimethylmorpholin-4-yl)pyridin-3-amine. Used (as its phosphate salt) for treatment of locally advanced basal cell carcinoma.		2.0810aminopyridine;
aromatic ether;
benzamides;
biphenyls;
morpholines;
organofluorine compound;
tertiary amino compound		antineoplastic agent;
Hedgehog signaling pathway inhibitor;
SMO receptor antagonist
gdc 0449
HhAntag691: inhibits the hedgehog pathway and ABC transporters; has antineoplastic activity		2.4920benzamides;
monochlorobenzenes;
pyridines;
sulfone		antineoplastic agent;
Hedgehog signaling pathway inhibitor;
SMO receptor antagonist;
teratogenic agent
sgx 523
[no description available]		2.0810aryl sulfide;
biaryl;
pyrazoles;
quinolines;
triazolopyridazine		c-Met tyrosine kinase inhibitor;
nephrotoxic agent
bms 754807
BMS 754807: an IGR-1R kinase inhibitor; structure in first source		2.8930pyrazoles;
pyridines;
pyrrolidines;
pyrrolotriazine		antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
bms 777607
N-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide: a Met kinase inhibitor; structure in first source		2.0810aromatic amide
sgi 1776
SGI 1776: a Pim kinase inhibitor; structure in first source		2.0810imidazoles
lomibuvir
lomibuvir: an antiviral agent with polymerase NS5 inhibitory activity		2.610thiophenecarboxylic acid
delanzomib
[no description available]		6.7140C-terminal boronic acid peptide;
phenylpyridine;
secondary alcohol;
threonine derivative		antineoplastic agent;
apoptosis inducer;
proteasome inhibitor
canagliflozin
canagliflozin hydrate : A hydrate that is the hemihydrate form of canagliflozin. Used for treatment of type II diabetes via inhibition of sodium-glucose transport protein subtype 2.		7.610C-glycosyl compound;
organofluorine compound;
thiophenes		hypoglycemic agent;
sodium-glucose transport protein subtype 2 inhibitor
pci 32765
ibrutinib: a Btk protein inhibitor. ibrutinib : A member of the class of acrylamides that is (3R)-3-[4-amino-3-(4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine in which the piperidine nitrogen is replaced by an acryloyl group. A selective and covalent inhibitor of the enzyme Bruton's tyrosine kinase, it is used for treatment of B-cell malignancies.		6.25113acrylamides;
aromatic amine;
aromatic ether;
N-acylpiperidine;
pyrazolopyrimidine;
tertiary carboxamide		antineoplastic agent;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor
ponatinib
[no description available]		3.0740(trifluoromethyl)benzenes;
acetylenic compound;
benzamides;
imidazopyridazine;
N-methylpiperazine		antineoplastic agent;
tyrosine kinase inhibitor
pitavastatin(1-)
pitavastatin(1-) : A hydroxy monocarboxylic acid anion that is the conjugate base of pitavastatin, obtained by deprotonation of the carboxy group.		2.610hydroxy monocarboxylic acid anion
amg 900
N-(4-((3-(2-amino-4-pyrimidinyl)-2-pyridinyl)oxy)phenyl)-4-(4-methyl-2-thienyl)-1-phthalazinamine: a pan-aurora kinase inhibitor; structure in first source		2.0810
mk-1775
adavosertib: a Wee1 kinase inhibitor; structure in first source		3.6620piperazines
bag956
BAG956: an imidazo[4,5-c]quinoline; dual PI3K/PDK-1 inhibitor, used in antileukemic therapies		2.0810
quizartinib
[no description available]		3.0740benzoimidazothiazole;
isoxazoles;
morpholines;
phenylureas		antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
necroptosis inhibitor
PP121
[no description available]		2.8930aromatic amine;
cyclopentanes;
pyrazolopyrimidine;
pyrrolopyridine		antineoplastic agent;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor;
tyrosine kinase inhibitor
GRL-0617
GRL-0617 : A benzamide resulting from the formal condensation of the carboxy group of 5-amino-2-methylbenzoic acid with the amino group of (1R)-1-(naphthalen-1-yl)ethan-1-amine. It is a potent noncovalent inhibitor (IC50 = 600 nM) of severe acute respiratory syndrome-coronavirus papain-like protease (SARS-CoV PLpro).		2.610benzamides;
naphthalenes;
secondary carboxamide;
substituted aniline		anticoronaviral agent;
protease inhibitor
N-[4-[3-[[[7-(hydroxyamino)-7-oxoheptyl]amino]-oxomethyl]-5-isoxazolyl]phenyl]carbamic acid tert-butyl ester
CAY10603: a HDAC6 inhibitor		2.5820carbamate ester
niraparib
niraparib: structure in first source. niraparib : A 2-[4-(piperidin-3-yl)phenyl]-2H-indazole-7-carboxamide that has S-configuration. It is a potent inhibitor of PARP1 and PARP2 (IC50 of 3.8 and 2.1 nM, respectively) and approved as a first-line maintenance treatment for women with advanced ovarian cancer after responding to platinum-based chemotherapy.		5.3212-[4-(piperidin-3-yl)phenyl]-2H-indazole-7-carboxamideantineoplastic agent;
apoptosis inducer;
EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor;
radiosensitizing agent
tak 733
[no description available]		2.0810
mk 2206
MK 2206: a protein kinase inhibitor and antineoplastic agent		2.0810organic heterotricyclic compoundEC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor
navitoclax
[no description available]		3.460aryl sulfide;
monochlorobenzenes;
morpholines;
N-sulfonylcarboxamide;
organofluorine compound;
piperazines;
secondary amino compound;
sulfone;
tertiary amino compound		antineoplastic agent;
apoptosis inducer;
B-cell lymphoma 2 inhibitor
sns 314
SNS 314: an aurora kinase inhibitor; structure in first source		2.0810ureas
jzl 184
JZL 184: inhibits monoacylglycerol lipase; structure in first source		2.5820benzodioxoles
gsk 650394
[no description available]		3.1640phenylpyridine
belactosin a
belactosin A: isolated from Streptomyces; structure in first source		2.7930
n-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide
N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide: a Janus kinase 1 and Janus kinase 2 inhibitor; structure in first source. momelotinib : A benzamide obtained by formal condensation of the carboxy group of 4-{2-[4-(morpholin-4-yl)anilino]pyrimidin-4-yl}benzoic acid with the primary amino group of aminoacetonitrile. It is an ATP-competitive JAK1/JAK2 inhibitor with IC50 of 11 nM and 18 nM, respectively. Used for the treatment of patients with intermediate- or high-risk myelofibrosis.		2.0810aminopyrimidine;
benzamides;
morpholines;
nitrile;
secondary amino compound;
tertiary amino compound		anti-anaemic agent;
antineoplastic agent;
apoptosis inducer;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor
dcc-2036
rebastinib: an inhibitor of Tie2 tyrosine kinase receptor and antineoplastic agent		3.0740organofluorine compound;
phenylureas;
pyrazoles;
pyridinecarboxamide;
quinolines		tyrosine kinase inhibitor
oprozomib
ONX 0912: antineoplastic; an orally active proteasome inhibitor; structure in first source		6.94180
az 960
[no description available]		2.610
cabozantinib
cabozantinib: a multikinase inhibitor. cabozantinib : A dicarboxylic acid diamide that is N-phenyl-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide in which the hydrogen at position 4 on the phenyl ring is substituted by a (6,7-dimethoxyquinolin-4-yl)oxy group. A multi-tyrosine kinase inhibitor, used (as its malate salt) for the treatment of progressive, metastatic, medullary thyroid cancer.		3.0740aromatic ether;
dicarboxylic acid diamide;
organofluorine compound;
quinolines		antineoplastic agent;
tyrosine kinase inhibitor
golgicide a
golgicide A: inhibits the cis-golgi ArfGEF GBF1; structure in first source. golgicide A : A diastereoisomeric mixture comprising racemic cis- and racemic trans-goglioside A in a 10:1 ratio. It is a potent and rapidly reversible GBF1 (Golgi-specific brefeldin A-resistance guanine nucleotide exchange factor 1) inhibitor. The (3aS,4R,9bR) isomer is the most active (see Bioorg. Med. Chem. Lett., 2012, 22, 5177-5181).		2.610diastereoisomeric mixturecis-Golgi ArfGEF GBF inhibitor
N-(2,6-difluorophenyl)-5-[3-[2-[5-ethyl-2-methoxy-4-[4-(4-methylsulfonyl-1-piperazinyl)-1-piperidinyl]anilino]-4-pyrimidinyl]-2-imidazo[1,2-a]pyridinyl]-2-methoxybenzamide
[no description available]		2.0810benzamides
incb-018424
[no description available]		2.5520nitrile;
pyrazoles;
pyrrolopyrimidine		antineoplastic agent;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor
bix 01294
[no description available]		2.0810piperidines
cobicistat
[no description available]		2.6101,3-thiazoles;
carbamate ester;
monocarboxylic acid amide;
morpholines;
ureas		P450 inhibitor
bms-790052
daclatasvir: an HCV NS5A inhibitor. daclatasvir : A member of the class of biphenyls that is a potent inhibitor of nonstructural protein 5A and is used (as its hydrochloride salt) for treatment of hepatitis C.		2.610biphenyls;
carbamate ester;
carboxamide;
imidazoles;
valine derivative		antiviral drug;
nonstructural protein 5A inhibitor
pf 3845
PF 3845: inhibits fatty acid amide hydrolase		2.0810piperidines
TAK-580
MLN 2480: brain-penetrant RAF dimer antagonist. TAK-580 : A 1,3-thiazolecarboxamide that is 2-[(1R)-1-aminoethyl]-1,3-thiazole-5-carboxylic acid in which the carboxy group undergoes formal condensation with the amino group of 5-chloro-4-(trifluoromethyl)pyridin-2-amine and in which the amino group undergoes formal condensation with the carboxy group of 6-amino-5-chloropyrimidine-4-carboxylic acid. It is a pan-RAF kinase inhibitor which is currently in clinical development for the treatment of radiographically recurrent or progressive low-grade glioma in children and young adults.		2.89301,3-thiazolecarboxamide;
aminopyrimidine;
chloropyridine;
organofluorine compound;
pyrimidinecarboxamide;
secondary carboxamide		antineoplastic agent;
apoptosis inducer;
B-Raf inhibitor
gsk 2126458
omipalisib: inhibitor of mTOR protein. omipalisib : A member of the class of quinolines that is quinoline which is substituted by pyridazin-4-yl and 5-[(2,4-difluorobenzene-1-sulfonyl)amino]-6-methoxypyridin-3-yl groups at positions 4 and 6, respectively. It is a highly potent inhibitor of PI3K and mTOR developed by GlaxoSmithKline and was previously in human phase 1 clinical trials for the treatment of idiopathic pulmonary fibrosis and solid tumors.		2.0810aromatic ether;
difluorobenzene;
pyridazines;
pyridines;
quinolines;
sulfonamide		anticoronaviral agent;
antineoplastic agent;
autophagy inducer;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor;
mTOR inhibitor;
radiosensitizing agent
8-(4-aminophenyl)-2-(4-morpholinyl)-1-benzopyran-4-one
[no description available]		2.8930chromones
ixazomib
ixazomib: a proteasome inhibitor with antineoplastic activity; MLN2238 is the biologically active form of MLN9708; structure in first source. ixazomib : A glycine derivative that is the amide obtained by formal condensation of the carboxy group of N-(2,5-dichlorobenzoyl)glycine with the amino group of [(1R)-1-amino-3-methylbutyl]boronic acid. The active metabolite of ixazomib citrate, it is used in combination therapy for treatment of multiple myeloma.		10.19401benzamides;
boronic acids;
dichlorobenzene;
glycine derivative		antineoplastic agent;
apoptosis inducer;
drug metabolite;
orphan drug;
proteasome inhibitor
ldn 193189
LDN 193189: inhibits bone morphogenetic protein signaling		2.0810pyrimidines
ucph 101
2-amino-4-(4-methoxyphenyl)-7-(naphthalen-1-yl)-5-oxo-5,6,7,8-tetrahydro-4H-chromene-3-carbonitrile: structure in first source		2.610
pf 3758309
PF 3758309: a PAK4 p21-activated kinase inhibitor; structure in first source		2.8930organic heterobicyclic compound;
organonitrogen heterocyclic compound;
organosulfur heterocyclic compound
(5-(2,4-bis((3s)-3-methylmorpholin-4-yl)pyrido(2,3-d)pyrimidin-7-yl)-2-methoxyphenyl)methanol
(5-(2,4-bis((3S)-3-methylmorpholin-4-yl)pyrido(2,3-d)pyrimidin-7-yl)-2-methoxyphenyl)methanol: a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity; structure in first source		2.6320benzyl alcohols;
morpholines;
pyridopyrimidine;
tertiary amino compound		antineoplastic agent;
apoptosis inducer;
mTOR inhibitor
plx4032
[no description available]		5.8431aromatic ketone;
difluorobenzene;
monochlorobenzenes;
pyrrolopyridine;
sulfonamide		antineoplastic agent;
B-Raf inhibitor
(2S)-2-[[2-(2,3-dihydro-1H-inden-5-yloxy)-9-[(4-phenylphenyl)methyl]-6-purinyl]amino]-3-phenyl-1-propanol
[no description available]		2.0810biphenyls
gsk 1363089
GSK 1363089: a multikinase inhibitor that acts on Met, RON, Axl, and VEGFR; structure in first source		2.0810aromatic ether
kin-193
[no description available]		2.0810pyridopyrimidine
5-(2-benzofuranyl)-4-[(1-methyl-5-tetrazolyl)thio]thieno[2,3-d]pyrimidine
[no description available]		2.8930aryl sulfide;
thienopyrimidine
5-(3-methylsulfonylphenyl)-4-[(1-methyl-5-tetrazolyl)thio]thieno[2,3-d]pyrimidine
[no description available]		3.1640aryl sulfide;
thienopyrimidine
5-bromo-4-[(1-methyl-5-tetrazolyl)thio]thieno[2,3-d]pyrimidine
[no description available]		2.8930aryl sulfide;
thienopyrimidine
glycolipids
[no description available]		2.2110
bay 869766
[no description available]		2.0810
baricitinib
[no description available]		3.1640azetidines;
nitrile;
pyrazoles;
pyrrolopyrimidine;
sulfonamide		anti-inflammatory agent;
antirheumatic drug;
antiviral agent;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor;
immunosuppressive agent
4-[6-[4-(methoxycarbonylamino)phenyl]-4-(4-morpholinyl)-1-pyrazolo[3,4-d]pyrimidinyl]-1-piperidinecarboxylic acid methyl ester
WYE-354: an mTOR inhibitor; structure in first source		2.0810carbamate ester
6-(1,3-benzodioxol-5-yl)-N-methyl-N-(thiophen-2-ylmethyl)-4-quinazolinamine
[no description available]		2.8930quinazolines
arry 520
filanesib: a kinesin spindle protein inhibitor		5.1721
KOM70144
KOM70144 : A benzamide that is GRL-0617 in which one of the hydrogen's of the primary amino group is replaced by an acetyl group. It an inhibitor of SARS-CoV and SARS-CoV-2 papain-like protease (PLpro) with an IC50 of 2.6 muM and 5.0 muM, respectively. It also inhibits SARS-CoV and SARS-CoV-2 infection of Vero E6 cells in vitro (EC50 values are 13.1 and 21 muM, respectively).		2.610acetamides;
benzamides;
naphthalenes;
secondary carboxamide		anticoronaviral agent;
protease inhibitor
piperidines
Piperidines: A family of hexahydropyridines.		8.28134
6-[(3-aminophenyl)methyl]-4-methyl-2-methylsulfinyl-5-thieno[3,4]pyrrolo[1,3-d]pyridazinone
ML-265: a small molecule activator of PKM2		3.0740organic heterobicyclic compound;
organonitrogen heterocyclic compound;
organosulfur heterocyclic compound
e-52862
[no description available]		2.610
ly2811376
[no description available]		2.610
interleukin-8
Interleukin-8: A member of the CXC chemokine family that plays a role in the regulation of the acute inflammatory response. It is secreted by variety of cell types and induces CHEMOTAXIS of NEUTROPHILS and other inflammatory cells.		2.5920
N-[(5-bromo-8-hydroxy-7-quinolinyl)-thiophen-2-ylmethyl]acetamide
[no description available]		2.8930hydroxyquinoline
p505-15
[no description available]		2.8930
dabrafenib
[no description available]		3.25101,3-thiazoles;
aminopyrimidine;
organofluorine compound;
sulfonamide		anticoronaviral agent;
antineoplastic agent;
B-Raf inhibitor
mrt67307
MRT67307: IKK (IκB(inhibitor of NF-κB (nuclear factor κB)) kinase) family inhibitor; structure in first source		2.8930aromatic amine
anagliptin
anagliptin: anagliptin hydrochloride salt is the active compound		2.610amino acid amide
3-[[4-(2,3-dihydro-1,4-benzodioxin-6-ylsulfonyl)-1,4-diazepan-1-yl]sulfonyl]aniline
[no description available]		2.0810benzenes;
sulfonamide
cp 466722
[no description available]		2.0810quinazolines
gardiquimod
[no description available]		2.610
CAY10626
[no description available]		2.0810ureas
grazoprevir
grazoprevir: has antiviral activity; component of Zepatier. grazoprevir : An azamacrocyclic compound that is a hepatitis C protease inhibitor used in combination with elbasvir (under the brand name Zepatier) for treatment of chronic HCV genotypes 1 or 4 infection in adults.		2.610aromatic ether;
azamacrocycle;
carbamate ester;
cyclopropanes;
lactam;
N-sulfonylcarboxamide;
quinoxaline derivative		antiviral drug;
hepatitis C protease inhibitor;
hepatoprotective agent
N-[3-[[5-chloro-2-[4-(4-methyl-1-piperazinyl)anilino]-4-pyrimidinyl]oxy]phenyl]-2-propenamide
[no description available]		2.8930piperazines
thiopental sodium
[no description available]		2.0810organochlorine compound;
piperazines;
pyrimidines		antineoplastic agent;
tyrosine kinase inhibitor
ribociclib
ribociclib: inhibits both CDK4 and CDK6		2.8930
1-[3-[4-[(1-methyl-5-tetrazolyl)thio]-5-thieno[2,3-d]pyrimidinyl]phenyl]ethanone
[no description available]		2.8930aromatic ketone;
thienopyrimidine
abt-450
paritaprevir: inhibits HCV NS3 protease. paritaprevir : An azamacrocycle which is used which is in combination with dasabuvir sodium hydrate, ombitasvir and ritonavir (under the trade name Viekira Pak) for treatment of chronic hepatitis C virus genotype 1 infection as well as cirrhosis of the liver.		2.610
letermovir
letermovir: has antiviral activity; structure in first source		2.610
gx 15-070
obatoclax: a pan-Bcl-2 inhibitor potentially useful in treating mantle cell lymphoma		2.5420
sofosbuvir
Sofosbuvir: A uridine monophosphate analog inhibitor of HEPATITIS C VIRUS (HCV) polymerase NS5B that is used as an ANTIVIRAL AGENT in the treatment of CHRONIC HEPATITIS C.. sofosbuvir : A nucleotide conjugate that is used in combination with ledipasvir (under the trade name Harvoni) for the treatment of chronic hepatitis C genotype 1 infection.		2.610isopropyl ester;
L-alanyl ester;
nucleotide conjugate;
organofluorine compound;
phosphoramidate ester		antiviral drug;
hepatitis C protease inhibitor;
prodrug
5-(4-amino-1-propan-2-yl-3-pyrazolo[3,4-d]pyrimidinyl)-1,3-benzoxazol-2-amine
sapanisertib: an mTOR inhibitor		2.610benzoxazole
blz 945
[no description available]		2.610
pha 793887
[no description available]		3.0740piperidinecarboxamide
azd3839
AZD3839: a BACE1 inhibitor; structure in first source		2.610
gsk 2334470
GSK 2334470: a PDK1 inhibitor; structure in first source		2.2110indazoles
pr-957
PR-957: immunoproteasome inhibitor; inhibits Lmp7 protein; structure in first source		3.3660
pf 3084014
nirogacestat: an antineoplastic agent. nirogacestat : A member of the class of imidazoles that is 1H-imidazole substituted by a 1-[(2,2-dimethylpropyl)amino]-2-methylpropan-2-yl group at position 1 and a {N-[(2S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl]-L-norvalyl}amino group at position 4. It is a gamma-secretase inhibitor whose hydrobromide salt is indicated for adult patients with progressing desmoid tumours who require systemic treatment.		2.610
unc 0638
UNC 0638: inhibits lysine methyltransferases G9a and GLP; structure in first source		2.610quinazolines
gs-9620
[no description available]		2.610
nvp-bsk805
[no description available]		2.0810
ml228 probe
ML228 probe: structure in first source. ML228 : A member of the class of 1,2,4-triazines in which the triazine ring is substituted at positions 3, 5, and 6 by pyridin-2-yl, ([biphenyl]-4-ylmethyl)amin, and methyl groups, respectively. It is an activator of the hypoxia inducible factor (HIF) pathway.		2.89301,2,4-triazines;
biphenyls;
pyridines;
secondary amino compound		hypoxia-inducible factor pathway activator
xmd 8-92
XMD8-92 : A dimethylpyrimido[4,5-b][1,4]benzodiazepin-6-one carrying at C-2 on the pyrimidine ring a [2-ethoxy-4-(4-hydroxypiperidin-1-yl)phenyl]amino substituent. It is an inhibitor of the BMK1 kinase pathway.		2.0810pyrimidobenzodiazepineprotein kinase inhibitor
n-((5-(methanesulfonyl)pyridin-2-yl)methyl)-6-methyl-5-(1-methyl-1h-pyrazol-5-yl)-2-oxo-1-(3-(trifluoromethyl)phenyl)-1,2-dihydropyridine-3-carboxamide
N-((5-(methanesulfonyl)pyridin-2-yl)methyl)-6-methyl-5-(1-methyl-1H-pyrazol-5-yl)-2-oxo-1-(3-(trifluoromethyl)phenyl)-1,2-dihydropyridine-3-carboxamide: structure in first source		2.610
pf-03882845
[no description available]		2.8930
bms 708163
BMS 708163: structure in first source		2.610oxadiazole;
ring assembly
jq1 compound
[no description available]		3.2850carboxylic ester;
organochlorine compound;
tert-butyl ester;
thienotriazolodiazepine		angiogenesis inhibitor;
anti-inflammatory agent;
antineoplastic agent;
apoptosis inducer;
bromodomain-containing protein 4 inhibitor;
cardioprotective agent;
ferroptosis inducer
jnj38877605
[no description available]		2.0810quinolines
N-[3-(1,3-benzothiazol-2-yl)-5,6-dihydro-4H-thieno[2,3-c]pyrrol-2-yl]acetamide
[no description available]		2.0810benzothiazoles
dinaciclib
[no description available]		2.0810pyrazolopyrimidine
pf-04620110
PF-04620110: a DGAT1 inhibitor; structure in first source		2.8930
1-(5-((2,4-difluorophenyl)thio)-4-nitrothiophen-2-yl)ethanone
1-(5-((2,4-difluorophenyl)thio)-4-nitrothiophen-2-yl)ethanone: a USP7 inhibitor; structure in first source		2.610
gsk525762a
molibresib: mimicks acetylated histones; structure in first source		3.3450benzodiazepine
ML240
ML240 : A member of the class of quinazolines that is quinazoline which is substituted at positions 2, 5 and 8 by 2-amino-1H-benzimidazol-1-yl, benzylnitrilo and methoxy groups, respectively. It is a ATP-competetive inhibitor of AAA ATPase p97, also known as valosin-containing protein (VCP).		2.610aromatic amine;
aromatic ether;
benzimidazoles;
primary amino compound;
quinazolines;
secondary amino compound		antineoplastic agent
birinapant
birinapant: a Smac mimetic with antineoplastic activity		2.7220dipeptide
torin 1
torin 1 : A member of the class of pyridoquinolines that is 9-(quinolin-3-yl)benzo[h][1,6]naphthyridin-2-one bearing an additional 4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl substituent at position 1. It is a potent inhibitor of mTOR and exhibits anti-cancer properties.		3.0740N-acylpiperazine;
N-arylpiperazine;
organofluorine compound;
pyridoquinoline;
quinolines		antineoplastic agent;
mTOR inhibitor
ly2886721
[no description available]		2.610
nms-p118
NMS-P118: a PARP-1 inhibitor; structure in first source		2.610
abt-199
venetoclax: A BCL-2 inhibitor with antineoplastic activity that is used in the treatment of CHRONIC LYMPHOCYTIC LEUKEMIA associated with chromosome 17p deletion; structure in first source.. venetoclax : A member of the class of pyrrolopyridines that is a potent inhibitor of the antiapoptotic protein B-cell lymphoma 2. It is used for treamtment of chronic lymphocytic leukemia with 17p deletion.		8.32101aromatic ether;
C-nitro compound;
monochlorobenzenes;
N-alkylpiperazine;
N-arylpiperazine;
N-sulfonylcarboxamide;
oxanes;
pyrrolopyridine		antineoplastic agent;
apoptosis inducer;
B-cell lymphoma 2 inhibitor
ly2940680
[no description available]		2.0810
tubastatin a
[no description available]		2.610hydroxamic acid;
pyridoindole;
tertiary amino compound		EC 3.5.1.98 (histone deacetylase) inhibitor
1-[4-fluoro-3-(trifluoromethyl)phenyl]-3-(5-pyridin-4-yl-1,3,4-thiadiazol-2-yl)urea
[no description available]		3.0740ureas
N-(4-methyl-2-pyridinyl)-4-[3-(trifluoromethyl)anilino]-1-piperidinecarbothioamide
[no description available]		2.8930(trifluoromethyl)benzenes
pracinostat
pracinostat : A hydroxamic acid that is N-hydroxyacrylamide which is substituted at position 3 by a 2-butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl group (the E isomer). An orally available pan-histone deacetylase inhibitor with demonstrated activity in the treatment of advanced solid tumours.		2.610benzimidazole;
hydroxamic acid;
olefinic compound;
tertiary amino compound		antimalarial;
antineoplastic agent;
apoptosis inducer;
EC 3.5.1.98 (histone deacetylase) inhibitor
ro 4929097
[no description available]		2.0810dibenzoazepine;
dicarboxylic acid diamide;
lactam;
organofluorine compound		EC 3.4.23.46 (memapsin 2) inhibitor
mln 9708
[no description available]		2.110
ncgc00242364
NCGC00242364: structure in first source		2.8930quinazolines
gsk4112
GSK4112: a Rev-erbalpha agonist; structure in first source		2.0810
ipi-145
[no description available]		2.1110isoquinolines
spautin-1
[no description available]		2.610
torin 2
torin 2 : A member of the class of pyridoquinolines that is benzo[h][1,6]naphthyridin-2-one carrying additional 3-(trifluoromethyl)phenyl and 6-aminopyridin-3-yl substituents at positions 1 and 9 respectively. It is a potent inhibitor of mTOR and exhibits anti-cancer properties.		2.0810aminopyridine;
organofluorine compound;
primary amino compound;
pyridoquinoline		antineoplastic agent;
mTOR inhibitor
pf-4708671
[no description available]		2.0810
ldn 57444
LDN 57444: inhibitor of ubiquitin C-terminal hydrolase-L1; structure in first source		2.610
gsk1210151a
GSK1210151A: inhibitor of the BET family of proteins; structure in first source		3.3450imidazoquinoline
i-bet726
[no description available]		2.610
apr-246
eprenetapopt: works in tandem with cisplatin to cause apoptosis of tumor cells; structure in first source		2.1310
hs-173
[no description available]		2.8930
sr1664
[no description available]		2.8930indolecarboxamide
4-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-n-(4-methoxypyridin-2-yl)piperazine-1-carbothioamide
4-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-methoxypyridin-2-yl)piperazine-1-carbothioamide: inhibits phosphopantetheinyl transferase; structure in first source		2.8930
natriuretic peptide, brain
Natriuretic Peptide, Brain: A PEPTIDE that is secreted by the BRAIN and the HEART ATRIA, stored mainly in cardiac ventricular MYOCARDIUM. It can cause NATRIURESIS; DIURESIS; VASODILATION; and inhibits secretion of RENIN and ALDOSTERONE. It improves heart function. It contains 32 AMINO ACIDS.		3.9220polypeptide
acy-1215
ricolinostat: an HDAC6 inhibitor; structure in first source		4.240pyrimidinecarboxylic acid
N-[4-(1-benzoyl-4-piperidinyl)butyl]-3-(3-pyridinyl)-2-propenamide
[no description available]		2.8330benzamides;
N-acylpiperidine
N-[4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl]-4-(dimethylamino)-2-butenamide
[no description available]		2.5920aminoquinoline
2-methoxy-N-[3-[4-[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]anilino]-6-quinazolinyl]prop-2-enyl]acetamide
2-methoxy-N-[3-[4-[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]anilino]-6-quinazolinyl]prop-2-enyl]acetamide : A member of the class of quinazolines that is quinazoline substituted by {3-methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl}amino and 3-(2-methoxyacetamido)prop-1-en-1-yl groups at positions 4 and 6, respectively.		2.0810aromatic ether;
methylpyridines;
olefinic compound;
quinazolines;
secondary amino compound;
secondary carboxamide;
toluenes
belinostat
[no description available]		2.0810olefinic compound
lesinurad
lesinurad: a uric acid reabsorption inhibitor. lesinurad : A member of the class of triazoles that is [(3-bromo-1,2,4-triazol-5-yl)sulfanyl]acetic acid substituted at position 1 of the triazole ring by a 4-cyclopropylnaphthalen-1-yl group. Used for treatment of gout.		2.1310aryl sulfide;
cyclopropanes;
monocarboxylic acid;
naphthalenes;
organobromine compound;
triazoles		uricosuric drug
cudc-907
[no description available]		3.1640
methacycline
Methacycline: A broad-spectrum semisynthetic antibiotic related to TETRACYCLINE but excreted more slowly and maintaining effective blood levels for a more extended period.. methacycline : A tetracycline that is the 6-methylene analogue of oxytetracycline, obtained by formal dehydration at position 6.		2.2110
mobic
Meloxicam: A benzothiazine and thiazole derivative that acts as a NSAID and cyclooxygenase-2 (COX-2) inhibitor. It is used in the treatment of RHEUMATOID ARTHRITIS; OSTEOARTHRITIS; and ANKYLOSING SPONDYLITIS.. meloxicam : A benzothiazine that is piroxicam in which the pyridin-2-yl group is replaced by a 5-methyl-1,3-thiazol-2-yl group. A non-steroidal anti-inflammatory drug and selective inhibitor of COX-2, it is used particularly for the management of rheumatoid arthritis.		2.6101,3-thiazoles;
benzothiazine;
monocarboxylic acid amide		analgesic;
antirheumatic drug;
cyclooxygenase 2 inhibitor;
non-steroidal anti-inflammatory drug
ethyl 1-benzyl-3-hydroxy-2(5h)-oxopyrrole-4-carboxylate
ethyl 1-benzyl-3-hydroxy-2(5H)-oxopyrrole-4-carboxylate: RN & structure given in first source		2.0810carboxylic acid;
pyrroline
tipranavir
tipranavir: inhibits HIV-1 protease. tipranavir : A pyridine-2-sulfonamide substituted at C-5 by a trifluoromethyl group and at the sulfonamide nitrogen by a dihydropyrone-containing m-tolyl substituent. It is an HIV-1 protease inhibitor.		2.610sulfonamideantiviral drug;
HIV protease inhibitor
tasquinimod
tasquinimod: a lead second generation quinoline-3-carboxamide anti-angiogenic agent for the treatment of prostate cancer; structure in first source		2.610
methacycline monohydrochloride
[no description available]		2.5920
2-[[[4-hydroxy-2-oxo-1-(phenylmethyl)-3-quinolinyl]-oxomethyl]amino]acetic acid
[no description available]		2.8930quinolines
a 769662
[no description available]		2.0810biphenyls
gsk1265744
[no description available]		2.610difluorobenzene;
monocarboxylic acid amide;
organic heterotricyclic compound;
secondary carboxamide		HIV-1 integrase inhibitor
eravacycline
eravacycline: has antibacterial activity		3.1710tetracyclines
abt-267
ombitasvir: inhibits HCV NS5A protein, component of Viekirax. ombitasvir : A dipeptide derivative which is used which is in combination with dasabuvir sodium hydrate, paritaprevir and ritonavir (under the trade name Viekira Pak) for treatment of chronic hepatitis C virus genotype 1 infection as well as cirrhosis of the liver.		2.610aromatic amide;
carbamate ester;
dipeptide;
pyrrolidines		antiviral drug;
hepatitis C virus nonstructural protein 5A inhibitor
abt-333
dasabuvir: an antiviral agent. dasabuvir : A member of the class of pyrimidone, which is (as the monohydrate of its sodium salt) in combination with ombitasvir, paritaprevir and ritonavir (under the trade name Viekira Pak) for treatment of chronic hepatitis C virus genotype 1 infection as well as cirrhosis of the liver.		2.610aromatic ether;
naphthalenes;
pyrimidone;
sulfonamide		antiviral drug;
nonnucleoside hepatitis C virus polymerase inhibitor
agi-5198
AGI-5198: inhibits isocitrate dehydrogenase 1; structure in first source		2.8930
byl719
[no description available]		5.1421proline derivative
rgfp966
[no description available]		2.610
rg2833
RG2833: a histone deacetylase inhibitor; structure in first source		2.610
transforming growth factor beta
Transforming Growth Factor beta: A factor synthesized in a wide variety of tissues. It acts synergistically with TGF-alpha in inducing phenotypic transformation and can also act as a negative autocrine growth factor. TGF-beta has a potential role in embryonal development, cellular differentiation, hormone secretion, and immune function. TGF-beta is found mostly as homodimer forms of separate gene products TGF-beta1, TGF-beta2 or TGF-beta3. Heterodimers composed of TGF-beta1 and 2 (TGF-beta1.2) or of TGF-beta2 and 3 (TGF-beta2.3) have been isolated. The TGF-beta proteins are synthesized as precursor proteins.		3.1910
cep-32496
agerafenib: inhibitor of RAF family kinases; structure in first source		2.8930
pi-1840
PI-1840: has both antineoplastic and proteasome inhibitory activities; structure in first source		2.7220
epz004777
[no description available]		2.8930N-glycosyl compound
3-[[2-(2-pyridinyl)-6-(1,2,4,5-tetrahydro-3-benzazepin-3-yl)-4-pyrimidinyl]amino]propanoic acid
[no description available]		2.8930organonitrogen heterocyclic compound
LimKi 3
LIMKi3: LIMK inhibitor. LimKi 3 : A member of the class of pyrazoles that is 1-(2,6-dichlorophenyl)-1H-pyrazole which is substituted by a difluoromethyl group at position 3 and by a 2-(isobutyrylamino)-1,3-thiazol-5-yl group at position 5. It is a a potent cell-permeable inhibitor of LIM kinase 1 and 2.		2.08101,3-thiazoles;
dichlorobenzene;
organofluorine compound;
pyrazoles;
secondary carboxamide		LIM kinase inhibitor
1-[4-amino-7-[3-(2-methoxyethylamino)propyl]-5-(4-methylphenyl)-6-pyrrolo[2,3-d]pyrimidinyl]-2-fluoroethanone
[no description available]		2.0810pyrroles
okadaic acid
Okadaic Acid: A specific inhibitor of phosphoserine/threonine protein phosphatase 1 and 2a. It is also a potent tumor promoter. It is produced by DINOFLAGELLATES and causes diarrhetic SHELLFISH POISONING.. okadaic acid : A polycyclic ether that is produced by several species of dinoflagellates, and is known to accumulate in both marine sponges and shellfish. A polyketide, polyether derivative of a C38 fatty acid, it is one of the primary causes of diarrhetic shellfish poisoning (DSP). It is a potent inhibitor of specific protein phosphatases and is known to have a variety of negative effects on cells.		2.1510ketal
entecavir
[no description available]		2.8930benzamides;
N-acylpiperidine
2-[5-[(3,5-dimethyl-1H-pyrrol-2-yl)methylidene]-4-methoxy-2-pyrrolylidene]indole
[no description available]		2.0810dipyrrins
acy-738
[no description available]		2.610
pelabresib
CPI-0610: a bromodomain and extra-terminal protein inhibitor with antineoplastic activity; structure in first source		2.610monochlorobenzenes;
organic heterotricyclic compound;
primary carboxamide		antineoplastic agent;
bromodomain-containing protein 4 inhibitor
N-hydroxy-3-[4-[[2-(2-methyl-1H-indol-3-yl)ethylamino]methyl]phenyl]-2-propenamide
[no description available]		2.0810tryptamines
3-[(5-tert-butyl-1H-imidazol-4-yl)methylidene]-6-(phenylmethylene)piperazine-2,5-dione
[no description available]		2.0810pyrazines
gsk837149a
GSK837149A: structure in first source		2.0810
N-[4-(3-chloro-4-fluoroanilino)-7-[[(3S)-3-oxolanyl]oxy]-6-quinazolinyl]-4-(dimethylamino)-2-butenamide
[no description available]		2.0810quinazolines
N-[4-(3-chloro-4-fluoroanilino)-7-methoxy-6-quinazolinyl]-4-(1-piperidinyl)-2-butenamide
[no description available]		2.0810quinazolines
wnt-c59
2-(4-(2-methylpyridin-4-yl)phenyl)-N-(4-(pyridin-3-yl)phenyl)acetamide: a PORCN acyltransferase inhibitor; structure in first source		2.0810
5-[1-(2-hydroxyethyl)-3-pyridin-4-yl-4-pyrazolyl]-2,3-dihydroinden-1-one oxime
[no description available]		2.0810indanes
gs-5806
presatovir: a respiratory syncytial virus entry inhibitor		2.610
doravirine
[no description available]		2.610
gkt137831
setanaxib: NOX4/NOX1 inhibitor; a pyrazolopyridine dione derivative		2.8930
cc-292
spebrutinib: inhibits Bruton's tyrosine kinase; structure in first source		7.110
vx-509
[no description available]		2.8930
vx-970
berzosertib: an ATR kinase inhibitor		2.8930sulfonamide
gs-9973
[no description available]		2.8930
amg 925
AMG-925 : An organic heterotricyclic compound that is 9H-pyrido[4',3':4,5]pyrrolo[2,3-d]pyrimidine which is substituted by a [6-(hydroxyacetyl)-5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl]nitrilo group at position 2 and by a trans-4-methylcyclohexyl group at position 9. It is a FLT3 and CDK4 dual kinase inhibitor that has antineoplastic activity. Currently under clinical investigation in patients with relapsed or refractory acute myeloid leukemia (AML).		2.8930
gn6958
GN6958: inhibits SUMO-sentrin specific protease 1 (SENP1); structure in first source		2.610
gne-618
GNE-618: inhibits nicotinamide phosphoribosyl transferase; structure in first source		2.8930
vx-787
pimodivir: non‐nucleotide inhibitor of the polymerase basic protein 2 (PB2) subunit of the influenza A that is active against H1N1, H7N9 and H5N1, as well as influenza A strains with reduced susceptibility to NAIs		2.610
ledipasvir
ledipasvir : A benzimidazole derivative that is used in combination with sofosbuvir (under the trade name Harvoni) for the treatment of chronic hepatitis C genotype 1 infection.		2.610azaspiro compound;
benzimidazole;
bridged compound;
carbamate ester;
carboxamide;
fluorenes;
imidazoles;
L-valine derivative;
N-acylpyrrolidine;
organofluorine compound		antiviral drug;
hepatitis C protease inhibitor
gs-5816
velpatasvir: an NS5A inhibitor used for treating hepatitis C infections. velpatasvir : A complex organic heteropentacyclic compound that is a hepatitis C virus nonstructural protein 5A inhibitor used in combination with sofosbuvir (under the brand name Epclusa) for treatment of patients with chronic hepatitis C of all six major genotypes.		2.610carbamate ester;
ether;
imidazoles;
L-valine derivative;
N-acylpyrrolidine;
organic heteropentacyclic compound;
ring assembly		antiviral drug;
hepatitis C virus nonstructural protein 5A inhibitor
g007-lk
G007-LK: potent and specific small-molecule tankyrase inhibitor; structure in first source		3.1640
volitinib
[no description available]		2.8930
ML355
ML355: 12-Lipoxygenase inhibitor. ML355 : A sulfonamide resulting from the formal condensation of the amino group of 2-aminobenzothiazole with the sulfo group of 4-[(2-hydroxy-3-methoxybenzyl)amino]benzenesulfonic acid. It is an inhibitor of 12-lipoxygenase, being developed by Veralox Therapeutics for the treatment of heparin-induced thrombocytopenia and thrombosis.		2.8930benzothiazoles;
monomethoxybenzene;
phenols;
secondary amino compound;
substituted aniline;
sulfonamide		EC 1.13.11.31 (arachidonate 12-lipoxygenase) inhibitor;
platelet aggregation inhibitor
acp-196
acalabrutinib: inhibits Bruton’s tyrosine kinase; has antineoplastic activity. acalabrutinib : A member of the class of imidazopyrazines that is imidazo[1,5-a]pyrazine substituted by 4-(pyridin-2-ylcarbamoyl)phenyl, (2S)-1-(but-2-ynoyl)pyrrolidin-2-yl, and amino groups at positions 1, 3 and 8, respectively. It is an irreversible second-generation Bruton's tyrosine kinase (BTK) inhibitor that is approved by the FDA for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.		2.8930aromatic amine;
benzamides;
imidazopyrazine;
pyridines;
pyrrolidinecarboxamide;
secondary carboxamide;
tertiary carboxamide;
ynone		antineoplastic agent;
apoptosis inducer;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor
gsk343
GSK343: an EZH2 methyltransferase inhibitor. GSK343 : A member of the class of indazoles that is 1-isopropyl-1H-indazole-4-carboxamide in which the nitrogen of the carboxamide group is substituted by a (6-methyl-2-oxo-4-propyl-1,2-dihydropyridin-3-yl)methyl group and in which the indazole ring is substituted at position 6 by a 2-(4-methylpiperazin-1-yl)pyridin-4-yl group. A highly potent and selective EZH2 inhibitor (IC50 = 4 nM).		2.8930aminopyridine;
indazoles;
N-alkylpiperazine;
N-arylpiperazine;
pyridone;
secondary carboxamide		antineoplastic agent;
apoptosis inducer;
EC 2.1.1.43 (enhancer of zeste homolog 2) inhibitor
sc 26196
[no description available]		2.3110
agi-6780
AGI-6780: inhibits isocitrate dehydrogenases 1 and 2; structure in first source		2.8930
khs101
KHS101: a small molecule accelerates neuronal differentiation in the adult rat		2.8930
4-((1-butyl-3-phenylureido)methyl)-n-hydroxybenzamide
4-((1-butyl-3-phenylureido)methyl)-N-hydroxybenzamide: inhibits HDAC6; structure in first source		2.610
selinexor
selinexor: inhibits karyopherin XPO1		8.27103
verdinexor
verdinexor: a selective inhibitor of nuclear export		2.610
cb-839
[no description available]		8.3150
mk-8742
elbasvir: inhibits NS5A protein of hepatitis C virus. elbasvir : A complex organic heterotetracyclic compound that is a hepatitis C virus nonstructural protein 5A inhibitor used in combination with grazoprevir (under the brand name Zepatier) for treatment of chronic HCV genotypes 1 or 4 infection in adults.		2.610carbamate ester;
imidazoles;
L-valine derivative;
N-acylpyrrolidine;
organic heterotetracyclic compound;
ring assembly		antiviral drug;
hepatitis C virus nonstructural protein 5A inhibitor;
hepatoprotective agent
atglistatin
atglistatin: inhibits adipose triglyceride lipase; structure in first source. atglistatin : A biphenyl that is 1,1'-biphenyl substituted by (dimethylcarbamoyl)amino and dimethylamino groups at positions 3 and 4', respectively. It is a potent inhibitor of adipose triglyceride lipase activity (IC50 = 700nM).		2.610
gsk-j4
GSK-J4: a JMJD3 inhibitor; structure in first source		2.8930organonitrogen heterocyclic compound
pf-06424439
PF-06424439: an inhibitor of diacylglycerol acyltransferase 2; structure in first source		2.8930
etp-46464
ETP-46464: inhibits ATM and Rad3-related kinase; structure in first source		2.8930
xen445
[no description available]		2.610
santacruzamate a
santacruzamate A: HDAC2 inhibitor from the Panamanian marine cyanobacterium cf. Symploca sp.; structure in first source		2.610organonitrogen compound;
organooxygen compound
glutaminase
[no description available]		7.1510
onc201
TIC10 compound: a TRAIL-dependent antitumor agent; structure in first source		3.1140
kai407
KAI407: an antimalarial; structure in first source		2.8930
ldc4297
LDC4297: a CDK7 inhibitor with antineoplastic activity; structure in first source. LDC4297 : A pyrazolotriazine that is pyrazolo[1,5-a][1,3,5]triazine substituted by a piperidin-3-yloxy group, [2-(1H-pyrazol-1-yl)benzyl]nitrilo group and an isopropyl group at positions 2, 4 and 8 respectively. It is a potent and selective CDK7 inhibitor and exhibits antiviral activity.		2.610aromatic ether;
piperidines;
pyrazoles;
pyrazolotriazine;
secondary amino compound		antineoplastic agent;
antiviral agent;
apoptosis inducer;
EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
6,7-dimethoxy-2-(pyrrolidin-1-yl)-n-(5-(pyrrolidin-1-yl)pentyl)quinazolin-4-amine
6,7-dimethoxy-2-(pyrrolidin-1-yl)-N-(5-(pyrrolidin-1-yl)pentyl)quinazolin-4-amine: a SETD8 inhibitor; structure in first source		2.8930
benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone
benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone: an interleukin-1beta converting enzyme (ICE)-like protease inhibitor		2.1110
enasidenib
[no description available]		3.16401,3,5-triazines;
aminopyridine;
aromatic amine;
organofluorine compound;
secondary amino compound;
tertiary alcohol		antineoplastic agent;
EC 1.1.1.42 (isocitrate dehydrogenase) inhibitor
oicr-9429
OICR-9429: antineoplastic; structure in first source		2.8930
lly-507
LLY-507: inhibits methyltransferase SMYD2; structure in first source. LLY-507 : A secondary carboxamide resulting from the formal condensation of the carboxy group of 5-cyano-2'-{4-[2-(3-methyl-1H-indol-1-yl)ethyl]piperazin-1-yl}[biphenyl]-3-carboxylic acid with the amino group of 3-(pyrrolidin-1-yl)propan-1-amine. It is a potent and selective inhibitor of SMYD2 and inhibits the ability of SMYD2 to methylate p53. It serves as a valuable chemical probe to aid in the dissection of SMYD2 function in cancer and other biological processes.		2.8930
s 8932
[no description available]		2.610aromatic amine;
C-nucleoside;
carboxylic ester;
nitrile;
phosphoramidate ester;
pyrrolotriazine		anticoronaviral agent;
antiviral drug;
prodrug
cyclosporine
Cyclosporine: A cyclic undecapeptide from an extract of soil fungi. It is a powerful immunosupressant with a specific action on T-lymphocytes. It is used for the prophylaxis of graft rejection in organ and tissue transplantation. (From Martindale, The Extra Pharmacopoeia, 30th ed).		8.2310
lactoferrin
Lactoferrin: An iron-binding protein that was originally characterized as a milk protein. It is widely distributed in secretory fluids and is found in the neutrophilic granules of LEUKOCYTES. The N-terminal part of lactoferrin possesses a serine protease which functions to inactivate the TYPE III SECRETION SYSTEM used by bacteria to export virulence proteins for host cell invasion.		7.610
at 9283
[no description available]		2.8930
entecavir
entecavir (anhydrous) : Guanine substituted at the 9 position by a 4-hydroxy-3-(hydroxymethyl)-2-methylidenecyclopentyl group. A synthetic analogue of 2'-deoxyguanosine, it is a nucleoside reverse transcriptase inhibitor with selective antiviral activity against hepatitis B virus. Entecavir is phosphorylated intracellularly to the active triphosphate form, which competes with deoxyguanosine triphosphate, the natural substrate of hepatitis B virus reverse transcriptase, inhibiting every stage of the enzyme's activity, although it has no activity against HIV. It is used for the treatment of chronic hepatitis B.		2.6102-aminopurines;
oxopurine;
primary alcohol;
secondary alcohol		antiviral drug;
EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor
chir 258
[no description available]		2.0810
acyclovir
Acyclovir: A GUANOSINE analog that acts as an antimetabolite. Viruses are especially susceptible. Used especially against herpes.. acyclovir : An oxopurine that is guanine substituted by a (2-hydroxyethoxy)methyl substituent at position 9. Used in the treatment of viral infections.		2.6102-aminopurines;
oxopurine		antimetabolite;
antiviral drug
osi 027
OSI 027: inhibits both mTORC1 and mTORC2; structure in first source		2.0810
nu 1025
NU 1064: structure in first source		2.610phenols;
quinazolines		EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor
guanosine diphosphate
Guanosine Diphosphate: A guanine nucleotide containing two phosphate groups esterified to the sugar moiety.		2.3110guanosine 5'-phosphate;
purine ribonucleoside 5'-diphosphate		Escherichia coli metabolite;
mouse metabolite;
uncoupling protein inhibitor
guanosine triphosphate
Guanosine Triphosphate: Guanosine 5'-(tetrahydrogen triphosphate). A guanine nucleotide containing three phosphate groups esterified to the sugar moiety.		2.3110guanosine 5'-phosphate;
purine ribonucleoside 5'-triphosphate		Escherichia coli metabolite;
mouse metabolite;
uncoupling protein inhibitor
hypoxanthine
[no description available]		2.8930nucleobase analogue;
oxopurine;
purine nucleobase		fundamental metabolite
rifampin
Rifampin: A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1160)		3.2710cyclic ketal;
hydrazone;
N-iminopiperazine;
N-methylpiperazine;
rifamycins;
semisynthetic derivative;
zwitterion		angiogenesis inhibitor;
antiamoebic agent;
antineoplastic agent;
antitubercular agent;
DNA synthesis inhibitor;
EC 2.7.7.6 (RNA polymerase) inhibitor;
Escherichia coli metabolite;
geroprotector;
leprostatic drug;
neuroprotective agent;
pregnane X receptor agonist;
protein synthesis inhibitor
clozapine
Clozapine: A tricylic dibenzodiazepine, classified as an atypical antipsychotic agent. It binds several types of central nervous system receptors, and displays a unique pharmacological profile. Clozapine is a serotonin antagonist, with strong binding to 5-HT 2A/2C receptor subtype. It also displays strong affinity to several dopaminergic receptors, but shows only weak antagonism at the dopamine D2 receptor, a receptor commonly thought to modulate neuroleptic activity. Agranulocytosis is a major adverse effect associated with administration of this agent.. clozapine : A benzodiazepine that is 5H-dibenzo[b,e][1,4]diazepine substituted by a chloro group at position 8 and a 4-methylpiperazin-1-yl group at position 11. It is a second generation antipsychotic used in the treatment of psychiatric disorders like schizophrenia.		2.8930benzodiazepine;
N-arylpiperazine;
N-methylpiperazine;
organochlorine compound		adrenergic antagonist;
dopaminergic antagonist;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
environmental contaminant;
GABA antagonist;
histamine antagonist;
muscarinic antagonist;
second generation antipsychotic;
serotonergic antagonist;
xenobiotic
didanosine
Didanosine: A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. Didanosine is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA by binding to reverse transcriptase; ddI is then metabolized to dideoxyadenosine triphosphate, its putative active metabolite.. didanosine : A purine 2',3'-dideoxyribonucleoside that is inosine in which the hydroxy groups at both the 2' and the 3' positions on the sugar moiety have been replaced by hydrogen. An antiviral drug, it is used as a medication to treat HIV/AIDS.		2.610purine 2',3'-dideoxyribonucleosideantimetabolite;
antiviral drug;
EC 2.4.2.1 (purine-nucleoside phosphorylase) inhibitor;
geroprotector;
HIV-1 reverse transcriptase inhibitor
ganciclovir
[no description available]		2.6102-aminopurines;
oxopurine		antiinfective agent;
antiviral drug
valacyclovir
Valacyclovir: A prodrug of acyclovir that is used in the treatment of HERPES ZOSTER and HERPES SIMPLEX VIRUS INFECTION of the skin and mucous membranes, including GENITAL HERPES.		2.610L-valyl esterantiviral drug
penciclovir
penciclovir : A member of the class of 2-aminopurines that is guanine in which the hydrogen at position 9 is substituted by a 4-hydroxy-3-(hydroxymethyl)but-1-yl group. An antiviral drug, it is administered topically for treatment of herpes labialis. A prodrug, famciclovir, is used for oral administration.		2.6102-aminopurines;
propane-1,3-diols		antiviral drug
hli 373
[no description available]		2.0810
4-hydroxyquinazoline
4-oxo-3,4-dihydroquinazoline: structure in first source		2.610quinazolines
tegaserod
tegaserod: a nonbenzamide 5-hydroxytryptamine(4) agonist; used in treatment of irritable bowel syndrome; marketing suspended 2007 in US due to higher incidence of MI, stroke, and unstable angina; structure given in first source		2.610carboxamidine;
guanidines;
hydrazines;
indoles		gastrointestinal drug;
serotonergic agonist
norclozapine
norclozapine: structure given in first source. N-desmethylclozapine : A dibenzodoazepine substituted with chloro and piperazino groups which is a major metabolite of clozapine; a potent and selective 5-HT2C serotonin receptor antagonist.		2.610dibenzodiazepine;
organochlorine compound;
piperazines		delta-opioid receptor agonist;
metabolite;
serotonergic antagonist
pemetrexed
pemetrexed disodium : An organic sodium salt that is the disodium salt of N-{4-[2-(2-amino-4-oxo-4,7-dihydro-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl}-L-glutamic acid. Inhibits thymidylate synthase (TS), 421 dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT).		3.9430N-acyl-L-glutamic acid;
pyrrolopyrimidine		antimetabolite;
antineoplastic agent;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor;
EC 2.1.1.45 (thymidylate synthase) inhibitor;
EC 2.1.2.2 (phosphoribosylglycinamide formyltransferase) inhibitor
1-hydroxyphenazine
1-hydroxyphenazine: a virulence factor of Pseudomonas aeruginosa. 1-hydroxyphenazine : A phenazine carrying a hydroxy substituent at the 1-position.		2.8930phenazines
sildenafil citrate
Sildenafil Citrate: A PHOSPHODIESTERASE TYPE-5 INHIBITOR; VASODILATOR AGENT and UROLOGICAL AGENT that is used in the treatment of ERECTILE DYSFUNCTION and PRIMARY PULMONARY HYPERTENSION.. sildenafil citrate : The citrate salt of sildenafil.		2.0810citrate saltEC 3.1.4.35 (3',5'-cyclic-GMP phosphodiesterase) inhibitor;
vasodilator agent
aprepitant
Aprepitant: A morpholine neurokinin-1 (NK1) receptor antagonist that is used in the management of nausea and vomiting caused by DRUG THERAPY, and for the prevention of POSTOPERATIVE NAUSEA AND VOMITING.. aprepitant : A morpholine-based antiemetic, which is or the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. Aprepitant is a selective high-affinity antagonist of human substance P/neurokinin 1 (NK1) receptors.		2.5820(trifluoromethyl)benzenes;
cyclic acetal;
morpholines;
triazoles		antidepressant;
antiemetic;
neurokinin-1 receptor antagonist;
peripheral nervous system drug;
substance P receptor antagonist
azilsartan
azilsartan: an angiotensin type 1 receptor blocker; receptor blocker. azilsartan : A benzimidazolecarboxylic acid that is benzimidazole-7-carboxylic acid substituted at position 2 by a methoxy group and at position 1 by a 2'-[(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]methyl group. Used (as the prodrug, azilsartan medoxomil) for treatment of hypertension.		2.6101,2,4-oxadiazole;
aromatic ether;
benzimidazolecarboxylic acid		angiotensin receptor antagonist;
antihypertensive agent
xav939
XAV939: selectively inhibits beta-catenin-mediated transcription; structure in first source. XAV939 : A thiopyranopyrimidine in which a 7,8-dihydro-5H-thiopyrano[4,3-d]pyrimidine skeleton is substituted at C-4 by a hydroxy group and at C-2 by a para-(trifluoromethyl)phenyl group.		2.0810(trifluoromethyl)benzenes;
thiopyranopyrimidine		tankyrase inhibitor
2-carboxyarabinitol 1-phosphate
[no description available]		2.0810
hesperadin
[no description available]		2.610
ro 24-7429
Ro 24-7429: blocks the action of the HIV tat protein; an analog of Ro 5-3335; Proc Natl Acad Sci U S A 1993 Jul 15;90(14):6395-9		2.8930benzodiazepine
nintedanib
nintedanib : A member of the class of oxindoles that is a kinase inhibitor used (in the form of its ethylsulfonate salt) for the treatment of idiopathic pulmonary fibrosis and cancer.		3.0740
6-bromoindirubin-3'-acetoxime
6-bromoindirubin-3'-acetoxime: a synthetic derivative of a compound from the Mediterranean mollusk Hexaplex trunculus, protects cells from varicella infection		2.610
n'-(3,4-dihydroxybenzylidene)-3-hydroxy-2-naphthahydrazide
[no description available]		3.1640catechols;
hydrazide;
hydrazone;
naphthols		EC 3.6.5.5 (dynamin GTPase) inhibitor
ver 52296
luminespib : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-(2,4-dihydroxy-5-isopropylphenyl)-4-[4-(morpholin-4-ylmethyl)phenyl]-1,2-oxazole-3-carboxylic acid with the amino group of ethylamine.		3.0740aromatic amide;
isoxazoles;
monocarboxylic acid amide;
morpholines;
resorcinols		angiogenesis inhibitor;
antineoplastic agent;
Hsp90 inhibitor
sb-590885
N-{5-[2-{4-[2-(dimethylamino)ethoxy]phenyl}-4-(pyridin-4-yl)-1H-imidazol-5-yl]-2,3-dihydro-1H-inden-1-ylidene}hydroxylamine : A ketoxime that is the oxime of indan-1-one in which the hydrogen at position 5 has been replaced by an imidazol-5-yl group which has itself been substituted at positions 2 and 4 by p-[2-(dimethylamino)ethoxy]phenyl and pyridin-4-yl groups, respectively.		2.0810aromatic ether;
imidazoles;
ketoxime;
pyridines;
tertiary amino compound
XL413
XL413 : A benzofuropyrimidine that is 3,4-dihydro[1]benzofuro[3,2-d]pyrimidine substituted by (2S)-pyrrolidin-2-yl, oxo and chloro groups at positions 2, 4, and 8, respectively. It is a potent ATP competitive inhibitor of Cdc7 kinase (IC50 = 3.4 nM) and exhibits anticancer properties.		2.610benzofuropyrimidine;
organochlorine compound;
pyrrolidines		antineoplastic agent;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor
rvx 208
apabetalone: a bromodomain and extra-terminal domain protein (BET) inhibitor; prevents interactions between BET proteins and acetyl-lysine residues on histone tails to modify epigenetic regulation		2.8930
bmn 673
talazoparib: inhibits both PARP1 and PARP2; structure in first source		2.8930
pf-477736
PF 00477736: a Chk1 inhibitor; structure in first source. PF-00477736 : A diazepinoindole that is 8-amino-4,5-dihydro-6H-[1,2]diazepino[4,5,6-cd]indol-6-one which is substituted at position 2 by a 1-methylpyrazol-4-yl group and in which the amino group at position 8 has undergone condensation with the carboxy group of (2R)-2-cyclohexylglycine to give the corresponding carboxamide. It is an inhibitor of checkpoint kinase 1 (Chk 1).		2.0810
bay 80-6946
copanlisib: an antineoplastic agent with PI3K inhibitory activity; structure in first source. copanlisib : An imidazoquinazoline that is 2,3-dihydroimidazo[1,2-c]quinazoline substituted by (2-aminopyrimidine-5-carbonyl)amino, methoxy, and 3-(morpholin-4-yl)propoxy groups at positions 5, 7 and 8, respectively. It is a intravenous pan-class I PI3K inhibitor used for the treatment of relapsed follicular lymphoma in patients who have received at least 2 prior systemic therapies.		2.2110
me0328
ME0328: inhibits ARTD3; structure in first source		2.610
fenobam
fenobam: in USAN fenobam refers to monohydrate		2.0810ureas
nvp-tnks656
[no description available]		2.610
metallothionein
Metallothionein: A low-molecular-weight (approx. 10 kD) protein occurring in the cytoplasm of kidney cortex and liver. It is rich in cysteinyl residues and contains no aromatic amino acids. Metallothionein shows high affinity for bivalent heavy metals.		2.110
leptin
Leptin: A 16-kDa peptide hormone secreted from WHITE ADIPOCYTES. Leptin serves as a feedback signal from fat cells to the CENTRAL NERVOUS SYSTEM in regulation of food intake, energy balance, and fat storage.		4.811
ConditionIndicatedRelationship StrengthStudiesTrials
Kahler Disease
[description not available]		025.68659239
Multiple Myeloma
A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY.		127.68659239
Experimental Neoplasms
[description not available]		02.5120
Adjuvant Arthritis
[description not available]		02.1710
Rheumatoid Arthritis
[description not available]		02.1710
Arthritis, Rheumatoid
A chronic systemic disease, primarily of the joints, marked by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures. Etiology is unknown, but autoimmune mechanisms have been implicated.		02.1710
Hematologic Malignancies
[description not available]		010.06125
Autoimmune Disease
[description not available]		03.9520
Autoimmune Diseases
Disorders that are characterized by the production of antibodies that react with host tissues or immune effector cells that are autoreactive to endogenous peptides.		03.9520
Hematologic Neoplasms
Neoplasms located in the blood and blood-forming tissue (the bone marrow and lymphatic tissue). The commonest forms are the various types of LEUKEMIA, of LYMPHOMA, and of the progressive, life-threatening forms of the MYELODYSPLASTIC SYNDROMES.		010.06125
Congenital Zika Syndrome
[description not available]		02.2510
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		010.92309
Zika Virus Infection
A viral disease transmitted by the bite of AEDES mosquitoes infected with ZIKA VIRUS. Its mild DENGUE-like symptoms include fever, rash, headaches and ARTHRALGIA. The viral infection during pregnancy, in rare cases, is associated with congenital brain and ocular abnormalities, called Congenital Zika Syndrome, including MICROCEPHALY and may also lead to GUILLAIN-BARRE SYNDROME.		02.2510
Acute Confusional Senile Dementia
[description not available]		02.3110
Alzheimer Disease
A degenerative disease of the BRAIN characterized by the insidious onset of DEMENTIA. Impairment of MEMORY, judgment, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROPIL THREADS. (From Adams et al., Principles of Neurology, 6th ed, pp1049-57)		02.3110
Asymptomatic Multiple Myeloma
[description not available]		05.921
Smoldering Multiple Myeloma
An asymptomatic and slow-growing PLASMA CELL dyscrasia characterized by presence of MYELOMA PROTEINS and clonal bone marrow plasma cells without end-organ damage (e.g., renal impairment). It is distinguished from MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE by a much higher risk of progression to symptomatic MULTIPLE MYELOMA.		05.921
Diathesis
[description not available]		04.3331
Recrudescence
[description not available]		020.4613368
Kidney Failure
A severe irreversible decline in the ability of kidneys to remove wastes, concentrate URINE, and maintain ELECTROLYTE BALANCE; BLOOD PRESSURE; and CALCIUM metabolism.		07.8483
Renal Insufficiency
Conditions in which the KIDNEYS perform below the normal level in the ability to remove wastes, concentrate URINE, and maintain ELECTROLYTE BALANCE; BLOOD PRESSURE; and CALCIUM metabolism. Renal insufficiency can be classified by the degree of kidney damage (as measured by the level of PROTEINURIA) and reduction in GLOMERULAR FILTRATION RATE.		07.8483
Diffuse Lymphocytic Lymphoma, Poorly-Differentiated
[description not available]		07.26112
Lymphoma, Mantle-Cell
A form of non-Hodgkin lymphoma having a usually diffuse pattern with both small and medium lymphocytes and small cleaved cells. It accounts for about 5% of adult non-Hodgkin lymphomas in the United States and Europe. The majority of mantle-cell lymphomas are associated with a t(11;14) translocation resulting in overexpression of the CYCLIN D1 gene (GENES, BCL-1).		19.26112
Lymphoma, T Cell, Peripheral
[description not available]		03.811
Local Neoplasm Recurrence
[description not available]		019.3412569
Lymphoma, T-Cell, Peripheral
A group of malignant lymphomas thought to derive from peripheral T-lymphocytes in lymph nodes and other nonlymphoid sites. They include a broad spectrum of lymphocyte morphology, but in all instances express T-cell markers admixed with epithelioid histiocytes, plasma cells, and eosinophils. Although markedly similar to large-cell immunoblastic lymphoma (LYMPHOMA, LARGE-CELL, IMMUNOBLASTIC), this group's unique features warrant separate treatment.		15.811
Cardiac Toxicity
[description not available]		015.52291
Cardiac Failure
[description not available]		09.57104
Heart Failure
A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION.		09.57104
Cardiotoxicity
Damage to the HEART or its function secondary to exposure to toxic substances such as drugs used in CHEMOTHERAPY; IMMUNOTHERAPY; or RADIATION.		010.52291
Adenocarcinoma, Basal Cell
[description not available]		02.8930
Cancer of Pancreas
[description not available]		02.6920
Adenocarcinoma
A malignant epithelial tumor with a glandular organization.		02.8930
Pancreatic Neoplasms
Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).		02.6920
Aging
The gradual irreversible changes in structure and function of an organism that occur as a result of the passage of time.		07.3110
Chromosomal Translocation
[description not available]		04.6241
Age-Related Osteoporosis
[description not available]		02.4110
Osteoporosis
Reduction of bone mass without alteration in the composition of bone, leading to fractures. Primary osteoporosis can be of two major types: postmenopausal osteoporosis (OSTEOPOROSIS, POSTMENOPAUSAL) and age-related or senile osteoporosis.		07.4110
Cancer of Lung
[description not available]		06.85112
Lung Neoplasms
Tumors or cancer of the LUNG.		06.85112
Minimal Disease, Residual
[description not available]		014.693223
Thrombotic Microangiopathies
Diseases that result in THROMBOSIS in MICROVASCULATURE. The two most prominent diseases are PURPURA, THROMBOTIC THROMBOCYTOPENIC; and HEMOLYTIC-UREMIC SYNDROME. Multiple etiological factors include VASCULAR ENDOTHELIAL CELL damage due to SHIGA TOXIN; FACTOR H deficiency; and aberrant VON WILLEBRAND FACTOR formation.		06.44200
Debility
[description not available]		02.4110
Intestinal Volvulus
A twisting in the intestine (INTESTINES) that can cause INTESTINAL OBSTRUCTION.		02.4110
AL Amyloidosis
[description not available]		02.6920
Immunoglobulin Light-chain Amyloidosis
A nonproliferative disorder of the PLASMA CELL characterized by excessive production and misfolding of IMMUNOGLOBULIN LIGHT CHAINS that form insoluble amyloid fibrils (see AMYLOID DEPOSITS) in various tissues. Clinical features include LIVER FAILURE; MULTIPLE MYELOMA; NEPHROTIC SYNDROME; RESTRICTIVE CARDIOMYOPATHY, and neuropathies.		14.6920
Blood Pressure, High
[description not available]		013.893125
Hypertension
Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more.		013.893125
Leukemia, Plasmacytic
[description not available]		03.4350
Leukemia, Plasma Cell
A rare, aggressive variant of MULTIPLE MYELOMA characterized by the circulation of excessive PLASMA CELLS in the peripheral blood. It can be a primary manifestation of multiple myeloma or develop as a terminal complication during the disease.		15.4350
Breast Cancer
[description not available]		08.62104
Breast Neoplasms
Tumors or cancer of the human BREAST.		08.62104
Abnormalities, Autosome
[description not available]		07.4874
Lymph Node Metastasis
[description not available]		02.4110
Benign Neoplasms
[description not available]		08.77182
Neoplasms
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.		112.71364
Adverse Drug Event
[description not available]		07.62113
Drug-Related Side Effects and Adverse Reactions
Disorders that result from the intended use of PHARMACEUTICAL PREPARATIONS. Included in this heading are a broad variety of chemically-induced adverse conditions due to toxicity, DRUG INTERACTIONS, and metabolic effects of pharmaceuticals.		07.62113
Benign Meningeal Neoplasms
[description not available]		02.610
Angioblastic Meningioma
[description not available]		02.610
Meningeal Neoplasms
Benign and malignant neoplastic processes that arise from or secondarily involve the meningeal coverings of the brain and spinal cord.		02.610
Meningioma
A relatively common neoplasm of the CENTRAL NERVOUS SYSTEM that arises from arachnoidal cells. The majority are well differentiated vascular tumors which grow slowly and have a low potential to be invasive, although malignant subtypes occur. Meningiomas have a predilection to arise from the parasagittal region, cerebral convexity, sphenoidal ridge, olfactory groove, and SPINAL CANAL. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2056-7)		07.610
Diffuse Large B-Cell Lymphoma
[description not available]		05.2152
Lymphoma, Large B-Cell, Diffuse
Malignant lymphoma composed of large B lymphoid cells whose nuclear size can exceed normal macrophage nuclei, or more than twice the size of a normal lymphocyte. The pattern is predominantly diffuse. Most of these lymphomas represent the malignant counterpart of B-lymphocytes at midstage in the process of differentiation.		17.2152
Plasma Cell Tumor
[description not available]		04.0140
Plasmacytoma
Any discrete, presumably solitary, mass of neoplastic PLASMA CELLS either in BONE MARROW or various extramedullary sites.		16.0140
Thrombopenia
[description not available]		014.213430
Thrombocytopenia
A subnormal level of BLOOD PLATELETS.		014.213430
Neoplasms, Plasma Cell
Neoplasms associated with a proliferation of a single clone of PLASMA CELLS and characterized by the secretion of PARAPROTEINS.		02.610
Carcinoma, Non-Small Cell Lung
[description not available]		05.4541
Carcinoma, Non-Small-Cell Lung
A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.		05.4541
Hematochezia
The passage of bright red blood from the rectum. The blood may or may not be mixed with formed stool in the form of blood, blood clots, bloody stool or diarrhea.		02.610
Gastrointestinal Hemorrhage
Bleeding in any segment of the GASTROINTESTINAL TRACT from ESOPHAGUS to RECTUM.		07.610
2019 Novel Coronavirus Disease
[description not available]		09.9976
Crow-Fukase Syndrome
[description not available]		02.6920
POEMS Syndrome
A multisystemic disorder characterized by a sensorimotor polyneuropathy (POLYNEUROPATHIES), organomegaly, endocrinopathy, monoclonal gammopathy, and pigmentary skin changes. Other clinical features which may be present include EDEMA; CACHEXIA; microangiopathic glomerulopathy; pulmonary hypertension (HYPERTENSION, PULMONARY); cutaneous necrosis; THROMBOCYTOSIS; and POLYCYTHEMIA. This disorder is frequently associated with osteosclerotic myeloma. (From Adams et al., Principles of Neurology, 6th ed, p1335; Rev Med Interne 1997;18(7):553-62)		07.6920
Chronic Lung Injury
[description not available]		02.610
Pulmonary Hypertension
[description not available]		02.6320
Hypertension, Pulmonary
Increased VASCULAR RESISTANCE in the PULMONARY CIRCULATION, usually secondary to HEART DISEASES or LUNG DISEASES.		02.6320
Extravascular Hemolysis
[description not available]		03.1440
Hemolysis
The destruction of ERYTHROCYTES by many different causal agents such as antibodies, bacteria, chemicals, temperature, and changes in tonicity.		03.1440
Thromboembolism, Venous
[description not available]		03.830
Venous Thromboembolism
Obstruction of a vein or VEINS (embolism) by a blood clot (THROMBUS) in the blood stream.		03.830
Diffuse Mixed Small and Large Cell Lymphoma
[description not available]		05.7832
Lymphoma, Non-Hodgkin
Any of a group of malignant tumors of lymphoid tissue that differ from HODGKIN DISEASE, being more heterogeneous with respect to malignant cell lineage, clinical course, prognosis, and therapy. The only common feature among these tumors is the absence of giant REED-STERNBERG CELLS, a characteristic of Hodgkin's disease.		17.7832
Necrosis
The death of cells in an organ or tissue due to disease, injury or failure of the blood supply.		02.2110
Reticulocytosis
An increase in circulating RETICULOCYTES, which is among the simplest and most reliable signs of accelerated ERYTHROCYTE production. Reticulocytosis occurs during active BLOOD regeneration (stimulation of red bone marrow) and in certain types of ANEMIA, particularly CONGENITAL HEMOLYTIC ANEMIA.		07.2510
Cell Transformation, Neoplastic
Cell changes manifested by escape from control mechanisms, increased growth potential, alterations in the cell surface, karyotypic abnormalities, morphological and biochemical deviations from the norm, and other attributes conferring the ability to invade, metastasize, and kill.		03.0540
Malignant Melanoma
[description not available]		05.1931
Melanoma
A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)		05.1931
Brugada ECG Pattern
[description not available]		07.2510
Brugada Syndrome
An autosomal dominant defect of cardiac conduction that is characterized by an abnormal ST-segment in leads V1-V3 on the ELECTROCARDIOGRAM resembling a right BUNDLE-BRANCH BLOCK; high risk of VENTRICULAR TACHYCARDIA; or VENTRICULAR FIBRILLATION; SYNCOPAL EPISODE; and possible sudden death. This syndrome is linked to mutations of gene encoding the cardiac SODIUM CHANNEL alpha subunit.		02.2510
Bilirubinemia
[description not available]		04.5111
Hypoalbuminemia
A condition in which albumin level in blood (SERUM ALBUMIN) is below the normal range. Hypoalbuminemia may be due to decreased hepatic albumin synthesis, increased albumin catabolism, altered albumin distribution, or albumin loss through the urine (ALBUMINURIA).		04.5111
Cardiac Diseases
[description not available]		010.25162
Disease, Pulmonary
[description not available]		02.2510
Heart Diseases
Pathological conditions involving the HEART including its structural and functional abnormalities.		010.25162
Lung Diseases
Pathological processes involving any part of the LUNG.		02.2510
Orphan Diseases
Rare diseases that have not been well studied.		02.2510
Bone Cancer
[description not available]		04.0140
Bone Neoplasms
Tumors or cancer located in bone tissue or specific BONES.		04.0140
ER-Negative PR-Negative HER2-Negative Breast Cancer
[description not available]		02.8730
Triple Negative Breast Neoplasms
Breast neoplasms that do not express ESTROGEN RECEPTORS; PROGESTERONE RECEPTORS; and do not overexpress the NEU RECEPTOR/HER-2 PROTO-ONCOGENE PROTEIN.		02.8730
Disease Exacerbation
[description not available]		012.11189
Benign Monoclonal Gammopathies
[description not available]		03.1710
Carcinoma, Small Cell Lung
[description not available]		04.2631
Small Cell Lung Carcinoma
A form of highly malignant lung cancer that is composed of small ovoid cells (SMALL CELL CARCINOMA).		16.2631
Hospital-Acquired Condition
[description not available]		02.2510
Focal Segmental Glomerulosclerosis
[description not available]		05.8232
Glomerulosclerosis, Focal Segmental
A clinicopathological syndrome or diagnostic term for a type of glomerular injury that has multiple causes, primary or secondary. Clinical features include PROTEINURIA, reduced GLOMERULAR FILTRATION RATE, and EDEMA. Kidney biopsy initially indicates focal segmental glomerular consolidation (hyalinosis) or scarring which can progress to globally sclerotic glomeruli leading to eventual KIDNEY FAILURE.		05.8232
Proteinuria
The presence of proteins in the urine, an indicator of KIDNEY DISEASES.		07.8864
Gastrointestinal Stromal Neoplasm
[description not available]		02.2510
Gastrointestinal Stromal Tumors
All tumors in the GASTROINTESTINAL TRACT arising from mesenchymal cells (MESODERM) except those of smooth muscle cells (LEIOMYOMA) or Schwann cells (SCHWANNOMA).		02.2510
Infections, Coronavirus
[description not available]		05.921
Pneumonia, Viral
Inflammation of the lung parenchyma that is caused by a viral infection.		05.921
Coronavirus Infections
Virus diseases caused by the CORONAVIRUS genus. Some specifics include transmissible enteritis of turkeys (ENTERITIS, TRANSMISSIBLE, OF TURKEYS); FELINE INFECTIOUS PERITONITIS; and transmissible gastroenteritis of swine (GASTROENTERITIS, TRANSMISSIBLE, OF SWINE).		05.921
Cancer of Cervix
[description not available]		02.2510
Uterine Cervical Neoplasms
Tumors or cancer of the UTERINE CERVIX.		02.2510
Acute Kidney Failure
[description not available]		010.35146
Acute Kidney Injury
Abrupt reduction in kidney function. Acute kidney injury encompasses the entire spectrum of the syndrome including acute kidney failure; ACUTE KIDNEY TUBULAR NECROSIS; and other less severe conditions.		010.35146
Gasser Syndrome
[description not available]		02.8630
Hemolytic-Uremic Syndrome
A syndrome that is associated with microvascular diseases of the KIDNEY, such as RENAL CORTICAL NECROSIS. It is characterized by hemolytic anemia (ANEMIA, HEMOLYTIC); THROMBOCYTOPENIA; and ACUTE RENAL FAILURE.		02.8630
Blood Diseases
[description not available]		07.4253
Familial Waldenstrom's Macroglobulinaemia
[description not available]		06.8681
Symptom Cluster
[description not available]		02.2510
Hematologic Diseases
Disorders of the blood and blood forming tissues.		07.4253
Waldenstrom Macroglobulinemia
A lymphoproliferative disorder characterized by pleomorphic B-LYMPHOCYTES including PLASMA CELLS, with increased levels of monoclonal serum IMMUNOGLOBULIN M. There is lymphoplasmacytic cells infiltration into bone marrow and often other tissues, also known as lymphoplasmacytic lymphoma. Clinical features include ANEMIA; HEMORRHAGES; and hyperviscosity.		113.8681
Syndrome
A characteristic symptom complex.		02.2510
Carcinoma, Ductal, Pancreatic
[description not available]		02.2510
Carcinoma, Pancreatic Ductal
Carcinoma that arises from the PANCREATIC DUCTS. It accounts for the majority of cancers derived from the PANCREAS.		02.2510
Ischemia
A hypoperfusion of the BLOOD through an organ or tissue caused by a PATHOLOGIC CONSTRICTION or obstruction of its BLOOD VESSELS, or an absence of BLOOD CIRCULATION.		05.0221
Atypical Lipomatous Tumor
[description not available]		02.3110
Liposarcoma
A malignant tumor derived from primitive or embryonal lipoblastic cells. It may be composed of well-differentiated fat cells or may be dedifferentiated: myxoid (LIPOSARCOMA, MYXOID), round-celled, or pleomorphic, usually in association with a rich network of capillaries. Recurrences are common and dedifferentiated liposarcomas metastasize to the lungs or serosal surfaces. (From Dorland, 27th ed; Stedman, 25th ed)		07.3110
Genetic Predisposition
[description not available]		04.8821
Chronic Illness
[description not available]		04.6211
Attachment Loss, Periodontal
[description not available]		04.6211
Chemical Dependence
[description not available]		04.6211
Cerebral Infarction, Middle Cerebral Artery
[description not available]		04.6211
Osteoarthritis of Knee
[description not available]		04.6211
Deafness, Transitory
[description not available]		04.6211
Liver Abscess, Pyogenic
Single or multiple areas of PUS due to bacterial infection within the hepatic parenchyma. It can be caused by a variety of BACTERIA, local or disseminated from infections elsewhere such as in APPENDICITIS; CHOLECYSTITIS; PERITONITIS; and after LIVER TRANSPLANTATION.		04.6211
Complications of Diabetes Mellitus
[description not available]		07.7444
Acute Liver Injury, Drug-Induced
[description not available]		05.8132
Carcinogenesis
The origin, production or development of cancer through genotypic and phenotypic changes which upset the normal balance between cell proliferation and cell death. Carcinogenesis generally requires a constellation of steps, which may occur quickly or over a period of many years.		07.7444
Fatty Liver, Nonalcoholic
[description not available]		04.6211
Esophageal Squamous Cell Carcinoma
A carcinoma that originates usually from cells on the surface of the middle and lower third of the ESOPHAGUS. Tumor cells exhibit typical squamous morphology and form large polypoid lesions. Mutations in RNF6, LZTS1, TGFBR2, DEC1, and WWOX1 genes are associated with this cancer.		04.6211
Ancylostomiasis
Infection of humans or animals with hookworms of the genus ANCYLOSTOMA. Characteristics include anemia, dyspepsia, eosinophilia, and abdominal swelling.		04.6211
Auricular Fibrillation
[description not available]		04.6211
Bladder Cancer
[description not available]		04.8721
Bladder Disorder, Neurogenic
[description not available]		04.6211
Acute Brain Injuries
[description not available]		04.6211
Benign Neoplasms, Brain
[description not available]		08.0164
Carcinoma, Epidermoid
[description not available]		05.1231
Cerebral Ischemia
[description not available]		04.6211
Caries, Dental
[description not available]		04.6211
Alloxan Diabetes
[description not available]		04.6211
Diabetes Mellitus, Adult-Onset
[description not available]		04.9421
Canine Diseases
[description not available]		04.9421
Cancer of Esophagus
[description not available]		04.6211
Fistula
Abnormal communication most commonly seen between two internal organs, or between an internal organ and the surface of the body.		04.6211
Cancer of Gastrointestinal Tract
[description not available]		06.6232
Astrocytoma, Grade IV
[description not available]		05.1931
Glial Cell Tumors
[description not available]		04.6211
Bleeding
[description not available]		05.1831
Hepatocellular Carcinoma
[description not available]		05.8441
Innate Inflammatory Response
[description not available]		08.0164
Infections, Klebsiella
[description not available]		04.6211
Cirrhosis, Liver
[description not available]		04.6211
Liver Dysfunction
[description not available]		04.6211
Cancer of Liver
[description not available]		06.0151
Mitral Incompetence
[description not available]		04.6211
Cardiomyopathies, Primary
[description not available]		04.921
Angiogenesis, Pathologic
[description not available]		07.7444
Morbid Obesity
[description not available]		04.6211
Arthritis, Degenerative
[description not available]		04.6211
Pocket, Periodontal
[description not available]		04.6211
Pericementitis
[description not available]		04.6211
Complication, Postoperative
[description not available]		05.8321
Condition, Preneoplastic
[description not available]		04.6211
Cancer of Prostate
[description not available]		07.8654
Embolism, Pulmonary
[description not available]		06.6432
Acute Respiratory Distress Syndrome
[description not available]		04.921
Sarcoma, Epithelioid
[description not available]		04.9221
Linear Skull Fracture
[description not available]		04.6211
Cancer of Stomach
[description not available]		09.9399
Nicotine Addiction
[description not available]		04.6211
Zoonoses
Diseases of non-human animals that may be transmitted to HUMANS or may be transmitted from humans to non-human animals.		04.6211
Coxarthrosis
[description not available]		04.6211
Injury, Ischemia-Reperfusion
[description not available]		07.7444
MPTP Neurotoxicity Syndrome
[description not available]		04.6211
Shoulder Injuries
Injuries involving the SHOULDERS and SHOULDER JOINT.		04.6211
Hemorrhage, Gingival
[description not available]		04.6211
Acute Disease
Disease having a short and relatively severe course.		04.6211
Atrial Fibrillation
Abnormal cardiac rhythm that is characterized by rapid, uncoordinated firing of electrical impulses in the upper chambers of the heart (HEART ATRIA). In such case, blood cannot be effectively pumped into the lower chambers of the heart (HEART VENTRICLES). It is caused by abnormal impulse generation.		04.6211
Biliary Tract Diseases
Diseases in any part of the BILIARY TRACT including the BILE DUCTS and the GALLBLADDER.		04.6211
Urinary Bladder Neoplasms
Tumors or cancer of the URINARY BLADDER.		04.8721
Urinary Bladder, Neurogenic
Dysfunction of the URINARY BLADDER due to disease of the central or peripheral nervous system pathways involved in the control of URINATION. This is often associated with SPINAL CORD DISEASES, but may also be caused by BRAIN DISEASES or PERIPHERAL NERVE DISEASES.		04.6211
Brain Injuries
Acute and chronic (see also BRAIN INJURIES, CHRONIC) injuries to the brain, including the cerebral hemispheres, CEREBELLUM, and BRAIN STEM. Clinical manifestations depend on the nature of injury. Diffuse trauma to the brain is frequently associated with DIFFUSE AXONAL INJURY or COMA, POST-TRAUMATIC. Localized injuries may be associated with NEUROBEHAVIORAL MANIFESTATIONS; HEMIPARESIS, or other focal neurologic deficits.		04.6211
Brain Neoplasms
Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain.		08.0164
Carcinoma, Squamous Cell
A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed)		05.1231
Cardiovascular Diseases
Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM.		013.2195
Brain Ischemia
Localized reduction of blood flow to brain tissue due to arterial obstruction or systemic hypoperfusion. This frequently occurs in conjunction with brain hypoxia (HYPOXIA, BRAIN). Prolonged ischemia is associated with BRAIN INFARCTION.		04.6211
Chronic Disease
Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).		04.6211
Dental Caries
Localized destruction of the tooth surface initiated by decalcification of the enamel followed by enzymatic lysis of organic structures and leading to cavity formation. If left unchecked, the cavity may penetrate the enamel and dentin and reach the pulp.		04.6211
Diabetes Mellitus
A heterogeneous group of disorders characterized by HYPERGLYCEMIA and GLUCOSE INTOLERANCE.		04.6211
Diabetes Mellitus, Type 2
A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.		04.9421
Esophageal Neoplasms
Tumors or cancer of the ESOPHAGUS.		04.6211
Gingival Hemorrhage
The flowing of blood from the marginal gingival area, particularly the sulcus, seen in such conditions as GINGIVITIS, marginal PERIODONTITIS, injury, and ASCORBIC ACID DEFICIENCY.		04.6211
Glioblastoma
A malignant form of astrocytoma histologically characterized by pleomorphism of cells, nuclear atypia, microhemorrhage, and necrosis. They may arise in any region of the central nervous system, with a predilection for the cerebral hemispheres, basal ganglia, and commissural pathways. Clinical presentation most frequently occurs in the fifth or sixth decade of life with focal neurologic signs or seizures.		010.1931
Glioma
Benign and malignant central nervous system neoplasms derived from glial cells (i.e., astrocytes, oligodendrocytes, and ependymocytes). Astrocytes may give rise to astrocytomas (ASTROCYTOMA) or glioblastoma multiforme (see GLIOBLASTOMA). Oligodendrocytes give rise to oligodendrogliomas (OLIGODENDROGLIOMA) and ependymocytes may undergo transformation to become EPENDYMOMA; CHOROID PLEXUS NEOPLASMS; or colloid cysts of the third ventricle. (From Escourolle et al., Manual of Basic Neuropathology, 2nd ed, p21)		04.6211
Hemorrhage
Bleeding or escape of blood from a vessel.		010.1831
Carcinoma, Hepatocellular
A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.		05.8441
Inflammation
A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.		013.0164
Kidney Diseases
Pathological processes of the KIDNEY or its component tissues.		09.96112
Klebsiella Infections
Infections with bacteria of the genus KLEBSIELLA.		04.6211
Liver Cirrhosis
Liver disease in which the normal microcirculation, the gross vascular anatomy, and the hepatic architecture have been variably destroyed and altered with fibrous septa surrounding regenerated or regenerating parenchymal nodules.		04.6211
Liver Diseases
Pathological processes of the LIVER.		04.6211
Liver Neoplasms
Tumors or cancer of the LIVER.		06.0151
Mitral Valve Insufficiency
Backflow of blood from the LEFT VENTRICLE into the LEFT ATRIUM due to imperfect closure of the MITRAL VALVE. This can lead to mitral valve regurgitation.		04.6211
Cardiomyopathies
A group of diseases in which the dominant feature is the involvement of the CARDIAC MUSCLE itself. Cardiomyopathies are classified according to their predominant pathophysiological features (DILATED CARDIOMYOPATHY; HYPERTROPHIC CARDIOMYOPATHY; RESTRICTIVE CARDIOMYOPATHY) or their etiological/pathological factors (CARDIOMYOPATHY, ALCOHOLIC; ENDOCARDIAL FIBROELASTOSIS).		04.921
Obesity, Morbid
The condition of weighing two, three, or more times the ideal weight, so called because it is associated with many serious and life-threatening disorders. In the BODY MASS INDEX, morbid obesity is defined as having a BMI greater than 40.0 kg/m2.		04.6211
Osteoarthritis
A progressive, degenerative joint disease, the most common form of arthritis, especially in older persons. The disease is thought to result not from the aging process but from biochemical changes and biomechanical stresses affecting articular cartilage. In the foreign literature it is often called osteoarthrosis deformans.		04.6211
Periodontal Pocket
An abnormal extension of a gingival sulcus accompanied by the apical migration of the epithelial attachment and bone resorption.		04.6211
Periodontitis
Inflammation and loss of connective tissues supporting or surrounding the teeth. This may involve any part of the PERIODONTIUM. Periodontitis is currently classified by disease progression (CHRONIC PERIODONTITIS; AGGRESSIVE PERIODONTITIS) instead of age of onset. (From 1999 International Workshop for a Classification of Periodontal Diseases and Conditions, American Academy of Periodontology)		04.6211
Postoperative Complications
Pathologic processes that affect patients after a surgical procedure. They may or may not be related to the disease for which the surgery was done, and they may or may not be direct results of the surgery.		05.8321
Precancerous Conditions
Pathological conditions that tend eventually to become malignant.		04.6211
Pregnancy
The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.		07.7444
Prostatic Neoplasms
Tumors or cancer of the PROSTATE.		07.8654
Pulmonary Embolism
Blocking of the PULMONARY ARTERY or one of its branches by an EMBOLUS.		06.6432
Respiratory Distress Syndrome
A syndrome characterized by progressive life-threatening RESPIRATORY INSUFFICIENCY in the absence of known LUNG DISEASES, usually following a systemic insult such as surgery or major TRAUMA.		04.921
Sarcoma
A connective tissue neoplasm formed by proliferation of mesodermal cells; it is usually highly malignant.		04.9221
Stomach Neoplasms
Tumors or cancer of the STOMACH.		09.9399
Tobacco Use Disorder
Tobacco used to the detriment of a person's health or social functioning. Tobacco dependence is included.		04.6211
Vitiligo
A disorder consisting of areas of macular depigmentation, commonly on extensor aspects of extremities, on the face or neck, and in skin folds. Age of onset is often in young adulthood and the condition tends to progress gradually with lesions enlarging and extending until a quiescent state is reached.		04.6211
Osteoarthritis, Hip
Noninflammatory degenerative disease of the hip joint which usually appears in late middle or old age. It is characterized by growth or maturational disturbances in the femoral neck and head, as well as acetabular dysplasia. A dominant symptom is pain on weight-bearing or motion.		04.6211
Reperfusion Injury
Adverse functional, metabolic, or structural changes in tissues that result from the restoration of blood flow to the tissue (REPERFUSION) following ISCHEMIA.		07.7444
Substance-Related Disorders
Disorders related to substance use or abuse.		04.6211
Infarction, Middle Cerebral Artery
NECROSIS occurring in the MIDDLE CEREBRAL ARTERY distribution system which brings blood to the entire lateral aspects of each CEREBRAL HEMISPHERE. Clinical signs include impaired cognition; APHASIA; AGRAPHIA; weak and numbness in the face and arms, contralaterally or bilaterally depending on the infarction.		04.6211
Osteoarthritis, Knee
Noninflammatory degenerative disease of the knee joint consisting of three large categories: conditions that block normal synchronous movement, conditions that produce abnormal pathways of motion, and conditions that cause stress concentration resulting in changes to articular cartilage. (Crenshaw, Campbell's Operative Orthopaedics, 8th ed, p2019)		04.6211
Hearing Loss
A general term for the complete or partial loss of the ability to hear from one or both ears.		04.6211
Lipid Metabolism Disorders
Pathological conditions resulting from abnormal anabolism or catabolism of lipids in the body.		04.6211
Chemical and Drug Induced Liver Injury
A spectrum of clinical liver diseases ranging from mild biochemical abnormalities to ACUTE LIVER FAILURE, caused by drugs, drug metabolites, herbal and dietary supplements and chemicals from the environment.		05.8132
Non-alcoholic Fatty Liver Disease
Fatty liver finding without excessive ALCOHOL CONSUMPTION.		04.6211
Graft-Versus-Host Disease
[description not available]		08.2310
Graft vs Host Disease
The clinical entity characterized by anorexia, diarrhea, loss of hair, leukopenia, thrombocytopenia, growth retardation, and eventual death brought about by the GRAFT VS HOST REACTION.		03.2310
Bullous Dermatoses
[description not available]		02.3110
Albuminuria
The presence of albumin in the urine, an indicator of KIDNEY DISEASES.		09.0421
Hypophosphatemia
A condition of an abnormally low level of PHOSPHATES in the blood.		07.754
Neuroblastoma
A common neoplasm of early childhood arising from neural crest cells in the sympathetic nervous system, and characterized by diverse clinical behavior, ranging from spontaneous remission to rapid metastatic progression and death. This tumor is the most common intraabdominal malignancy of childhood, but it may also arise from thorax, neck, or rarely occur in the central nervous system. Histologic features include uniform round cells with hyperchromatic nuclei arranged in nests and separated by fibrovascular septa. Neuroblastomas may be associated with the opsoclonus-myoclonus syndrome. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2099-2101; Curr Opin Oncol 1998 Jan;10(1):43-51)		02.9330
Osteogenic Sarcoma
[description not available]		02.6320
Osteosarcoma
A sarcoma originating in bone-forming cells, affecting the ends of long bones. It is the most common and most malignant of sarcomas of the bones, and occurs chiefly among 10- to 25-year-old youths. (From Stedman, 25th ed)		07.6320
Neoplasms, Pleural
[description not available]		03.5520
Acute Promyelocytic Leukemia
[description not available]		02.3110
Leukemia, Promyelocytic, Acute
An acute myeloid leukemia in which abnormal PROMYELOCYTES predominate. It is frequently associated with DISSEMINATED INTRAVASCULAR COAGULATION.		02.3110
Peripheral Nerve Diseases
[description not available]		09.4123
Peripheral Nervous System Diseases
Diseases of the peripheral nerves external to the brain and spinal cord, which includes diseases of the nerve roots, ganglia, plexi, autonomic nerves, sensory nerves, and motor nerves.		09.4123
Acute Lymphoid Leukemia
[description not available]		04.5422
Hypocalcemia
Reduction of the blood calcium below normal. Manifestations include hyperactive deep tendon reflexes, Chvostek's sign, muscle and abdominal cramps, and carpopedal spasm. (Dorland, 27th ed)		03.711
Hyponatremia
Deficiency of sodium in the blood; salt depletion. (Dorland, 27th ed)		03.711
Precursor Cell Lymphoblastic Leukemia-Lymphoma
A neoplasm characterized by abnormalities of the lymphoid cell precursors leading to excessive lymphoblasts in the marrow and other organs. It is the most common cancer in children and accounts for the vast majority of all childhood leukemias.		16.5422
Pulmonary Arterial Hypertension
A progressive rare pulmonary disease characterized by high blood pressure in the PULMONARY ARTERY.		07.3110
Vascular Diseases
Pathological processes involving any of the BLOOD VESSELS in the cardiac or peripheral circulation. They include diseases of ARTERIES; VEINS; and rest of the vasculature system in the body.		03.9521
Atypical Hemolytic-Uremic Syndrome
[description not available]		02.7220
Congenital Thrombotic Thrombocytopenic Purpura
[description not available]		02.3110
Purpura, Thrombotic Thrombocytopenic
An acquired, congenital, or familial disorder caused by PLATELET AGGREGATION with THROMBOSIS in terminal arterioles and capillaries. Clinical features include THROMBOCYTOPENIA; HEMOLYTIC ANEMIA; AZOTEMIA; FEVER; and thrombotic microangiopathy. The classical form also includes neurological symptoms and end-organ damage, such as RENAL FAILURE. Mutations in the ADAMTS13 PROTEIN gene have been identified in familial cases.		02.3110
Atypical Hemolytic Uremic Syndrome
An hereditary hemolytic uremic syndrome associated with variations in the gene that encodes COMPLEMENT FACTOR H, or the related proteins CFHR1 and CFHR3. Disease often progresses to CHRONIC KIDNEY FAILURE without the prodromal symptoms of ENTEROCOLITIS and DIARRHEA that characterize typical hemolytic uremic syndrome.		07.7220
Cholera Infantum
[description not available]		04.9221
Adenohypophyseal Hyposecretion
[description not available]		03.711
MODS
[description not available]		03.711
Hypopituitarism
Diminution or cessation of secretion of one or more hormones from the anterior pituitary gland (including LH; FOLLICLE STIMULATING HORMONE; SOMATOTROPIN; and CORTICOTROPIN). This may result from surgical or radiation ablation, non-secretory PITUITARY NEOPLASMS, metastatic tumors, infarction, PITUITARY APOPLEXY, infiltrative or granulomatous processes, and other conditions.		03.711
Multiple Organ Failure
A progressive condition usually characterized by combined failure of several organs such as the lungs, liver, kidney, along with some clotting mechanisms, usually postinjury or postoperative.		03.711
DRESS Syndrome
[description not available]		07.3110
Colorectal Cancer
[description not available]		02.5720
Invasiveness, Neoplasm
[description not available]		02.9130
Colorectal Neoplasms
Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.		02.5720
Leucocythaemia
[description not available]		03.7130
Leukemia
A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006)		110.7130
Anoxemia
[description not available]		02.1510
Hypoxia
Sub-optimal OXYGEN levels in the ambient air of living organisms.		02.1510
Muscle Spasm
[description not available]		02.1510
Spasm
An involuntary contraction of a muscle or group of muscles. Spasms may involve SKELETAL MUSCLE or SMOOTH MUSCLE.		02.1510
Systolic Heart Failure
[description not available]		02.1510
Heart Failure, Systolic
Heart failure caused by abnormal myocardial contraction during SYSTOLE leading to defective cardiac emptying.		02.1510
Anterior Cerebral Circulation Infarction
[description not available]		02.1710
Anterior Circulation Transient Ischemic Attack
[description not available]		02.1710
Ischemic Attack, Transient
Brief reversible episodes of focal, nonconvulsive ischemic dysfunction of the brain having a duration of less than 24 hours, and usually less than one hour, caused by transient thrombotic or embolic blood vessel occlusion or stenosis. Events may be classified by arterial distribution, temporal pattern, or etiology (e.g., embolic vs. thrombotic). (From Adams et al., Principles of Neurology, 6th ed, pp814-6)		02.1710
Brain Infarction
Tissue NECROSIS in any area of the brain, including the CEREBRAL HEMISPHERES, the CEREBELLUM, and the BRAIN STEM. Brain infarction is the result of a cascade of events initiated by inadequate blood flow through the brain that is followed by HYPOXIA and HYPOGLYCEMIA in brain tissue. Damage may be temporary, permanent, selective or pan-necrosis.		02.1710
Gammapathy, Monoclonal
[description not available]		03.4720
Retinal Pigment Epithelial Detachment
[description not available]		02.1710
Macular Holes
[description not available]		02.1710
Paraproteinemias
A group of related diseases characterized by an unbalanced or disproportionate proliferation of immunoglobulin-producing cells, usually from a single clone. These cells frequently secrete a structurally homogeneous immunoglobulin (M-component) and/or an abnormal immunoglobulin.		03.4720
Retinal Detachment
Separation of the inner layers of the retina (neural retina) from the pigment epithelium. Retinal detachment occurs more commonly in men than in women, in eyes with degenerative myopia, in aging and in aphakia. It may occur after an uncomplicated cataract extraction, but it is seen more often if vitreous humor has been lost during surgery. (Dorland, 27th ed; Newell, Ophthalmology: Principles and Concepts, 7th ed, p310-12).		02.1710
Retinal Perforations
Perforations through the whole thickness of the retina including the macula as the result of inflammation, trauma, degeneration, etc. The concept includes retinal breaks, tears, dialyses, and holes.		02.1710
Epithelial Ovarian Cancer
[description not available]		02.1710
Carcinoma, Colloid
[description not available]		02.1710
Cancer of Ovary
[description not available]		02.5920
Cystadenoma, Mucinous
A multilocular tumor with mucin secreting epithelium. They are most often found in the ovary, but are also found in the pancreas, appendix, and rarely, retroperitoneal and in the urinary bladder. They are considered to have low-grade malignant potential.		02.1710
Carcinoma, Ovarian Epithelial
A malignant neoplasm that originates in cells on the surface EPITHELIUM of the ovary and is the most common form of ovarian cancer. There are five histologic subtypes: papillary serous, endometrioid, mucinous, clear cell, and transitional cell. Mutations in BRCA1, OPCML, PRKN, PIK3CA, AKT1, CTNNB1, RRAS2, and CDH1 genes are associated with this cancer.		02.1710
Adenocarcinoma, Mucinous
An adenocarcinoma producing mucin in significant amounts. (From Dorland, 27th ed)		02.1710
Ovarian Neoplasms
Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.		02.5920
Lassitude
[description not available]		09.3898
Anemia
A reduction in the number of circulating ERYTHROCYTES or in the quantity of HEMOGLOBIN.		019.113229
Fatigue
The state of weariness following a period of exertion, mental or physical, characterized by a decreased capacity for work and reduced efficiency to respond to stimuli.		09.3898
Asymptomatic Conditions
[description not available]		02.1710
Left Ventricular Dysfunction
[description not available]		03.9821
Ventricular Dysfunction, Left
A condition in which the LEFT VENTRICLE of the heart was functionally impaired. This condition usually leads to HEART FAILURE; MYOCARDIAL INFARCTION; and other cardiovascular complications. Diagnosis is made by measuring the diminished ejection fraction and a depressed level of motility of the left ventricular wall.		03.9821
Diarrhea
An increased liquidity or decreased consistency of FECES, such as running stool. Fecal consistency is related to the ratio of water-holding capacity of insoluble solids to total water, rather than the amount of water present. Diarrhea is not hyperdefecation or increased fecal weight.		06.4933
Malignant Mesothelioma
[description not available]		02.1710
Mesothelioma
A tumor derived from mesothelial tissue (peritoneum, pleura, pericardium). It appears as broad sheets of cells, with some regions containing spindle-shaped, sarcoma-like cells and other regions showing adenomatous patterns. Pleural mesotheliomas have been linked to exposure to asbestos. (Dorland, 27th ed)		02.1710
Heart Disease, Ischemic
[description not available]		02.1710
Myocardial Ischemia
A disorder of cardiac function caused by insufficient blood flow to the muscle tissue of the heart. The decreased blood flow may be due to narrowing of the coronary arteries (CORONARY ARTERY DISEASE), to obstruction by a thrombus (CORONARY THROMBOSIS), or less commonly, to diffuse narrowing of arterioles and other small vessels within the heart. Severe interruption of the blood supply to the myocardial tissue may result in necrosis of cardiac muscle (MYOCARDIAL INFARCTION).		02.1710
Acute Hepatic Failure
[description not available]		02.1710
Liver Failure, Acute
A form of rapid-onset LIVER FAILURE, also known as fulminant hepatic failure, caused by severe liver injury or massive loss of HEPATOCYTES. It is characterized by sudden development of liver dysfunction and JAUNDICE. Acute liver failure may progress to exhibit cerebral dysfunction even HEPATIC COMA depending on the etiology that includes hepatic ISCHEMIA, drug toxicity, malignant infiltration, and viral hepatitis such as post-transfusion HEPATITIS B and HEPATITIS C.		02.1710
Babesia Infection
[description not available]		02.1710
Milk-Alkali Syndrome
[description not available]		02.1710
Ache
[description not available]		02.1710
Hypercalcemia
Abnormally high level of calcium in the blood.		02.1710
Pain
An unpleasant sensation induced by noxious stimuli which are detected by NERVE ENDINGS of NOCICEPTIVE NEURONS.		02.1710
Active Hyperemia
[description not available]		02.1710
Hyperemia
The presence of an increased amount of blood in a body part or an organ leading to congestion or engorgement of blood vessels. Hyperemia can be due to increase of blood flow into the area (active or arterial), or due to obstruction of outflow of blood from the area (passive or venous).		02.1710
Metastase
[description not available]		02.5520
Neoplasm Metastasis
The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.		02.5520
Emesis
[description not available]		02.2510
Tumour Lysis Syndrome
[description not available]		04.1650
Nausea
An unpleasant sensation in the stomach usually accompanied by the urge to vomit. Common causes are early pregnancy, sea and motion sickness, emotional stress, intense pain, food poisoning, and various enteroviruses.		07.7454
Neutropenia
A decrease in the number of NEUTROPHILS found in the blood.		08.2164
Vomiting
The forcible expulsion of the contents of the STOMACH through the MOUTH.		02.2510
Tumor Lysis Syndrome
A syndrome resulting from cytotoxic therapy, occurring generally in aggressive, rapidly proliferating lymphoproliferative disorders. It is characterized by combinations of hyperuricemia, lactic acidosis, hyperkalemia, hyperphosphatemia and hypocalcemia.		04.1650
Lung Injury, Acute
[description not available]		02.2110
Vascular Injuries
[description not available]		07.2110
Acute Lung Injury
A condition of lung damage that is characterized by bilateral pulmonary infiltrates (PULMONARY EDEMA) rich in NEUTROPHILS, and in the absence of clinical HEART FAILURE. This can represent a spectrum of pulmonary lesions, endothelial and epithelial, due to numerous factors (physical, chemical, or biological).		02.2110
B-Cell Lymphoma
[description not available]		09.231
Lymphoma, B-Cell
A group of heterogeneous lymphoid tumors generally expressing one or more B-cell antigens or representing malignant transformations of B-lymphocytes.		04.231
Allergy, Drug
[description not available]		02.2110
Delayed Hypersensitivity
[description not available]		02.2110
Drug Hypersensitivity
Immunologically mediated adverse reactions to medicinal substances used legally or illegally.		07.2110
Cancer of Testis
[description not available]		02.2110
Cancer, Second Primary
[description not available]		03.9521
Testicular Neoplasms
Tumors or cancer of the TESTIS. Germ cell tumors (GERMINOMA) of the testis constitute 95% of all testicular neoplasms.		02.2110
Afibrinogenemia, Congenital
[description not available]		02.2110
Afibrinogenemia
A deficiency or absence of FIBRINOGEN in the blood.		02.2110
ANS (Autonomic Nervous System) Diseases
[description not available]		02.2110
B-Cell Chronic Lymphocytic Leukemia
[description not available]		04.5951
Leukemia, Lymphocytic, Chronic, B-Cell
A chronic leukemia characterized by abnormal B-lymphocytes and often generalized lymphadenopathy. In patients presenting predominately with blood and bone marrow involvement it is called chronic lymphocytic leukemia (CLL); in those predominately with enlarged lymph nodes it is called small lymphocytic lymphoma. These terms represent spectrums of the same disease.		16.5951
Lymphocytopenia
[description not available]		04.3911
Lymphopenia
Reduction in the number of lymphocytes.		04.3911
Infections, Parvoviridae
[description not available]		02.0810
Eosinophilia, Tropical
[description not available]		02.110
Herpes Simplex Virus Infection
[description not available]		02.110
Shingles
[description not available]		02.110
Insect Bites
[description not available]		02.110
Paraneoplastic Syndromes
In patients with neoplastic diseases a wide variety of clinical pictures which are indirect and usually remote effects produced by tumor cell metabolites or other products.		02.110
Pemphigoid
[description not available]		02.110
Dermatoses
[description not available]		02.110
Eosinophilia
Abnormal increase of EOSINOPHILS in the blood, tissues or organs.		02.110
Herpes Simplex
A group of acute infections caused by herpes simplex virus type 1 or type 2 that is characterized by the development of one or more small fluid-filled vesicles with a raised erythematous base on the skin or mucous membrane. It occurs as a primary infection or recurs due to a reactivation of a latent infection. (Dorland, 27th ed.)		02.110
Herpes Zoster
An acute infectious, usually self-limited, disease believed to represent activation of latent varicella-zoster virus (HERPESVIRUS 3, HUMAN) in those who have been rendered partially immune after a previous attack of CHICKENPOX. It involves the SENSORY GANGLIA and their areas of innervation and is characterized by severe neuralgic pain along the distribution of the affected nerve and crops of clustered vesicles over the area. (From Dorland, 27th ed)		02.110
Insect Bites and Stings
Bites and stings inflicted by insects.		02.110
Pemphigoid, Bullous
A chronic and relatively benign subepidermal blistering disease usually of the elderly and without histopathologic acantholysis.		02.110
Skin Diseases
Diseases involving the DERMIS or EPIDERMIS.		02.110
Bone Loss, Osteoclastic
[description not available]		02.7930
Leukoencephalopathy Syndrome, Posterior
[description not available]		02.5320
Polyneuropathy, Acquired
[description not available]		02.1310
Absence Seizure
[description not available]		02.5320
Polyneuropathies
Diseases of multiple peripheral nerves simultaneously. Polyneuropathies usually are characterized by symmetrical, bilateral distal motor and sensory impairment with a graded increase in severity distally. The pathological processes affecting peripheral nerves include degeneration of the axon, myelin or both. The various forms of polyneuropathy are categorized by the type of nerve affected (e.g., sensory, motor, or autonomic), by the distribution of nerve injury (e.g., distal vs. proximal), by nerve component primarily affected (e.g., demyelinating vs. axonal), by etiology, or by pattern of inheritance.		02.1310
Seizures
Clinical or subclinical disturbances of cortical function due to a sudden, abnormal, excessive, and disorganized discharge of brain cells. Clinical manifestations include abnormal motor, sensory and psychic phenomena. Recurrent seizures are usually referred to as EPILEPSY or seizure disorder.		02.5320
Cancer of Head
[description not available]		02.7730
Head and Neck Neoplasms
Soft tissue tumors or cancer arising from the mucosal surfaces of the LIP; oral cavity; PHARYNX; LARYNX; and cervical esophagus. Other sites included are the NOSE and PARANASAL SINUSES; SALIVARY GLANDS; THYROID GLAND and PARATHYROID GLANDS; and MELANOMA and non-melanoma skin cancers of the head and neck. (from Holland et al., Cancer Medicine, 4th ed, p1651)		02.7730
Nervous System Disorders
[description not available]		02.9810
Nervous System Diseases
Diseases of the central and peripheral nervous system. This includes disorders of the brain, spinal cord, cranial nerves, peripheral nerves, nerve roots, autonomic nervous system, neuromuscular junction, and muscle.		02.9810
Breathlessness
[description not available]		07.7354
Pyrexia
[description not available]		07.5444
Glomerular Necrosis
[description not available]		07.5444
Dyspnea
Difficult or labored breathing.		07.7354
Fever
An abnormal elevation of body temperature, usually as a result of a pathologic process.		07.5444
Anasarca
[description not available]		02.5120
Hypertension, Renal
Persistent high BLOOD PRESSURE due to KIDNEY DISEASES, such as those involving the renal parenchyma, the renal vasculature, or tumors that secrete RENIN.		02.110
Endotoxin Shock
[description not available]		02.110
Edema
Abnormal fluid accumulation in TISSUES or body cavities. Most cases of edema are present under the SKIN in SUBCUTANEOUS TISSUE.		02.5120
Shock, Septic
Sepsis associated with HYPOTENSION or hypoperfusion despite adequate fluid resuscitation. Perfusion abnormalities may include but are not limited to LACTIC ACIDOSIS; OLIGURIA; or acute alteration in mental status.		02.110
Bewilderment
[description not available]		02.1110
Coagulation, Disseminated Intravascular
[description not available]		02.1110
Dyskinesia, Medication-Induced
[description not available]		02.1110
Disseminated Intravascular Coagulation
A disorder characterized by procoagulant substances entering the general circulation causing a systemic thrombotic process. The activation of the clotting mechanism may arise from any of a number of disorders. A majority of the patients manifest skin lesions, sometimes leading to PURPURA FULMINANS.		02.1110
Dyskinesia, Drug-Induced
Abnormal movements, including HYPERKINESIS; HYPOKINESIA; TREMOR; and DYSTONIA, associated with the use of certain medications or drugs. Muscles of the face, trunk, neck, and extremities are most commonly affected. Tardive dyskinesia refers to abnormal hyperkinetic movements of the muscles of the face, tongue, and neck associated with the use of neuroleptic agents (see ANTIPSYCHOTIC AGENTS). (Adams et al., Principles of Neurology, 6th ed, p1199)		02.1110
Urinary Tract Infections
Inflammatory responses of the epithelium of the URINARY TRACT to microbial invasions. They are often bacterial infections with associated BACTERIURIA and PYURIA.		02.1110
Cancer of Colon
[description not available]		02.1110
Colonic Neoplasms
Tumors or cancer of the COLON.		02.1110
Germinoblastoma
[description not available]		05.7641
Lymphoma
A general term for various neoplastic diseases of the lymphoid tissue.		112.7641
Cachexia
General ill health, malnutrition, and weight loss, usually associated with chronic disease.		07.1110
Bone Diseases
Diseases of BONES.		02.1110
Acute Myelogenous Leukemia
[description not available]		05.3141
Leukemia, Myeloid, Acute
Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES.		17.3141
Granuloma, Hodgkin
[description not available]		02.1110
Hodgkin Disease
A malignant disease characterized by progressive enlargement of the lymph nodes, spleen, and general lymphoid tissue. In the classical variant, giant usually multinucleate Hodgkin's and REED-STERNBERG CELLS are present; in the nodular lymphocyte predominant variant, lymphocytic and histiocytic cells are seen.		14.1110
Thyroid Cancer, Anaplastic
[description not available]		02.5220
Cancer of the Thyroid
[description not available]		02.5220
Thyroid Neoplasms
Tumors or cancer of the THYROID GLAND.		02.5220
Thyroid Carcinoma, Anaplastic
An aggressive THYROID GLAND malignancy which generally occurs in IODINE-deficient areas in people with previous thyroid pathology such as GOITER. It is associated with CELL DEDIFFERENTIATION of THYROID CARCINOMA (e.g., FOLLICULAR THYROID CARCINOMA; PAPILLARY THYROID CANCER). Typical initial presentation is a rapidly growing neck mass which upon metastasis is associated with DYSPHAGIA; NECK PAIN; bone pain; DYSPNEA; and NEUROLOGIC DEFICITS.		02.5220
Injuries, Spinal Cord
[description not available]		02.1110
Spinal Cord Injuries
Penetrating and non-penetrating injuries to the spinal cord resulting from traumatic external forces (e.g., WOUNDS, GUNSHOT; WHIPLASH INJURIES; etc.).		02.1110
Plasmodium falciparum Malaria
[description not available]		02.1110
Cerebral Malaria
[description not available]		02.1110
Malaria, Falciparum
Malaria caused by PLASMODIUM FALCIPARUM. This is the severest form of malaria and is associated with the highest levels of parasites in the blood. This disease is characterized by irregularly recurring febrile paroxysms that in extreme cases occur with acute cerebral, renal, or gastrointestinal manifestations.		02.1110
Experimental Lung Inflammation
Inflammation of any part, segment or lobe, of the lung parenchyma.		013.742726
Pneumonia
Infection of the lung often accompanied by inflammation.		013.742726
Cardiac Hypertrophy
Enlargement of the HEART due to chamber HYPERTROPHY, an increase in wall thickness without an increase in the number of cells (MYOCYTES, CARDIAC). It is the result of increase in myocyte size, mitochondrial and myofibrillar mass, as well as changes in extracellular matrix.		02.1510
Cardiomegaly
Enlargement of the HEART, usually indicated by a cardiothoracic ratio above 0.50. Heart enlargement may involve the right, the left, or both HEART VENTRICLES or HEART ATRIA. Cardiomegaly is a nonspecific symptom seen in patients with chronic systolic heart failure (HEART FAILURE) or several forms of CARDIOMYOPATHIES.		02.1510
Aortic Stenosis
[description not available]		02.1510
Bradyarrhythmia
[description not available]		02.1510
A-V Dissociation
[description not available]		02.1510
Aortic Valve Stenosis
A pathological constriction that can occur above (supravalvular stenosis), below (subvalvular stenosis), or at the AORTIC VALVE. It is characterized by restricted outflow from the LEFT VENTRICLE into the AORTA.		02.1510
Bradycardia
Cardiac arrhythmias that are characterized by excessively slow HEART RATE, usually below 50 beats per minute in human adults. They can be classified broadly into SINOATRIAL NODE dysfunction and ATRIOVENTRICULAR BLOCK.		02.1510
Opportunistic Infections
An infection caused by an organism which becomes pathogenic under certain conditions, e.g., during immunosuppression.		02.1310
Cerebral Nocardiosis
[description not available]		02.1310
Bright Disease
A historical classification which is no longer used. It described acute glomerulonephritis, acute nephritic syndrome, or acute nephritis. Named for Richard Bright.		03.0410
Glomerulonephritis, Lupus
[description not available]		03.4220
Glomerulonephritis
Inflammation of the renal glomeruli (KIDNEY GLOMERULUS) that can be classified by the type of glomerular injuries including antibody deposition, complement activation, cellular proliferation, and glomerulosclerosis. These structural and functional abnormalities usually lead to HEMATURIA; PROTEINURIA; HYPERTENSION; and RENAL INSUFFICIENCY.		03.0410
Lupus Nephritis
Glomerulonephritis associated with autoimmune disease SYSTEMIC LUPUS ERYTHEMATOSUS. Lupus nephritis is histologically classified into 6 classes: class I - normal glomeruli, class II - pure mesangial alterations, class III - focal segmental glomerulonephritis, class IV - diffuse glomerulonephritis, class V - diffuse membranous glomerulonephritis, and class VI - advanced sclerosing glomerulonephritis (The World Health Organization classification 1982).		03.4220
ATLL
[description not available]		02.1310
Leukemia-Lymphoma, Adult T-Cell
Aggressive T-Cell malignancy with adult onset, caused by HUMAN T-LYMPHOTROPIC VIRUS 1. It is endemic in Japan, the Caribbean basin, Southeastern United States, Hawaii, and parts of Central and South America and sub-Saharan Africa.		02.1310
Central Nervous System Neoplasm
[description not available]		03.0610
Central Nervous System Neoplasms
Benign and malignant neoplastic processes that arise from or secondarily involve the brain, spinal cord, or meninges.		03.0610
Adrenocortical Carcinoma
A malignant neoplasm of the ADRENAL CORTEX. Adrenocortical carcinomas are unencapsulated anaplastic (ANAPLASIA) masses sometimes exceeding 20 cm or 200 g. They are more likely to be functional than nonfunctional, and produce ADRENAL CORTEX HORMONES that may result in hypercortisolism (CUSHING SYNDROME); HYPERALDOSTERONISM; and/or VIRILISM.		02.1310
Adrenal Cortex Cancer
[description not available]		02.1310
Adrenal Cortex Neoplasms
Tumors or cancers of the ADRENAL CORTEX.		02.1310
Gout
Metabolic disorder characterized by recurrent acute arthritis, hyperuricemia and deposition of sodium urate in and around the joints, sometimes with formation of URIC ACID calculi.		02.1310
Cancer of Endometrium
[description not available]		02.1310
Endometrial Neoplasms
Tumors or cancer of ENDOMETRIUM, the mucous lining of the UTERUS. These neoplasms can be benign or malignant. Their classification and grading are based on the various cell types and the percent of undifferentiated cells.		02.1310
Cells, Neoplasm Circulating
[description not available]		02.1510
Experimental Mammary Neoplasms
[description not available]		02.1510
Libman-Sacks Disease
[description not available]		02.0710
Lupus Erythematosus, Systemic
A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow.		02.0710
Hyperglycemia, Postprandial
Abnormally high BLOOD GLUCOSE level after a meal.		07.544
Hyperglycemia
Abnormally high BLOOD GLUCOSE level.		07.544
Neoplasms, Squamous Cell
Neoplasms of the SQUAMOUS EPITHELIAL CELLS. The concept does not refer to neoplasms located in tissue composed of squamous elements.		02.0710
Cancer of Kidney
[description not available]		02.9910
Kidney Neoplasms
Tumors or cancers of the KIDNEY.		14.9910
Carcinoma, Squamous Cell of Head and Neck
[description not available]		02.0710
Squamous Cell Carcinoma of Head and Neck
The most common type of head and neck carcinoma that originates from cells on the surface of the NASAL CAVITY; MOUTH; PARANASAL SINUSES, SALIVARY GLANDS, and LARYNX. Mutations in TNFRSF10B, PTEN, and ING1 genes are associated with this cancer.		02.0710
Infections, Plasmodium
[description not available]		02.0710
Malaria
A protozoan disease caused in humans by four species of the PLASMODIUM genus: PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX; PLASMODIUM OVALE; and PLASMODIUM MALARIAE; and transmitted by the bite of an infected female mosquito of the genus ANOPHELES. Malaria is endemic in parts of Asia, Africa, Central and South America, Oceania, and certain Caribbean islands. It is characterized by extreme exhaustion associated with paroxysms of high FEVER; SWEATING; shaking CHILLS; and ANEMIA. Malaria in ANIMALS is caused by other species of plasmodia.		02.0710